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    Oral anticoagulation with warfarin represents a major challenge to successful drug 
therapy in children. The aims of this study was to investigate the implementation in 
routine clinical practice, personalised warfarin dosing using a PK/PD model, in children 
after congenital heart surgery and to explore the experience of patients/parents and health 
care professionals with managing long-term warfarin treatment as well as their experience 
with the model-based dosing approach. 
The predictive performance of the PK/PD model was first validated using retrospectively 
collected data from a cohort of 60 children on long-term warfarin treatment. Seventy 
percent of the predicted doses were ideal with bias of -0.10 and precision of 0.19. 
A prospective interventional quantitative study was then conducted in two groups of 
children. Group 1 included 5 patients who started warfarin treatment for the first time 
after cardiac surgery. For the case subjects compared to the controls, the median time to 
achieve the first therapeutic INR values was longer (5 vs 2 days), the median time to 
stable anticoagulation was shorter (29.0 vs 96.5 days), the median time to over-
anticoagulation was longer (15.0 vs 4.0 days), the median percentage of the INR 
observations within the target range (%ITR) was higher (70% vs 47.4%), the median 
percentage of time in therapeutic range (%TTR) was higher (83.4% vs 62.3%), the 
median frequency of INR measurements per month was comparable (5.0 vs 6.3) and the 
median frequency of dose alterations was also comparable (20.0 vs 21.0).  
Group 2 included 26 patients who were established on maintenance warfarin therapy. For 
the model-based dosing phase compared to the traditional dosing phase, the mean %ITR 
was 68.82% compared to 67.9% (p=0.84) and the mean %TTR was 85.47% compared to 
80.2% (p=0.09). After excluding 5 patients who experienced medical issues during either 
phases of treatment, the mean %ITR was 71.28% compared to 65.51% (p=0.22) and the 
median %TTR was 91.8% compared to phase 77.3 % (p=0.03). The median frequency of 
INR measurements per month was 2.3 compared to 1.9 (p=0.08) and the median 
frequency of dose alteration was 6.5 compared to 2.5 (p=0.02). Patients with Fontan 
circulation had significantly higher %TTR during the model-based dosing phase than 
during the traditional dosing phase after excluding the 5 patients with medical issues 
(p=0.02).  
Semi-structured interviews were conducted with 3 doctors, 2 cardiac liaison nurses and 
four family representatives. Three thematic areas emerged from the doctors’ interviews; 
‘medical and clinical knowledge’, ‘INR monitoring’ and ‘dose decision’. Four thematic 
areas emerged from the nurses’ interviews; ‘role of the cardiac liaison nurses in managing 
warfarin treatment’, ‘INR monitoring’, ‘dose decision’ and ‘adherence to the prescribed 
regimen’. Three thematic areas emerged from the families’ interviews; ‘managing 
warfarin treatment and the coping mechanism’, ‘warfarin dose decision’ and ‘adherence 
to warfarin treatment’. Both doctors and nurses found the new dosing approach useful 
and acceptable in patients with stable medical condition. Additionally, three of the 
families favoured that dosing be performed by a professional experienced with warfarin 
treatment regardless of the method used. 
This study has shown that model-based dosing can improve the anticoagulation control 
of warfarin and hence reduce its adverse events in children after congenital heart surgery. 
Further work is required to establish the clinical effectiveness and cost-effectiveness of 
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Chapter 1: Introduction 
1.1. Overview 
        This thesis focuses on a new approach to personalise warfarin dosing in children. 
However, before considering warfarin and the challenges encountered in optimising its 
effects in children, this overview sets out the problems encountered in drug dosing in this 
population. 
       Therapeutic doses for most drugs are proposed depending upon population-level 
information that focus on the typical patient and recommend a standard fixed dose. 
However, this ‘one size fits all’ approach to dosing does not in large part account for the 
inter-individual variability in drug exposure (pharmacokinetics (PK)) and the biological 
response (pharmacodynamics (PD)). Demographic, genetic, clinical and environmental 
factors have been found to contribute significantly to this variability resulting in variable 
responses to drug therapy or susceptibility to adverse drug reactions (Beumer et al., 2014; 
Hawwa et al., 2008; Roberts et al., 2014). This is most important in drugs with narrow 
therapeutic ranges where variability can lead to serious toxicity or otherwise treatment 
failure (Miyakis et al., 2010; Slattery et al., 1997). 
In children, drug doses are usually extrapolated linearly from adult doses and adjusted 
according to age, body weight or body surface area. This approach is simple, easy and 
does not entail the use of complex dosing algorithms. However, children are in a 
continuous state of development and maturation that can significantly impact the 
pharmacokinetics and pharmacodynamics of drugs, and hence, the relationship between 
dose and age may not necessarily be linear (Cella et al., 2010). Developmental changes 
in drug absorption, distribution, metabolism and excretion as well as the response to drugs 
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have been well documented in children (Kearns et al., 2003). The oral absorption and 
bioavailability of drugs are altered in young children because of age-related changes in 
the gastrointestinal tract (Lu and Rosenbaum, 2014). Similarly, drug distribution is 
influenced by age-related changes in body composition and plasma protein binding (van 
den Anker, Schwab and Kearns, 2011). Moreover, the maturation of the hepatic 
metabolising enzymes and the renal excretory function affect the elimination of drugs in 
children (Fernandez et al., 2011). Furthermore, the response to drugs may be affected by 
age-related differences in drug-receptor interaction (Kearns et al., 2003; Mulla, 2010). 
Therefore, simple linear extrapolation of adult doses to children may result in inequivalent 
systemic exposure and/or response in the two populations. In addition, the effect of 
genetic polymorphisms on the drugs’ pharmacokinetics and pharmacodynamics impose 
an additional source of variability that should be considered in drug dosing (Vear, Stein 
and Ho, 2013). As a result, understanding the pharmacokinetics and pharmacodynamics 
of drugs and the factors that contribute to their inter- and intra- individual variability is 
pivotal in order to optimise drug therapy in children. 
An additional important aspect in optimising therapy in children is adherence to the 
prescribed regimen. With the help of their family, children on drug treatment and 
especially those on long-term therapy for chronic illnesses, need to adhere to the 
prescribed regimens to control the underlying disease. This may involve making 
significant behavioural and lifestyle changes that can affect adherence to the prescribed 
regimen. There is a range of factors that can affect adherence in children such as age, 
family factors, the socioeconomic status, disease/treatment regimen and relationship with 
the healthcare provider (Cheng and Walter, 2006). Therefore, in order to enhance 
adherence to drug therapy in children, it is important to obtain a thorough understanding 
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of the health behaviour from the perspective of children/families and health care 
professionals.  
1.1.1. Personalising drug dosing in children using Bayesian forecasting and 
population PK/PD models 
      The concept of personalised dosing recognises every individual has unique 
pharmacokinetic and pharmacodynamic characteristics which govern the time course of 
the drug effect. Therefore, to optimise drug dosing and hence improve treatment response, 
knowledge of the individual’s PK/PD parameters is essential. This is obtained at a more 
frequent basis at the beginning of treatment and at longer time intervals when the target 
therapeutic levels are obtained. 
Bayesian forecasting is a proactive approach to dose individualisation of drugs with 
narrow therapeutic ranges that was first introduced by Sheiner et al. in 1979. The method 
utilises population PK/PD models, incorporating significant covariates that explain the 
inter- and intra-individual variability, to prospectively identify individual’s 
pharmacokinetic and pharmacodynamic parameters and hence individualise dosing 
(Sheiner et al., 1979). The population models provide a very useful tool to investigate the 
pharmacokinetics and pharmacodynamics of drugs in children to ensure the safe and 
effective use of medicines in this population. The models are very useful as they can be 
used during complex drug dosing regimens, at non-steady state conditions and when only 
a limited number of concentration measurements is available. Population models were 
developed to optimise dosing regimens of drugs that present a major challenge in 
children, for example anticancer drugs, antimicrobials in critically ill patients, and the 
oral anticoagulant, warfarin (McCune et al., 2014; Felton et al., 2014; Lala et al., 2013). 
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Population PK/PD models of anticancer drugs can help to identify and quantify the 
complex pharmacokinetics of these agents and the relationship between pharmacokinetics 
and pharmacodynamics as well as the influence of pharmacogenetics (Buil-Bruna et al., 
2016). In addition, these models can be used to optimise dosing of single-agent as well as 
combination regimens and identify possible drug interactions with the anticancer agents. 
In children, these models can assist in describing the wide variability in this population 
and identifying the covariates that explain this variability to optimise dosing regimens 
and hence prevent toxicity and treatment failure in this population (Zandvliet et al., 2008). 
For example, personalising oral busulfan dosing in children has been shown to improve 
the clinical outcomes, reduced doses in 69% of children, lower incidence of liver toxicity 
and successful engraftment in all patients (Bleyzac et al., 2001).  
Another therapy area where personalised dosing through population models has been 
proved to improve the clinical outcome is antimicrobial therapy in critically ill children. 
Such patients frequently have severely altered and marked inter-individual variability in 
pharmacokinetics (Roberts et al., 2014) that can increase the likelihood of either treatment 
failure and emergence of antimicrobial resistance due to low systemic exposure or drug 
toxicity due to high systemic exposure. Individualising vancomycin dosing in children 
with malignant haematological disease using population modelling was shown to achieve 
the target therapeutic range significantly better than the fixed dosing method (Zhao et al., 
2014). Also, population model-based individualisation of voriconazole treatment was 
shown to accurately manage therapy in children independently of steady state conditions 




1.1.2. Personalising warfarin dosing in children using Bayesian forecasting and 
population PK/PD models 
       Warfarin, the most widely prescribed oral anticoagulant, represents a major challenge 
to successful therapy in children. The drug is indicated for the long-term prevention of 
thromboembolism that is mostly associated with underlying disorders like congenital 
heart disease with or without mechanical prosthetic valves, cancer, renal disorders and 
long-term total parenteral nutrition (Andrew et al., 1994; Tait et al., 1996). However, 
warfarin has a narrow therapeutic range and exhibits large inter- and intra-individual 
variability in its pharmacokinetics and pharmacodynamics which are also influenced by 
the genetic polymorphisms of the enzymes Cytochrome P450 2C9 (CYP2C9), and 
vitamin K epoxide reductase (VKOR), respectively (Hamberg et al., 2014). The results 
from the largest cohort study of 319 children treated with warfarin, has shown that the 
proportion of International Normalised Ratio (INR) measurements within the target range 
was only 47% for the range of 2.0-3.0 and 61% for the range of 2.5-3.5 (Streif et al., 
1999). This can lead to either under-anticoagulation with subsequent thrombosis or 
otherwise over-anticoagulation with consequent bleeding. The incidence of major 
bleeding events was shown to be 0.5% per patient year (Streif et al., 1999), with patients 
with mechanical heart valves having a higher incidence of up to 4% per patient year (Rao 
et al., 1989). Therefore, individualising warfarin dosing is essential to optimise its 
anticoagulant control.  
Population PK/PD models of warfarin that incorporate pharmacogenetic variables have 
been developed to optimise warfarin dosing in children (Hamberg and Wadelius, 2014). 
These models are mechanistic-based, describing the exposure-response (or PK-PD) 
relationship and address the inter- and intra-individual variability in warfarin 
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pharmacokinetics and pharmacodynamics to improve warfarin treatment in children 
(Hamberg and Wadelius, 2014). A population PK/PD model for warfarin dose 
individualisation in children was developed by Lala et al. (Lala et al., 2013) based on a 
previous adult model (J. Lee et al., 2009). The model involved a starting dose nomogram 
based on weight and CYP2C9 and VKORC1 genotypes and a titration scheme for dose 
adjustment according to the observed INR values. A warfarin dose individualisation 
kinetic/pharmacodynamic (K/PD) model was also developed in children by Hamberg et 
al. (Hamberg et al., 2013). The model was an extension of a previous K/PD model in 
adults that describes the relationship between warfarin dose and INR response to 
overcome the lack of PK data (plasma warfarin concentration) (Hamberg et al., 2010). 
The predictive performance of the bridged model was evaluated in a cohort of 49 children 
treated with warfarin. It has been shown that the model was able to predict ideal 
maintenance doses (within ± 20% of the observed doses) in 41% of patients with the 
percentage increased to 70% when 3 or more INR observations were available (Hamberg 
et al., 2013). The paediatric model has subsequently been implemented in a user-friendly, 
Java-based decision support tool that utilises the patient’s age, baseline INR value, target 
INR range and CYP2C9 and VKORC1 genotypes to predict warfarin dose. The tool can 
be used for the prediction of both a priori (initial) doses and a posteriori (maintenance) 
doses (Hamberg et al., 2015). 
       In order to optimise warfarin therapy, it is pivotal to personalise its dosing, however, 
adherence to the prescribed regimen is equally important. As described earlier, warfarin 
is a narrow therapeutic range drug that requires accurate dosing and frequent monitoring 
of the INR to achieve stable anticoagulation. Furthermore, this drug has many diet- and 
drug-interactions and can be associated with serious adverse events. Thus, children 
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receiving lifelong warfarin therapy and their families need to adhere to a lifelong regimen 
to achieve adequate warfarin anticoagulation and prevent the occurrence of adverse 
events. This involves taking the prescribed dose and monitoring the INR at set times, 
restricting vitamin K-containing diet, restricting alcohol intake for teenagers and being 
cautious about potential drug interactions and physical activities that can predispose to 
injuries and bleeding are also essential to control warfarin treatment. This can add a 
significant burden both on the patient and the family which may affect adherence. 
Therefore, understanding the perspectives and experiences of both children/families and 
health care providers of managing warfarin therapy is essential to enhance adherence to 
this drug. 
        Population models for individualising warfarin dosing in children have been 
developed and evaluated in children. However, these models were never tested clinically, 
on a prospective basis to assess their clinical utility. In addition, the lived experience of 
children/families and health care providers with the process of warfarin 
dosing/monitoring was not previously investigated. The aim of this research project is to 
first, validate the Hamberg model using the existing cohort of patients managed by the 
East Midlands Congenital Heart Centre. Second, to prospectively compare warfarin dose 
management using the Hamberg model with the traditional, ‘trial and error’ approach. 
Thirdly, the project will also explore the views of children/parents and health care 
providers about the usual warfarin dosing/monitoring process as well as their views about 
the new warfarin dosing method. 
This introductory chapter will discuss the oral anticoagulant, warfarin, its pharmacology 
and monitoring, pharmacokinetics and clinical use in children. The chapter will also 
discuss the factors that contribute to the inter- and intra-individual variability in warfarin 
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pharmacokinetics and pharmacodynamics leading to the variability in its dose 
requirements. The models developed to identify factors contributing to this variability 
and personalise its dosing in children will be reviewed. Clinical trials conducted to assess 
genotype-guided dosing of warfarin in adults and children will be also be reviewed. In 
addition, adherence in children and the factors contributing to non-adherence in this 
ppulation will also be discussed. 
1.2. Warfarin  
1.2.1. Warfarin history 
       Warfarin is the most widely prescribed oral anticoagulant for the prevention and 
treatment of thromboembolic events in the world. In the UK, over 1% of the population 
and 8% of those aged over 80 years have been estimated to be using warfarin therapy 
(Pirmohamed, 2006). The story of warfarin’s discovery started following an outbreak of 
fatal internal bleeding in cattle after ingestion of spoiled sweet clover hay in Northern 
USA and Canada in the 1920s. In 1933, Link and co-workers were able to isolate the 
active compound which they named dicoumarol (3,3ʹ-methylene-bis[4-
hydroxycoumarin]). The group continued working to identify more potent coumarin-
based anticoagulants for use as rodenticides which led to the discovery of warfarin. It was 
first approved as a rodenticide in 1948, afterwards, it was approved for human use in 
1954. The name warfarin was made by combining ‘WARF’ from the first letters of the 
Wisconsin Alumni Research Foundation with ‘-arin’ from coumarin (LINK, 1959).  
1.2.2. Pharmacology and monitoring 
      Warfarin is a vitamin K antagonist that produces its anticoagulant effect by inhibiting 





reduced vitamin K, the active form of vitamin K. Reduced vitamin K is a cofactor for the 
γ-carboxylation of the coagulation factors II, VII, IX and X resulting in the production of 
inactive forms of these proteins (Figure 1). Warfarin also inhibits the γ-carboxylation of 
the anticoagulant proteins C, S and Z, consequently, it has a potential procoagulant effect 
(Ansell et al., 2008).  
Monitoring the anticoagulant effect of warfarin is accomplished by measuring the 
prothrombin time (PT) expressed as the International Normalised Ratio (INR). PT 
measures the time taken for the blood to clot after the addition of exogenous 
thromboplastin. The INR is the ratio of the patient’s PT and the control PT to the 
International Sensitivity Index (ISI) which is used to overcome the differences in 
commercial thromboplastins used in different laboratories (Ronghe, Halsey and Goulden, 
2003). 
R- S- warfarin 
  
Vitamin K epoxide reductase 
  





Reduced vitamin K Oxidised vitamin K 
  
Vitamin K-dependant carboxylase 
Factors II, VII, IX, X 
Proteins C, S & Z 
Factors IIa, VIIa, IXa & 
Xa 
Active proteins C, S & Z 
  
Figure 1. Warfarin mechanism of action. 
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                                  INR= (PT patient/PTcontrol)
 ISI 
The onset of warfarin action depends upon the clearance of the fully carboxylated 
coagulation factors from the circulation, and hence, their elimination half-lives. The 
initial changes in PT following the initial dose, and thus the INR, reflect the initial 
depletion of factor VII which has the shortest half-life (~ 6 hours). Partial anticoagulant 
effect of warfarin usually develops within two days of treatment initiation. Full 
antithrombotic effect of warfarin requires up to 6 days of treatment as it is principally 
dependant on factor II which has the longest elimination half-life of approximately 60 to 
72 hours (Hirsh et al., 2003; Wittkowsky, 2003). 
1.2.3. Pharmacokinetics 
       After oral administration, warfarin has almost complete bioavailability and peak 
plasma concentration attainable in 2-8 hours of administration. The rate of dissolution of 
generic warfarin tablets may vary, which may result in some variation in the rate and 
extent of absorption. The drug is highly bound (99%) to plasma proteins, mainly albumin 
(Hogg and Weitz, 2018). Warfarin is available as a racemic mixture of two enantiomers, 
the S- and the R- isomers, with the S-isomer being about 3 to 5-fold more potent than the 
R-counterpart. The two isomers undergo hepatic metabolism through different pathways; 
the S-warfarin is metabolised by Cytochrome P450 2C9 (CYP2C9) while the R- isomer 
is metabolised by CYP1A1, CYP1A2 and CYP3A4. The half-life (t1/2) of warfarin varies 
between 25 to 60 hours and the duration of action is 2 to 5 days (Hogg and Weitz, 2018).  
In children, warfarin pharmacokinetic data are lacking. In a cross-sectional study warfarin 
was also found to be highly protein bound (about 99%). The mean clearance of S-warfarin 
(standard deviation SD) was estimated to be 18.1 (9.2) and 12.6 (8.1) ml/min/kg for 
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children aged 1-11 and 12-18 years, respectively, whereas that of R-warfarin was 4.7 (1.4) 
and 4.2 (1.6) ml/min/kg for the same age groups, respectively (Takahashi et al., 2000). 
1.2.4. Indications for warfarin therapy  
        Warfarin is used for the primary and secondary prevention of thromboembolism in 
patients with deep venous thrombosis, pulmonary embolism, mechanical prosthetic heart 
valves, atrial fibrillation and post myocardial infarction (Hirsh et al., 2003). In children, 
it is also indicated for the prevention of thromboembolism that is mostly associated with 
underlying disorders like congenital heart disease (CHD) with or without mechanical 
prosthetic valves, cancer, renal disorders and long-term total parenteral nutrition (Andrew 
et al., 1994; Tait et al., 1996). The main indication for oral anticoagulation with warfarin 
in children after cardiac surgery is prophylaxis of thromboembolism after Fontan 
procedure and mechanical prosthetic valve replacement (Tait et al., 1996). Therefore, 
these conditions will be discussed in the following sections. 
1.2.4.1. The Fontan procedure 
     Fontan operation is the definitive procedure in a 3-staged palliation for children born 
with complex congenital cardiac defects such as tricuspid atresia, hypoplastic left heart 
syndrome and double inlet single ventricle. In such congenital anomalies, 2-ventricle 
repair cannot be performed resulting in a functionally single ventricle heart. The 
procedure involves diverting the systemic venous blood directly to the pulmonary arteries 
without a requirement for pumping by the right ventricle; with the single functioning 
ventricle working as the left ventricle. The procedure was first introduced by Fontan and 
Baudet (Fontan and Baudet, 1971). This palliative procedure has led to an increase in the 
life expectancy of children born with univentricular hearts resulting in an increasing 
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number entering adulthood. It has been estimated that the UK population having single-
ventricle physiology is composed of 1040 adults and 1700 children and the adult number 
expected to increase by 60% in the next decade (Coats et al., 2014). However, the 
procedure has been associated with clinically significant sequelae including arrhythmias, 
systemic ventricular dysfunction, liver dysfunction, protein-losing enteropathy and 
thromboembolic disease (Giannico et al., 2006; Pundi et al., 2015). 
A-  Risk of thromboembolism after the Fontan procedure 
       Thromboembolic (TE) disease is one of the major complications following Fontan 
procedure with an incidence ranging from 17 to 33% (Stümper et al., 1991; Fyfe et al., 
1991; Balling et al., 2000). TE events can occur in the perioperative period (Todd 
Tzanetos et al., 2012), immediately post-operatively (McCrindle et al., 2013), during the 
first post-operative year (Kaulitz et al., 2005) and up to 5 to 10 years postoperatively 
(Egbe et al., 2016). Thrombotic and embolic events can occur in the venous circulation, 
the Fontan circuit, intracardiac or in the arterial circulation leading to significant 
morbidity and mortality. Occlusion of the Fontan circuit by thrombus can result in the 
failure of the procedure itself. In addition, there are a number of reports about patients 
developing significant events like pulmonary embolism, myocardial infarction, stroke or 
cerebrovascular events (Varma et al., 2003; Wilson, Wisheart and Stuart, 1995; Chun et 
al., 2004; Barker et al., 2005). Moreover, TE disease has been reported to be associated 
with mortality of up to 25% (Khairy et al., 2008; Monagle et al., 1998).  
The slow blood flow resulting from the absence of the ventricular pump, the turbulence 
occurring in the Fontan circuit and the use of thrombogenic prostheses are all potential 
risk factors for TE disease (Viswanathan, 2016). Abnormalities in both procoagulant and 
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anticoagulant proteins have also been well-documented in children with single ventricle 
palliation. Decreased levels of the procoagulant factors II, V, VII, IX, X and fibrinogen 
as well as the anticoagulant proteins C and S and antithrombin III were documented after 
the Fontan procedure. In contrast, levels of factor VIII were shown to be increased after 
the Fontan palliation contributing to increased risk of thrombosis (Odegard et al., 2003; 
Odegard et al., 2009; Jahangiri et al., 2000; van Nieuwenhuizen et al., 1999; Goldenberg, 
Knapp-Clevenger and Manco-Johnson, 2004). Furthermore, endothelial dysfunction in 
patients with Fontan circulation, as evidenced by increased levels of von Willebrand 
factor, imposes an additional risk factor for thrombosis (Binotto, Maeda and Lopes, 
2008). 
B- Anticoagulant therapy after Fontan procedure 
     Considerable controversy exists in the literature with regard to the type of 
thromboembolism prophylaxis after the Fontan procedure. Some authors recommend oral 
anticoagulation (Balling et al., 2000; Seipelt et al., 2002; Egbe et al., 2016), while others 
recommend prophylaxis with aspirin (antiplatelet therapy) (Jacobs et al., 2002). 
Moreover, a prospective randomised clinical trial conducted by Monagle et al and other 
observational studies found no significant difference between aspirin and warfarin as 
thromboprophylaxis after the Fontan procedure (Monagle et al., 2011; Potter et al., 2013; 
Iyengar et al., 2016). Interestingly, a study conducted in adult patients with Fontan 
circulation has shown that in addition to having increased platelet activity, systemic 
inflammation, and endothelial dysfunction, a significant number of patients treated with 
aspirin also experienced aspirin resistance which may have contributed to their increased 
incidence of TE events (Tomkiewicz-Pajak et al., 2015).  
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When oral anticoagulation is recommended after the Fontan procedure, warfarin or 
another vitamin K antagonist (VKA) is usually used to attain a target INR of 2.5 (range 
2.0-3.0) (Giglia et al., 2013; Monagle et al., 2012; Patricia Massicotte and Olley Chair, 
2005) 
1.2.4.2. Mechanical prosthetic heart valves 
       In children, congenital lesions of the aortic and/or mitral valves may necessitate valve 
replacement. Valve lesions due to congenital defects account for 5% of valve operations 
worldwide (Chambers and Bridgewater, 2014). Replacement mechanical valves impose 
a significant risk of thrombosis and thromboembolism due to alteration of blood flow, 
surgical disruption of vessel walls and exposure of circulating blood to artificial surfaces 
(Sun et al., 2009). The annual incidence of TE events in children after mechanical valve 
replacement receiving no anticoagulation has been estimated to be 5.7% (Sade et al., 
1988). The incidence varies with the type and position of the prosthetic valve with older-
generation mechanical valves and valves implanted in the mitral position having higher 
incidence of thrombosis. The risk of TE is highest in the early postoperative period up to 
one year postoperatively followed by a decrease in TE incidence thereafter. TE 
complications related to mechanical prostheses are associated with significant morbidity 
including valve obstruction and systemic emboli. Moreover, obstructive mechanical 
valve thrombosis has been shown to be associated with up to 10 % mortality (Roudaut, 
Serri and Lafitte, 2007). 
1.2.4.2.1. Anticoagulant therapy after mechanical valve replacement 
         Children with mechanical heart valves require indefinite oral anticoagulation with 
a vitamin K antagonist (VKA) to prevent thromboembolism (Giglia et al., 2013). The 
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intensity of anticoagulation (the target INR value) depends upon the type and the position 
of the mechanical valve and the presence of TE risk factors (Vahanian et al., 2012; 
Nishimura et al., 2014). Risk factors for TE include previous TE events, left ventricular 
dysfunction or hypercoagulable condition (Nishimura et al., 2014). Therefore, 
anticoagulants should be commenced as early as possible in the first postoperative days, 
and they are usually bridged with either unfractionated heparin or low molecular weight 
heparin (Vahanian et al., 2012; Whitlock et al., 2012). Patients with mechanical aortic 
valve are anticoagulated to a target INR of 2.5 (range 2.0-3.0); with a higher target of 3.0 
(range 2.5-3.5) being recommended for patients with risk factors of TE or having older-
generation valves in place (Vahanian et al., 2012; Nishimura et al., 2014). The target INR 
for patients with mechanical mitral valves is also 3.0 (range 2.5-3.5) (Nishimura et al., 
2014; Whitlock et al., 2012), however, higher target INR of 3.5 or 4.0 may be 
recommended for highly thrombogenic valves in patients with risk factors of TE 
(Vahanian et al., 2012; Keeling et al., 2011). 
Despite the use of oral anticoagulants in patients with mechanical valves, there is still a 
potential for TE events in addition to the bleeding risk. TE complications were reported 
in up to 4% of patients, with a similar rate of bleeding events reported in children with 
mechanical valves receiving warfarin therapy (Rao et al., 1989). Major bleeding events 
can be fatal and TE events can lead to life-threatening consequences like stroke, 
pulmonary embolism and organ failure. Therefore, accurate dosing of warfarin to avoid 





1.2.5. Dosing of warfarin in children  
     Various guidelines have been established to help clinicians calculate the loading and 
maintenance doses of warfarin. The British National Formulary for Children (BNFC) 
recommends commencing warfarin therapy for children with a dose of 0.2 mg/kg/day 
with subsequent doses adjusted per INR measurements and the usual maintenance dose 
is 0.1-0.3 mg/kg once daily (Monagle et al., 2012; Paediatric Formulary Committee., 
2016). The American College of Chest Physicians (ACCP) guidelines recommend an 
initial dose of 0.2 mg/kg in the first day and dose adjustments are made according to an 
INR nomogram afterward (Monagle et al., 2012). A lower starting dose of 0.1 mg/kg/day 
is recommended for patients after the Fontan procedure (Giglia et al., 2013).  
However, these guidelines are more general and do not consider the individual patient 
characteristics and factors that affect warfarin pharmacokinetics (PK) and 
pharmacodynamics (PD). There is large inter-individual variability in warfarin dose 
requirements in children where daily maintenance doses can vary from 0.5 to 12.5 mg 
(Biss et al., 2012). Demographic, genetic, clinical and environmental factors have been 
shown to contribute considerably to the inter-individual variability in the PK and the PD of 
warfarin and hence influence the degree of anticoagulation. 
1.2.6. Age-related changes in the pharmacokinetics and pharmacodynamics of 
warfarin in children 
        Children are in a continuous state of development and maturation which can have a 
significant impact on the drugs’ PK and/or PD. These are referred to as developmental 
pharmacokinetics and developmental pharmacodynamics, respectively. These 
developmental changes in PK and/or PD can predispose to either supra-therapeutic 
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exposure and/or response to the drug resulting in serious toxicity or sub-therapeutic 
exposure and/or response to the drug resulting in treatment failure. 
1.2.6.1. Developmental pharmacokinetics 
        PK in very simple terms describes what the body does to the drug and it includes 
absorption, distribution, metabolism and elimination.  
A- Absorption  
     Age-related changes in the gastrointestinal tract have a significant impact on both the 
rate and the extent of oral drug absorption and hence bioavailability. Gastric pH, as 
reported in review articles, is neutral at birth (pH 6-8) then it falls to 1-3 during the first 
24-48 hours (Lu and Rosenbaum, 2014). It returns to neutral at 8-10 days and starts to 
decline slowly afterwards until reaching adult values at the age of 2-3 years (Fernandez 
et al., 2011; Lu and Rosenbaum, 2014; Matalová, Urbánek and Anzenbacher, 2016). This 
is closely correlated with the maturation of the gastric mucosa and the gastric pH is further 
affected by the relatively alkaline milk consumed by the infant (Koren, 1997). This 
overview has been contradicted by other authors who claimed that gastric pH is 
comparable in children of all ages and adults and attributed the high gastric pH in the 
younger infants to the buffering effects of milk (Mooij et al., 2012). This elevated gastric 
pH can increase the bioavailability of acid-labile drugs such as beta-lactam antibiotics 
and reduce the bioavailability of weak basic drugs such as phenytoin and phenobarbital 
(Lu and Rosenbaum, 2014). Alternatively, intestinal pH has been reported to be similar 
in children and adults, although data on intestinal pH in infants less than two years of age 
is lacking (Kaye, 2011).  
27 
 
In addition, gastric emptying is thought to be delayed immediately after birth and 
approaches adult values after 6-8 months (Bowles et al., 2010; Debotton and Dahan, 
2014; Fernandez et al., 2011; Matalová, Urbánek and Anzenbacher, 2016). This is 
anticipated to decrease the rate of absorption of drugs where the rate limiting is gastric 
emptying, for example paracetamol which was shown to have increased absorption half-
life and delayed absorption in neonates infants less than 3 months of age (B. J. Anderson, 
Woollard and Holford, 2000; B. J. Anderson et al., 2002). In contrast, a model-based 
meta-analysis of studies in premature neonates through adults has shown that the meal 
type was the significant covariate for gastric emptying, but not age (Bonner et al., 2015). 
Similarly, the intestinal transit time is prolonged in neonates as a result of decreased 
motility and peristalsis, but it is shortened in older infants due to increased intestinal 
motility (Bartelink et al., 2006). The exact age at which intestinal transit time approaches 
the adult level is less clear (Bowles et al., 2010).  
Immature secretion and activity of bile and pancreatic fluid in the first few months of life 
causes impaired absorption of fat-soluble vitamins (such as vitamin D and E) and 
lipophilic compounds (Strolin Benedetti, Whomsley and Baltes, 2005). Moreover, the 
immaturity of the intestinal drug metabolising enzymes and transport proteins can change 
the bioavailability of drugs (Lu and Rosenbaum, 2014). Midazolam, for example, was 
found to have marked decreased oral clearance as a result of the immature intestinal 
CYP3A4 enzyme which leads to decreased intestinal metabolism of the drug and hence 
increase in its bioavailability (de Wildt et al., 2002). The oral clearance of gabapentin, in 
contrast, was found to be higher in children less than 5 years than those older than 5 years 
or adults as a result of the immature L-amino acid transporter system in the intestinal 
membrane which causes a reduction in the bioavailability of the drug (Ouellet et al., 
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2001). Furthermore, there are other factors that may affect intestinal absorption of drugs 
like the immaturity of the intestinal mucosa, decreased first-pass metabolism and varying 
bacterial colonisation (van den Anker, Schwab and Kearns, 2011; Fernandez et al., 2011). 
Therefore, the absorption of drugs that are affected by the aforementioned factors, and 
hence their bioavailability, may not approach adult levels until 5 years of age (G. D. 
Anderson, 2010). 
B- Distribution  
      Drug distribution is also subject to the developmental changes occurring particularly 
in the first year of life. Very young infants have high total body water (80-90% of body 
weight) reaching adult level of 55-60% by one year of age which affects the distribution 
of both hydrophilic and lipophilic drugs. In addition, protein binding is also influenced 
by the ontogeny process where decreased amount and affinity of plasma proteins, albumin 
and α1-acid glycoprotein has been documented in neonates and young infants (van den 
Anker, Schwab and Kearns, 2011; Fernandez et al., 2011). This can lead to increased free 
fraction of the drug available for target interaction as well as clearance. 
C- Metabolism  
      Developmental changes in the liver metabolising enzymes affect drug clearance from 
the body. The most important enzymes involved in drug metabolism, the Cytochrome 
P450 (CYP 450) isoforms, have low activity at birth and subsequently the activity 
increases in the first year of life to reach adult values at 1-2 years of age (Fernandez et 
al., 2011). However, some isoforms, like CYP2C19, may not approach the adult values 
till more than 10 years of age (Koukouritaki et al., 2004). By the age of 2-3 years, the 
enzyme activity of specific isoforms of CYP 450, CYP1A2 and CYP3A4, exceed adult 
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levels; then the activity decreases to adult values by puberty. Therefore, children of this 
age group require significantly higher weight-adjusted doses of drugs metabolised by 
these enzymes as compared to adults (G. D. Anderson, 2010). For example, theophylline 
clearance, which is mainly metabolised by CYP1A2, has been shown to be about 50% 
above adult values by five years of age and decreases to adult values by 15 years of age 
(Björkman, 2005). 
This linear (weight-adjusted) extrapolation from adult values can underestimate the drug 
clearance and hence the dose as the relationship between weight and clearance is non-
linear. A more accurate estimation can be obtained by allometric scaling of the clearance 
parameter using a coefficient of 0.75, i.e. bodyweight0.75 is used to scale clearance (B. J. 
Anderson and Holford, 2008). 
The developmental expression of CYP2C9, the enzyme involved in the metabolism of 
the pharmacologically more potent S-warfarin was investigated (Koukouritaki et al., 
2004). The enzyme content and its catalytic activity were found to be 30% of the adult 
levels in foetal samples in the third trimester of pregnancy. The CYP2C9 protein levels 
were significantly higher in neonates and infants of 0-5 months of age, however, they 
were associated with 35-fold inter-individual variation; with 51% of samples showing 
values proportionate to mature levels. The variability in the protein level and catalytic 
activity was less pronounced in the age range 5 months to 18 years with most of the 
samples of 1-2 years possessing the mature protein levels (Koukouritaki et al., 2004). 
D- Elimination  
      The renal excretion of drugs is also subject to developmental changes particularly in 
the first year of life. The glomerular filtration rate (GFR) is low in term neonates, rapidly 
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increases in the first two weeks of life and then steadily increases to approach the adult 
level at 8-12 months (van den Anker, Schwab and Kearns, 2011). A model-based analysis 
of GFR maturation has revealed that GFR approaches half the adult values at 47.7 post-
menstrual weeks, whereas at one year of age the GFR was predicted to be 90% of the 
adult levels (Rhodin et al., 2009). Tubular secretion too is only 20-30% of adult levels at 
birth and only at around 7-8 months of age approaches adult levels (Hines, 2008). 
     The impact of developmental changes on warfarin PK has been investigated in a cross-
sectional study on prepubertal (age 1-11 years), pubertal (age 12-18 years) and adult (age 
37-76 years) patients on long-term warfarin treatment (Takahashi et al., 2000). The mean 
unbound plasma concentration of S-warfarin was comparable in all age groups. Whereas 
the body weight-normalised clearance of S-warfarin in the prepubertal group was 
significantly higher than that in the adult group (18.1 ± 9.2 vs 11.6 ± 5.4 ml/min/kg) and 
showed a negative correlation with age and high inter-individual variability. The weight-
adjusted dose of the prepubertal group was 40% higher than that of the adult group (0.081 
vs 0.058 mg/kg/day). However, clearance normalised to estimated liver weight was not 
different across the three age groups suggesting that liver weight may be a better 
parameter for estimating warfarin dose in children. In contrast, the pubertal group showed 
comparable pharmacokinetics to that of the adult group (Takahashi et al., 2000). 
1.2.6.2. Developmental pharmacodynamics: 
     Pharmacodynamics (PD) describes what the drug does to the body and comprises the 
biological response to the drug. The coagulation system is dynamically evolving and 
maturing throughout childhood, a process known as developmental haemostasis. At birth, 
the levels of most of the haemostatic proteins are approximately 50% of the adult levels 
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and they approach near-adult values by 6 months of life. However, the mean values of 
most of these proteins are 20% lower than that of adults; which is significantly different, 
until late teenage years. A similar developmental pattern was observed for the vitamin K-
dependant coagulant proteins (II, VII, IX, and X) and the anticoagulant proteins (protein 
C and protein S), however, protein C and S still have low levels till late teenage years 
(Andrew et al., 1987; Andrew et al., 1988; Monagle et al., 2006; Andrew et al., 1992; 
APPEL et al., 2012). The functional maturity of the coagulation system in children under 
2 years of age has also been investigated. It was revealed that there were no defects in 
coagulation and that the haemostatic process is functionally intact even in neonates. 
However, the study demonstrated that infants of less than 1 year of age can initiate and 
develop clot faster than adults. The process approaches the adult rate after 1 year of life 
(Miller et al., 1997). In contrast, the bleeding time upper limit of normal was shown to be 
longer in the first 10 years of life and approaching the adult level in the teenage years 
(Andrew et al., 1992).  
The effect of developmental changes on warfarin PD in children has also been 
investigated. It has been shown that the capacity of plasma of children on warfarin 
treatment to generate thrombin (activated factor II) is decreased and delayed as compared 
to adults with similar INR values. This is reflected by a significantly lower concentration 
of prothrombin fragment 1+2 (the endogenous marker for thrombin generation) in 
children as compared to adults (Massicotte et al., 1998) indicating a higher sensitivity to 
warfarin in paediatric patients. Takahashi et al also investigated the developmental 
changes in warfarin PD in his study and it was shown that the prepubertal group had 
significantly lower concentrations of protein C and prothrombin fragment 1+2 and greater 
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INR and INR/dose ratio suggesting greater response to warfarin in this age group 
(Takahashi et al., 2000). 
1.2.7. Influence of genetic polymorphisms on warfarin PKs and PDs: 
        Genetic polymorphisms of genes that encode for proteins involved in warfarin 
metabolism and pharmacodynamics have been shown to contribute to the inter-individual 
variability in warfarin dose requirements and response. Polymorphisms of the gene 
encoding for CYP2C9 and that encoding for VKOR (vitamin K epoxide reductase 
complex subunit 1) have been well-established to affect warfarin PK and PD respectively 
(Takeuchi et al., 2009). 
1.2.7.1. Genetic polymorphisms of CYP2C9: 
     The two most common variant alleles of CYP2C9 that are associated with reduced 
enzyme activity are CYP2C9*2 (Arg144Cys; rs1799853) and CYP2C9*3 (Ile359Leu; 
rs1057910) (Rettie et al., 1994; Haining et al., 1996). The CYP2C9*2 and CYP2C9*3 
genes encode enzymes that are about 12% and 5% as efficient as the wild-type allele 
CYP2C9*1, respectively, leading to reduction in the hepatic clearance of warfarin and 
increase in the plasma concentration of the drug (Zhou, Liu and Chowbay, 2009). The 
allele frequency of CYP2C9 varies among different ethnic groups (Table 1) (PharmGKB, 
2017). As compared to patients with the wild-type (*1/*1) genotype, patients who are 
heterozygous for CYP2C9*2 and CYP2C9*3 (i.e. *1/*2 and *1/*3) require 19.6% and 
33.7% reduction in warfarin dose, respectively (Lindh et al., 2009). In contrast, patients 
who are homozygous of CYP2C9*2 and CYP2C9*3 (i.e. *2/*2 and *3/*3) require 36% 
and 78% reduction in warfarin dose, respectively (Lindh et al., 2009). Moreover, those 
who are compound heterozygotes (i.e. *2/*3) require about 56.7% reduction in dose to 
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achieve the same level of anticoagulation as those of the wild-type allele (Lindh et al., 
2009). In children, Zhang et al. conducted a meta-analysis of 8 studies with a total of 507 
paediatric patients to assess the influence of CYP2C9 polymorphism on warfarin 
maintenance dose requirement. The analysis has shown that CYP2C9*1/*2 allele was 
associated with 15% lower maintenance dose than that of the wild-type (*1/*1), whereas 
the CYP2C9*1/*3 variant allele was associated with 41% lower maintenance dose. 
Additionally, warfarin maintenance doses in carriers of CYP2C9 variants which contain 
at least one variant allele (*2 or *3) were 26% lower than those of the wild-type allele 
(Zhang et al., 2017). 
Table 1. CYP2C9 allele frequency in different ethnic groups.† 
CYP2C9 
allele 
Allele frequency in different ethnic groups (%) 
African African 
American 
Caucasian East Asian South/ 
Central 
Asian 
*1 86.4 86.7 80 96.6 78.9 
*2 2.4 2.3 12.6 0.06 10.7 
*3 1 1.2 7.1 3.4 10.2 
† (PharmGKB, 2017) 
 
 
Additional variant alleles of CYP2C9 that are associated with reduced enzyme activity 
were found to occur almost exclusively in populations of African ancestry and include 
CYP2C9*5, CYP2C9*6, CYP2C9*8 and CYP2C9*11 (PharmGKB, 2017). Carriers of 
these variant alleles were found to require significantly lower warfarin doses than those 
with the wild type allele, CYP2C9*1 (Cavallari et al., 2010). However, there are no 
studies to date that have investigated the effect of these variant alleles on warfarin dose 




1.2.7.2. Genetic polymorphisms of VKORC1: 
         Similarly, several polymorphisms have been identified in VKORC1, the gene 
encoding the enzyme VKOR, and found to be associated with variable warfarin dose 
requirements. These include -1639G>A (rs9923231), 1173C>T (rs9934438), 2255C>T 
(rs2359612), 1542G>C (rs8050894) and -4931T>C (rs7196161) (Rieder et al., 2005). 
The presence of any of these polymorphisms was designated as haplotype A and was 
shown to be associated with reduced expression of VKOR and lower warfarin dose 
(Rieder et al., 2005). The wild-type haplotype which is associated with higher dose 
requirement was designated as B (or G depending on the source of nomenclature) (Rieder 
et al., 2005). These polymorphisms are in strong linkage disequilibrium which means that 
they are inherited almost always together and therefore assessment of any of these 
polymorphisms would be informative about others (Rieder et al., 2005; S. Lee et al., 2006; 
Mushiroda et al., 2006). The most commonly investigated polymorphism is -1639G>A, 
with patients having the GG, GA and AA genotypes referred to as high-, intermediate- 
and low- dose warfarin groups, respectively (Rieder et al., 2005; Yuan et al., 2005; Sconce 
et al., 2005). Patients with the GA genotype require about 25% lower warfarin dose as 
compared with those of the GG genotype; whereas those with the AA genotype require 
about 50% lower dose as compared with the wild-type group (Rieder et al., 2005; Yuan 
et al., 2005; Sconce et al., 2005; Aquilante et al., 2006; Mushiroda et al., 2006; S. Lee et 
al., 2006). Similar findings were obtained in children where carriers of the GA and AA 
genotypes have been shown to require 26% and 50% lower warfarin doses as compared 
to the GG genotype, respectively (Zhang et al., 2015). The VKORC1 -1639G>A allele 
frequency also varies among different ethnic/racial populations. The average allele 
frequency is 88.2% in the East Asian population, 41.2% in Caucasians, 15.3% in the 
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South/Central Asian population, 12.9% in the Africans and 10.3% in the African 
Americans (PharmGKB, 2017).  
1.2.7.3. Other genetic polymorphisms influencing warfarin dose requirements: 
           There are other important genetic polymorphisms that were found to be associated 
with warfarin dose requirements (Johnson et al., 2017). CYP4F2 is an enzyme involved 
in the metabolism of vitamin K (McDonald et al., 2009). The variant allele of CYP4F2 
(Val433Met; rs2108622) is associated with reduced enzyme activity resulting in the 
accumulation of vitamin K and increased warfarin dose requirement in adults (Caldwell 
et al., 2008). The effect of CYP4F2 genetic polymorphism on warfarin dose requirement 
has also been investigated in children. In a study of 37 Japanese children, Hirai et al. have 
shown that genetic polymorphism of CYP4F2 was associated with about 30% increase in 
warfarin dose requirement (Hirai et al., 2013). In contrast, several other studies have 
found no effect of this polymorphism on warfarin dose requirement in children (Biss et 
al., 2012; Hamberg et al., 2014; Moreau et al., 2012; Shaw et al., 2014; Wakamiya et al., 
2016). 
Additionally, a novel genetic polymorphism in the CYP2C enzyme, CYP2Crs12777823, 
has been identified in African-American adults. Carriers of this variant allele were found 
to require reduced warfarin doses (Perera et al., 2013). Yet, there are no studies 






1.2.7.4. The clinical significance of the CYP2C9 and VKORC1 genetic 
polymorphisms on anticoagulation with warfarin: 
    The influence of genetic polymorphisms of CYP2C9 and VKORC1 on anticoagulation 
with warfarin has been extensively investigated in adults particularly during initiation of 
warfarin therapy (Jorgensen et al., 2012). Possession of variant alleles of CYP2C9 and/or 
VKORC1 was shown to be associated with shorter time to therapeutic INR, longer time 
to stable dose, higher frequency of dosage adjustments, increased number of above-range 
INR values, less time in target therapeutic range, increased risk of over anticoagulation 
(INR>4.0) and increased risk of bleeding complications during the first 30-90 days of 
treatment initiation (Limdi et al., 2009; Ozer et al., 2010; Gaikwad et al., 2013; Mega et 
al., 2015). Some investigators have shown the predominant effects of the variant allele of 
VKORC1 during the initiation phase (Lund et al., 2012); whereas others have 
demonstrated that variant alleles of CYP2C9 (particularly CYP2C9*3) have the 
predominant effects on warfarin anticoagulation during initiation (Meckley et al., 2008; 
Ma et al., 2012; Mega et al., 2015). The associated higher risk of bleeding complications 
with variant alleles of CYP2C9 and/or VKORC1 was not only shown during the initiation 
phase of warfarin therapy but also during the maintenance phase. Carriers of variant 
alleles of CYP2C9 and/or VKORC1 were shown to be at increased risk of major bleeding 
complications during initiation, stabilisation and all nonstable periods of anticoagulation 
with warfarin (Limdi et al., 2008; Tomek et al., 2013).  
In contrast, fewer studies were conducted in children to address the clinical significance 
of CYP2C9 and VKORC1 polymorphisms in children during initiation of warfarin 
treatment. Details of these studies’ populations and findings are demonstrated in Table 2. 
Carriers of variant alleles of CYP2C9 or VKORC1 have been shown to attain the target  
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INR range sooner than those with the wild type (Ruud et al., 2008; Shaw et al., 2014). In 
addition, carriers of variant alleles of VKORC1 have also been shown to have shorter 
time to over-anticoagulation (INR>4.0) (Shaw et al., 2014). Moreover, carriers of 
CYP2C9 variant allele have been shown to have more frequent INR values above the 
target range than those of the wild type (Ruud et al., 2008; BISS et al., 2013; Hawcutt et 
al., 2014). Furthermore, possession of VKORC1 variant allele and CYP2C9*3 variant 
allele has been shown to be associated with increased risk of minor and major bleeding 
events, respectively (Hawcutt et al., 2014; Shaw et al., 2014). Interestingly, possession of 
variant allele of VKORC1 has been shown to be associated with greater time spent in the 
target therapeutic range in the first 6 months of therapy (Hawcutt et al., 2014). 
1.2.8. Non-pharmacogenetic factors influencing warfarin PK and PD: 
     There are other factors that can have a significant effect on warfarin PK and PD in 
children. Inter-current illnesses like infections, diarrhoea and vomiting commonly occur 
at high frequency in children. The complex underlying medical conditions, for instance 
CHD, may have a considerable impact on warfarin absorption and metabolism (Monagle, 
Newall and Campbell, 2010).  
Additionally, concurrent use of medications, whether for short- or long-term, may result 
in PK or PD interactions with warfarin. PK interactions include altered absorption, 
induction or inhibition of metabolism and displacement from plasma protein binding 
sites; whereas PD interactions include antagonising or potentiating the pharmacological 
response to warfarin. Examples of drugs that enhance warfarin effect and increase the 
INR include amiodarone, cimetidine, cotrimoxazole, fluconazole and metronidazole  
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Table 2. Characteristics and major findings of studies conducted in children to evaluate the influence of CYP2C9 and VKORC1 
genetic polymorphisms on warfarin anticoagulation. 
Reference  N Male/female 
(n) 
Age, median 









Ruud et al. 
2008 
62 (29 on 
warfarin) 






Not tested Children with heterozygous CYP2C9 
genotype attained the target INR sooner 
and had more frequent above-range INR 
values than those with the wild type.  
Biss et al. 2013 51 39/12  4 (1-17) Caucasian 
(64.7) 










- CYP2C9 variant allele carriers and 
VKORC1 AA allele carriers had 
significantly higher mean peak INR 
during the first week of therapy. 
- CYP2C9 variant allele carriers had 
significantly higher proportion of 
above-range INR values in the first 
month of therapy. 
- VKORC1 AA allele carriers had 
higher proportion of above-range INR 
values in the first month of therapy (not 
statistically significant). 





















- VKORC1 variant allele associated 
with greater time in therapeutic range in 
the first 6 months of therapy. 
- CYP2C9*2 variant allele associated 
with higher proportion of above-range 
INR values in the first week of therapy. 
- VKORC1 variant allele associated 
with increased chance of minor 
bleeding complications. 
Shaw et al. 
2014 

















- VKORC1 genotype had shorter time 
to first therapeutic INR and time to 
over-anticoagulation. 
- CYP2C9*3 genotype had significant 
association with major bleeding events. 
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through inhibition of warfarin metabolism and aspirin and cephalosporins through 
potentiating the anticoagulant response to warfarin. Whereas examples of drugs inhibiting 
warfarin effect and decreasing the INR include cholestyramine that impairs warfarin 
absorption and barbiturates, carbamazepine, phenytoin and rifampicin that induce 
warfarin metabolism (Ronghe, Halsey and Goulden, 2003; Greenblatt and von Moltke, 
2005). The effect of drug interactions which are due to displacement from plasma protein 
binding sites is transient and rarely of clinical significance (Greenblatt and von Moltke, 
2005). 
Furthermore, diet also has a considerable influence on anticoagulation with warfarin. 
High vitamin K-containing diet antagonises the anticoagulant effect of warfarin resulting 
in increased dose requirement or even resistance to warfarin. Infant formulas contain 
vitamin K, hence formula-fed infants tend to be resistant to warfarin as compared to 
breast-fed infants who are usually more sensitive to it (Greenblatt and von Moltke, 2005; 
Biss et al., 2011).  
Moreover, alcohol consumption by adolescents also affects the anticoagulant effect of 
warfarin. Acute alcohol intoxication can inhibit the hepatic microsomal system and hence 
warfarin metabolism and thus potentiate its anticoagulant effect whereas chronic heavy 
alcohol consumption can stimulate the hepatic enzymes and increase warfarin metabolism 
resulting in a decrease in its anticoagulant effect (Hansten and Horn, 2008). Therefore, 
patients are usually advised to restrict alcohol intake to avoid such interactions. 
      Due to the large number of factors and variables that potentially affect the 
anticoagulant efficacy of warfarin, dosing in children is intensely challenging. There is 
large between and within-individual variability in warfarin dosing requirements and 
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treatment with fixed doses of warfarin has been shown to be associated with large inter-
individual variability in response which can affect the quality of anticoagulation. The 
largest cohort study of 319 children treated with warfarin has shown that the proportion 
of INR measurements within the target range was only 47% for the range of 2.0-3.0 and 
61% for the range of 2.5-3.5 (Streif et al., 1999). For a narrow therapeutic range drug like 
warfarin, this can result in either under-anticoagulation with subsequent thrombosis or 
otherwise over-anticoagulation with consequent bleeding. The incidence of major 
bleeding events was shown to be 0.5% per patient year (Streif et al., 1999), with patients 
with mechanical heart valves having a higher incidence of up to 4% per patient year (Rao 
et al., 1989) due to the more intense level of anticoagulation required. Therefore, to 
improve the anticoagulation control of warfarin, it is very important to personalise its 
dosing by understanding the drug’s pharmacokinetics and pharmacodynamics and the 
factors that contribute to its inter- and intra-individual variability. 
1.2.9. Personalising warfarin dosing in children: 
           The current, conventional approach to dosing warfarin in children is to initiate 
doses according to the standard guidelines and then to individualise by adjusting doses 
incrementally according to the INR observations (Monagle et al., 2012; Paediatric 
Formulary Committee., 2016). However, this ‘one-size-fits-all’ approach results in sub-
optimal anticoagulation control and imposes the risk of over- or under-anticoagulation 
(Streif et al., 1999). For this reason, attempts have been made to develop models for 
warfarin dose prediction by considering the demographic and pharmacogenomic factors 
affecting inter-individual variation in an attempt to personalise (individualise) warfarin 




1.2.9.1. Warfarin dose prediction models: 
       Due to the substantial impact of genetic, demographic, clinical and environmental 
factors on warfarin dose requirements (see sections 1.2.6 – 1.2.8), various attempts were 
made to develop dose prediction models that incorporate these factors in order to 
individualise warfarin therapy (Eriksson and Wadelius, 2012). Warfarin dose prediction 
models fall into two categories; linear regression models which are based on multiple 
linear regression analysis and pharmacokinetic/ pharmacodynamic-based (PK/PD-based) 
models which are mechanism-based models (Hamberg and Wadelius, 2014). 
A- Linear regression models: 
     Many studies have been conducted in adults to assess the effect of genetic, 
demographic and clinical factors on inter-individual variability of warfarin maintenance 
dose (Gage et al., 2008; Klein et al., 2009). Linear regression analysis was used in these 
studies to associate these factors with stable warfarin doses and the output was 
represented by equations to predict warfarin maintenance doses in adults. These 
pharmacogenetic-based models explained up to 54% of the variability in warfarin 
maintenance dose requirements (Gage et al., 2008).  
Similarly, several studies were conducted in children to assess the effect of these factors 
on warfarin maintenance dose variability (Nowak-Göttl et al., 2010; Kato et al., 2011; 
Biss et al., 2012; Moreau et al., 2012; Nguyen et al., 2013; Kamal El-Din et al., 2014; 
Shaw et al., 2014; Vear et al., 2014; Wakamiya et al., 2016). The output of these models 
was also represented by equations to estimate warfarin maintenance doses in children. 
The characteristics of children involved in these studies are summarised in Table 3 and 
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details of the predictors of warfarin dose variability assessed in each study together with 
the final equations are summarised in Table 4. 
The number of patients included in these investigations ranged from 37 to 120. The 
models derived from these studies explained 38% (Nowak-Göttl et al., 2010) to 82% 
(Nguyen et al., 2013) of the variability in warfarin maintenance dose requirements in 
children. Genetic polymorphism of CYP2C9 was shown to contribute to 0.4% (Nowak-
Göttl et al., 2010) to 12.8% (Biss et al., 2012) of dose variance, whereas genetic 
polymorphism of VKORC1 was shown to contribute to 3.7% (Nowak-Göttl et al., 2010) 
to 47% (Nguyen et al., 2013) of the dose variance.  
The effect of demographic factors on the variability in warfarin maintenance dose has 
also been investigated. Age was shown to contribute to 12% (Nguyen et al., 2013) to 31% 
(Vear et al., 2014) of dose variability whereas weight was shown to contribute to 52.8% 
of this variability (Shaw et al., 2014). In addition, height was shown to contribute to 
29.8% (Biss et al., 2012) to 48.1% (Moreau et al., 2012) of the dose variance. 
Interestingly, age was found to be the only significant determinant of warfarin dose in 
one study (Kamal El-Din et al., 2014). 
Moreover, the effect of clinical factors on warfarin dose variability has also been 
investigated. The indication for warfarin treatment was shown to contribute to 2.4% 
(Shaw et al., 2014) to 3.2% (Biss et al., 2012) of dose variability. In addition, the target 
INR value was shown to contribute to 4.4% (Moreau et al., 2012) to 18% (Nguyen et al., 
2013) of the dose variability. 
Linear regression models are a standard approach used to describe the relationship 
between a dependant variable, in this case warfarin dose, and explanatory variable(s), in
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Table 3. Characteristics of children involved in the development of the linear regression models. 
 Nowack-Göttl et 
al. 2010 
Kato et al. 
2011 
Biss et al. 
2012 
Moreau et al. 
2012 
Nguyen et al. 
2013 
Shaw et al. 
2014 
Vear et al. 
2014 
Kamal El-Din 
et al. 2014 
Wakamiya et 
al. 2016 
N 59 (34 on 
warfarin) 
48 120 118 (83 on 
warfarin) 
37 93 100 41 45 
Sex: Male/Female 
(n) 
27/32 33/ 15 82/38 46/37 26/11 52/41 46/54 23/18 38/7 
Age, median 
(range), year 
15 (1-19) 6.6* (0.4-
19.3) 
11 (1-18) 8.4* (3 
months-18) 
9.6* (1.8-18.6) 4.8 (2 
months-17.8) 








37.8* (7.6-95) Not reported Not reported 20.8* 24.6 (3.8-55.6) 


























Indication  Thrombosis  Cardiac Mostly 
cardiac 




Mostly cardiac Mostly cardiac 
CYP2C9 genotype (%)  
*1/*1 66.1 98 70 64 73 69.9 67 65.9 100 
*1/*2 18.6 0 14.2 † 19 15 16 12.2 0 
*1/*3 13.6 2 14.2 † 8 12.9 9 14.6 0 
*2/*2 1.7 0 0.8 † 0 2.2 0 0 0 
*2/*3 0 0 0.8 † 0 0 1 4.9 0 
*3/*3 0 0 0 † 0 0 0 2.4 0 
VKORC1 genotype (%) 
-1639G/G or 1173 
C/C 
45.7 2§ 35.8 30 27§ 41.9 32 19.5§ 0§ 
-1639G/A or 
1173C/T 
42.4 19§ 45.8 52 46§ 39.8 54 56.1§ 17.1§ 
-1639A/A or 
1173T/T 
11.9 79§ 18.3 18 27§ 18.3 10 24.4§ 82.9§ 
* Results reported as mean. 
† CYP2C9*2 and *3 heterozygotes, 30.0%, CYP2C9*2 and *3 homozygotes and compound heterozygotes, 6.0%. 
§ VKORC1 genotype test for 1173C>T. 
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Table 4. Linear regression models and the factors describing percentage variability 
in warfarin maintenance dose requirements in children. 
 
this case the genetic and/or non-genetic factors that can explain the variability in warfarin 
dose requirements. The development of the model is relatively rapid and does not require 
a high level of technical expertise with the output being equations that are easy to 
implement in dose prediction. However, these models are only empirical and descriptive 
in nature. They fail to explain the underlying relationship between dose variability and 
the predictors of this variability. In addition, the data in the model are limited to steady 


























et al. 20168 
Demographic factors 
Age  28.3% NA   12%  31%  
Weight   NA    52.8%   




0.4%  12.8% 2% 5% 8.9% 6%  
VKORC1 
genotype 
3.7% NA 26.6% 18.2% 47% 12.2% 13% 27% 
Age*VKORC1       3%  
Clinical factors 
Indication   3.2%   2.4%   
Target INR  NA  4.4% 18%    
Full model 
All predictors 38%  72.4% 69.% 82% 76.3% 53% 78.2% 
1 √Dose (mg/kg/day) = 0.49 - 0.013 (age) - 0.08 (VKORC1AA]) + 0.01 (VKORC1[GA]) - 0.02 
(Cyp2C9). 
2 INR = 1.26 + 6.70 × (dose/weight) × (1 + 0.105 × [age – 6.6]) × 0.523VKORC1. 
3 √dose (mg/day) = - 0.009 + 0.011 (height) + 0.357 (VKORC1) - 0.478 (CYP2C9*3) - 0.277 
(CYP2C9*2) + 0.186 (indication). 
4 Dose (mg/week) = -10.77 + 0.28 x height - 5.44 x number of VKORC1 variant allele(s) +7.83 (if 
target INR of 2.5) or 11.52 (if target INR of 3.3) - 3.29 x number of CYP2C9 variant alleles. 
5 Dose (mg/kg/day) = - 0.090 – 0.00060 x age + 0.11 x VKORC1CC + 0.043 x VKORC1TC + 0.045 x 
CYP2C9*1*1 + 0.039 x CYP2C9*1*2 + 0.073 x Target INR. 
6 √Dose (mg/day) = 1.711 + 0.014 (weight) - 0.257 (number of VKORC1 variant alleles) - 0.127 
(number of CYP2C9*2 alleles) - 0.463 (number of CYP2C9*3 alleles) - 0.161 (indication). 
7 Log dose (mg/day) = 1.098 + 0.027 x Age - 1.124 x VKORC1A/A - 0.733 x VKORC1G/A + 0.345 x 
CYP2C9WT + 0.031 x (Age x VKORC1A/A) + 0.037 x (Age x VKORC1G/A). 
8 √Dose = 0.235 + 0.011 x height – 0.3 VKORC1TT genotype. 
NA predictor was included in the final model but data on the percentage of contribution to variability is not available. 
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response (Hamberg and Wadelius, 2014). In the case of warfarin, there is a time delay 
between the drug exposure and the increase in INR value which is dependent on the half-
lives of the circulating clotting factors (Wittkowsky, 2003). Moreover, linear regression 
models are restricted to the population on which they were developed and can only be 
used for the prediction of warfarin maintenance doses (Hamberg and Wadelius, 2014). 
Yet, during the initiation of warfarin therapy in children, VKORC1 and CYP2C9 
genotypes have been shown to have a significant effect on the anticoagulant response and 
are associated with increased risk of over-anticoagulation and bleeding events (BISS et 
al., 2013; Hawcutt et al., 2014). It could therefore be argued that, to successfully 
personalise warfarin treatment, models should ideally include the prediction of both initial 
and maintenance doses of warfarin (Eriksson and Wadelius, 2012). 
B- Personalising warfarin dosing using population PK/PD models and Bayesian 
forecasting: 
        Bayesian forecasting is a proactive approach to dose individualisation of drugs with 
narrow therapeutic ranges that was first introduced by Sheiner et al. in 1979. The method 
utilises population PK/PD models, incorporating significant covariates that explain the 
inter- and intra-individual variability, to prospectively identify individual’s PK and PD 
parameters and hence individualise dosing (Sheiner et al., 1979).  
The population PK/PD models are developed using population PK/PD data that cover all 
phases of treatment i.e. the initial phase as well as the maintenance phase. The databases 
required for model development are usually complex and need accurate information about 
date and timing of drug administration and sample collection as well as information about 
the amount of drug administered, patients’ demographics and laboratory tests. The 
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population PK/PD models consist of three components: a structural model, a stochastic 
model and a covariate model.  
The structural model describes the PK and PD of the drug. It utilises ‘fixed effects’ 
parameters like clearance (Cl) and volume of distribution (V) for PK and Emax (maximum 
effect) and EC50 (concentration required to produce 50% of maximum effect) for PD. The 
population values of these parameters are called typical values.  
The stochastic model describes the extent of the ‘random effects’ which include the inter-
individual and intra-individual variability. This is very important clinically in adjusting 
the dosing of drugs with narrow therapeutic window and wide variability.  
The covariate model describes the predictors (or covariates) such as demographic, genetic 
or clinical factors that explain the variability in PK and PD (Mould and Upton, 2012).  
In the first step, an individual patient’s PK/PD parameters can be estimated (a priori) 
using the typical PK/PD parameters of the population and the individual patient’s 
covariates (age, weight, genotype. etc.). The parameters can subsequently be refined by 
taking into consideration the patient’s measured drug concentrations taken at any time 
with no need to attain the steady state. The individual PK/PD parameter estimates are 
then used to predict subsequent drug dose (a posteriori) to achieve the required target 
concentration. After the first few observed drug concentrations, the individual parameter 
estimates become patient data driven with less effect from the population parameters 
(Jelliffe et al., 1993). The Bayesian forecasting approach is illustrated in Figure 2. 
The population models provide a very useful tool to investigate the PK and PD of drugs 
in children to ensure the safe and effective use of medicines in this population. The 
models are versatile as they can be used during complex drug dosing regimens, at non-
steady state conditions and when only a limited number of concentration measurements 
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is available (Thomson and Whiting, 1992). Moreover, models developed in adults can be 
extrapolated to children by allometric scaling of body size (weight) and addition of 
maturation function to account for ontogeny of the renal function and drug metabolising 
enzymes (B. J. Anderson and Holford, 2008). This can help to overcome the difficulties 
in conducting clinical trials in children due to the ethical restrictions, limited number of 




Figure 2. The Bayesian forecasting approach. The approach involves developing a population 
PK/PD model using population PK/PD data. A priori (initial) dose for a new patient is estimated 
using the mean population PK/PD parameters and the individual patient’s covariates (age, 
weight, etc.). The parameters can subsequently be refined using the individual’s drug blood 
concentrations taken at non-steady state for a posteriori dose estimation (dose adjustment). 
 





A priori (initial dose) 
estimation 
Blood samples taken 
at non-steady state 





          Population PK/PD models of warfarin dose prediction incorporating 
pharmacogenetic variables have been developed and implemented as a tool for Bayesian 
forecasting. The models describe the exposure-response (or PK-PD) relationship, address 
the inter- and intra-individual variability in PK and PD and account for the time delay 
between warfarin exposure and response (increase in INR). In addition, the population 
models can be extrapolated from one population to another (for instance from adults to 
children), and can be used for the prediction of initial as well as maintenance doses 
(Hamberg and Wadelius, 2014). Bridging from adult PK/PD models to children based on 
pharmacological principles has been used by Hamberg et al (Hamberg et al., 2013) and 
Lala et al (Lala et al., 2013). In both instances, parameters from adult PK/PD models were 
utilised as priors for the derivation of paediatric model by considering the effect of body 
size on clearance and volume of distribution, the established maturation pattern of 
warfarin metabolising enzymes and warfarin mechanism of action. Lee and colleagues 
(2009) utilised a PK/PD model based on the Bayesian approach to aid in optimising 
warfarin dosing in adults. The model included a starting dose nomogram for initial dose 
prediction based on CYP2C9 and VKORC1 genotypes, and a titration scheme for 
maintenance dose revisions based on the measured INR values (J. Lee et al., 2009). The 
model was used to derive a paediatric PK/PD model which included a starting dose 
nomogram based on CYP2C9 and VKORC1 genotypes and body weight and a titration 
scheme for dose adjustments.  
Similarly, Hamberg and colleagues developed a population model in adults that was then 




Figure 3. Development of the Hamberg population model in children from previous models in 
adults. 
 
The original adults’ PK/PD model was developed using data from 150 patients with a 
median age of 71 years. Information on S- and R- warfarin plasma concentrations, INR 
and CYP2C9 and VKORC1 genotypes was used to develop the model. The model 
accounted for the time delay between warfarin exposure and INR response, and S-
warfarin was found to be the only exposure predictor for INR response. Covariates 
(predictors) for the inter-individual variability in S-warfarin clearance were CYP2C9 
genotype and age, whereas VKORC1 was identified as the covariate for the inter-
individual variability in warfarin PD (EC50). The authors emphasised the importance of 
taking these covariates into account to improve the individualisation of warfarin therapy 
during the induction as well as the maintenance phases (Hamberg et al., 2007). This model 
was then updated using data from 1,426 patients with median age of 68 years. The updated 
model was a kinetic-pharmacodynamic (K/PD) model that described the relationship 
between warfarin dose and INR response to overcome the lack of PK data (plasma 
warfarin concentration) which is not routinely measured. Information on dose, age, INR 
and CYP2C9 and VKORC1 genotypes were used to develop the model. The model 
accounted for the time delay between warfarin exposure and INR response and 
characterised variability in k10 (the rate constant which governs the drug elimination) and 
PK/PD model 
in adults 
N = 150 











Evaluated in 64 
children 




EC50. Covariates of variability included age and CYP2C9 genotype on clearance (Cl) and 
VKORC1 genotype on EC50. CYP2C9 was found to account for up to a 4.2-fold 
difference in warfarin maintenance dose, whereas VKORC1 was found to account for up 
to 2.1-fold difference and age to cause about 6% reduction in dose requirement per decade 
(Hamberg et al., 2010).  
This K/PD model was bridged to children by allometric weight scaling of the clearance 
and volume of distribution and the addition of a function to account for the ontogeny of 
the metabolising enzymes. The predictive performance of the bridged model was 
evaluated in a cohort of 49 children treated with warfarin. It has been shown that the 
model was able to predict ideal maintenance doses (within ± 20% of the observed doses) 
in 41% of patients with the percentage increased to 70% when 3 or more INR observations 
were available (Hamberg et al., 2013). The paediatric model has subsequently been 
implemented in a user-friendly, Java-based decision support tool that utilises the patient’s 
age, baseline INR value, target INR range and CYP2C9 and VKORC1 genotypes to 
predict warfarin dose. The tool can be used for the prediction of both a priori (initial) 
doses and a posteriori (maintenance) doses (Hamberg et al., 2015). The tool is available 
free on the website http://www.warfarindoserevision.com.  
1.2.10. Evidence supporting pharmacogenetic-based and model-based warfarin 
dosing 
Due to the substantial evidence supporting the effect of genetic polymorphisms as well 
as the clinical and demographic factors on warfarin PK and PD, current guidelines 
recommend the use of pharmacogenetic-guided dosing algorithms that also incorporate 
the clinical and demographic determinants of warfarin dose variability when estimating 
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warfarin doses for both adults and children (Johnson et al., 2017). The Clinical 
Pharmacogenetics Implementation Consortium guidelines have recommended to use the 
Biss et al. model (Biss et al., 2012) or the Hamberg model (Hamberg et al., 2015) to 
calculate warfarin dose in children of European ancestry if information about CYP2C9*2 
and CYP2C9*3 and VKORC1 genotypes is available (Johnson et al., 2017). 
        Randomised clinical trials have been conducted in adults to evaluate prospectively 
the clinical utility of pharmacogenetic-guided dosing of warfarin. The EU-PACT trial 
involved 455 patients (mean age 67.3 years) starting warfarin therapy for atrial fibrillation 
(72.1%) or deep venous thrombosis (27.9%) (Pirmohamed et al., 2013). The patients were 
randomised to either genotype-based warfarin dosing (n=227) or to standard dosing 
(n=228). The study population was mostly of white ethnicity (more than 98%) and 
patients were genotyped for CYP2C9*2, CYP2C9*3 and VKORC1. The study has 
revealed that genotype-based dosing of warfarin has resulted in a higher proportion of 
time in therapeutic INR range, fewer incidents of over-anticoagulation and shorter time 
to therapeutic INR than the standard dosing approach (Pirmohamed et al., 2013). Also, a 
randomised trial (GIFT trial) was conducted to evaluate the safety and effectiveness of 
genotype-based warfarin dosing as compared with clinical algorithm dosing in 
orthopaedic patients (Gage et al., 2017). The study recruited a total of 1,650 patients 
(mean age 72.1 years) who were randomised to either genotype-based dosing (n=831) or 
clinical algorithm based dosing (n=819). The majority of the study population were of 
White ethnicity (91%) with only about 6.5% of Black ancestry and about 2% of the Asian 
ancestry in both arms of the study. The genotypes tested in the study included CYP2C9*2, 
CYP2C9*3, VKORC1 and CYP4F2. The trial has shown that genotype-based dosing 
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reduced the risk of major bleeding, INR measurements of 4 or more, venous 
thromboembolism and death (Gage et al., 2017). 
The COAG randomised controlled trial involved 1015 patients who were randomised to 
either genotype-based dosing (n=514) or clinical algorithm-based dosing (n=501). 
Twenty seven percent of the study population in each arm were of Black ethnicity. Study 
participants were genotyped for CYP2C9*2, CYP2C9*3 and VKORC1. The study has 
shown non-significant difference in the proportion of time in therapeutic INR range 
between the genotype-based and the clinical algorithms tested in the trial. The proportion 
of time in target therapeutic range in the Black patients was found to be lower in the 
genotype-based group than in the clinically-based group (Kimmel et al., 2013). However, 
it is worth noting that the study did not test the CYP2C9*5, *6, *8 *11 and 
CYP2Crs12777823 genotypes which are more prevalent in the African American 
ancestry which may have led to the inaccurate dosing in this group of patients.    
PK/PD models have also been assessed prospectively in adults. In a clinical trial 
conducted by Perlstein et al. three different pharmacogenetic-based dosing algorithms of 
warfarin were developed and prospectively tested (Perlstein et al., 2012). The first 
algorithm was based on clinical practice guidelines and the published pharmacogenetic 
data of warfarin. The other two algorithms were PK/PD models based on modelling of 
dose, INR and genetic and clinical data. All algorithms were prospectively evaluated, and 
it was shown that the PK/PD models significantly outperformed the clinical algorithm. 
The proportion of time in target therapeutic range was higher, the proportion of out-of-
range INRs was lower, time to first therapeutic INR and stable anticoagulation was 
shorter in patients treated according to the PK/PD algorithms (Perlstein et al., 2012). 
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In contrast, only one prospective clinical trial has been conducted in children to evaluate 
the genotype-guided dosing of warfarin. The study involved 200 Iranian children who 
started warfarin therapy after cardiac surgery for valve replacement or single ventricle 
physiology. The study population was divided according to their consent for genotyping 
into either the genotype-based dosing group (n=50) or the standard dosing group (n=150). 
The mean age and weight for the genotype-based group and the standard-dosing group 
was 11.4 versus 11.0 years and 36.8 versus 34.9kg, respectively (Tabib et al., 2015). The 
algorithm used to predict warfarin doses was the International Warfarin 
Pharmacogenetics Consortium (IWPC) algorithm (Klein et al., 2009) and doses were 
adjusted according to body weight, height and body surface area. The study revealed that 
genotype-guided dosing of warfarin significantly decreased the time to stable dose and 
hospital stay days but found no difference in time to first therapeutic INR, time to over-
anticoagulation and bleeding events (Tabib et al., 2015). Paediatric models were 
compared where model predicted doses were compared with actual doses administered to 
children. The Hamberg model was shown to be superior to other models in predicting 
ideal doses, i.e. predicted doses within 20% of the actual observed doses (Hamberg and 
Wadelius, 2014; Marek et al., 2016). To date however, there have been no prospectively 
conducted studies to evaluate the clinical utility of paediatric PK/PD models of warfarin 
when used in routine clinical practice. 
1.2.11. Adherence to warfarin therapy in children: 
      An important aspect in optimising warfarin therapy in children is adherence to the 
prescribed warfarin regimen. Patients on medical treatment, especially those on long-term 
therapy for chronic illnesses, are usually asked to follow certain regimens to control the 
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underlying disease. This may involve making significant behavioural and lifestyle 
changes that can affect the patient’s adherence to the prescribed regimen.  
     Adherence is defined as the extent of coincidence between a person’s behaviour and 
the medical or health advice in terms of medication, diet or lifestyle. The term compliance 
was originally used, yet as it implies an asymmetric relationship between the patient and 
the physician with a more paternalistic role of the latter, hence the terms adherence or 
concordance are more favoured (Bosworth, Weinberger and Oddone, 2006). Medication 
non-adherence includes not only taking the medications other than as prescribed and the 
premature discontinuation of medications but also not starting the prescribed treatment at 
all (Hugtenburg et al., 2013). Non-adherence to medications can be either unintentional 
due to for instance forgetfulness to take the medicine or misunderstanding of the provided 
instructions or intentional especially in patients with chronic diseases who require long-
term treatment. Unintentional non-adherence is the most common form of non-adherence 
in children (Cheng and Walter, 2006).  
1.2.11.1. Factors contributing to non-adherence in children: 
1- Age:   
        One of the significant determinants of adherence in children is age. Young children 
are often reliant on their parents’ assistance to adhere to take their medications; hence, 
adherence in this age group is dependent on both the parents and the child. In contrast, 
adolescence years are associated with increased socialisation, less dependence on the 
parents and more influence of peers raising the issue of non-adherence (Cheng and 
Walter, 2006). In a review article of medication adherence in adolescents, the rate of 
adherence in this population was shown to be around 50% (Staples and Bravender, 2002). 
In a study of warfarin therapy in children, patients older than 15 years were more likely 
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to have non-therapeutic INR levels because of omitted doses than any other age group 
(Newall et al., 2004).  
2- Family factors: 
        Family factors are another important determinant of adherence in children. This is 
of particular importance in children with chronic illness who are required to adhere to a 
long-term medical regimen that may also need modifications in their lifestyle, for instance 
diet and physical activity. Adherence to such medical regimens requires the assistance of 
the family. Parents who are supportive, flexible, engaged, less critical and good at 
problem resolution can play a pivotal role on their child’s adherence to the medical 
therapy (Fielding and Duff, 1999; Friedrich, Jawad and Miller, 2016). The cohesive 
family environment and team-based management practices to accommodate the needs of 
the child’s medical regimen into the family daily routines can promote adherence to the 
prescribed regimen (Friedrich, Jawad and Miller, 2016; Fiese and Everhart, 2006). 
However, this is more influenced by the child’s age where autonomy-seeking adolescents 
may perceive this support as a threat to their personal freedom leading to poorer 
adherence (Staples and Bravender, 2002; Fiese and Everhart, 2006). Parents’ marital 
status can also have a significant contribution to children’s medical adherence (Fielding 
and Duff, 1999). Single parenthood and marital conflict were shown to be among the 
important risk factors of non-adherence in children with cardiac disease (Ittenbach et al., 
2009).  
3- The socioeconomic status:  
         The socioeconomic status of the family is a further determinant of adherence where 
families from low socioeconomic groups can face difficulties to adhere to medical and 
dietary regimens (Fielding and Duff, 1999). Adolescents with type 1 diabetes mellitus 
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from families from low socioeconomic groups were found to have lower adherence than 
those from families from upper or middle socioeconomic groups (Pereira et al., 2008). 
4- Adjustment and coping:  
         Adjustment and coping of children and families to disease and treatment can also 
affect adherence. Chronic illnesses usually place children and their families at chronic 
stress that can cause emotional and behavioural problems and can lead to non-adherence. 
High levels of coping with stress and adjustment to the diagnosis and treatment is 
essential to enhance adherence (Compas et al., 2012).  
5- Disease/treatment regimen:  
        Adherence can also be affected by the disease and the treatment regimen used. 
Chronic diseases whose regimens require frequent dosing/monitoring and changes in diet 
and physical activity can be associated with lower levels of adherence (Cheng and Walter, 
2006). Disease duration was found to be one of the predictors of adherence in adolescents 
with type 1 diabetes (Pereira et al., 2008). These patients were also found to have low 
adherence rates to diet (15% of patients completely followed the diet advice) and physical 
exercise (33% of patients followed the advice for physical exercise) (Pereira et al., 2008). 
In addition, the acceptability of the medicinal product is another critical determinant of 
adherence. Acceptability is influenced by both patient characteristics, such as age, ability 
to take the medicinal product and disease state, as well as product characteristics, such as 
palatability, swallowability, the required dose and dosing frequency and treatment 
duration (Kozarewicz, 2014). In addition, the acceptability of both patients and health 
care providers is influenced by the quality of medicine for example the use of generic 
medicines compared to the brand (Jacomet et al., 2015). Moreover, the cost of treatment 
is another important determinant of adherence. Treatment price was described as a barrier 
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to adherence by 12% of adolescents with cystic fibrosis (Dziuban et al., 2010). In 
addition, treatment cost includes not only the medication cost but also the cost of 
travelling to perform blood tests required for treatment monitoring. Hospital INR 
monitoring was dissatisfying to patients and parents because it involved travelling costs, 
time off school/work and frequent venepuncture (Duggan, Pearce and Guilbert, 2001). 
6- Relationship with the healthcare provider: 
           The relationship between the patient/parents and the healthcare provider impacts 
adherence significantly. Effective communication that involves building a collaborative 
relationship between the patient/parents and the healthcare provider can significantly 
enhance adherence to the prescribed regimen, which is particularly important in patients 
with chronic conditions. This includes close follow-up of patient/parents, establishing a 
partnership relationship to encourage them to express their beliefs and concerns about the 
disease and treatment and the barriers to adherence, and providing empathy and education 
to enhance their satisfaction and adherence to treatment (Brand, Klok and Kaptein, 2013; 
Croom et al., 2011).  
            As described earlier, warfarin is a narrow therapeutic range drug that requires 
accurate dosing and frequent monitoring of the INR to achieve stable anticoagulation. In 
addition, this drug has many diet- and drug-interactions and can be associated with serious 
adverse events including bleeding and thrombosis that can further complicate the 
treatment. For this reason, children with congenital heart disease who are on lifelong 
warfarin therapy and their families need to adhere to a lifelong regimen to achieve 
adequate warfarin anticoagulation and prevent the occurrence of adverse events. 
Adherence to the warfarin regimen involves taking the prescribed dose and monitoring 
the INR at set times taking into consideration that children often require frequent INR 
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tests and subsequent dose changes, particularly those below one year of age (Streif et al., 
1999). In addition, restricting vitamin K-containing diet, restricting alcohol intake for 
teenagers and being cautious about potential drug interactions and physical activities that 
can predispose to injuries and bleeding are also essential to control warfarin treatment. 
This can add a significant burden both on the patient and the family. 
Adherence to warfarin treatment has been investigated in adults. Non-adherence to taking 
the medication was estimated to be around 21% of patients (Platt et al., 2010). Non-
adherence to warfarin, diet or INR monitoring can lead to non-therapeutic INR values 
and subsequent risk of adverse events. Missed doses, misunderstanding of dosage 
instructions and consumption of varying amounts of vitamin K-containing diet was found 
to be the most common cause of out-of-range INR values (Waterman et al., 2004). Non-
adherence to INR monitoring was found to result in more than 55% of out-of-range INR 
values and about 50% increase in the risk of thromboembolism (Witt et al., 2013). 
Whereas, patients’ and healthcare providers’ perspectives and experiences with warfarin 
treatment in adults have been studied (Bajorek et al., 2006; Dantas et al., 2004; Borg 
Xuereb, Shaw and Lane, 2012; Borg Xuereb, Shaw and Lane, 2016), similar studies of 
adherence to warfarin in children with congenital heart disease is lacking. Adherence 
issues in children are different from those in adults; warfarin chronic use in adult 
population is mostly for older patients who encounter health, behaviour and lifestyle 
issues that are different from those encountered in children and adolescents.  
One study has investigated the impact of warfarin treatment on children with congenital 
heart disease and their parents focusing mainly on INR monitoring in the hospital 
(Duggan, Pearce and Guilbert, 2001). Patients/parents expressed their dissatisfaction with 
hospital monitoring as it involved time off school/work, travelling cost and inconvenience 
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of venepuncture. The participants were also asked about their experience with long-term 
warfarin use. Both children and parents expressed their concerns about the risk of 
bleeding and the responsibility of ensuring regular intake of the medication and keeping 
the INR within the target therapeutic range (Duggan, Pearce and Guilbert, 2001). 
Nevertheless, the experience of children/parents with warfarin treatment is still not fully 
investigated, including the child’s/parents’ involvement in the dosing/monitoring 
process. In addition, the health care providers’ experience in this process has not been 
investigated. 
       Warfarin dose management in children can be intensely challenging because of the 
many factors discussed earlier. Therefore, attempts have been made to develop models 
for managing warfarin dose taking into consideration inter- and intra-individual 
variations. However, these models were never tested clinically on a prospective basis and 
the models’ estimated doses were compared with actual doses administered to patients. 
The current practice in the East Midlands Congenital Heart Centre, Glenfield Hospital, is 
to initiate warfarin treatment with loading doses and then to adjust incrementally 
according to INR observations (Appendix 1) which imposes the risk of fluctuations in 
doses and INR response. Furthermore, the lived experience of children/ families and 
health care providers with warfarin dosing/monitoring process has not previously been 
investigated. 
1.2.12. Aim of the research project: 
           The current, traditional approach to dosing warfarin in post-operative cardiac 
children is to initiate doses according to the BNFC recommendations, and then to 
individualise by adjusting doses incrementally according to the INR observations. The 
aims of this research project are to investigate for the first time the implementation, in 
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routine clinical practice, warfarin dose management using a pharmacokinetic-
pharmacodynamic (PK/PD) model and to explore the views of both patients/parents and 
health care professionals. 
1.2.12.1.  Validation of the Hamberg model:  
       To validate the Hamberg PK/PD model for use in the East Midlands Congenital Heart 
Centre (EMCHC), a retrospective study to assess the accuracy and precision of the model 
in predicting warfarin maintenance doses will be assessed. The data will be collected from 
a cohort of post-operative cardiac children on long-term warfarin treatment. 
1.2.12.2. Prospective clinical study: 
        To prospectively compare warfarin dose management in warfarin-naïve and 
warfarin-established patients using the Hamberg PK/PD model, with the traditional, ‘trial 
and error’ approach. All patients will be genotyped for CYP2C9 and VKORC1 
polymorphisms. 
1.2.12.3. Exploration of Patients/Parents/Health Care Professionals views on 
warfarin 
To explore the lived experience of patients/parents with warfarin dosing/monitoring as 
well as their experience with the new warfarin dosing model. The health care providers’ 
experience with warfarin dosing/monitoring as well as their experience with the new 




     
 





Chapter 2: Methodology  
2.1. Introduction 
         The pharmacogenetic-based warfarin dosing algorithms have, to date, been 
evaluated using two approaches. The first approach is a retrospective evaluation 
comparing the algorithm-predicted doses with the actual doses administered to patients 
on stable therapeutic doses of warfarin (Klein et al., 2009). The second approach involves 
prospective clinical evaluation in randomised clinical trials of patients starting warfarin 
for the first time (Kimmel et al., 2013; Pirmohamed et al., 2013). The paediatric warfarin 
dose prediction models were mostly evaluated using the former approach (Hamberg and 
Wadelius, 2014; Marek et al., 2016) with only one study evaluating pharmacogenetic-
guided warfarin dosing in a prospective clinical trial (Tabib et al., 2015).  
This research project can be separated into three parts. The first was a retrospective 
evaluation of the Hamberg model in a cohort of post-operative cardiac children on long-
term warfarin therapy. The second was a prospective evaluation of the model in two 
groups of post-operative cardiac children. The first group (Group 1) included paediatric 
patients starting warfarin treatment for the first time post-operative congenital heart 
surgery. The second group (Group 2) was a sample of children who had already been 
established on long-term warfarin treatment. In the third and final stage, a subsample of 
patients, from Group 1 and 2, were selected in order to conduct a qualitative study to 
explore experience of patients/parents, together with their doctors and nurses who were 
involved in the regular monitoring and determination of warfarin doses in order to 




2.2. The Hamberg warfarin PK/PD model and personalised dosing software 
operation 
    Before describing the personalised dosing software operation, it is important to 
describe ‘how best’ the model parameters are estimated. Population models that utilise 
the Bayesian forecasting approach provide parameter estimation based on minimizing the 
objective function value (OFV) using maximum likelihood estimation. OFV is a number 
that overall summarises how closely the predicted data match the observations (Mould 
and Upton, 2013). To describe maximum likelihood estimation, a given set of observed 
and predicted data values is assumed. The predicted data values are assumed to have a 
normal distribution with a mean and a standard deviation. The likelihood of the observed 
data is the deviation of the observed data from the centre of this distribution. OFV is 
expressed as the negative sum of the log of the likelihoods (Mould and Upton, 2012). 
Within a particular model, OFV is used to compare parameter values where the lowest 
OFV is associated with the best fit parameters. OFV can also be used to rank the 
goodness-of-fit of different models with the same dataset (Mould and Upton, 2012). 
       As described earlier, the Hamberg PK/PD model (Hamberg et al., 2013), has been 
implemented in a user-friendly, Java-based decision support tool to predict both initial (a 
priori) and maintenance (a posteriori) warfarin doses in children (Hamberg et al., 2015). 
For initial (a priori) dose prediction, data on patient’s age, weight, CYP2C9 and 
VKORC1 genotypes, baseline INR value and target INR range are entered into the 
corresponding fields in the model (Figure 4). The initial dose is estimated using the typical 








covariates (age, weight and CYP2C9 and VKORC1 genotypes). For dose estimation, the 
tool uses the mean of the target INR range as the target INR. For example, if the target 
INR range is 2.0-3.0, the tool will use 2.5 as the target INR to estimate the dose  (Hamberg 
et al., 2015). The output is presented as a text field of the predicted a priori dose in mg/day 
and mg/week as well as a plot of the predicted typical INR curve from the first dose until 
steady state achievement. The plot also depicts the marked target INR range to assist in 
interpreting the predicted INR curve. The text field also shows the equivalent number of 
2.5 mg tablets/week which is an adaptation to Swedish conditions where only 2.5 mg 
tablets are licensed (Hamberg et al., 2015).  
When one or more INR observations are available, the tool can be used to predict the 
adjusted maintenance dose. The process of predicting the maintenance (a posteriori) dose 
includes two steps. In the first step, each patient’s data including demographics, CYP2C9 
Figure 4. Example of initial (a priori) dose prediction. This figure shows an example of initial (a 
priori) dose prediction of a 6.0-year-old child, with 16-kg bodyweight, CYP2C9*1/*1 and VKORC1 
G/G genotypes, target INR range of 2.0-3.0 and baseline INR value of 1.4. The predicted initial dose is 
2.18 mg/day, 15.26mg/week. The plot depicts the predicted typical INR curve starting from the first dose 
until steady state attainment. 
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and VKORC1 genotypes, warfarin doses and the corresponding INR observations and 
times of dosing and blood sampling for INR tests is entered into the model to estimate 







The model parameters include K10, the rate constant which governs the drug elimination 
and EC50, the concentration required to produce 50% of the maximum effect. When more 
INR observations are obtained, the individual model parameter estimates are refined and 
become specific to the individual patient which helps to increase the accuracy and 
precision of the dose predicted. The individual patients’ data can be either entered 
Figure 5. Example of data input into the model. The patient’s demographic data and data of warfarin 
dosing, INR observations and timing of dose administration and blood sampling for INR tests are imported 
from the patient’s Excel file. The genotype data of CYP2C9 and VKORC1 are input as “missing” in the 
related fields as they were not available. The baseline INR value is set at 1.0 for all patients. By pressing 
the “Estimate” button, the model will estimate the individual parameter estimates of the patient. 
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manually or imported from individual patients’ Excel files that have specific requirements 
of file naming and data format (Hamberg et al., 2015). If genotype information of 
CYP2C9 and VKORC1 is not available, it can be entered as “missing” in the 
corresponding fields in the model. If the baseline INR value is not available, it can be set 
at the default value of 1.0. The output is presented in a new screen (Figure 6) of two fields; 
a text field showing the typical (mean) and the individual parameter estimates of K10 and 
EC50, and a plot of the predicted INR curves of the population (black curve) and the 
individual (red curve). The observed INR values of the patient are also shown in the plot 






Figure 6. Example of individual patient’s parameter estimation. The model output shows the typical 
and individual parameter estimates of K10 and EC50. It also shows the predicted INR curves of the 
population (black) and the patient (red) as well as the patient’s actual IR observations. 
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In the second step, the individual patient’s maintenance dose is predicted utilising the 
individual patient’s parameters (Figure 7). The output is presented as a text field 
displaying the predicted maintenance dose in mg per day and mg per week as well as the 
equivalent number of 2.5 mg tablets per week, an adaptation to Swedish conditions where 
only 2.5 mg tablets are licensed. The output also includes a plot of the patient’s predicted 
INR curve after the administration of the predicted dose and the target therapeutic range 








Figure 7. Example of a posteriori (maintenance) dose prediction. This figure shows an example of 
maintenance dose prediction of a 5.6-year-old child, with 13.9 kg body weight, target INR range of 2.0-
3.0 and baseline INR value of 1.0. Dose prediction is made using the estimated individual parameters in 
Figure 4. The predicted maintenance dose is 2.88 mg/day, 20.16 mg/week. The plot depicts the 




2.3.Validation of the Hamberg PK/PD model 
2.3.1. Aim of the study 
The aim of the study was to validate the use of the Hamberg model in routine clinical 
practice at the EMCHC by assessing its accuracy and precision in predicting warfarin 
maintenance doses using retrospectively collected data from an existing cohort of post-
operative cardiac children on long-term warfarin treatment. 
2.3.2. Study subjects 
Children below the age of 18 years who were currently receiving warfarin treatment at 
the EMCHC in Glenfield hospital, Leicester were included in the assessment. Eligible 
study subjects were identified from the EMCHC database at Glenfield hospital. 
2.3.3. Data collection  
Demography and retrospective, longitudinal warfarin prescription data was collected 
from the patients’ medical records and INR monitoring charts. The data collected 
included date of birth, gender, ethnicity, weight, indication of warfarin, target INR range, 
date warfarin started, warfarin doses and the corresponding INR observations.  
Ethical approval to use this data was not required because this study was conducted as an 
audit under the supervision of the clinical supervisor, who is a member of the direct care 
team, as well as the direct care team. 
2.3.4. Assessment of warfarin maintenance dose prediction 
The Java-based warfarin dosing model version 1.0.1 (Hamberg et al., 2015)  was used to 
predict each individual patient’s warfarin maintenance doses that were then compared to 
the actual doses prescribed by the doctors. The assessment was conducted during the 
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period children were observed to have stable maintenance warfarin dosing. The period of 
stable warfarin treatment was defined as at least three consecutive INR measurements in 
the target therapeutic INR range over a period of at least four weeks with no change in 
warfarin dose (Hamberg et al., 2013).  
Excel files that have specific requirements of file naming and data format (Hamberg et 
al., 2015) were initiated for each individual patient. These files contained data about 
patient’s weight, warfarin doses and the corresponding INR observations and times of 
dosing and blood sampling for INR tests from the first day of warfarin therapy up to the 
first stable treatment period. These data were used for the estimation of individual 
patient’s model parameters and subsequent dose prediction as described in section 2.2. 
The predicted daily maintenance dose was then compared with the actual observed daily 
maintenance dose that was prescribed by the doctors. When the prescribed dose was 
alternating, for e.g. 1 and 1.5 mg, the average daily maintenance dose was used, i.e. 1.25 
mg. 
2.3.5. Statistical analysis 
Statistical analysis was conducted using Excel (Microsoft Corp., 2010) and SPSS (IBM 
Corp., 2013). The demographic and clinical characteristics of the study population were 
reported descriptively. Model accuracy was evaluated by calculating the difference 
between model predicted and observed doses, and the results were expressed as prediction 
error (PE): 






The bias (mean PE) and precision (root mean squared error) were also calculated. Clinical 
accuracy was evaluated by calculating the percentage of patients in which the model 
predicted dose was ideal (within 20% of the observed dose), under-predicted (at least 20% 
below the observed dose) or over-predicted (at least 20% above the observed dose) 
(Hamberg et al., 2013). The associations between continuous variables and the observed 
warfarin dose were assessed using Spearman’s correlation. The associations between 
categorical variables and the observed warfarin dose were assessed using Mann-Whitney 
U test and Kruskal-Wallis test. A p-value of less than 0.05 was considered to be 
statistically significant.  
2.4.  The prospective clinical study 
2.4.1.  Aim of the prospective clinical study 
The aim of the prospective clinical study was to compare warfarin dose management 
using the Hamberg PK/PD based model with the traditional, ‘trial and error’ approach.  
2.4.2.  Objectives of the prospective clinical study 
    The study objectives were first to compare the performance of the Hamberg PK/PD 
warfarin model estimated dosing with the traditional ‘trial and error’, protocol guided-
adjustments approach to dosing in post-operative cardiac surgical children. The second 
study objective was to assess the incidence of warfarin-related minor bleeding events. 
2.4.3.  Study design  
      A prospective interventional quantitative study was conducted to assess warfarin 
dosing using the Hamberg PK/PD model in two groups of post-operative cardiac surgical 
children.  
Group 1 included patients who had just started warfarin treatment for the first time after 
cardiac surgery, thus they were considered warfarin naïve patients. In this group, initial 
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and maintenance warfarin doses were estimated using the model over a 6 month duration 
and compared to historical case-matched controls dosed according to the traditional ‘trial 
and error’ approach. The historical control design was adopted in this group as there is 
only a limited number of children presenting for cardiac surgery who are eligible for post-
operative oral anticoagulation with warfarin. These include children presented for Fontan 
procedure or replacement of the mitral or aortic valves and their number can be as low as 
one patient presented for surgery per month. Therefore, such type of study design would 
reduce the time required to accomplish recruitment of participants (Friedman, Furberg 
and DeMets, 1998).  
Group 2 patients (Figure 8) included children who were established on maintenance 
warfarin therapy. These patients entered a randomised crossover study comparing model-
estimated dose adjustments with the traditional approach, over a 12-month period. No 
washout period was included in this study as these patients should be maintained on the 
recommended level of anticoagulation. Warfarin treatment could not be stopped unless it 
was otherwise recommended by the doctors prior to undergoing certain procedures like 
cardiac catheterisation or dental procedures where warfarin treatment should be stopped 
a few days before the procedure and resumed immediately after it. The crossover study 
design was considered to be advantageous for the present study because of several 
reasons. First, each patient serves as his/her own control which allows a within-patient 
comparison of treatment interventions, thus it helps to reduce inter-individual variability 
in response. In addition, a smaller sample size, in comparison with parallel design, can be 
used to detect statistically significant differences in treatment response and also gives the 
best unbiased estimations of the differences between treatments (Friedman, Furberg and 
DeMets, 1998; Chow and Liu, 2014).  
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This study was a reality research project conducted at the EMCHC where patients were 
maintained on different dosage forms of warfarin including different generic warfarin 
tablets and warfarin suspension. Warfarin has almost complete bioavailability after oral, 
rectal and intravenous administration (Hogg and Weitz, 2018). In addition, 
bioequivalence should be demonstrated for the different generics and formulations of a 





2.4.4. Study participants 
       Eligible participants for the study were children from birth to 18 years who are under 
the care of the EMCHC at Glenfield Hospital, Leicester. Eligible participants for Group 
1 were identified pre-operatively during the pre-operative clinic visits or from the weekly 
surgical lists of patients to be admitted for cardiac surgery. However, there was one 







  Doctor phase 
Maintenance 
dose estimated 




by the model 




by the model 
  Doctor phase 
Maintenance 
dose estimated 
by the doctors  
Figure 8. Design of the randomised, open label, two-period, cross-over study of Group 2 
patients. Patients were randomised to either the Model phase or the Doctor phase and followed 
up for 6 months in each phase. They were then crossed-over to the alternative phase and followed 
up for further 6 months. 
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Therefore, the patient was identified post-operatively in the intensive care unit. The 
control patients were identified from the EMCHC database based on age, indication for 
warfarin therapy and target INR range. For Group 2, eligible participants were identified 
from the EMCHC database. They were first approached by one of the cardiac liaison 
nursing team either during the regular phone calls to report the scheduled INR 
measurements or during the scheduled follow up hospital visits. 
2.4.4.1. Inclusion criteria 
     The inclusion criteria included children from birth to 18 years with congenital heart 
disease who had been treated or would be treated with warfarin after undergoing 
reconstructive heart surgery.  
2.4.4.2. Exclusion criteria 
The exclusion criteria included patients aged over 18 years who were treated as adults, 
children who refused assent and parents who refused consent and any significant disease 
which, in the opinion of the direct care team, might either put the participant at risk 
because of study participation or adversely affect the participants’ ability to participate in 
the study. 
2.4.5. Study outcomes 
     The outcome measure of the study was to assess the difference between the model-
based and traditional warfarin dosing approaches in:  
Group 1: 
1. Time taken to achieve first therapeutic INR. 
2. Time taken to achieve stable anticoagulation.  
3. Time taken to over-anticoagulation. 
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Group 1 and Group 2: 
1.  The percentage of INR measurements within the target therapeutic range (%ITR). 
2. Percentage of time in target therapeutic range (%TTR). 
3. Frequency of INR measurements expressed as the number of INR measurements per 
month per patient. 
4. Frequency of dose alterations. 
5. Number of INR values ≥4.0 and ≥ 5.0. 
6. The incidence of warfarin-related minor bleeding events. 
Stable anticoagulation was defined as at least three consecutive INR measurements in the 
target therapeutic range (TTR) over a minimum period of four weeks with no change in 
warfarin dose (Hamberg et al., 2013). The percentage of time in therapeutic range 
(%TTR) was determined by linear interpolation (Rosendaal et al., 1993).  
2.4.6. Rationale for the chosen study outcomes 
       Several outcomes have been used as measures to assess the quality of oral 
anticoagulation. The most commonly used surrogate of the safety and efficacy of warfarin 
therapy is time in therapeutic range. In children, this has been reported either as the 
percentage of INR values within the therapeutic range (%ITR) (Streif et al., 1999) or 
alternatively as percentage of time in therapeutic range (%TTR) estimated by linear 
interpolation approach (Rosendaal et al., 1993; Bauman et al., 2010). The former 
measure, %ITR, is easy to calculate; however, it underestimates the time in therapeutic 
range, particularly in the periods of instability during which the INR is tested more 
frequently for dose adjustment. On the other hand, the linear interpolation approach 
allocates an INR value for each day between subsequent INR tests and thus is more likely 
to decrease the impact of multiple out-of-range INR values during unstable periods. At 
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the same time, it gives more importance to the longer stable periods of less INR tests. 
Nevertheless, this approach also has its own limitations. It involves more complex 
calculations to estimate time in therapeutic range, it assumes a linear change of INR 
between each time point which may not be true and it can be biased by INR values that 
are far outside the target range (BISS et al., 2011). Therefore, both approaches were used 
to estimate time in therapeutic range in the current study. 
Other outcome measures that are commonly used to assess anticoagulation control 
include dosing requirements, time to first therapeutic INR, number of INR tests (per 
patient per month), number of dose changes (per patient per month), INR values above 
the target therapeutic range and the incidence of warfarin-related adverse events (Streif 
et al., 1999; BISS et al., 2013). These outcomes were also included in the present study. 
2.4.7. Regulatory and ethical considerations 
2.4.7.1. Ethical approvals  
       Conducting any research that involves human subjects requires that the study 
protocol be reviewed and approved by an independent research ethics committee. 
Therefore, in accordance with De Montfort University’s research ethics guidelines, the 
study protocol was submitted to the Ethics Committee of the Faculty of Health and Life 
Sciences at De Montfort University and approval was granted in 25/03/2015 (Reference 
number 1527). As the research involved patients under the NHS care, the regional ethics 
committee approval and the University Hospitals of Leicester (UHL) approval were also 
required. Hence, the study protocol was submitted to East Midlands – Nottingham 1 
Research Ethics Committee and approval was obtained in 16/09/2015 (Reference number 
15/EM/0325). The ethical approval of the Research and Innovation Office at the UHL 
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was subsequently obtained in 14/10/2015 (Reference number UHL 11438) after which 
the study commenced (Appendix 2).  
2.4.7.2. Informed consent 
     Before children’s participation in the study, their parents/legal guardians were asked 
to give written informed consent to participation. Children over 12 years of age were also 
asked to provide written informed assent before their participation in the study. 
2.4.7.3. Ethical issues  
   This study involved the evaluation of a new PK/PD based model of warfarin dosing in 
children. The main ethical issues relating to this study were that children would be 
subjected to a warfarin dose estimation model that had not been tested in routine clinical 
practice. Therefore, any unforeseen risks of under- or over-dosing were mitigated by the 
following measures. First, all model-estimated doses were reviewed and then prescribed 
by a member of the paediatric cardiology medical team. Second, prescribers were free to 
override model-estimated doses and select an alternative dose. Third, regular INR 
monitoring would identify over- or under-anticoagulation. 
2.4.8.  Study procedures 
2.4.8.1. The process of warfarin dosing/monitoring at the EMCHC in Glenfield 
hospital 
   Warfarin treatment usually starts 2-3 days post-operatively depending on the patient’s 
general condition. During their hospital stay, parents and patients, if old enough, receive 
information about warfarin including the dosing, monitoring, adverse events and drug and 
food interactions. After discharge from the hospital warfarin monitoring is performed 
mostly using home INR monitoring machines apart from some families where the INR 
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monitoring is performed in the hospital. Families who use the home monitoring machines 
telephone the cardiac liaison nursing (CLN) team at Glenfield hospital with the INR test 
result together with information about any intercurrent illness and/or medication use that 
may affect the anticoagulation stability. The CLN team then transfers this information 
into the patient’s INR charts which are subsequently transferred to the doctors who 
prescribe the next warfarin dose and INR test schedule. The INR test results for patients 
who perform their INR tests in the hospital are also transferred into their INR charts and 
provided to the doctors for warfarin prescription. The CLN team then telephone the 
families back with the next warfarin dose and INR test schedule. This process is 
performed by the nurses on the children’s ward when families telephone the INR test 
results or come to the hospital to perform the INR test out of the workday hours. 
Therefore, the hospital visits of patients on home INR monitoring is infrequent, usually 
every 3-6 months. This has affected the consent process of Group 2 patients as will be 
described in the next section. 
During the study, the families reported the INR test results as described earlier. The nurses 
then telephoned these results to the researcher to adjust warfarin dose and telephone it 
back to the nurses. 
2.4.8.2. The consent process 
   For Group 1 patients, participant information sheets were provided to the parents to 
consider participation in the study. Written informed consent was obtained either pre-
operatively, on the day of admission, or post-operatively prior to commencing warfarin 
treatment. 
For Group 2 patients, because of the infrequent hospital visits of these patients, study 
packages were posted by the researcher to the families. These packages contained 
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participant information sheets and blank consent forms for the parents and participant 
information sheets and blank assent forms for patients older than 12 years. Subsequent 
phone calls were arranged by the researcher to discuss the study with the families who 
were asked to sign the consent/assent forms, if they were interested to participate, and 
post them back to the research team. 
Consent and assent forms for Group 1 and Group 2 participants are demonstrated in 
Appendix 3. 
2.4.8.3. Randomisation of Group 2 patients 
      The randomisation of Group 2 patients was performed using the envelopes method. 
Fifteen paper slips were labelled (A→B) for patients to be randomised to the Doctor phase 
and 15 others were labelled as (B→A) for those to be randomised to the Model phase. An 
independent person was asked to randomly allocate the paper slips into 30 consecutively 
numbered envelopes and seal them. The envelopes were then consecutively allocated to 
patients enrolled in the study. 
2.4.8.4. Mouth swab and genetic test 
     Mouth swabs for genotyping of CYP2C9 and VKORC1 were obtained from Group 1 
patients either pre-operatively or post-operatively prior to the initiation of warfarin 
treatment. For Group 2 patients, mouth swabs were obtained on the day of their hospital 
visits. Genetic testing was performed using a point of care genotype testing instrument, 
the ParaDNA® (from LGC). This instrument is a rapid Polymerase Chain Reaction (PCR) 
thermal cycler that uses the HyBecon® probes (Howard et al., 2011) to genotype 
CYP2C9*2, CYP2C9*3 and VKORC1 -1639G>A in less than one hour. The samples 
were obtained from the patients and were then transferred to ParaDNA® instrument for 
target DNA sequence amplification by PCR and detection by melting curve analysis 
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(Figure 9). The ParaDNA® analysis software (version 2.0) reports CYP2C9*2, 
CYP2C9*3 and VKORC1 genotypes based on duplicated test results. The software also 
enables the user to view the melting curve data to determine how a particular genotype 






A- B- C- 
D- E- 
Figure 9†. Example of the genotyping process of CYP2C9*2 and *3 and VKORC1. (A) The 
buccal sample is obtained by swabbing the inside of each cheek for 15 seconds. (B) The buccal 
swab is sub-sampled into the ParaDNA® Sample Collector (C) The Sample Collector is inserted 
into the ParaDNA® reaction plate (D) The reaction plate is inserted into the ParaDNA® instrument 
for the PCR which takes 45 minutes to complete (E) The sample genotype result is shown after 
the reaction is complete. 
†Picture A was obtained from Isohelix® website available at 
http://www.isohelix.com/products/isohelix-dna-buccal-swabs/.  Pictures B through E were 








2.4.8.5.Warfarin dose estimation 
          After obtaining the genotyping results of Group 1 patients, initial warfarin doses 
were estimated using the warfarin dosing model as described earlier in section 2.2. The 
model predicted doses were then rounded to practical doses for convenient administration 
to the patient according to the dosage forms available (0.5 mg, 1.0 mg, 3.0 mg and 5.0 
mg tablets and 5.0 mg/5.0ml suspension) (Appendix 4). The practical doses were then 
reviewed and prescribed by the doctors before administration to the patients. Excel files 
were created for each individual patient and they were updated after every INR feedback 
for the estimation of individual patient’s parameters and subsequent prediction of the 
tailored maintenance (a posteriori) dose (section 2.2). The individual fits of the predicted 
A- 
B- 
Figure 10†. Example of melting curve data.  A- A homozygote *1/*1 confident call. B- A call 
with uncertainty  
The bar charts on the left represent the tests that should be passed for the call to be confident. The 
red lines represent a threshold value and the yellow bands represent areas of uncertainty. 
† Picture A was obtained from the LGC ParaDNA® User Guide after permission. Picture B is the 
genotype call of one of the study participants. 
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INR curves (Figure 5) were assessed. It was sometimes necessary to exclude some INR 
observations, particularly those that are far above or below the target range, to get the best 
fit curve for more accurate dose adjustment.  
For Group 2 patients who were allocated to the Model phase, Excel files were created for 
each patient using the last two-months history of warfarin dosing/INR monitoring. This 
data was used for the prediction of individual patients’ parameter estimates and 
subsequently, maintenance doses (section 2.2). In case of stable patients where the INR 
tests were infrequent, for example once every 3 to 4 weeks, at least 3 to 5 INR test results 
were initially used. The Excel files were updated after every INR feedback was obtained 
from the patients for the estimation of individual patient’s parameters and subsequent 
dose adjustments. The model estimated doses were also rounded to practical doses 
(Appendix 4) which were then reviewed and prescribed by the doctors. Genetic testing 
was not required in this group to estimate warfarin maintenance doses as the model is 
capable of predicting the phenotype based on the previous warfarin doses and INR values 
of the patient. However, the genotyping results were used in the final analysis to gain a 
better understanding of warfarin doses and INR responses in this population. 
Warfarin dosing for the control subjects of Group 1 patients and during the Doctor phase 
for Group 2 patients were prescribed by the doctors according to the usual clinical practice 
at the EMCHC in Glenfield hospital (Appendix 1). 
2.4.8.6. Symptom diary cards 
     Symptom diary cards were provided to parents of Group 1 patients during their 
hospital stay. The symptom diary cards were posted to parents of Group 2 patients after 
the signed consent/assent forms were received. The parents were asked to record any 
minor bleeding events which included bruising, nose bleeds, bleeding gums or the 
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presence of blood in vomit, cough, urine and faeces. The parents were also asked to record 
the start/end date and time of the bleeding episodes. In addition, they were asked to record 
the action taken to deal with these events whether there was no action required, telephone 
advice was sought, GP was contacted, or hospital appointment/admission was required. 
At the end of their enrolment in the study, the parents were asked to send the symptom 
diary cards back to the research team.  
2.4.8.7. Study duration 
    The follow up period for Group 1 patients was 6 months. The study outcomes were 
then compared to historical case matched controls. Cases were matched according to age 
(± 1.0 year), indication and target INR range. 
For Group 2 patients, the follow up period was 6 months in each phase of treatment, i.e. 
a total period of 12 months. The study outcomes were then compared between the two 
phases of treatment. 
2.4.9. Statistical analysis 
2.4.9.1. Sample size estimate 
     The sample size for the Group 1 was based on clinical practicalities, depending on the 
number of patients admitted for surgery, and study feasibility within a reasonable time 
frame. Hence, for Group1, approximately 10 subjects were estimated to be recruited over 
a 12-month period.  
Sample size for Group 2 was estimated using the method described by Julious et al for 
paired continuous data (Julious, Campbell and Altman, 1999). The primary outcome 
measure, proportion of observed INR measurements within the therapeutic range, has 
been utilised. The mean (standard deviation SD) of the proportion of INR measurements 
within the therapeutic range for the existing database of children at Glenfield hospital was 
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determined to be 54.06% (16.85). Based on a clinically relevant effect size (difference 
between model-based and traditional method) of 11% (to increase the proportion of 
within-range INR measurements to 65%), a standardised effect size (computed using the 
SD estimate from the existing database) was derived. Hence for 80% power and two-
sided 5% significance level, a sample size of 25 was estimated. To allow for some patients 
dropping out, a total of 30 patients were to be recruited. 
2.4.9.2. Data analysis 
      Data analysis was performed using Excel (Microsoft Corp., 2010) and SPSS (IBM 
Corp., 2013). For Group 1 patients, the characteristics of the study population and the 
study outcomes were summarised using descriptive statistics as the sample size was very 
small. For Group 2 patients, the characteristics of the study population were summarised 
using descriptive statistics. The continuous variables were described as mean (SD) and 
range for normally distributed data or median and range for data that was not normally 
distributed. The categorical variables were described as numbers and percentages.  
Comparison of the study outcomes between the Model phase and the Doctor phase was 
performed using paired sample t-test or Wilcoxon test as appropriate. Sensitivity analysis 
was performed to compare the %ITR and %TTR between the two treatment phases by 
taking into account the effect of covariates. The covariates included age, weight, 
indication, target INR range, CYP2C9 genotype, VKORC1 genotype and dosage form 
used. Therefore, patients were sub-grouped based on these covariates and comparisons 
were performed accordingly. A Forest plot was used to depict the results of the sensitivity 
analysis of %TTR for the age, indication and VKORC1 genotype sub-groups and %ITR 
for CYP2C9 genotype sub-group (because %TTR data for CYP2C9 genotype sub-group 
was not normally distributed). In addition, sensitivity analysis was performed to compare 
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the number of dose changes and over-anticoagulation (INR ≥ 4.0 and INR ≥ 5.0) between 
the two treatment phases by taking into account the effect of indication and target INR 
range. The patients were sub-grouped based on these covariates and comparison was 
performed accordingly. The sensitivity analyses were performed using paired sample t-
test or Wilcoxon test as appropriate.  
The effect of genetic and non-genetic variables on warfarin daily dose requirement and 
time in therapeutic range, measured as %ITR and %TTR, was also evaluated. The 
variables included age groups, gender, ethnicity, indication of warfarin, target INR range, 
CYP2C9 genotype and VKORC1 genotype. The evaluation was performed using 
independent sample t-test, Mann-Whitney test, analysis of variance (ANOVA) or 
Kruskal-Wallis test as appropriate.  
A p-value of less than 0.05 was considered to be significant. 
2.5. The qualitative study: Exploration of the experience of patients/parents and 
health care professionals of warfarin treatment and the new dosing approach 
2.5.1. Aim of the qualitative study 
       The aim of the qualitative study was to explore the experience of children, parents 
and health care professionals about managing warfarin therapy as well as their views of 
the new warfarin dosing method. 
2.5.2. Objectives of the qualitative study 
      The objective of the qualitative study was to explore the lived experience of patients, 
parents and health care professionals with respect to dosing and monitoring of warfarin 
therapy. The second study objective was to assess the perceived acceptability of using the 




2.5.3. Study design 
       Qualitative research approaches have been widely used in health research to gain an 
in-depth understanding of health, health behaviour and health services. Obtaining a 
thorough understanding of the human behaviour and the causes, attitudes and incentives 
of that behaviour can help to enhance health and health services (Green and Thorogood, 
2014). The interpretative phenomenological approach was adopted as it involves studying 
the human experience and how people make sense of their life world (Langdridge, 2007). 
Interpretative Phenomenological Analysis (IPA) is an idiographic approach that is 
concerned with the in-depth examination of lived experience and usually involves 
studying small homogenous samples of individuals who share a particular experience 
(Smith, Flowers and Larkin, 2009). This would enable the lived experience of being 
involved in warfarin dosing and monitoring to be described and understood from the 
perspective of key stakeholders; patients, parents and health care professionals. 
Stakeholders’ perceived value of the new warfarin dosing method was also appraised.  
2.5.4. Study participants  
       Eligible participants for the qualitative study were patients older than 12 years and/or 
parents of children on long-term warfarin treatment. Also, doctors and nurses who were 
involved in the process of warfarin dosing/monitoring at the EMCHC at Glenfield 
hospital were eligible. 
The inclusion criteria were children older than 12 years who had been treated with 






2.5.5. Outcome measures 
       The qualitative study aimed at exploring two outcomes. First, the experience of 
medical and nursing staff when managing warfarin therapy in children and their 
perceptions of the value of the model-based warfarin dosing. Second, patients’ and/or 
parents’ lived experience of managing warfarin therapy and their experience of using the 
model-based warfarin dosing. 
2.5.5.1. Rationale for the study outcomes 
       In order to ensure the safe and effective use of warfarin and enhance adherence to its 
therapy, it is pivotal to obtain an insight into the experience of both the health care 
professionals and patients/carers with warfarin treatment. Exploring the experiences of 
doctors, nurses, patients/carers with warfarin prescribing and monitoring has been used 
in adult patients to get an in-depth understanding of the attitudes about warfarin therapy, 
the barriers encountered in the process of warfarin prescribing and monitoring, the 
individual role in this process and the best strategies to improve warfarin use (Bajorek et 
al., 2006; Bajorek et al., 2007; Stafford et al., 2012). Thus, it is essential to explore the 
experience of the key stakeholders of warfarin therapy in children where the treatment is 
intensely challenging.  
2.5.6. Study procedures 
2.5.6.1. Informed consent  
      The written informed consent/assent of patients/parents for the qualitative study was 
obtained as part of their consent/assent for participation in the prospective clinical study. 
Health care professionals were also asked to provide written informed consent prior to 
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their participation in the qualitative study. The consent form of health care professionals 
is demonstrated in Appendix 3. 
2.5.6.2. Data collection 
       To achieve the objectives of the study, in-depth semi-structured interviews were 
chosen as the data collection approach with representatives from all the key stakeholders. 
Interviews were chosen because they enable the exploration of the participants’ 
perceptions, feelings, beliefs, attitudes and experiences with the topic under investigation 
(Holloway and Wheeler, 2010). Semi-structured interviews are widely used in qualitative 
research (Holloway and Wheeler, 2010). The interview questions are relatively few and 
specific, focusing on the principal areas required to be explored. The researcher, however, 
can further explore these areas by prompting the participants for more elaboration to 
obtain a better understanding of the issues under investigation. The order of questions is 
not the same for every interview and depends on the responses of participants. The 
interview questions (and prompts) are contained in an interview guide which helps the 
researcher to collect similar data from all participants (Holloway and Wheeler, 2010).  
2.5.6.3. Sampling and sample size 
        The sampling method adopted in recruiting participants was purposive. This is the 
most commonly used method of sampling in qualitative research that involves selecting 
participants that are more likely to generate detailed rich data depending on the topic 
under research and the practicalities of the research (Green and Thorogood, 2014). IPA 
aims at selecting participants on the basis that they can provide a particular perspective 
of the investigated phenomena (Smith, Flowers and Larkin, 2009). The perspectives of 
parents of children, teenager patients receiving warfarin treatment and healthcare 
professionals were sought in this study. Therefore, for Group 1 and Group 2 participants, 
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interviewees were recruited from those study participants who come to Glenfield Hospital 
either for routine medical visits or for hospital INR monitoring for more convenience to 
the researcher and participants. The sample included parents of young children as well as 
a parent and a teenager patient to get an insight of the experience of managing warfarin 
treatment from the perspective of parents as well as the teenage patient. For the health 
care professionals, interviewees included doctors who are involved in warfarin 
dosing/monitoring as well as cardiac liaison nurses who are involved in warfarin 
monitoring. 
       IPA is usually based on small samples as the issue is the quality of data, not quantity, 
and hence, sample sizes of 3 to 6 participants has been suggested (Smith, Flowers and 
Larkin, 2009). Therefore, interviews were planned to be conducted with 4 families (2 
from Group 1 and 2 from Group 2) and 5 healthcare professionals (1 paediatric cardiology 
consultant, 2 paediatric cardiology registrars and 2 paediatric cardiac liaison nurses). 
2.5.6.4. Interviewing of patients/parents and health care professionals 
       Topic guides were developed for Group 1 participants, Group 2 participants and 
health care professionals (Appendix 5). Potential interviewees from Group 1 and Group 
2 families were approached either during their hospital visits or through phone calls to 
ask them if they were willing to be interviewed. If participants were interested to be 
interviewed, an interview appointment was made at a convenient time in Glenfield 
Hospital. Potential participants from the health care professionals were approached at 
their usual work place and were asked if they were willing to be interviewed. Interviews 
were conducted with the health care professionals who agreed to participate in the study 
at a convenient time in Glenfield Hospital.  
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For Group 1 participants, the interviews were conducted around the end of the 6-month 
period of model-based warfarin treatment. In contrast, two interviews were conducted for 
each Group 2 participant; the first interview was conducted around the end of the 6-month 
period of doctors’ dosing and prior to cross-over to the model-based dosing phase, 
whereas the second interview was conducted around the end of the 6-month model-based 
treatment phase. Interviews with health care professionals were conducted about 6 
months after the study has started. This period was roughly chosen to allow the health 
care professionals to have adequate experience with model-based warfarin 
dosing/monitoring before exploring their views of the new dosing approach. The 
interviews were all face-to-face except for the second interview of a Group 2 patient and 
his mother where it was not convenient for them to come to Glenfield Hospital, therefore 
a telephone interview was arranged. The interviews were audio-recorded and then 
transcribed verbatim and analysed manually by the researcher. Thematic analysis, using 
a phenomenological approach, was used to code important words/statements in the 
transcripts into themes to help understand the experience of patients/parents and health 







     Chapter Three 





Chapter 3: Validation of the Hamberg PK/PD model 
3.1. Introduction 
      Oral anticoagulation with warfarin represents a major challenge to successful drug 
therapy in children due to various factors. Demographic, genetic, clinical and 
environmental factors have been shown to contribute to the wide inter-individual 
variability in the drug’s dose requirements and treatment outcome (Biss et al., 2012; 
Hamberg et al., 2014).  
For this reason, various attempts have been made to develop models that account for the 
factors that contribute to this variability in an attempt to individualise warfarin dose in 
children and hence improve the treatment outcome. These models were either linear 
regression models (See Chapter 1 Table 4) or PK/PD models (Hamberg et al., 2013; Lala 
et al., 2013). The predictive performance of these models has been evaluated by 
comparing the model-predicted doses with the actual prescribed doses. The Hamberg 
model (Hamberg et al., 2013) was shown to be superior to other models in predicting 
ideal doses, i.e. those that are within 20% of the actual doses prescribed to children 
(Hamberg and Wadelius, 2014; Marek et al., 2016). 
This study was undertaken as a first step, and prior to the prospective clinical study, to 
assess the predictive performance of the Hamberg model in a cohort of post-operative 
cardiac children on long-term warfarin treatment at the EMCHC.  
3.2. Methodology  





3.3.1. Patient characteristics 
     Data from 87 warfarin-treated patients who were present on the EMCHC database was 
collected during July and August 2014. Twenty-seven patients were excluded from the 
analysis due to missing treatment and monitoring histories. Sixty patients with data from 
the initiation of warfarin treatment as well as a stable treatment period were used for the 
evaluation of the model. The characteristics of the study subjects are summarised in Table 
5.  
Table 5. Characteristics of paediatric patients included in the evaluation of the Hamberg 
model. 
Age* (years), median (range) 5.2 (1-15.9) 
Weight* (kg), median (range) 16.75 (8.4-66.6) 
Gender, N (%) 
Male  39 (65) 
Female  21 (35) 
Ethnicity, N (%) 
White  43 (71.7) 
Asian  8 (13.3) 
Other‡ 8 (13.3) 
Missed  1 (1.7) 
Indication for warfarin, N (%) 
Fontan  41 (68.3) 
AVR 10 (16.7) 
MVR 6 (10) 
Other† 3 (5) 
Target INR range, N (%) 
2.0-3.0 23 (38.3) 
1.5-2.5 16 (26.7) 
2.5-3.5 8 (13.3) 
2.0-2.5 7 (11.7) 
Other§ 6 (10) 
*At the time of first dose/INR observation. 
‡ Other ethnicity include Black, mixed White and Asian, mixed White and Black Caribbean 
and Middle Eastern.  
† Other indications include Kawasaki disease and stroke. 
§ Other target INR ranges include 1.5-3.0, 1.5-3.5, 2.0-3.5, 2.5-3.0 and 3.0-3.5. 
AVR is aortic valve replacement. 




The median age was 5.2 years and the median weight was 16.75 kg. Most of the study 
subjects were male (65%) and most of the patients were of white ethnicity (71.7%). The 
most common indication for warfarin anticoagulation was Fontan procedure (68.3%) 
and the most common target INR range was 2.0-3.0 (38.3%). 
3.3.2. Study outcomes 
      Results of the validation of the Hamberg model are presented in Table 6. Seventy 
percent of the dose predictions were ideal, i.e. within ± 20% of the observed doses 
whereas 25% of the predicted doses were underestimated and 5% were overestimated 
(Figures 11 and 12). The bias was -0.10 which implies an overall dose underprediction of 
0.1 mg. The precision was 0.19 which gives an idea of the proximity of dose predictions 
to each others (Figure 11). This implies an imprecision of 19%. 
Table 6. Results of the validation of the Hamberg model on a cohort of 60 children 







Bias Precision  
70 5 25 -0.10 0.19 
 
 






Age was found to be significantly positively correlated with the observed dose (p= 0.001, 
r= 0.43). However, there was a non-significant negative correlation of age with the 
weight-adjusted dose (p= 0.29, r= -0.14) (Figure 13). Younger patients aged 1-5 years 
required significantly lower maintenance doses than the older ones i.e. those aged 6-10 
and 11-18 years (Figure 14 and Table 7). In contrast, the weight-adjusted daily dose did 
not vary significantly among the three age groups (p= 0.34) (Table 7). Weight was also 
found to correlate significantly with the observed dose (p<0.05, r= 0.49). 
Patients anticoagulated after Fontan procedure required significantly lower daily 
maintenance doses than all other indications of warfarin use (p= 0.005) (Figure 15 and 
Table 7). In contrast, the weight-adjusted daily dose did not vary significantly among the 






















Figure 12. Model-predicted doses were plotted against residual doses calculated as (observed 
dose-predicted dose). Data points with positive values on the Y axis indicate dose underprediction 
while those with negative values indicate dose overprediction. 
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maintenance dose varied significantly among the target INR ranges (p= 0.015) (Figure 16 
and Table 7). However, the weight-adjusted dose did not vary significantly among the 
target INR ranges (p= 0.23) (Table 7). Ethnicity was not found to significantly influence 
the daily dose (p= 0.73) and the weight-adjusted dose (p= 0.82). In addition, gender did 
not significantly affect the daily dose (p= 0.27) and the weight-adjusted dose (p= 0.31) 






























Figure 13. Relationship between observed warfarin maintenance doses (mg/kg/day) and age. 
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                         Table 7. Descriptive statistics and p-values of the effect of demographic and clinical variables on warfarin dose. 
  Warfarin dose (mg/day) Warfarin dose (mg/kg/day) 
Variable N Median Minimum Maximum p-value Median Minimum Maximum p-value 
Age groups (years) 
1-5 39 2.0 0.5 5.75 0.002† 0.13 0.03 0.64 0.34† 
6-10 14 2.9 0.75 5.5 0.12 0.05 0.32 
11-18 7 4.5 1.75 5.5 0.11 0.05 0.15 
Gender  
Male 39 2.5 0.75 5.75 0.27§ 0.12 0.04 0.64 0.31§ 
Female 21 2.0 0.5 5.5 0.11 0.03 0.32 
Ethnicity  
White 43 2.2 0.5 5.5 0.73† 0.12 0.03 0.32 0.82† 
Asian 8 2.13 0.75 4.0 0.13 0.05 0.21 
Other 8 2.25 1.0 3.5 0.13 0.06 0.19 
Indication  
Fontan 41 2.0 0.5 4.25 0.005† 0.12 0.03 0.22 0.12† 
AVR 10 3.88 2.0 5.5 0.11 0.05 0.22 
MVR 6 3.63 0.75 5.75 0.2 0.05 0.64 
Other  3 2.5 1.25 4.5 0.13 0.1 0.18 
Target INR range 
1.5-2.5 16 2.0 0.5 2.5 0.02† 0.11 0.03 0.18 0.23† 
2.0-3.0 23 2.25 0.8 5.0 0.12 0.05 0.22 
2.5-3.5 8 4.13 0.75 5.75 0.19 0.05 0.64 
2.0-2.5 7 2.75 0.75 3.5 0.17 0.05 0.32 
Other 6 1.75 1.25 4.75 0.12 0.03 0.64 
§ Mann-Whitney U test. 
















Figure 14. Box plot showing the relationship between observed warfarin maintenance 
doses and age. 
Figure 15. Box plot showing the influence of treatment indication on the observed 









3.4. Discussion  
      This study has evaluated the predictive performance of the Hamberg model using 
retrospectively collected data from a cohort of children on the EMCHC database who 
were maintained on long-term warfarin treatment. The model performed well in 
predicting warfarin doses in this cohort (70% ideal dose predictions, bias -0.1 and 
precision 0.19), however, a tendency towards dose underestimation was observed. The 
predictive performance of the Hamberg model has also been evaluated in a cohort of 49 
children on warfarin treatment (Hamberg et al., 2013). The ideal dose prediction was 70% 
with bias of -0.04 and precision of 0.57. In this study, the model showed a tendency to 
underestimate warfarin doses in children younger than 2 years of age. This has been 




attributed to the likelihood of PK parameters underestimation due to underestimation of 
the metabolic capacity by the bridged model in this age group (Hamberg et al., 2013). 
However, the underestimated doses in the current retrospective evaluation were observed 
in children aged between approximately 3 and 16 years and hence PK parameters 
underestimation is unlikely to be an explanation for these findings. Information about 
CYP2C9 and VKORC1 genotypes was not available for dose predictions in this 
retrospective analysis. Yet, the model estimates maintenance (a posteriori) doses based 
on the individual parameter estimates which become more refined and patient-specific as 
more INR observations are obtained (Hamberg et al., 2015). It is also important to know 
that warfarin dose predictions in the current study were performed in a slightly different 
way than was performed by Hamberg et al. (2013). In the current study, the warfarin dose 
predictions were based on INR observations from the beginning of warfarin treatment 
until the first stable warfarin treatment period was achieved. In contrast, only 3 INR 
observations prior to the stable treatment period were used by Hamburg et al. (2013). The 
reason behind this was the low percentage of ideal predicted doses (48.3%) obtained using 
only 3 INR observations prior to the stable treatment period. Therefore, longer treatment 
history was required for better dose prediction. This may be attributed to the software 
used for dose predictions. Warfarin dose predictions in the current study were performed 
using the Java-based dose decision tool (Hamberg et al., 2015), whereas NONMEM 
software was used for dose predictions in Hamberg et al. (2013) study. Comparison of 
the maintenance (a posteriori) dose predictions between the Java-based dose decision tool 
and NONMEM software has shown a mean difference of 5% in dose predictions between 
the two software (Hamberg et al., 2015).  
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    The effect of demographic and clinical factors on warfarin maintenance dose was also 
evaluated in this cohort. Age and weight were found to be significantly positively 
correlated with dose. This is consistent with previous findings obtained in children that 
have shown statistically significant correlations for age and weight with warfarin dose 
(Biss et al., 2012; Moreau et al., 2012; Shaw et al., 2014; Wakamiya et al., 2016). In 
agreement with previous studies in children (Streif et al., 1999; Biss et al., 2012; Shaw et 
al., 2014), patients with Fontan circulation were found to require significantly lower 
maintenance doses than other indications of warfarin use. This may be attributed to the 
lower levels of anticoagulation required for these patients as indicated by the lower target 
INR ranges used or to an underlying abnormality in liver function (Whiteside et al., 2016; 
Kaulitz et al., 1997). The target INR range was also shown to significantly affect the 
warfarin dose requirements. This finding was similar to that obtained in two previous 
studies in children that have demonstrated the significant effect of the target INR range 
on warfarin maintenance dose (Moreau et al., 2012; Wakamiya et al., 2016). 
    The most important advantage of the Hamberg model is its ability to adjust warfarin a 
posteriori (maintenance) doses by taking into account factors other than those included 
in the model for dose prediction. By estimating the individual model parameters, all 
factors that can affect warfarin PK and PD can be taken into consideration. For example, 
the effect of vitamin K intake, drug interactions and underlying medical condition. In 
addition, the model can handle INR values measured during non-steady state conditions 
which can help to give information about the rate and extent of response to warfarin 
treatment in individual patients (Hamberg et al., 2015). However, an important weakness 
in the model is the tendency toward dose underestimation. Theoretically, this can carry 
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the risk of under-anticoagulation and subsequent risk of thrombosis, however, it needs to 
be applied clinically on a prospective basis to evaluate its clinical significance. 
The results of clinical accuracy, bias and precision obtained from this retrospective 
evaluation provided adequate validation for the use of Hamberg model in a prospective 






     Chapter Four 
The prospective clinical 
study 
 (Group 1) 
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Chapter 4: The prospective clinical study: Patients starting warfarin 
for the first time post-cardiac surgery (Group 1) 
4.1. Introduction 
     The anticoagulation treatment outcomes during initiation of warfarin therapy in 
children have been shown to be influenced by genetic and non-genetic factors. (BISS et 
al., 2013; Hawcutt et al., 2014; Shaw et al., 2014; Ruud et al., 2008). In addition, warfarin 
dose requirements have been shown to be associated with wide inter-individual variability 
due to various demographic, genetic and clinical factors (Biss et al., 2012; Hamberg et 
al., 2014; Moreau et al., 2012; Nguyen et al., 2013; Shaw et al., 2014). Therefore, to 
individualise warfarin dosing in children and hence improve the treatment outcome, 
models incorporating variables affecting warfarin dose/response have been developed 
(Biss et al., 2012; Hamberg et al., 2013; Lala et al., 2013; Vear et al., 2014). However, 
these models were never tested clinically on a prospective basis. Only one prospective 
clinical study has been conducted to compare genotype-guided warfarin dosing with the 
standard dosing in children (Tabib et al., 2015). The genotype-guided dosing was found 
to significantly decrease the time to stable dose and hospital stay days (Tabib et al., 2015). 
     This research project involves, for the first time, the prospective clinical evaluation of 
a mechanistic PK/PD model (Hamberg et al., 2015) in children starting warfarin treatment 





4.2. Methodology  
See Chapter 2, Section 2.4. 
4.3. Results 
4.3.1. Patient characteristics 
      Patient recruitment occurred between October 2015 and December 2016. Nine 
consecutive patients were screened from whom only 5 consented to participate. The 
characteristics of Group 1 patients are summarised in Table 8. Five patients were enrolled 
in Group 1, all were female with age range of 3.8-8.9 years and weight range of 15.4-30.3 
kg. Three patients were of Asian ancestry, three patients had Fontan procedure, all the 
patients were of the wild type CYP2C9 genotype (*1/*1) and three of them were of the 
wild type VKORC1 genotype (G/G). Only one patient had a concomitant chronic disease 
which was Type 1 diabetes mellitus. Four of the patients were on the tablet dosage form 
of warfarin, and in 3 of the cases the tablets were crushed and mixed with water for ease 
of administration. The comparative characteristics of the control patients are shown in 
Table 8. The age range of the control subjects was 3.4-9.3 years and the weight range was 
16.0-36.5 kg. All the control subjects were of the white ethnicity and 3 of 5 patients were 
male. The median average daily dose of warfarin was 0.2 mg/kg/day (range 0.1-0.3 
mg/kg/day) for the case subjects and 0.1 mg/kg/day (range 0.1-0.2 mg/kg/day) for the 
control subjects. One patient had Noonan syndrome and hypothyroidism secondary to 
amiodarone use and one patient had migraine. 
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Case 1 5.4 18.3 F Asian MVR 2.5-3.5 *1/*1 G/G 0.3 1.8 Type 1 DM Tablet3 
Control 1 4.2 19.1 M White MVR 2.5-3.5 NA NA 0.2 1.1 None NA 
Case 2 6 16 F Asian Fontan 2.0-3.0 *1/*1 G/G 0.2 1.4 None  Tablet3 
Control 2 5.3 16 F White Fontan 2.0-3.0 NA NA 0.1 NA* None NA 
Case 3 3.8 15.4 F White Fontan 2.0-3.0 *1/*1 G/G 0.2 1.1 None Liquid  
Control 3 3.4 17 F White Fontan 2.0-3.0 NA NA 0.1 1.2 None NA 
Case 4 6 15.4 F White MVR 2.5-3.5 *1/*1 G/A 0.2 1.5 None Tablet3 






Case 5 8.9 30.3 F Asian Fontan 2.0-3.0 *1/*1 G/A 0.1 1.2 None Tablet4 
Control 5 9.3 36.5 M White Fontan 2.0-3.0 NA NA 0.1 NAǂ Migraine NA 
1 Age of the case subjects was at enrolment and that of the controls was at the time of first dose/INR observation. 2 Weight of the case subjects was at enrolment and that of the 
controls was at the time of first dose/INR observation. 3 Tablets are crushed & mixed with water. 4 Tablet swallowed whole but halved to get the 0.5 mg dose. MVR mitral valve 
replacement. DM diabetes mellitus. NA not available. * INR after a 3.0-mg loading dose was 1.4. ǂ INR after a 3.6-mg loading dose was 1.0. 
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4.3.2. Study outcomes 
      A total of 436 INR measurements was collected from the case and control subjects 
over a total follow up period of 5 years. Results of the study outcomes for Group 1  
patients and controls are shown individually in Table 9. Descriptive statistics of the 
results are shown in Table 10. 
4.3.2.1. Time to first therapeutic INR, stable anticoagulation and over-
anticoagulation 
      The median time to achieve the first INR values within the target therapeutic range 
was 5 days for the case subjects compared to 2 days for the control ones (Figure 17). Two 
of the case patients and one control patient did not achieve stable anticoagulation during 
the 6-month period of follow up. The median time to stability for the remaining three case 
patients was 29 days as compared to 96.5 days for the remaining control patients (Figure 
18). For the three case patients who achieved stable anticoagulation, two patients attained 
stability 9 and 15 days faster than their control subjects, respectively. The third patient 
achieved stability after 29 days of warfarin treatment whereas her control patient did not 
achieve stability in the 6-month follow up period. The two case patients who did not 
achieve stability were anticoagulated with warfarin for mechanical mitral valves, their 
age was 5.4 and 6 years, respectively whereas the control patient who did not achieve it 
was anticoagulated for Fontan circulation and aged 9.3 years.  
The median time to the first INR value ≥4.0 (over-anticoagulation) was 15 days for the 
case subjects as compared to 4 days for the control group (Figure 17). 
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Table 9. Results of the study outcomes for Group 1 case and control subjects. 




















Time to first therapeutic INR (days) 6 1 5 2 2 2 5 3 2 3 
Time to stable anticoagulation (days) NA⁑ 138 87 96 9 24 NA⁑ 97 29 NA⁑ 
Time to over-anticoagulation (INR≥4.0) 
(days) 
4 14 17 2 NA§ 1 15 4 NA§ 10 
%ITR 53.2 47.4 70 54.2 76.9 45.5 62.2 55.1 73.9 43.6 
%TTR 69 62.4 83.9 62.3 83.4 45.5 84.4 71.3 77.9 38.2 
Number of dose changes 50 21 20 12 10 14 23 36 8 21 
Frequency of INR measurements (per 
month) 
13.2 3.6 5 4 4.3 5.5 6.2 11.5 3.8 6.5 
No. of INR values ≥ 4.0 11 5 2 2 0 2 5 6 0 2 
No. of INR values ≥ 5.0 2 3 0 1 0 1 1 3 0 2 
⁑ Stable anticoagulation was not achieved in these patients. 
§ Patients did not have INR measurements ≥ 4.0. 
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Table 10. Descriptive statistics of the study outcomes for Group 1 case and control subjects. 
Outcome   N Median Minimum Maximum 
Time to first 
therapeutic INR 
(days) 
Case  5 5 2 6 
Control  5 2 1 3 
Time to stable 
anticoagulation 
(days) 
Case  3 29 9 87 




Case  3 15 4 17 
Control  5 4 1 14 
%ITR Case  5 70 53.2 76.9 
Control  5 47.4 43.6 55.1 
%TTR Case  5 83.4 69 84.4 
Control  5 62.3 38.2 71.3 
Number of dose 
changes 
Case  5 20 8 50 
Control  5 21 12 36 
Frequency of INR 
measurements (per 
month) 
Case  5 5 3.8 13.2 
Control  5 6.3 4 11.5 
No. of INR values ≥ 
4.0 
Case  3 2 0 11 
Control  5 2 2 6 
No. of INR values ≥ 
5.0 
Case  2 0 0 2 




Figure 17. Time to first therapeutic INR and time to over-anticoagulation in Group 1 case and 






4.3.2.2. Time in therapeutic range 
      The median percentage of the INR observations within the target range (%ITR) for 
the case subjects was 70% whereas the median %ITR for the control subjects was 47.4%. 
The median percentage of time in therapeutic range (%TTR) for the case subjects was 
83.4% whereas that of the control group was 62.3% (Figure 19). All the case subjects had 
higher %ITR and %TTR than their controls, yet due to the very small sample size, it was 
not appropriate to perform a statistical test to assess the significance of the difference in 
%ITR and %TTR between the two groups. 
Figure 18. Time to stable anticoagulation in Group 1 case and control subjects. Black horizontal 





4.3.2.3. Frequency of INR measurements per month and frequency of dose 
alterations 
The median frequency of INR measurements was 5 measurements/month for the case 
subjects as compared to 6.3 measurements/month for the controls. Three (out of 5) of the 
case subjects had lower frequency of measurements than their control subjects. 
The median frequency of dose alterations was 20 for the case subjects as compared to 21 
for the controls. The frequency of dose alterations was lower in three of the case subjects 
than their controls (Figure 20). 
4.3.2.4. Number of INR values ≥ 4.0 and ≥ 5.0 
      The median number of INR values ≥ 4.0 was 2 for both the case and the control 
groups. In contrast, the median of the number of INR values ≥ 5.0 was zero for the case 
group as compared to 2 for the control group (Figure 21). 
Figure 19. The percentage of INR measurements in target therapeutic range (%ITR) and percentage of time 








Figure 20. The frequency of dose changes and the frequency of INR measurements per 
month for Group 1 case and control subjects. Black horizontal lines represent the median 
values. 
Figure 21. Over-anticoagulation in Group 1 case and control subjects. Black horizontal 
lines represent the median values. 
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4.3.2.5.  Minor bleeding events 
       Only two symptom diary cards were received back from the families. There were no 
minor bleeding events recorded in these cards. The first card was for case 1, aged 5.4 
years, who was taking warfarin for a mechanical heart valve (MVR) with a target INR 
range of 2.5-3.5. The second card was for case 5, aged 8.9 years, who was receiving 
warfarin therapy after a Fontan procedure. 
4.3.2.6. Concomitant medications used 
     The medications used in the post-operative period was comparable between the case 
and control groups. These included medications like antibiotics, analgesics, diuretics, 
angiotensin converting enzyme (ACE) inhibitors and medications for post-operative 
gastrointestinal symptoms. The most common concomitant medications prescribed upon 
discharge from the hospital were diuretics including furosemide and spironolactone in 
addition to other drugs like insulin, digoxin, amiodarone, propranolol, sildenafil and 
lisinopril that were prescribed for particular patients/controls. These medications do not 
have a potential interaction with warfarin apart from amiodarone which can increase the 
anticoagulant effects of warfarin. Amiodarone was used in control number 4 in whom the 
%ITR was 55.1% and %TTR was 71.3% as compared to 62.2% and 84.4% for case 
number 4, respectively. However, the exact date of stopping amiodarone treatment could 
not be obtained, therefore, the lower %ITR and %TTR for this patient could not only be 
attributed to amiodarone use. In addition, warfarin is usually closely monitored in the 




4.3.2.7. Assessment of extremely above- and below-range INR measurements 
       To assess the extreme above-range INR measurements, the number of occasions 
where warfarin treatment was withheld and/or vitamin K was used was estimated. 
Warfarin treatment was withheld in 4 control subjects on 5 occasions, including one 
occasion when vitamin K was also used compared to none in the case group.  
Similarly, to assess extreme below-range INR measurements, the number of occasions 
where intravenous (IV) heparin or low molecular weight heparin (LMWH) was used was 
also estimated. IV heparin was used in two case subjects on one occasion for each of them 
compared to two occasions of IV heparin use in one control subject and one occasion of 
LMWH use in another control subject. 
4.3.2.8. Missed and overridden doses 
       From a total of 218 INR measurements, missed dosing occurred on 6 occasions 
(2.8%). In addition, there were 4 occasions of dose overriding out of a total of 212 dose 
recommendations made by the model (1.9%) in Group 1 patients.  
4.4. Discussion 
      This study has evaluated, for the first time, on a prospective basis, warfarin dose 
management in children using the model-based approach. Dosing management involved 
both initial doses as well as dose adjustments made after every INR feedback obtained 
from the patients. The results of this study have shown that model-based warfarin dosing 
has resulted in a longer time to reach a therapeutic INR. However, there was a greater 
percentage of INR measurements within the target therapeutic range and also a greater 
percentage of time within this range when compared to the traditional dosing approach. 
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In addition, model-based warfarin dosing has resulted in a desirable longer period of time 
before over-anticoagulation occurred and there were fewer over-anticoagulated patients 
and a shorter time to reach stable anticoagulation when compared with the traditional 
dosing approach. 
The median time to first therapeutic INR was longer for the case subjects as compared to 
the controls (median 5 days vs 2 days). This was due to the difference between the two 
dosing approaches. The usual clinical practice is to start with a loading dose of 0.1-0.2 
mg/kg (maximum 10 mg) which may be repeated if the subsequent INR value is between 
1.1-1.4 (Appendix 1). In contrast, the model predicts the initial warfarin dose based on 
typical population parameter estimates and the individual patient’s covariates (age, 
weight and CYP2C9 and VKORC1 genotypes). Subsequent dose adjustments are made 
after the INR feedback is obtained from the patient (Chapter 2, Section 2.2). In addition, 
there was one patient (case 4) with mechanical mitral valve and target INR range of 2.5-
3.5 who attained the target therapeutic INR after 5 days as compared to 3 days for the 
control. This patient started warfarin treatment at a lower target (2.0-3.0) because there 
was a risk of bleeding. This target range was attained after 2 days of treatment when it 
was then changed to 2.5-3.5 and the patient required further 3 days of treatment to attain 
the new target range. Therefore, this has also affected the result of time to first therapeutic 
INR for the case subjects. Also, the loading dose approach was found to be associated 
with high above-range INR values for two of the control subjects. The INR values after 
loading doses were 7.1 and 5.4 for control 2 and 3, respectively. The results obtained for 
the time to first therapeutic INR in this research study are comparable to that 
demonstrated by Tabib and colleagues’ study (Tabib et al., 2015). The mean time to first 
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therapeutic INR was 3.4 days (SD 1.2) in the genotype guided group as compared to 3.5 
days (SD 1.4) in the standard dosing arm.  
The model-based approach to warfarin dosing resulted in longer time to over-
anticoagulation (median 15 vs 4 days) and fewer over-anticoagulated patients (3 vs 5) as 
compared to the controls. This may be due to the model’s dose estimation approach where 
the dose is adjusted based on the mean of the target INR range (Chapter 2, Section 2.2). 
This can help to obtain better anticoagulation control by minimising the supra-therapeutic 
INR values that can predispose to bleeding complications. 
The model-based approach to warfarin dosing was shown to result in greater percentage 
of INR measurements in the target range (median 70% vs 47.4%) as well as greater 
percentage of time in therapeutic range (median 83.4% vs 62.3%) as compared to the 
traditional dosing approach. This can also help to obtain better anticoagulation control by 
minimising above and below range INR values and hence minimising the risk of bleeding 
and thrombosis, respectively. In adults, the genotype-guided warfarin dosing has also 
been shown to significantly improve the percentage of time in target therapeutic range as 
compared to the standard dosing approach (Pirmohamed et al., 2013). The percentage of 
time in target therapeutic range was 67.4% in the genotype-guided group as compared to 
60.3% in the standard dosing group (Pirmohamed et al., 2013). Also, the PK/PD model-
based warfarin dosing in adults was shown to result in a significant improvement in the 
time in the therapeutic range as compared to the pharmacogenetic/clinical based dosing 
(Perlstein et al., 2012). The mean time in the target therapeutic range for the 
pharmacogenetic/clinical algorithm was found to be 58.9% whereas that of the two 
PK/PD algorithms was found to be 59.7% and 65.8%, respectively (Perlstein et al., 2012).  
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The number of patients who achieved stable anticoagulation was comparable in the two 
dosing groups (3 cases vs 4 controls), however, model-based dosing has achieved stable 
anticoagulation faster than the traditional dosing approach (median 29 days for cases vs 
96.5 days for controls). The time to stable anticoagulation achieved by model-based 
dosing in this study is comparable to the results obtained by Tabib et al. where the mean 
time to stable anticoagulation was 32.8 days (SD 6) in the genotype-guided dosing group 
(Tabib et al., 2015). 
However, the local practice at the EMCHC is to keep the patients within an acceptable 
INR range rather than to strictly adhere to the prespecified target therapeutic ranges. In 
other words, the concern is more about how far the INR measurements are above or below 
the target range which can predispose to the risk of bleeding or thrombosis, respectively. 
This will be discussed in detail in Chapter 6. Warfarin treatment was withheld on 5 
occasions in the control group, including one occasion when vitamin K was also used 
compared to none in the case group. Conversely, IV heparin was used on two occasions 
in the case group compared to two occasions of IV heparin use and one occasion of 
LMWH use in the control group. This may imply that model-based warfarin dosing can 
improve the anticoagulation control of warfarin particularly that regarding reducing the 
incidence of having very high INR values that can predispose to bleeding events. 
The incidence of minor bleeding events could not be assessed because only two of the 
patients’ symptom diary cards were received back from the families. However, this might 
imply good anticoagulation control in the remaining 3 case subjects since no bleeding 
events were reported. 
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A major limitation of the present study is that the sample size was small to enable 
statistically valid comparisons to be made. The low recruitment rate was due to the limited 
number of patients presented for cardiac surgery during the 14 months recruitment period. 
Only 11 candidates presented for cardiac surgery during the entire recruitment period. 
Nine families were approached from whom only 5 consented to participate in the study. 
Two of the approached patients received antiplatelet therapy with aspirin as advised by 
the doctors. The two other approached families did not consent to participate in the study. 
The parents wanted warfarin treatment to be prescribed by the doctors as their children 
were to start it for the first time. There were two other candidates who presented for 
cardiac surgery but were not approached. One candidate was not approached because the 
patient originally presented for heart valve repair but a decision to replace the valve was 
made intra-operatively. The original study protocol that was in use during that period did 
not allow the researcher to approach this kind of candidate because of the limited time 
available to obtain consent/assent. Therefore, a major amendment to the protocol was 
made and subsequently submitted to the Research Ethics Committee for approval in order 
not to miss this kind of candidate (Appendix 2). The other candidate’s parent was not 
approached as she did not want her child to be involved in a research project. 
Besides, the effect of genetic and non-genetic factors on the study outcomes and warfarin 
dose requirement could not be assessed. This was because of the small sample size that 
contained only the wild type CYP2C9 and only two patients with heterozygous VKORC1 
variant allele. 
       The preliminary results obtained from this study have shown that model-based 
warfarin dosing has improved the anticoagulation control in children starting warfarin 
therapy for the first time after heart surgery. However, this new approach of warfarin 
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dosing/monitoring needs to be further explored in a larger sample size cohort to confirm 
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Chapter 5: The prospective clinical study: Patients maintained on 
warfarin treatment post-cardiac surgery (Group 2): 
5.1. Introduction  
       Children with congenital heart disease who require long-term warfarin treatment 
need to be closely monitored to avoid both thromboembolic and bleeding complications. 
Therefore, maintenance of the target INR range is pivotal to ensure the safety and 
effectiveness of warfarin treatment (Giglia et al., 2013). However, maintaining the target 
therapeutic INR is intensely challenging because of various factors that affect the drug’s 
PK and PD and hence affecting both the dose requirements and response to the drug. For 
this reason, it is crucial to individualise warfarin dosing in order to optimise its 
anticoagulant control.  
Population PK/PD models for individualising warfarin dosing have been developed and 
evaluated in children (Hamberg et al., 2013; Lala et al., 2013). However, these models 
were never tested clinically, on a prospective basis to assess their clinical utility. This 
research project involves, for the first time, the prospective clinical evaluation of a 
mechanistic PK/PD model (Hamberg et al., 2015) in children maintained on warfarin 
treatment after congenital heart surgery. 
5.2. Methodology  






5.3.1. Patient characteristics 
      Patient recruitment occurred between October 2015 and August 2016. Forty-eight 
patients were screened, 29 patients were enrolled in the study from whom 26 patients 
completed the follow up period and were included in the analysis. One patient died 
because of deterioration of his medical condition, one patient’s mother withdrew consent 
and one patient was withdrawn from the study because his warfarin treatment was stopped 
following replacement of his mechanical heart valve with a bioprosthetic valve. The 
characteristics of Group 2 patients are summarised in Table 11. The mean patients’ age 
was 9.01 years (SD 4.8) and the median weight was 24.9 kg. Most of the patients were 
males (69.2%) and the majority were of the White ethnicity (76.9%). The wild type 
CYP2C9 genotype was predominant (61.5%) whereas more than half of the patients were 
carriers of the heterozygous VKORC1 genotype (G/A) (53.8%). The most common 
indication for warfarin anticoagulation in this sample was Fontan procedure (76.9%). The 
most frequent target therapeutic INR range was 2.0-3.0 (46.2%) and the most commonly 
used dosage form was warfarin tablets (69.2%). 
5.3.2. Study outcomes 
      A total of 1073 INR measurements were collected during both phases of treatment 
over a total follow up period of 26 patient years. 
5.3.2.1. Time in therapeutic range 
      The mean percentage of INR measurements in the target range (%ITR) of the model 




Table 11. Characteristics of Group 2 patients. 
Age* (years), mean ± SD (range) 9.0 ± 4.8 (1-17.3) 
Weight (kg), median (range) 24.9 (9.5-62.8) 










































Dosage form used, N (%)  
Liquid  
Tablet (swallowed whole) 
Tablet (swallowed whole but halved for 0.5 
mg) 






Total number of patients (%) 26 (100) 
* Age at enrolment. 
§ Other: one patient mixed White and Black, one patient mixed White and Asian. 
† Other: one patient 1.8-3.0, one patient 2.0-2.5, one patient 3.0-4.0. 
MVR mitral valve replacement. 






mean difference in %ITR between the Model phase and the Doctor phase of 0.92% 
(p=0.84). The mean percentage of time in target range (%TTR) of the Model phase was 
85.47% as compared to that of the Doctor phase, 80.2%. The mean difference in %TTR 
between the Model phase and the Doctor phase was 5.27% (p = 0.09) (Table 12).  
 
Table 12. Time in therapeutic range (measured as %ITR and %TTR), frequency of INR 
measurements and frequency of dose alterations of Group 2 patients. 










%ITR, mean (SD) 26 68.82 
(19.8) 
67.9 (23.19) 0.92 (-8.25, 
10.09) 
0.84‡ 
%TTR, mean (SD) 26 85.47 
(13.03) 
80.2 (17.99) 5.27 (-0.78, 
11.32) 
0.09‡ 
%ITR (excluding 5 
cases), mean (SD) 
21 71.28 
(20.86) 
65.51 (23.3) 5.77 (-3.82, 
15.35) 
0.22‡ 
%TTR (excluding 5 






Frequency of INR 
measurements (per 






Frequency of dose 
alterations, median 
(IQR) 





† Values are the mean difference between the Model phase and the Doctor phase. 
‡ Paired sample t-test. 
§ Wilcoxon test. 
%ITR is the percentage of INR measurements in therapeutic range. 
%TTR is the percentage of time in therapeutic range.  
IQR is the interquartile range. 
 
However, there were five patients who underwent procedures (cardiac catheterization or 
dental procedure) and/or experienced periods of illness in one of the treatment phases and 
where warfarin treatment was stopped and then resumed afterwards which may have 
resulted in a biased comparison between the two phases. Therefore, an additional analysis 
was performed after excluding these five cases. The mean %ITR of the Model phase was 
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71.28% whereas that of the Doctor phase was 65.51%. The mean difference in %ITR 
between the Model phase and the Doctor phase was 5.77% (p = 0.22). Whereas the %TTR 
of the Model phase was significantly higher than that of the Doctor phase (median %TTR 
Model phase 91.8%, Doctor phase 77.3 %, p = 0.03) (Table 12). In Table 13 is shown the 
time within therapeutic range of these five patients for the two treatment phases. The 
medical issues occurred in the Doctor phase in patient number 1 whereas they occurred 
in the Model phase for the remaining patients.  
 
Table 13. The time in therapeutic range expressed as %ITR and %TTR of the two 
treatment phases for the patients with medical issues. 
 
 
5.3.2.2. Sensitivity analysis of the time in therapeutic range of the Model and 
Doctor phases 
A- Age and weight sub-groups  
      Patients were stratified into 3 age groups, 1-5, 6-10 and 11-18 years, and into 3 weight 
groups, ≤ 20, 21-40, and > 40 kg. The results of the analysis are demonstrated in Table 
14. 
     
Patient ID 
%ITR %TTR   
Model phase Doctor phase Model phase Doctor phase 
1 47.6 40.6 57 48.8 
7 69.6 85.7 86 94.9 
10 50 80 80.2 94.1 
23 56 100 79.7 100 






Table 14. Time in therapeutic range (%ITR and %TTR) in Group 2 patients stratified 
into age and weight groups. 










Age groups (year) 
















4.8 (-4.76, 14.36) 0.29 
















11 (-11.24, 33.24) 0.26 














2.3 (-6.83, 11.43) 0.58 
Weight groups (kg) 
















7.22 (-4.04, 18.48) 0.18 
















4.13 (-9.69, 17.95) 0.49 
















3.59 (-8.16, 15.34) 0.49 
† Values are the mean difference between the Model phase and the Doctor phase. 
§ Paired sample t-test. 
%ITR is the percentage of INR measurements in therapeutic range. 






The %ITR of the Model phase tended to be higher than that of the Doctor phase in the 6-
10 years age group only but this was not statistically significant (p = 0.48). The trend for 
%TTR in the Model phase was higher than that of the Doctor phase in all age groups but 
this was not statistically significant (Table 14 and Figure 22).  
The %ITR of the Model phase was higher for the weight groups ≤ 20 kg and > 40 kg 
although, again, these differences were not statistically significant (p = 0.77 and 0.98, 
respectively). The trend for %TTR in the Model phase was higher than that of the Doctor 
phase in all weight groups but this was not statistically significant (Table 14). 
B- Indication sub-groups 
    The patients were also grouped according to the indication of warfarin treatment into 
those with Fontan procedure and those with mechanical heart valves. The analysis of the 
indication group was performed before and after excluding the cases who experienced 
medical issues during either phase of treatment. The results are summarised in Table 15. 
The %ITR of the Model phase for Fontan patients was higher than that of the Doctor 
phase before and after the exclusion of the cases with medical issues but this was not 
statistically significant (p = 0.74 and 0.25, respectively). The %TTR during the Doctor 
phase was statistically significantly higher than that during the Model phase (p<0.05). 
However, after excluding the 5 cases with medical issues, the %TTR during the Model 
phase was statistically significantly higher than that during the Doctor phase (p = 0.02) 
(Figure 22).  
For patients with mechanical heart valves, the %ITR of the Model phase was higher than 
that of the Doctor phase after excluding the 5 cases with medical issues although  
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Table 15. Time in therapeutic range (%ITR and %TTR) in Group 2 patients grouped according to 
the indication of warfarin and the target therapeutic range. 










   Fontan procedure 











-17.45 (-22.86, -12.03) < 0.05 







6.53 (-5.15, 18.21) 0.25 







9.48 (1.79, 17.16) 0.02 
   Mechanical valves 











1.8 (-10.46, 14.06) 0.72 







2.53 (-19.24, 24.29) 0.74 







4.13 (-13.62, 21.87) 0.51 
Target INR range 
    1.5-2.5 











6.59 (-10.64, 23.81) 0.39 
    2.0-3.0 











3.31 (-5.73, 12.34) 0.44 
    2.5-3.5 











2.33 (-12.19, 16.84) 0.65 
    Other  











13.97 (-33.46, 61.39) 0.33 
† Values are the mean difference between the Model phase and the Doctor phase. 
§ Paired sample t-test. 
%ITR is the percentage of INR measurements in therapeutic range. 
%TTR is the percentage of time in therapeutic range. 
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Favours conventional approach Favours Model approach
Figure 22. Forest plot of the time in therapeutic range of the Model and Doctor phases for Group 2 patients. Patients were sub grouped according to age, 
indication and genotype subgroups. The mean differences (95% confidence intervals) are shown for each subgroup. The %TTR was used for the indication, age and 
VKORC1 subgroups whereas the %ITR was used for the CYP2C9 subgroup (because %TTR data was not normally distributed). 
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statistical significance was not achieved (p = 0.74). Similarly, the %TTR of the Model 
phase was higher both before and after excluding the cases with medical issues (p = 
0.72 and 0.51, respectively) (Figure 22). 
C- Target INR range sub-groups 
     For the target INR ranges, the %ITR of the Model phase was higher for the 1.5-2.5 
range (p = 0.51), the 2.5-3.5 range p = 0.87) and for the other target ranges (p = 0.73). 
The %TTR of the Model phase was higher than that of the Doctor phase for all target INR 
ranges. However, none of these differences were statistically significant (Table 15).  
D- CYP2C9 and VKORC1 sub-groups 
      The patients were also grouped according to CYP2C9 genotype (*1/*1 vs *1/*2 and 
*1/*3) and VKORC1 genotype (G/G vs G/A). The results of the analysis are summarised 
in Table 16. The %ITR of the Model phase was higher than that of the Doctor phase in 
the wild genotype (*1/*1) (p = 0.41). The median %TTR of the Model phase was higher 
than that of the Doctor phase (p = 0.1) for the *1/*1 genotype. The %TTR of the Model 
phase for the variant alleles (*1/*2 and *1/*3) was also higher than that of the Doctor 
phase. However, none of these differences was statistically significant (p =0.8). 
For VKORC1 genotypes, the %ITR of the Model phase was higher than that of the Doctor 
phase for both G/G and G/A genotypes (p = 0.8 and 0.97, respectively). The %TTR of 
the Model phase for both genotypes was also higher than that of the Doctor phase with p 
= 0.21 for G/G genotype and p = 0.26 for G/A genotype (Figure 22). Though, these 
differences were not statistically significant. 
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Table 16. Time in therapeutic range (%ITR and %TTR) in Group 2 patients grouped 















































1.07 (-8.08, 10.21) 0.8§ 
VKORC1 genotype 
















5.54 (-3.61, 14.7) 0.21§ 
















5.04 (-4.19, 14.26) 0.26§ 
† Values are the mean difference between the Model phase and the Doctor phase. 
§ Paired sample t-test. 
‡ Wilcoxon test. 
%ITR is the percentage of INR measurements in therapeutic range. 
%TTR is the percentage of time in therapeutic range. 
IQR is the interquartile range. 
 
E- Dosage form sub-groups 
     The patients were also stratified according to the dosage form used into liquid and 
tablet groups. The results of the analysis are shown in Table 17. The %ITR of the Model 
131 
 
phase was higher than that of the Doctor phase in the tablet group (p = 0.78). In contrast, 
the %TTR of the Model phase was higher than that of the Doctor phase for both the liquid 
group and the tablet group (p = 0.25 and 0.19, respectively). Though, none of these 
differences was statistically significant. 
Table 17. Time in therapeutic range (%ITR and %TTR) in Group 2 patients stratified 








Mean difference (95% 
Confidence Interval)† 
p-value§ 

































5.34 (-2.90, 13.58) 0.19 
 † Values are the mean difference between the Model phase and the Doctor phase. 
§ Paired sample t-test. 
%ITR is the percentage of INR measurements in therapeutic range. 
%TTR is the percentage of time in therapeutic range.  
 
5.3.2.3. Frequency of INR measurements per month  
      The frequency of INR measurements per month of the Model phase was slightly 
higher than that of the Doctor phase. The median of INR measurements was 2.3 
measurements/month for the Model phase and 1.9 measurements/month for the Doctor 
phase (p = 0.08) (Table 12). 
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5.3.2.4. Frequency of dose alterations 
     The frequency of dose alterations of the Model phase was statistically significantly 
higher than that of the Doctor phase (median 6.50 for the Model phase and 2.5 for the 
Doctor phase, p = 0.02) (Table 12). Patients were grouped according to the indication of 
warfarin treatment into those with Fontan procedure and those with mechanical heart 
valves. The number of dose changes of the Doctor phase was lower than that of the Model 
phase for both indications (p = 0.08 and p = 0.53 respectively) (Table 18). The number 
of dose changes of the Model phase was also higher than that of the Doctor phase for the 
target INR ranges 1.5-2.5, 2.0-3.0, and 2.5-3.5 (p = 0.56, p = 0.02 and p = 0.26, 
respectively). In contrast, there was a trend, though not statistically significant, for the 
number of dose changes during the Model phase to be lower than that of the Doctor phase 
for other target INR ranges (p = 0.47) (Table 18). 
Table 18. Number of dose alterations in Group 2 patients grouped according to the 
indication of warfarin and the target therapeutic range. 



























5.83 (-16.13, 27.8) 0.53 


























-8.67 (-51.28, 33.95) 0.47 
† Values are the mean difference between the Model phase and the Doctor phase. 




5.3.2.5. Over-anticoagulation (INR ≥ 4.0 and ≥ 5.0) 
      The number of INR measurements that were ≥ 4.0 and ≥ 5.0 was compared between 
the Model phase and the Doctor phase. There was no statistically significant difference 
between the two phases of treatment in the number of INR values ≥ 4.0 (p = 0.9) and 
those ≥ 5.0 (p = 0.8). Summary statistics of the INR values ≥ 4.0 and ≥ 5.0 of the Model 
phase and Doctor phase are shown in Table 19.  
Table 19. Descriptive Statistics and p-values for INR ≥4.0 and ≥5.0 for Group 2 patients. 
 Mean (SD) Minimum Maximum Interquartile range 
25th (Median) 75th 
INR ≥ 4 Model phase† 2.5 (5.26) 0 22 0 0 2 
INR ≥ 4 Doctor phase† 3.08 (7.04) 0 29 0 0 1.25 
INR ≥ 5 Model phase§ 0.69 (1.76) 0 8 0 0 0 
INR ≥ 5 Doctor phase§ 0.92 (2.54) 0 11 0 0 0 
† p-value = 0.9, Wilcoxon test. 
§ p-value = 0.8, Wilcoxon test. 
 
The 26 patients were stratified based on the indication of warfarin treatment into those 
with Fontan procedure (N=20) and those with mechanical heart valves (N=6). Summary 
statistics of over-anticoagulation for patients grouped according to the indication of 
warfarin and the target INR ranges are shown in Table 20. For Fontan patients, the 
maximum number of INR values ≥ 4.0 was similar for both treatment phases, whereas 
the maximum number of INR values ≥ 5.0 of the Model phase was lower than that of the 
Doctor phase, however these were not statitistically significant (p = 0.96 and p = 1.0, 
respectively). For patients with mechanical heart valves, the maximum number of INR 
values ≥ 4.0 and the maximum number of INR values ≥ 5.0 of the Model phase were 
lower than those of the Doctor phase, althought this was not statistically significant (p =  
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Table 20. Over-anticoagulation for the 26 patients in Group 2 patients grouped according 




 Nǂ Model phase Doctor phase p-value 
Mean 
(SD) 
Minimum  Maximum  Mean 
(SD) 





20 0† 0 4 0† 0 4 0.96‡ 
INR 
≥ 5.0 
20 0† 0 3 0† 0 1 1.0‡ 





0 22 11.67 
(11.36) 





0 8 3.67 
(4.5) 
0 11 0.49§ 
Target INR range 
   1.5-2.5 
INR 
≥ 4.0  
7 0.57 
(0.79) 
0 2 0.71 
(1.5) 
0 4 0.82§ 
INR 
≥ 5.0 
7 0† 0 0 0† 0 1 0.16‡ 
   2.0-3.0 
INR 
≥ 4.0  
12 0.67 
(1.23) 
0 4 0.33 
(0.65) 
0 2 0.46§ 
INR 
≥ 5.0 
12 0† 0 3 0† 0 0 0.32‡ 
   2.5-3.5 
INR 
≥ 4.0  
4 10.25 
(9.74) 
0 22 10.25 
(8.18) 





0 8 2.75 
(3.2) 
0 6 0.85§ 
   Other  
INR 
≥ 4.0  
3 4 
(6.08) 
0 11 10 
(16.46) 
0 29 0.42§ 
INR 
≥ 5.0 
3 0† 0 3 0† 0 11 0.32‡ 
† Median. 
‡ Wilcoxon test. 
§ Paired sample t-test. 
ǂ N represents the number of patients considered in each subgroup. 
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0.44 and p = 0.49, respectively). The maximum number of INR values ≥ 4.0 and the 
maximum number of INR values ≥ 5.0 for other target INR ranges was lower for the 
Model phase compared to the Doctor phase, however, this was not statistically significant 
(p = 0.42 and p = 0.32, respectively). 
5.3.2.6. Minor bleeding events 
      Only 8 symptom diary cards were received back from the families. Four families 
reported no bleeding events in the entire 12-month period of follow up. For the remaining 
4 cards received, the minor bleeding events were as follows:  
Patient number 2 experienced 5 episodes of excessive bruising from a cut during the 
Model phase. Two of these episodes lasted for 1 minute and the duration of the remaining 
episodes was not reported. No action was required for these events. This patient was in 
the target INR range 100% of the time during the Model phase. 
Patient number 3 experienced 2 episodes of excessive bruising from a cut and 1 episode 
of prolonged bleeding after tooth loss during the Doctor phase. The duration of bleeding, 
as reported by the parent, was one week for the episodes of excessive bruising and 40 
minutes for the bleeding episode after tooth loss. No action was required except in one of 
excessive bruising episodes where the patient was checked at the Accident and 
Emergency department. The INR measurements obtained around the dates specified for 
these events were within the target range for two of the events and slightly above the 
target range for the remaining event. 
Patient number 15 experienced 5 episodes of nose bleeds and 1 episode of excessive 
bruising from a cut during the Model phase. The nose bleeds lasted from 5-90 minutes as 
reported by the parent whereas the duration of the bruising episode was not reported. No 
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action was required for any of the reported episodes. The INR measurements obtained 
around the dates specified for these events were all within the target range. 
Patient number 28 experienced 2 episodes of nose bleeds during the Model phase. One of 
the episodes lasted for 5 minutes and the duration of the other episode was not reported 
by the parent. No action was required for both events. The INR measurements obtained 
around the dates specified for the two events were within and slightly above the target 
range, respectively. 
In addition, there was one patient, from whom the symptom diary card was not received, 
who experienced 2 episodes of nose bleeds and 1 episode of coughing blood during the 
Model phase. The bleeding episodes were reported during the routine phone calls made 
to report the INR measurements. The nose bleeds required cauterisation at the hospital, 
one of which was performed at Glenfield hospital where the consultant stated that the 
bleeds were not caused by warfarin but made worse by it. The INR measurements 
reported for these events were within the target range. 
5.3.2.7. Concurrent medications and intercurrent illness 
     Ten patients were receiving long-term medications concurrently with warfarin during 
both phases of treatment. The medications used and the number of patients using them 
were as follows: sodium valproate (1), enalapril (3), lisinopril (4), spironolactone (1), 
furosemide (1), bumetanide (1), digoxin (2), sotalol (1), sildenafil (1), sodium chloride 
(1), domperidone (1), omeprazole (3), Movicol® (1), loperamide (1), oxybutynin (1), 
desmopressin (1), and cephalexin (1). Of these, two medications have possible drug 
interactions with warfarin. Spironolactone can reduce the effects of warfarin (diuresis can 
increase clotting factors’ concentrations) and omeprazole can cause a minor increase in 
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the effects of warfarin (because of inhibition of R-warfarin metabolism) (Hansten and 
Horn, 2008). However, these medications were used on a long-term basis and any 
possible interaction could be overcome by regular monitoring of the INR. Antibiotics 
were used for intercurrent infections in 6 patients during the Model phase, the Doctor 
phase or both phases of treatment. The use of antibiotics was reported during the routine 
phone calls to report the INR measurements, hence the exact dates for starting/stopping 
antibiotics could not be obtained. Intercurrent illness included cold, infections and 
vomiting that occurred in both phases of treatment. The INR control was variable during 
the periods of antibiotic use and intercurrent illness and was included in the analysis of 
time in therapeutic range. 
5.3.2.8. Assessment of extremely above- and below-range INR measurements 
      To assess the extreme above-range INR measurements, the number of occasions 
where warfarin treatment was withheld and/or vitamin K was used was estimated. 
Warfarin treatment was withheld in 2 patients on 1 occasion for each of them during the 
Model phase. In contrast, the treatment was withheld in 3 patients on 1 occasion for each 
of them during the Doctor phase and vitamin K was used in one of these occasions. 
Similarly, to assess extreme below-range INR measurements, the number of occasions 
where intravenous (IV) heparin or low molecular weight heparin (LMWH) was used was 
also estimated. IV heparin was used in 4 patients on 6 occasions during the Model phase 
as compared to 3 patients on 4 occasions during the Doctor phase. LMWH was used in 
one patient on one occasion during the Model phase. However, this was because the 
teenage patient did not take his warfarin dose and consumed alcohol which led to a drop 
in the INR measurement. 
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5.3.2.9. Missed and overridden doses 
       From a total of 586 INR measurements, missed dosing occurred on 15 occasions 
(2.6%). In addition, there were 22 occasions of dose overriding out of a total of 571 dose 
recommendations made by the model (3.9%) in Group 2 patients. 
5.3.2.10. Effect of genetic and non-genetic factors on warfarin average daily dose 
       The average daily warfarin dose was found to be statistically significantly correlated 
with age (r= 0.64, p < 0.05) (Figure 23) and weight (r= 0.64, p < 0.05). However, body 
weight normalised dose was found to be non-significantly negatively correlated with age 
(r= -0.34, p = 0.09). There was one patient who required very high average daily dose of 
warfarin (about 18 mg/day) (Figure 23). The subsequent analysis was performed after 
excluding this patients. 
 































Patients aged 1-5 years required relatively higher median daily dose of warfarin compared 
to older age groups; however, the difference was not statistically significant (p= 0.17). 
Also, male patients required higher median doses than female patients, but the difference 
was not statistically significant (p= 0.11). Moreover, there was no statistically significant 
difference in warfarin daily dose requirements for the three ethnic groups (p= 0.35) (Table 
21).     
Patients with VKORC1 genotype G/G required statistically significantly higher doses 
than those with G/A genotype (p = 0.01). The median dose for patients with wild CYP2C9 
genotype (*1/*1) as well as those with variant alleles (*1/*2 and *1/*3) was similar (p 
=0.56). 
There was a trend for patients anticoagulated for Fontan procedure to require lower 
warfarin doses than those anticoagulated for mechanical valves but the difference was not 
statistically significant (p =0.16). Similarly, patients with target INR ranges of 1.5-2.5 
and 2.0-3.0 required lower median doses of warfarin compared to those with target range 
of 2.5-3.5 and other target ranges (p =0.07) (Table 21). 
Similar results for the effect of genetic and non-genetic factors on warfarin dose were 
obtained after excluding the patient who required very high warfarin dose. 
5.3.2.11. Effect of genetic and non-genetic factors on time in therapeutic range 
 
      The effect of genetic and non-genetic factors on time in therapeutic range is 
summarised in Table 22. Patients aged 1-5 years had the lowest time in therapeutic 
range compared to other age groups but this was not statistically significant (%ITR, 
p= 0.1, %TTR, p= 0.19). Patients with mechanical heart valves had statistically 
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significantly lower time within the therapeutic range than those with Fontan 
circulation (%ITR, p= 0.04, %TTR, p = 0.04). Patients with the target INR range of 
(2.5-3.5) also had the lowest time in therapeutic range compared to the other target 
ranges, however, this was not statistically significant (%ITR, p= 0.17, %TTR, p= 
0.21). Also, patients with variant CYP2C9 variant alleles (*1/*2 and *1/*3) had lower 
time in therapeutic range than those with the wild genotype (*1/*1) but this was not 
statistically significant (%ITR, p= 0.28, %TTR, p= 0.36). In contrast, patients with 
the wild type VKORC1 (G/G) had lower time in therapeutic range than those with the 
variant allele (G/A), however, this was not statistically significant (%ITR, p= 0.08, 
%TTR, p= 0.11). 
5.4. Discussion 
     This research project has evaluated, for the first time, on a prospective clinical 
basis, warfarin dose management in children using the model-based approach. Dosing 
management involved maintenance dose adjustments after every INR feedback 
obtained from the patients. 
The overall comparison of the percentage of INR measurements in target range 
(%ITR) between the two phases of treatment has shown a small improvement in 
%ITR in the Model phase compared to the Doctor phase (mean difference 0.92%, p 
= 0.84). A further analysis was performed after excluding the 5 patients with medical 
issues. The reason for this exclusion was that the medical issues occurred during the 
Model phase in 4 of these patients as compared to 1 that occurred during the Doctor 
phase. This, therefore, distorted the results of the time in therapeutic range of the 




Table 21. Descriptive statistics and p-values of the effect of genetic and non-genetic 
variables on daily warfarin dose (mg/kg/day)†
Variable N Median Minimum Maximum p-value 
Age groups (years) 
1-5 10 0.2 0.1 0.4 0.17§ 
6-10 6 0.1 0.1 0.2 
11-18 10 0.1 0.1 0.2 
Gender  
Male 18 0.2 0.1 0.4 0.11‡ 
Female 8 0.1 0.1 0.2 
Ethnicity  
White 20 0.1 0.1 0.4 0.35§ 
Asian 4 0.2 0.1 0.2 
Other 2 0.15 0.1 0.2 
Indication  
Fontan 20 0.1 0.1 0.2 0.16‡ 
Mechanical 
valves 
6 0.2 0.1 0.4 
Target INR range 
1.5-2.5 7 0.1 0.1 0.1 0.07§ 
2.0-3.0 12 0.1 0.1 0.2 
2.5-3.5 4 0.2 0.1 0.4 
Other 3 0.2 0.1 0.2 
CYP2C9 genotype 
*1/*1 16 0.1 0.1 0.2 0.56‡ 
*1/x 9 0.1 0.1 0.4 
VKORC1 genotype 
G/G 12 0.2 0.1 0.4 0.01‡ 
G/A 14 0.1 0.1 0.2 
§ Kruskal-Wallis test. 
‡ Mann-Whitney test. 
† Analysis performed after excluding the outlier in Figure 23. 
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Table 22. Descriptive statistics and p-values of the effect of genetic and non-genetic variables on time in therapeutic range (%ITR and %TTR) 
%ITR %TTR 
Variable N Mean (SD) Minimum Maximum p-value Median Minimum Maximum p-value 
Age groups (years)  
1-5 10 58.75(16.13) 36.4 78 0.1† 83.2 52.9 90.5 0.19§ 
6-10 6 72.63(16.51) 57.7 100 84.75 75.7 100 
11-18 10 75.41(18.76) 43.8 100 90.98 69.1 100 
Gender   
Male 18 67.13(18.83) 36.4 100 0.62‡ 86.15 52.9 100 0.94ǂ 
Female 8 71.13(18.07) 43.8 100 86.1 69.1 100 
Ethnicity   
White 20 67.97(19.49) 36.4 100 0.98† 86.15 52.9 100 0.8§ 
Asian 4 68.93 (9.66) 57.7 77.7 87.4 77.8 95.6 
Other 2 71.05(29.77) 50 92.1 88.3 82.2 94.5 
Indication   
Fontan 20 72.30(17.57) 36.4 100 0.04‡ 88.45 59.3 100 0.04ǂ 
Valve replacement 6 55.23(15.44) 44.1 82.3 65.55 52.9 94 
Target INR range  
1.5-2.5 7 79.74(15.52) 63.4 100 0.17† 88.95 75.7 100 0.21§ 
2.0-3.0 12 67.45(17.61) 36.4 94.5 85.75 59.3 99.8 
2.5-3.5 4 55.25(18.25) 44.1 82.3 63.28 52.9 94 
Other 3 62.9 (20.68) 45.4 85.7 77.75 61.5 97.1 
CYP2C9 genotype  
*1/*1 16 72.15(17.25) 36.4 100 0.28‡ 88.45 57.0 100 0.36ǂ 
*1/x 9 63.66(19.92) 43.8 100 80.5 52.9 100 
VKORC1 genotype  
G/G 12 61.50(15.31) 44.1 85.7 0.08‡ 83.25 52.9 97.1 0.11ǂ 
G/A 14 74.23(19.17) 36.4 100 89.4 59.3 100 
† ANOVA test. ‡ Independent sample t-test. § Kruskal-Wallis test. ǂ Mann-Whitney test. 
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The adjusted improvement in %ITR between the Model phase over the Doctor phase 
comparison made after excluding the 5 cases with medical issues has also shown a non-
significant difference between the two phases of treatment (mean difference 5.77%, p = 
0.22). However, the model-based dosing approach was able to achieve more than 50% of 
the estimated effect size (11%). It is also worth noting the difference in %ITR obtained 
from the retrospective data, upon which the effect size and sample size were estimated, 
and that obtained during the Doctor phase of the prospective study. The retrospective data 
included children who started their warfarin treatment between the years 2000 and 2014 
whereas the prospective study follow up period was between November 2015 and April 
2017. The %ITR obtained from the retrospective data was 54.06% whereas that of the 
Doctor phase was 67.9% and 65.5% after excluding the cases with issues. This difference 
may explain the non-significant results obtained from comparing the two phases of 
treatment. 
Similarly, the overall comparison of the percentage of time in target range (%TTR) 
between the Model phase and the Doctor phase has shown a non-significant difference 
between the two phases of treatment (mean difference 5.27%, p = 0.09). However, the 
%TTR of the Model phase was found to be statistically significantly better than that of 
the Doctor phase (p = 0.03) after excluding the 5 cases with medical issues. The reason 
behind obtaining non-significant difference in %ITR and significant difference in %TTR 
may be attributed to the difference between the two approaches in calculating the time in 
therapeutic range. The %ITR is simply the proportion of INR values within the target 
range whereas the %TTR allocates an INR value for each day between subsequent INR 
tests according to the linear interpolation approach (Rosendaal et al., 1993). Although 
having the advantage of being easy to calculate, the %ITR underestimates the time in 
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therapeutic range in children, particularly in the periods of instability during which the 
INR is tested more frequently for dose adjustment. Therefore, the %TTR can provide a 
better estimation of the time in therapeutic range in this population (BISS et al., 2011). In 
addition, in this research project there were many times where the INR measurements 
were very slightly above or below the target range and thus they were considered as out-
of-range measurements. This led to an underestimation of the time in therapeutic range 
calculated as %ITR whereas the %TTR provided a better estimation.  
The subgroup analysis of time in therapeutic range has shown that the model-based 
warfarin dosing has overall improved the time in therapeutic range, though it was not 
statistically significant for most of the subgroups because of the small sample size (Figure 
22). However, the %TTR of the Model phase was statistically significantly higher than 
that of the Doctor phase for patients with Fontan circulation after excluding the cases with 
medical issues. It is also important to note that the model-based approach to warfarin 
dosing did improve the time within therapeutic range for children who were described as 
being more challenging by the health care professionals (Chapter 6). These included 
children below 5 years of age (mean difference in %TTR 4.8%, p = 0.29), adolescents 
(mean difference in %TTR 2.3%, p = 0.58) and children with mechanical heart valves 
(mean difference in %TTR 4.1%, p = 0.51). 
    The median frequency of INR measurements per month was slightly higher for the 
Model phase as compared to the Doctor phase (2.3 vs 1.9 measurements per month). This 
was also because of the slightly above- or slightly below- range INR measurements. 
These measurements were strictly considered as out-of-range measurements during the 
Model phase dosing and hence earlier testing schedules were recommended. In 
comparison, during the Doctor phase of dosing, such measurements were considered to 
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be of little clinical significance by clinicians and hence longer testing schedules were 
recommended. In addition, these results might also have been affected by personal 
experience in warfarin dosing/monitoring during both the Model and Doctor phases. 
During the Model phase, the decision relating to the next INR test was made by the 
researcher and hence it depended on the researcher’s personal experience. Thus, the 
testing intervals tended to be shorter in the early months of study and then longer as more 
experience was gained during the study period. During the Doctor phase, there was also 
inter-individual variability in the dosing/monitoring process depending upon the 
individual doctor’s experience in this process. Senior doctors who were more experienced 
with the dosing/monitoring process tended to recommend longer testing intervals, 
whereas junior doctors with less experience in the process tended to recommend shorter 
intervals (Chapter 6). 
   The median frequency of dose changes was statistically significantly higher for the 
Model phase as compared with the Doctor phase (6.5 vs 2.5). This was because of the 
method of dose estimation by the model where it adjusts the dose to the mean of the target 
range and thus may recommend dose changes for only slight changes in the INR 
measurements (Chapter 2, Section 2.2). In contrast, such slight changes in the INR values 
were not considered of clinical significance and hence, no dose changes were 
recommended during the Doctor phase. The subgroup analysis of the frequency of dose 
changes has also shown that overall the Model phase has higher number of dose changes 
than the Doctor phase. This difference was higher for the target INR range of 2.0-3.0. 
However, this subgroup included three patients with medical issues whose periods of 
more frequent dose changes during the Model phase may have affected the result. 
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   The model-based warfarin dosing resulted in lower levels of over-anticoagulation 
shown as lower numbers of INR values ≥ 4.0 and ≥ 5.0, though this was not statistically 
significant. However, most of the minor bleeding complications reported on the received 
symptom diary cards occurred during the Model phase. Yet, these events occurred during 
periods where the INR measurements were within the target therapeutic range. Besides, 
only 8 out of 26 cards were received back from the families, thus it was not possible to 
estimate which phase of treatment had the greater number of minor bleeding events.  
     As described earlier in Chapter 4, Section 4.4, the local practice at the EMCHC is to 
keep the patients within an acceptable INR range with the concern being more about how 
far the INR measurements were above or below the target range that may predispose to 
the risk of bleeding or thrombosis, respectively. This will be discussed in detail in Chapter 
6. Warfarin treatment was withheld on 2 occasions during the Model phase. In contrast, 
the treatment was withheld on 3 occasions during the Doctor phase and vitamin K was 
used in one of these occasions. Alternatively, IV heparin was used in on 6 occasions 
during the Model phase as compared to 4 occasions during the Doctor phase. This may 
imply that model-based warfarin dosing can improve the anticoagulation control of 
warfarin particularly that regarding reducing the incidence of having very high INR 
values that can predispose to bleeding events. 
  Genotype-guided and PK/PD model-based dosing of warfarin in adults has been shown 
to significantly increase the time in therapeutic range (Pirmohamed et al., 2013; Perlstein 
et al., 2012) and decrease the incidence of over-anticoagulation (Pirmohamed et al., 
2013). However, these studies were conducted during initiation of warfarin treatment, 
hence comparison with the findings in this study was not possible.  
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    Age and weight were found to be significantly correlated with the average daily 
warfarin dose. This is consistent with the results obtained from studies conducted in 
children that have also found significant correlations between these demographic 
variables and warfarin dose (Biss et al., 2012; Moreau et al., 2012; Shaw et al., 2014; 
Wakamiya et al., 2016). Patients in the youngest age range (1-5 years) were found to 
require higher weight-adjusted warfarin doses than those in the older age groups, though 
this was not statistically significant. Results from the largest cohort study of children on 
warfarin treatment have shown that children between 1 and 6 years of age required 
significantly higher weight-adjusted warfarin maintenance doses compared to those in the 
older age groups (Streif et al., 1999). In another study, similar findings were observed in 
children aged 1-11 years compared to those aged 12-18 years. This was attributed in part 
to the developmental changes in the weight-adjusted clearance of S-warfarin that was also 
found to be significantly higher in the younger age group. In contrast, the same study 
found non-significant differences in the liver weight-adjusted   clearance of S-warfarin 
and the liver weight-adjusted dose of warfarin (Takahashi et al., 2000). This can be 
explained by the non-linear relationship that exists between drug clearance and body 
weight (B. J. Anderson and Holford, 2008). 
There was a non-significant difference in warfarin dose requirements between patients 
with the wild type CYP2C9 and those with the variant alleles. This may be due to the 
small number of the genotype subgroups. In addition, the study sample did not involve 
any patients with homozygous variant alleles that require the lowest warfarin dose 
requirements. CYP2C9 genotypes were found to significantly affect warfarin dose 
requirement in children in some studies (Biss et al., 2012; Vear et al., 2014) whereas 
others did not find a significant effect (Moreau et al., 2012; Nguyen et al., 2013; Nowak-
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Göttl et al., 2010). Conversely, patients in this study with the wild type VKORC1 were 
found to have statistically significantly higher warfarin doses than those with the 
heterozygous variant allele. Similar findings were obtained from previous studies 
conducted in children (Biss et al., 2012; Moreau et al., 2012; Nguyen et al., 2013; Vear 
et al., 2014; Wakamiya et al., 2016), however, other studies found non-significant 
difference in warfarin dose requirements between children with the wild type VKORC1 
and those with the heterozygous variant allele (Nowak-Göttl et al., 2010; Shaw et al., 
2014). It is also important to note that the study sample did not involve patients with 
homozygous VKORC1 variant allele, therefore it was not possible to assess its effect on 
warfarin dose requirement. 
Despite being non-significantly different, patients with Fontan circulation tended to 
receive lower warfarin doses than those with mechanical heart valves. This may be due 
to the lower target INR ranges used for patients with Fontan circulation due to the lower 
levels of anticoagulation required or due to the presence of an underlying abnormality in 
liver function (Whiteside et al., 2016; Kaulitz et al., 1997). Warfarin dose requirement 
was found to be significantly lower in patients with Fontan circulation as compared to 
other indications in some studies (Biss et al., 2012; Shaw et al., 2014), whereas other 
studies found non-significant difference (Nguyen et al., 2013; Wakamiya et al., 2016).  
Interestingly, there was one patient who required very high average warfarin maintenance 
dose (about 18 mg/day). This may be attributed to warfarin resistance due to rare 
mutations in VKORC1. However, malabsorption, poor adherence and PK interactions 
need to be excluded and serum warfarin concentration measured to confirm the likelihood 
of warfarin resistance (Rost et al., 2004; HARRINGTON et al., 2008). 
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    The effect of genetic and non-genetic factors on the time in therapeutic range was also 
evaluated. Patients in the lowest age range (1-5 years) tended to have lower time in 
therapeutic range than the other age groups, though the difference was not statistically 
significant. The largest cohort study in children has shown that children aged between 1 
and 6 years had significantly lower percentage of INR values in the target range than older 
patients (Streif et al., 1999). This can be attributed to several factors. The maturation of 
the coagulation system approaches near-adult levels by 6 months of age. However, the 
levels of the coagulant and anticoagulant proteins are still 20% lower than the adult values 
until late teenage years (Monagle et al., 2006) which can cause variable response to 
warfarin. Besides, children in this age group are more susceptible to inter-current illnesses 
such as infections, diarrhoea and vomiting  which may require the use of antibiotics and 
this may affect the absorption and metabolism of warfarin and hence the response to the 
it (Monagle, Newall and Campbell, 2010). These findings were also demonstrated in the 
accounts obtained from the doctors and nurses at the EMCHC (Chapter 6) who confirmed 
that warfarin treatment control was challenging in this age group. 
Patients with Fontan circulation had significantly higher time in the therapeutic range 
than those with mechanical heart valves. Streif et al. (1999) study found non-significant 
difference in the percentage of in-range INR values between children grouped into 
Fontan, congenital heart disease (CHD) and non-CHD indications (Streif et al., 1999). In 
contrast, in a different study, children anticoagulated for mechanical mitral valves were 
found to spend significantly lower time within the target therapeutic range than those 
anticoagulated for Fontan circulation and mechanical aortic valves (Bhat et al., 2010). 
Besides, mechanical mitral valve replacement was found to be the only factor associated 
with poor anticoagulation control (Bhat et al., 2010). Moreover, other study results have 
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shown that children with mechanical heart valves had the lowest time in the therapeutic 
range compared to other indications for warfarin in the cohort studied (Jones et al., 2016). 
Furthermore, in a study of a cohort of 25 children with mechanical heart valves, only 44% 
of the INR observations were within the target therapeutic range (Wong et al., 2011). 
However, none of these studies has identified factors associated with the low time in 
therapeutic range observed in children with mechanical heart valves. Interestingly, the 
doctors and nurses at the EMCHC thought that the frequent INR monitoring and dose 
changes in children with mechanical valves was the cause of the fluctuating INR control 
in this population. This will be discussed in detail in Chapter 6.  
Patients with the wild type CYP2C9 showed a tendency to have higher time in the target 
therapeutic range. This is consistent with a previous study results which showed that 
children with heterozygous variant alleles of CYP2C9 had higher frequency of above-
range INR values than those with the wild type allele (Ruud et al., 2008). In contrast, 
patients who were heterozygous for the variant VKORC1 allele showed a tendency to 
spend longer time in the therapeutic range. In a study conducted in children during the 
first 6 months of warfarin treatment, VKORC1 variant allele was also shown to be 
associated with greater time in the therapeutic range in children in the first 6 months of 
warfarin treatment (Hawcutt et al., 2014). 
    A limitation in this research project was the small sample size. However, this work was 
designed to be a pilot study to assess the model-based warfarin dosing in clinical practice 
and the sample size was estimated accordingly. The cross-over design was selected to 
minimise the likelihood of inter-individual variability in warfarin dose/response. The 
cross-over design was also chosen in order to reduce the sample size required to obtain a 
statistically significant difference as a parallel design would require larger sample sizes 
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that would be more difficult to recruit and manage within the limited time and resources 
available for the study. Another limitation of the study was that there was no wash-out 
period upon crossover from one phase to another and also upon randomisation to the 
Model phase. This may have affected the results of time in the therapeutic range when 
the INR on crossover/randomisation was out-of-range. However, the wash-out period was 
not feasible in this study as children required constant anticoagulation with warfarin to 
prevent TE events and withholding warfarin treatment could predispose children to 
serious events that might be life-threatening. 
    This study has also involved challenges in the recruitment and follow up periods. The 
recruitment process was difficult and time-consuming. Families had to be first 
approached by the cardiac liaison nurse during the regular phone calls to report the INR 
values or the hospital follow up visits. This was time-consuming taking into account the 
usual daily workload of the nurse. In addition, the consenting process was done through 
the post and was also very time-consuming. Posting the participant information sheets to 
families, making the phone calls to discuss the study details with the parents and getting 
the signed consent/assent forms back from the families were very-time consuming. 
Moreover, the recruitment process was difficult where there was a total of 48 families 
screened from whom only 29 families consented to participate in the study. Some families 
provided reasons for their declined consenting whereas others did not. The reasons 
provided by the families included either family circumstances, change in the child’s 
medical condition which made the parents no longer willing to participate or the parents’ 
concerns about their child’s involvement in the study despite reassurance that the model-
derived doses would be reviewed by the doctors before being prescribed to their children. 
Furthermore, there was a significant number of families who did not respond to the phone 
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calls made by the researcher. Some of these families sent signed consent/assent forms 
whereas others did not, the thing that was also difficult and time-consuming during the 
recruitment process. 
Besides, the follow up period was very challenging. Parents of children on long term 
warfarin treatment could ring or come to the hospital anytime during the day to report the 
INR test result or perform the INR test, respectively. Their warfarin dose could 
subsequently be reviewed and adjusted by any of the doctors available in the hospital. For 
children in the Model phase of treatment, this was challenging to the researcher as this 
could happen anytime during or out of the workday hours, for example very late in the 
evening or during weekends and bank holidays. The researcher had to chase the INR test 
results for the patients, and especially those who did not ring during the workday hours 
in order not to be mistakenly dosed by the doctors. However, dosing was missed on some 
occasions where the doctors/nurses did not recognise that those patients were on the 
Model phase of the study. The challenge of chasing the INR test results and dosing outside 
the workday hours involved inpatients too. Hospital admissions could be at Glenfield 
hospital, other hospitals in Leicester, or in hospitals that are outside Leicester. Despite 
being also dosed at the EMCHC, warfarin dosing was also missed on some occasions for 
the inpatients. In addition, there was the issue of some families who did not ring or come 
to hospital to test the INR on the prescheduled times and some others who used to ring 
only when the INR is outside the target range which has affected the study results.  
Despite all limitations and challenges, this research project in children on long-term 
warfarin treatment has shown that model-based warfarin treatment can improve the time 
in therapeutic range, particularly for children with Fontan circulation, and reduce over-
anticoagulation. Although the aimed 11% effect size was not achieved in the overall 
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results of %ITR and %TTR, it was obtained in the results of %TTR after excluding the 5 
cases with medical issues. However, model-based warfarin dosing was associated with a 
higher frequency of dose alterations. Further studies with larger sample size are required 
to assess the model-based warfarin dosing in children. A sample size that includes a 
greater number of children with mechanical heart valves and more children with variant 
alleles of CYP2C9 and VKORC1 would provide a more conclusive evaluation of the 
model-based warfarin dosing. This would also provide a better understanding of the 
effects of genetic and non-genetic factors on warfarin dose requirement and time in 







      
     Chapter Six 




Chapter 6: The qualitative study: Exploration of the experience of 
patients/parents and health care professionals of warfarin treatment 
and the new dosing approach 
6.1. Introduction 
       The maintenance of optimal warfarin therapy involves not only adherence to the 
prescribed regimen, but also careful attention to diet and medicines that may interact with 
warfarin, restriction of alcohol intake and being cautious about physical activities that can 
predispose to injuries and bleeding. It will therefore be appreciated that there is a 
multitude of factors that can add a significant burden both on the child and the parents. 
Therefore, it is pivotal to explore the lived-experience of being involved in warfarin 
dosing and monitoring to gain an in-depth understanding of how patients/parents handle 
the day-to-day warfarin treatment. Lived-experience means understanding the 
perceptions, beliefs and attitudes of managing warfarin treatment through the eyes of the 
patients and parents to enhance warfarin control in this population.  
Individualising warfarin dosing by taking into account the factors that affect its PK and 
PD is pivotal. However, the application of the new dosing approach in clinical practice 
requires not only the results of the clinical trial that indicate its clinical effectiveness but 
also the acceptance of both the health care professionals and the patients/parents. 
Therefore, it is important to also explore the experience of the doctors and nurses involved 
in warfarin dosing and monitoring as well as that of the patients/parents with the new 
dosing approach. In addition, it is essential to obtain an in-depth understanding of how 
warfarin dosing and monitoring is performed in usual clinical practice to improve the 
performance of the new dosing approach to be suitable for daily clinical care. Therefore, 
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it is pivotal to explore the lived-experience of the doctors and nurses with managing 
warfarin treatment.  
     This research project involves exploring the views and perspectives of patients/parents 
and health care providers about the long-term management of warfarin treatment in 
addition to their views of the new warfarin dosing approach. 
6.2. Methodology  
See Chapter 2 Section 2.5 
6.3. Results 
       Eleven interviews were conducted and transcribed verbatim (Appendix 7). In order 
to retain the participants’ confidentiality, pseudonyms have been used (Table 23). 
 
Table 23. Pseudonyms and descriptions of the study participants. 
John A 17-years old patient (Group 2) 
Grace Mother of John 
Michelle and Evan Parents of a 2-years old patient (Group 2) 
Sonya Mother of a 3-year old patient (Group 1) 
Kamya Mother of an 8-year old patient (Group 1) 
Sarah  Consultant paediatric cardiologist 
George  Paediatric cardiology registrar 
Taj Paediatric cardiology registrar 
Shirley  Cardiac liaison nurse 





6.3.1. Doctors’ experience with managing warfarin therapy post cardiac surgery 
       Analysis of the doctors’ interviews led to the emergence of three major thematic 
areas; the medical and clinical knowledge, the INR monitoring and the dose decision. 
6.3.1.1. The medical and clinical knowledge 
       The medical and clinical knowledge of the doctors was perceived to play a central 
role in the process of managing warfarin treatment in children. Management of warfarin 
treatment involved establishing the target INR range, initial warfarin dosing, overlap with 
heparin, INR monitoring and subsequent dose adjustments. The doctors agreed that the 
key determinants of managing warfarin treatment in children with congenital heart 
disease were the indication for warfarin use and the patient’s clinical condition. At the 
EMCHC, the indications for warfarin use after congenital heart surgery were Fontan 
procedure, mitral valve replacement (MVR) and aortic valve replacement (AVR).  
‘It is depend on the underlying diagnosis… and the difficulties during surgery 
and the size of the patient and… the artificial valve... and the cardiac function’  
(Dr. Sarah, Interview 4, Lines 2796-2798) 
 
‘Oh, when so that’s pretty much depends on the indication and on the 
patient’s condition’                                                                                       
(Dr. George, Interview 3, Lines 2409-2410) 
       The doctors agreed that different target INR ranges were used for the different 
indications of warfarin use. There was also variability in the target INR ranges for the 
same indication and this was dependent on the clinical condition of the patient and the 
consultant’s preference. Higher target INR ranges were used for patients with mechanical 
heart valves than those with Fontan procedure because of the perceived higher risk of 
thrombosis associated with the mechanical valves. According to the doctors, patients with 
MVR were even at more risk of thrombosis than those with AVR. Taj explained that the 
blood flow through the mitral valve is slower than that through the aortic valve and hence 
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there is more risk of thrombosis on the mechanical mitral valves than on the mechanical 
aortic valves. The target INR ranges could be tailored according to the patients’ clinical 
condition where lower target ranges were used when there was a risk of bleeding or 
conversely higher targets were used for patients with small heart valves. In addition, the 
target INR range could be transiently changed if there was an acute change in the patient’s 
clinical condition. Once the acute condition had resolved, the original target range was 
reused.  
‘… we have had patients who have had internal cranial bleeds and things like 
that we have… targeted lower INRs, other patients who have had narrow 
prosthetic valves who we have targeted slightly higher INRs and so it’s not a 
one size fits all’  
(Dr. George, Interview 3, Lines 2447-2450) 
‘Sometimes yes change the target temporary because there is an acute change 
in the situation then when it resolves you go back to your previous target’                                                                                                                  
(Dr. Sarah, Interview 4, Lines 2966-2967) 
    The doctors maintained that warfarin treatment was initiated at a relatively standard 
loading dose of 200 µg/kg. This loading dose might be repeated on the following day if 
the INR value was still low. Afterwards, the warfarin dose was adjusted according to the 
INR level. 
‘OK that tends to [be] a fairly standard initial dose of warfarin that we use 
within 200 micrograms per kilo up to a maximum of about 10 milligrams for 
an initial loading dose then we re-check the level the following day, if the 
level is still low then we’d repeat that and then if it’s at a reasonable level that 
point we’d half that dose of 200 micrograms per kilo’                                          
 (Dr. George, Interview 3, Lines 2401-2406) 
      The overlapping time of warfarin with heparin was also variable and depending on 
the indication for anticoagulation. Because of the perceived higher risk of thrombosis, 
adequate anticoagulation was required for patients with mechanical valves. Therefore, 
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these patients were required to achieve therapeutic levels of heparin and hence longer 
time of overlap with warfarin than those with Fontan procedure.  
     Monitoring warfarin treatment through INR testing and subsequent dose adjustments 
was also dependent on the indication for anticoagulation and the patient’s clinical 
condition. The doctors agreed that they were more cautious with patients with mechanical 
valves, particularly those with MVR, than those with Fontan procedure. The reason 
behind this, according to the doctors, was the perceived higher risk of thrombosis in 
patients with MVR, therefore, these patients were tested more frequently. 
‘… for example we are more lenient with the Fontans because there is no 
immediate risk if they drop significantly on the conduit but with valve 
especially mitral valve we become very anxious if there is.. a significant 
change in the INR.. so we tend to test the valves more frequently and less 
frequently for the Fontans’  
(Dr. Sarah, Interview 4, Lines 2881-2885) 
    The doctors believed that dose adjustments made for out-of-range INR values were 
also variable and dependant on the indication and how far the INR values were out of 
range. The doctors expressed their concerns about INR values that were on the lower side 
of the target range and those which were below the target range in patients with MVR 
because of the associated risk of thrombosis. The general approach adopted by the doctors 
was to keep slightly high INR values to avoid the risk of under-anticoagulation that would 
require hospital admission for intravenous heparin treatment. The doctors were also very 
cautious about stopping warfarin treatment with very high INR values in patients with 
MVR because of fears of severe drop in the INR level and subsequent risk of thrombosis. 
It is important to note that the doctors were more concerned about thrombotic events than 
about bleeding events when monitoring warfarin treatment in patients with MVR. 
Conversely, both below-range and above-range INR values in patients with Fontan 
160 
 
procedure were of less concern to the doctors because of the perceived lower risk of 
thrombosis and bleeding, respectively. 
‘Patients, for example with mechanical mitral valve, I tend to be very cautious 
about reducing the dose too rapidly and.. I’ll err on the side you keep the INR 
slightly high as long as there is no evidence of active bleeding… stop the 
warfarin at that dose, we often find that we get a rebound drop then that will 
need to be admitted for intravenous heparin treatment because he can’t have 
a lower INR with the mechanical mitral valve’.  
(Dr. George, Interview 3, Lines 2500-2510) 
Taj: … Fontan group... because you are not worried of bleeding even after 
6... in practice I haven’t seen patient who bled, so you are not worried, yes 
you want to maintain them somewhere between 1.5 to 4 but even 5 and 6 and 
7, we haven’t seen many bleeding in practice’  
Interviewer: OK so you so you do concern about those.. with low INRs greater 
than those with high [INRs]? 
Taj: Yeah especially with the mechanical valve because there is element of 
clotting. In Fontan group even their INR is low, we can still build up in next 
few days so we are not worried.. if they have a transient few days of low 
INR. 
(Dr. Taj, Interview 7, Lines 3340-3355) 
Treatment of the slightly out-of-range INR values was also dependant on the indication 
of warfarin use. The doctors were less concerned about patients with Fontan procedure 
who had slightly above- or below-range INR values. However, more concerns were 
expressed about patients with mechanical heart valves who had slightly below-range INR 
values, and once again, because of fears of risk of thrombosis. George also thought that 
these slightly out-of-range INR values could be attributed to the possibility of errors in 
the home INR testing machines.  
‘… If you’ve got a patient who has a Fontan circuit who’s on anticoagulation, 
it’s not a 100% critical where the INR is 2 as a long-term persisting 1.9 or 
1.8. If you have a patient with mechanical valve in and their INR is very 
slightly high you got a target of 3 to 4 and it’s 4.1, again I’m not worried 
about that so much. If you have patient his INR erring on the low side [and] 
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he’s got mechanical valve then yes I would do something about that, so it’s 
very much take the clinical picture in’  
(Dr. George, Interview 3, Lines 2531-2540) 
Personal experience in prescribing warfarin was perceived to be very important in dose 
decision in response to changes in the INR values. The doctors felt that there was 
variability in prescribing warfarin doses between different doctors where some doctors 
tended to over-treat the slightly out-of-range INR values. 
 ‘… even there is some.. interpersonal variation among the doctors. The dose 
which I’m going to prescribe not necessarily exactly the same dose would be 
prescribed by my other colleague’  
(Dr. Taj, Interview 7, Lines 3429-3431) 
‘I also think sometimes… some of the doctors over-treat the slightly high 
slightly low results and tend to not have the idea of what’s happening with 
trying to smooth everything out’  
(Dr. George, Interview 3, Lines 2756-2758) 
      In their accounts about the obstacles encountered in maintaining therapeutic INR 
levels, the doctors agreed that INR control was very difficult in young children, 
particularly those under one year of age. George explained that children in this age group 
were more susceptible to infections and illnesses like diarrhoea and vomiting which could 
affect warfarin absorption. Besides, the more frequent antibiotics’ use in this age group 
could interfere with the liver metabolism of warfarin. Moreover, the use of formula milk 
that contains vitamin K in this age group could counteract warfarin action. Furthermore, 
the accuracy of dosing of the liquid dosage form of warfarin was questioned, particularly 
that relating to adequate shaking of the bottles prior to administration and the variability 




The INR control was also difficult in adolescent patients, particularly those with 
mechanical valves. The doctors questioned the adherence of adolescent patients to 
warfarin treatment and pointed out the issue of alcohol intake in this age group that could 
affect the anticoagulation control of warfarin. 
‘The younger children, they can even have quite labile warfarin control 
particularly patients under the age of one, they are very very difficult…’ 
(Dr. George, Interview 3, Lines 2606-2607) 
‘There are few.. adolescent patient with the mechanical valves who we 
sometimes question their dosing and they have.. recreation thing or alcohol 
and all these things, so that sometimes interfere with the controlling of their 
INR within range and few of them would even miss warfarin..’  
(Dr. Taj, Interview 7, Lines 3163-3167) 
   According to the doctors, guidelines for warfarin dosing and INR monitoring were 
available, however, they were individualised according to the clinical conditions of the 
individual patients.  
‘There are guidelines but they can be individualised to a certain degree to 
various circumstances’  
(Dr. George, Interview 3, Lines 2453-2456) 
6.3.1.2. The INR monitoring 
       As described earlier, the key determinants of the process of monitoring the INR level 
were the indication for warfarin use and the patient’s clinical condition. As said by the 
doctors, the use of different target INR ranges for the different indications of warfarin 
was based on the differences in the risk of thrombosis between the different indications. 
Patients with mechanical heart valves were perceived to have higher risk of thrombosis 
than those with Fontan procedure. Besides, patients with MVR were perceived to be at 
higher risk of thrombosis than those with AVR because, as explained by the doctors, of 
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the slower blood flow through the mitral valve that can increase the risk of thrombus 
formation. Therefore, higher target INR ranges were used for patients with MVR and 
lower target ranges were used for patients with AVR and Fontan procedure. 
‘… patients with the extra-cardiac Fontan conduits.. tend to have a target INR 
of 2 to 3, patients with mechanical mitral valves tend to have a range between 
3 and 4, patients with mechanical aortic valves tend to have a range between 
2.5 and 3.5’  
(Dr. George, Interview 3, Lines 2440-2443) 
The target INR ranges could be individualised according to the clinical condition of the 
patient. For example, lower target ranges were used when there was a risk of bleeding or 
conversely, the use of higher target ranges in patients with very small valves. In addition, 
the target INR ranges could be temporarily changed when there was an acute change in 
the clinical condition of the patient. The original target range was reused when the clinical 
condition had resolved (Section 6.3.1.1). 
         The process of INR monitoring was also dependant on the indication for warfarin 
anticoagulation and the patient’s clinical condition. The doctors expressed more concerns 
about patients with mechanical heart valves, particularly those with MVR, than patients 
with Fontan procedure because of the perceived higher risk of thrombosis. Therefore, 
when monitoring the INR of patients with Fontan procedure, the doctors accepted a wide 
range of INR values above and below the target range. Besides, INR values that were 
slightly above or below the target range were not worrying to the doctors who attributed 
this to the possibility of errors in the home INR monitoring machines. In contrast, in 
patients with mechanical valves, particularly those with MVR, INR values that were on 
the lower side of the target range or those that were below the target range were very 
concerning to the doctors (Section 6.3.1.1). Therefore, the doctors were monitoring the 
INR of these patients more frequently to avoid any possibility of having low INR values.  
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‘And in Fontan group, you are relax because you know higher won’t give 
them bleeding… So there is much big room for them even [if] they fluctuate 
and even [if] they go lower [than] 1.5 or low still it’s not much that risk of 
clotting because there isn’t any mechanical valve’  
(Dr. Taj, Interview 7, Lines 3371-3380) 
‘For mitral valve we do very frequent INR monitoring and simple reason 
being there is more risk [of clotting] so we want to avoid any sort of low INR 
situation hidden…’  
(Dr. Taj, Interview 7, Lines 3131-3133) 
The doctors explained that patients with mechanical valves, particularly those with MVR, 
and having very low INR values needed to be admitted to the hospital to receive 
intravenous heparin treatment. This could be inconvenient for the patients because of the 
hospital admission itself and the need for intravenous access for frequent blood testing 
and receiving treatment. The most worrying group to the doctors were infants with small 
mechanical mitral valves because of the associated high risk of the valve not functioning 
well. Therefore, the doctors preferred to keep slightly high INR values when monitoring 
patients with mechanical heart valves.  
‘… most of the consultants would admit that patient [with MVR] to start an 
intravenous heparin if the INR goes below 2, particularly in smaller patients 
so, mechanical mitral valves in infants are very very high risk group.….. So 
to aid avoid the risk of having this thrombosis, I think it’s more dangerous to 
have a slightly low INR than to have a slightly higher INR. So therefore, when 
I’m dosing them I keep that in mind and I tend to err on the side of keeping it 
slightly high.’  
(Dr. George, Interview 3, Lines 2564-2580) 
More frequent INR testing was also required during the periods of intercurrent illness, 
infections and antibiotics’ use as this could cause a disturbance in the INR control of the 
patients. In contrast, the doctors indicated that patients with Fontan procedure required 
less frequent INR testing because of the perceived lower risk of thrombosis and the wide 
range of INR accepted. 
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‘For a Fontan.. since we have a big range acceptable range from low to [high], 
so we monitor three weekly or four weekly.… although in practice we had to 
do relatively sooner because of this population.. where you have some unseen 
things like diet and for kids.. intercurrent illness, sometimes they are on 
antibiotic or even infection so that determines their.. intermittent change in 
the follow up or frequency of INR checking’  
(Dr. Taj, Interview 7, Lines 3138-3151) 
    The doctors tried to make the time interval between the INR measurements as long as 
possible. After making a dose change, a minimum interval of three days was 
recommended before re-checking the INR level. However, it was sometimes 
recommended to perform the INR sooner to have an idea about the rate of change of the 
INR to help in deciding the next dose of warfarin.  
‘I try to extend the interval to as long as I can because I think if you measure 
a transitional INR, it’s OK as long as you realise that it’s a transitional INR.. 
you don’t react to it too much. And I think sometimes it’s useful to do short 
term INRs to see.. [the] rate of change so you can.. see where things are likely 
to head and if your rate of change is too high then it might make you come up 
a little bit on the next dose, but I usually if I do a dose change I’ll usually try 
and leave it at least 3 days before rechecking’ 
(Dr. George, Interview 3, Lines 2683-2690) 
 
     When the doctors were asked about the obstacles that they faced in maintaining the 
INR in the target therapeutic range, they agreed that the INR control was most difficult 
in two age groups; the young children and the adolescents. Children below 5 years of age 
were more prone to frequent intercurrent illnesses like diarrhoea and vomiting which 
could interfere with warfarin absorption and subsequently the INR control. In addition, 
young children were more susceptible to infections and antibiotics’ use which could affect 
warfarin metabolism and hence the INR control. Moreover, using formula milk which 
contains vitamin K in infants less than 1 year of age was also a contributing factor to the 
INR instability in this age group. Furthermore, the accuracy of the dose administered was 
doubted even when the liquid dosage form of warfarin was used. The other age group 
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where the INR was difficult to control was the adolescent patients. The adherence of 
adolescent patients to taking the medication or taking the prescribed dose of warfarin was 
questioned, besides, the use of alcohol in this age group was also a contributing factor to 
the INR instability (Section 6.3.1.1.).  
‘And we’ve also had some patients.. particularly teenagers.. where 
compliance with taking the medication, we can never know for sure, but we 
think that has been an issue in those patients as well.. you sometimes get these 
patients who you think probably don’t take as much as that been prescribed 
or don’t take it at all or miss some doses then their INR control tend to be 
extremely difficult’ 
(Dr. George, Interview 3, Lines 2628-2634) 
   As described earlier in Section 6.3.1.1, guidelines for the INR monitoring were 
available, however, they were customised according to the clinical conditions of the 
individual patients.  
6.3.1.3. Warfarin dose decision 
       Warfarin dose adjustments were usually made when the INR was out-of-range. Once 
again, the indication for warfarin use and the patient’s clinical condition were the key 
determinants of the dose decision. When deciding warfarin dose, the doctors expressed 
more caution with patients with mechanical heart valves, especially those with MVR, 
than those with Fontan procedure. The reason, as described earlier, was the perceived 
higher risk of thrombosis in patients with mechanical valves. Besides, the dose decision 
was also dependant on how far the INR values were out-of-range and the rate of change 
of INR. As described earlier, slightly out-of-range INR values in patients with Fontan 
procedure were not worrying to the doctors. However, INR values that were on the lower 
side of the target range and those which were below the target range in patients with 
mechanical valves were very concerning to the doctors because of the associated risk of 
thrombosis. Therefore, the doctors favoured keeping relatively high INR values when 
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deciding warfarin doses to avoid the risk of under-anticoagulation that might require 
hospital admissions for intravenous heparin. In addition, the doctors were less concerned 
about the bleeding events associated with very high INR values. Therefore, they were 
very cautious about reducing or stopping warfarin treatment when the INR values were 
very high because of fears of having rapid INR drop to very low levels that might 
predispose to thrombus formation (Section 6.3.1.1).  
     The doctors felt that dose decision was challenging in a group of patients in whom 
very small dose changes were associated with significant changes in the INR values. 
Another challenging group was the very young children with small mechanical valves in 
whom the dose adjustments were very small. Therefore, the doctors were even more 
cautious in deciding warfarin doses in such patients.  
‘It is true that there are a few patients… [who] have a greater response [to] 
little change in the dose so if you increase dose slightly because of their low 
reading you find it going very high so they have a very narrow.. dosing range’ 
(Dr. Taj, Interview 7, Lines 3263-3266) 
‘There’s also the group that have the hardest warfarin control as well because 
the dose change per body weight is such a fine thing even when you use the 
solutions that even a change of 0.2, 0.3 of a milligram can be very difficult 
and also administering that small dose makes the error can be mess, so they 
do tend to be patients with a higher risk as they’ve got a much rather a small 
valve and a small heart and they’ve got labile INRs anyway’ 
(Dr. George, Interview 3, Lines 2572-2579) 
      The doctors’ experience in prescribing warfarin was perceived to be essential in dose 
decision in response to INR changes. There was variability in prescribing warfarin doses 
between different doctors particularly when the INR values were slightly out-of-range, as 
described in the doctors’ accounts in Section 6.3.1.1.  
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Guidelines for warfarin dosing were available, however, they were individualised 
according to the patient’s clinical condition (Section 6.3.1.1). 
6.3.2. Nurses’ experience with managing warfarin therapy post cardiac surgery 
      Four main thematic areas emerged from the analysis of the nurses’ interviews. These 
were the role of the cardiac liaison nurses (CLN) in managing warfarin treatment, 
adherence to warfarin treatment, the INR monitoring and the dose decision. 
6.3.2.1. The role of the cardiac liaison nurses in managing warfarin treatment 
      At the beginning of warfarin treatment, the CLN role was first to educate the families 
on the drug itself, including its action, adverse events and interactions. According to the 
nurses’ accounts, practical ways were used in the teaching process for better 
understanding by the families and written information was provided. The education 
process also involved training on the home INR monitoring machines for the families 
who wished to monitor the INR at home.  
 ‘… practical things like vitamin K is found in for example green vegetables 
and teaching them simply that warfarin is used to thin the blood and there are 
certain food stuffs that contain vitamin K and vitamin K clots your blood… 
if you like broccoli, decide how much you gonna have, is it gonna be half a 
cupful or is it gonna be a cupful and stick to it…. and if you’re going to have 
a pint of beer, you can always have a pint of beer, what you can’t do.. is going 
to have a binge that down the pub at the weekend because that too will 
interfere with your warfarin levels.’  
(Nurse Madison, Interview 6, Lines 4133-4157) 
Nurse Madison felt that families needed time to take all the provided information into 
consideration because of the nature of the medical condition that required frequent 
hospital visits and admissions. She thought that education was a constant process that 
needed to be repeated regularly to enhance the families’ monitoring of warfarin treatment. 
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 ‘I find that it takes a while for that to register. I think because they have lots 
of the other things that they need to take on board with coming to clinics and 
why they’re coming and you know being stressed out because they might 
need to be admitted for a procedure..’ 
(Nurse Madison, Interview 6, Lines 4162-4167) 
‘.. and even now parents who‘ve been using the INR machines for a few years 
when they come in every 6 months to have their comparison check and you 
watch them prick the finger and the way they putting the blood on the strip, 
you thinking to yourself that’s not how I told you how to do it. So you have 
to re-go back and say actually no, don’t keep doing that….’ 
(Nurse Madison, Interview 6, Lines 4404-4409) 
     During monitoring warfarin treatment, the CLN role was to receive the answer phone 
messages from the families, transfer the information provided through these messages 
into the individual patients’ INR charts, transfer these charts to the doctors to prescribe 
warfarin dose and the next INR testing schedule and finally to ring the families back to 
provide them with the prescribed regimen. Nurse Madison felt that this process was 
mostly uncomplicated, however, she expressed her fears when it was occasionally 
unsuccessful to contact the families to provide them with the prescribed warfarin dose 
and the INR testing schedule. 
Interviewer: so is that process always straight forward?  
Madison: nine times out of ten. It only becomes as issue when you’re trying 
to call a parent back and they’re not answering their mobile or the mobile 
number says this phone is not available and then you’re in panic station 
thinking how am I going to get hold of these parents to tell them how much 
warfarin to give their child and when they’re going to retest and am I going 
to be able to get hold of them today. 
(Nurse Madison, Interview 6, Lines 4103-4109) 
     The nurses expressed the need for an anticoagulation service. This was attributed to 
the high volume of phone calls received daily from the families for warfarin monitoring 
which was time consuming. In addition, the nurses felt that the education process was 
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time consuming as well as being a constant ongoing process to improve the families’ 
management of warfarin treatment. Moreover, the nurses felt that having a dedicated 
anticoagulation nurse would enable better communication with the families. From the 
nurses’ perspective, this would enable obtaining better information about the patients’ 
conditions which would improve the dosing/monitoring process and also would give 
more time to answer any queries about warfarin treatment. 
‘The problem is that the message is left on the answer phone, so.. we can only 
do our best to tell parents if it’s out of range can you tell us are they on 
antibiotics, have they had a growth spurt, are they generally unwell…. you 
need to test their INR, you need to ring on the answer phone and you need to 
tell us…. sometimes you’d like to have a dialogue but you know with the 
work load in the day… I think we need full time anticoagulation nurse who’s 
going to be there all the time to constant education, a parents have queries 
whatever, so they can call you up and you can address the issue’ (Nurse 
Madison, Interview 6, Lines 4385-4424) 
6.3.2.2. The INR monitoring 
      The nurses felt that home INR monitoring was more convenient for families. Shirley 
explained that it saved the time of travelling and minimised the time taken off school and 
work for patients and parents respectively. Besides, it provided more flexibility to the 
families during holiday times as well as these periods when patients required more 
frequent INR testing which might be outside the working days. However, there were a 
few families where the nurses felt that hospital monitoring was more convenient for them.  
‘I think there is only a couple of patients who’ve actually preferred to come 
to the hospital and get checked. And I know a girl who lives down the road 
from here actually and she is a teenager and the family could have had an 
INR machine when she was a child, but she never wanted one… She just 
doesn’t want to do it, she just wants to come here and have it done… it’s 
more convenient for her to come here and have it done she doesn’t want 
one’ 
(Nurse Madison, Interview 6, Lines 4268-4281) 
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    Regarding the day-to-day monitoring of warfarin treatment, the nurses felt that the 
doctors were more cautious with patients with mechanical heart valves, particularly those 
with MVR, than patients with Fontan procedure. This was because of the perceived higher 
risk of thrombosis in patients with mechanical valves and its devastating consequences. 
In contrast, the nurses described patients with Fontan procedure as being stable and 
therefore, they were tested less frequently. However, these patients were also thought to 
have periods of INR fluctuations when they had growth spurt or had missed warfarin 
doses. 
‘… well certainly [doctors] are more cautious with the valve patients than 
they are.. with the Fontan circulation… and if their levels are lower then it’s 
not as a disastrous the fact as it would be if you got a mitral valve in place 
and their INR is low which obviously could be disastrous and the valve could 
block off so that’s why they’re more cautious with them’ 
(Nurse Shirley, Interview 5, Lines 3772-3780) 
‘For me, I find that nine times out of ten Fontan patients are quite stable… 
Obviously there are occasions.. if they’ve had a growth spurt or some parents 
have admitted that they’ve forgotten to give warfarin and that does actually 
have a massive impact that sometimes it can take about a week or two before 
they get back to being stable’ 
(Nurse Madison, Interview 6, Lines 4174-4180) 
 From the nurses’ perspective, the doctors’ experience played an important role in 
deciding the frequency of INR testing where less experienced doctors tended to 
recommend shorter testing interval than the more experienced ones.  
‘… so again it depends how much experience they have had of prescribing 
warfarin and they’re sometimes probably a little bit more cautious would 
maybe say check more sooner than some of the more senior doctors’  
(Nurse Shirley, Interview 5, Lines 3786-3789) 
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    When asked about the causes of the fluctuating INR control in children, Shirley thought 
that more frequent INR monitoring and dose changes could lead to such changes in the 
INR control. Besides, she thought that infections and antibiotics’ use could have a 
considerable impact on the INR control. Moreover, growth spurts in children, missed 
warfarin doses, diet, alcohol use by adolescent patients and use of warfarin in young 
children were all perceived as causes of unstable INR control in children.  
‘And again it seems sometimes just tweaking little doses or do not realising 
that actually it’ll take a couple of days to you actually see that effect so giving 
the medication, checking the next day and then making another change before 
allowing that to sort of coming, I think that you end up then sort of chasing 
your tail to try to get back in range’  
(Nurse Shirley, Interview 5, Lines 3816-3820) 
6.3.2.3. The dose decision 
       The nurses perceived that the doctors were more cautious in deciding warfarin doses 
in patients with mechanical valves than those with Fontan procedure because of the risk 
of thrombosis. They thought that dose decisions were also dependant on the doctors’ 
experience where some doctors’ dosing was not consistent. Besides, it was thought that 
sometimes unnecessary dose changes made by the doctors might have resulted in 
fluctuations in the INR control.  
 ‘And sometimes there is no consistency because you know we are all 
individual people. Some registrars, because they are all different, they will 
have their own perspective and will see things you know some are much more 
consistent some aren’t’ 
(Nurse Madison, Interview 6, Lines 4232-4235) 
‘… a lot of our girls will say their INR is very different when they’re 
menstruating and actually if you just look at that pattern but you leave them 
on the same dose, they will return back to normal. But I think people who 
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maybe aren’t as familiar with them will change the dose and then you spend 
weeks trying to get back to where you were to get back into range’  
(Nurse Shirley, Interview 5, Lines 3810-3814) 
Importantly, the nurses stated that there were a few families who were deciding warfarin 
doses themselves. They thought that these families were changing warfarin doses less 
frequently than the doctors. Besides, the nurses thought that the majority of these families 
were right in their decisions because they thought that parents know their child better than 
the doctor. They also stated that the doctors sometimes agreed with the dose decisions 
made by the parents.  
‘… we’ve certainly got some families who are very good and will say this is 
what their INR is today this is what they‘ve been having this is what I think 
they should have and then the doctors will say yeah that’s yes I agree with 
that. So and [families are] usually correct’ 
(Nurse Shirley, Interview 5, Lines 3862-3865) 
‘I think parents are often happier to say well actually it’s dropped before, we 
left it at this and it just went back. Whereas I think we’re probably a little bit 
more cautious and think OK we will change it but then often it’ll be out of 
range though’ 
(Nurse Shirley, Interview 5, Lines 3882-3885) 
‘Yes some consultants do agree the patients do their own dosing. Some say 
no but there are some who are quite happy because they know the parents and 
they think well they can do just a good job’ 
(Nurse Madison, Interview 6, Lines 4435-4438) 
6.3.2.4. Adherence to the prescribed regimen 
      The nurses pointed out that there were a few families who were non-adherent to the 
prescribed warfarin dose. These families were making their own dose decisions and were 
altering warfarin doses less frequently than the doctors. From the nurses’ perspectives, 
parents knew their child the best and they usually looked at the previous INR pattern of 
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their child when making their dose decisions and hence, they were mostly right in their 
decisions. The nurses also stated that sometimes the doctors agreed with the parents about 
their own dose decisions. In contrast, there were families who questioned the dose 
prescribed by the doctors. According to the nurses, these families were usually very 
adherent to the prescribed treatment. 
‘.. parents will say well I told you that the doctor who dosed it, you know 
I’ve said to you it would go up or down, we shouldn’t have done such and 
such, and that’s where sometimes parents actually do know their child 
better’ 
(Nurse Madison, Interview 6, Lines 4227-4230) 
‘There are a handful of families who are not compliant. And there are some 
families who will query what has been prescribed because they say they know 
their child better than the person doing the dosing… nine times out of ten the 
parents who do query the dose are actually the parents who are very 
compliant’ 
(Nurse Madison, Interview 6, Lines 4112-4117) 
    Non-adherence to the prescribed regimen was thought to cause fluctuations in the INR 
control. This was mainly thought to be caused by missed warfarin doses, increased intake 
of vitamin K containing diet or excessive alcohol consumption by the adolescent patients. 
The nurses stated that families usually admitted missing warfarin doses, however, they 
did not admit taking excessive amounts of vitamin K containing diet or excessive alcohol 
use by the adolescent patients. 
‘…parents have said have forgotten to give [the dose], they never say we’ve 
had too much of broccoli or we’ve had too much alcohol I mean nine times 
out of ten for some of my adolescent patients, I know that they’ve been 
drinking but they are not admitting to it but you just know that they are’ 





6.3.3. Families’ experience with managing warfarin therapy post cardiac surgery 
       Analysis of the families’ interviews revealed the emergence of three main thematic 
areas. These included managing warfarin treatment and the coping mechanisms, warfarin 
dose decision and adherence to warfarin treatment. 
6.3.3.1. Managing warfarin treatment and the coping mechanisms 
      The period at the beginning of warfarin treatment was perceived to be worrying to the 
parents. The perceived reason behind this was the nature of the drug itself that requires 
close monitoring to avoid the serious adverse events. Sonya, the mother of a patient with 
Fontan procedure, felt anxious and uncertain about warfarin and compared it to aspirin 
which was previously used. Kamya, also made a comparison with aspirin regarding the 
dose administered where she described warfarin dose as being ‘fluctuating’ and ‘flexible’. 
However, the families accepted the use of warfarin because they believed that it was very 
important for their children’s health.  
‘I was a bit anxious because I know it takes a bit more care or attention than 
the aspirin that she was on. I felt a bit like I didn’t really know what was to 
come whereas with the aspirin because she doing on it for so long we knew 
what to expect’ 
(Mother Sonya, Interview 8, Lines 1106-1112) 
 
‘.. it is very useful for her to take and means to thinner the bloods and for the 
smooth circulation of the blood so in that sense we have accepted that yeah if 
it is so good for [the child’s] health so we’ll accept it yeah’  
(Mother Kamya, Interview 11, Lines 1530-1533) 
 
Afterwards, it was perceived that families gradually started to adapt to warfarin treatment 
and adjust it to the routine daily life. John, the adolescent patient, has described warfarin 




‘I don’t mind it I suppose it’s just become part of my life really so, like I have 
to do it, carry on with it, so it’s like I guess eating now for me. It’s just I’m 
used to it so yeah that’s fine’ 
(Patient John, Interview 2, Lines 694-653) 
The day-to-day management of warfarin treatment involved many aspects. These 
included taking the medication, performing the INR tests and managing diet and 
medicines that might interact with warfarin. The information provided at the start of 
treatment helped the families in managing warfarin therapy. The families stated that they 
were provided with written information about the drug itself as well as lists of medicines 
and foods to avoid. According to the families, there was too much information to consider, 
therefore, time was required to read the information and then tailor it to the children’s 
daily life. 
‘There was a long list of stuff that he [the child] could and couldn’t do… If 
people tell you this is what you have to do on your driving license if you look 
at it all and then like ooh, then actually when you get in the driver seat and 
you do it yourself you learn your own techniques that how to do it, don’ you? 
So that exactly the same as me and Evan with warfarin. We got told the list, 
until you take that list dissect it down take it in and then process it and do it 
yourself, we’ve never have a problem, have we? Since day one’ (Mother 
Michelle, Interview 1, Lines 225-238) 
The families adopted different approaches to remember taking the medications, for 
example taking it with a certain meal, at a specific time of the day or using aids to remind 
them taking the medication. However, the families pointed out that they experienced 
difficulties in remembering to take the medication when it was out of the norm, for 
example when they had been on holidays. 
 ‘…it’s easy and like we’re taking warfarin, we put that in a little pot, don’t 
we? for the week so it makes easy to remember taking it…. It’s when we do 
something that’s outside the norm you know if we go out or something rather 
than, because normally he [John] take it at home with his meal’ 
(Mother Grace, Interview 2, Lines 669-692) 
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In addition, the dosage form of warfarin used was also very important to the families. 
Parents of the younger children expressed their preference of the liquid form. They 
believed that the liquid dosage form was more acceptable by the child, easier and more 
accurate to manage the prescribed dose and had better absorption and better response than 
the tablet form. In contrast parents of older children and the adolescent patient expressed 
their preference of the tablet dosage form. They expressed more convenience with taking 
the tablets, besides, the presence of different colours for the different tablet strengths 
made it easier for them to distinguish between the various strengths of warfarin tablets. 
‘She [the child] loves it which is very easy it’s probably easier to adjust with 
liquid form than it is with a tablet I’d imagine… I don’t know whether with 
warfarin that might be a little bit more difficult because the doses vary so 
much don’t they?’ 
(Mother Sonya, Interview 8, Lines 1287-1307) 
‘… and it [INR] wasn’t coming up and then Madison suggested try giving 
him out of the bottle, the solution, and then we went home, because I think 
[in] children… it seems to work better..’ 
(Father Evan, Interview 1, Lines 356-360) 
‘It’s just easy to get them [tablets] over and done we really just need put them 
in and then it’s done’ 
(Patient John, Interview 2, Lines 828-829) 
‘And I think with warfarin as well I mean I think the fact that there are 
different, the colours as well. I think that helps people with the dose as well’ 
(Mother Grace, Interview 2, Lines 832-833) 
    Monitoring the INR level was a very important aspect in managing warfarin treatment. 
The INR test itself was described to be ‘annoying’ and ‘bothering’ to the patients at the 
beginning of warfarin treatment. Despite adaptation to the test afterwards, John wished 
to have an INR machine that does not involve finger pricking.  
 ‘… I’m sure in about 30 years, surgery will be easier.. I guess there might 
be a different think of the INR machine, like easier, maybe jut you have to 
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put your finger there and scan it I don’t know like temperature or 
something’ 
(Patient John, Interview 2, Lines 1082-1087) 
The home INR monitoring was perceived to be more convenient for families, particularly 
for those who lived outside Leicester. The interviewed families of Group 2 patients had 
their own home INR monitoring machines. They felt more relieved to perform the INR 
tests at home because hospital INR testing would have involved travelling for long 
distances to perform the tests. These tests could be very frequent particularly at the 
beginning of warfarin treatment and also more frequent for younger children. In contrast, 
the interviewed families of Group 1 patients did not have home INR testing machines as 
they were not available to be provided at the hospital. These families lived in Leicester 
and they had to come to the hospital to perform the INR testing. The parents stated that 
they were managing to come to the hospital to perform the INR testing as it was very 
important to monitor warfarin treatment. 
‘.. it made a lot easier have the machine at home… we were probably testing 
too much at the start.. could we be more nervous and anxious about is he in 
range, has he got having a bad day, is it because of the warfarin…’ 
(Father Evan, Interview 1, Lines 253-260) 
‘It’s not too bad and it doesn’t bother us having to come to get it done because 
we know she [the child] needs it doing and I’d rather have it done than have 
to deal with any formal side effects with it so it’s not ideal but it’s not a pain’ 
(Mother Sonya, Interview 8, Lines 1245-1253) 
       Managing diet and medications that might interact with warfarin action was another 
important aspect in managing warfarin treatment. The families emphasised the 
importance of having a balanced diet that would not cause significant changes in the INR 
values. Michelle also mentioned the importance of diet in managing the INR level 
particularly when it was out of the range. 
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‘At home like we’ll say if it’s [INR] really high.. I’ll go to nursery and say to 
them today can he have greens on his plate because then I know naturally 
that’s gonna help bring it down and at home we would go let’s have spaghetti 
bolognese and give him two pieces of garlic bread’ 
(Mother Michelle, Interview 1, Lines 155-158) 
The families were also asked about whether antibiotics’ use had caused any fluctuations 
in the INR control. Families of Group 2 patients stated that they had not experienced such 
fluctuations with the antibiotics’ use whereas families of Group 1 patients stated that their 
children were only newly started on warfarin treatment and they had not experienced 
incidents of infections that required antibiotics’ use. In contrast, Michelle believed that 
growth spurts had significant impact on the INR control of her child. 
‘I think that the only time we struggle with INR dosing than anybody does.. 
is when he [the child] has a growth spurt because it just goes from perfect to 
completely out of the window.. it can go up it can go completely rock 
bottom..’ 
(Mother Michelle, Interview 1, Lines 79-83) 
        Several concerns about warfarin treatment were raised by the families, the 
commonest of which was the easiness of bruising associated with warfarin treatment. This 
was particularly experienced by families of Group 2 patients. For John, the adolescent 
patient, this made him ‘more careful’ whilst performing sports. In contrast, families of 
Group 1 had not experienced incidents of bruising, however, they were advised to be 
more careful about any activities that might cause bruising. 
‘So we’re definitely more careful we’re more aware with the warfarin than 
we were with the aspirin but that’s purely because we’ve been told by the 
professionals that the warfarin is a bit more not risky you just have to be a bit 
more careful’ 
(Mother Sonya, Interview 8, Lines 1212-1216) 
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A different concern was raised by Kamya, the mother of an 8 year old girl from Group 1. 
This was her fears about the menstruation and pregnancy that her daughter would 
experience in the future.  
‘There was some doubts regarding this dose that when she grow young what 
will the problems regarding her periods regarding her pregnancy and all’ 
(Mother Kamya, Interview 11, Lines 1864-1866)  
Grace expressed several concerns about her adolescent son, John, in addition to those 
previously mentioned regarding bruising. She pointed out the issue of alcohol restriction 
that was required with warfarin treatment and hence John would have been different from 
his friends. In addition, she raised the issue of the cost of warfarin tablets and the strips 
used with the home monitoring machine that they would need to pay for after John 
became 18 years old. Moreover, she expressed her concerns about her son’s adherence to 
taking his medication and performing the INR test when he was at college. 
‘…and then obviously when he came to teenages and his peers are drinking 
and John can’t drink really, so which I know it’s probably minor and 
everything but.. that was probably the concern’ 
(Mother Grace, Interview 2, Lines 554-561) 
‘… I think the worst thing is if you’re a bit later but he’s been a teenager, 
you’ve got to go to college and you perhaps miss checking it on that day… 
that’s the only thing that is important to do on the same day’ 
(Mother Grace, Interview 2, Lines 656-660) 
        There was a perceived pivotal role of the family in managing warfarin treatment for 
their sons/daughters. This involved the different aspects of warfarin treatment where 
parents were very careful about ensuring that their sons/daughters had their warfarin 
doses and performed their INR tests. The parents were also careful about managing the 
diet and medications that may interact with warfarin and also to be careful about the 
activities that may put the children at risk of bruising. The family role extended to the 
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financial support of the adolescent to cover the cost of warfarin treatment. Besides, a very 
important role of the family was noticed. This was the attempts of the parent to get older 
children and adolescents involved and hold responsibility of managing warfarin 
treatment. 
‘.. we can afford to pay for it, it’s just a concern like you know he’s lucky 
he’s got his family that will help him find the money but [it] just concerns me 
that’s for those people that aren’t you know’ 
(Mother Grace, Interview 2, Lines 961-963) 
‘I used to take one sentence warfarin is a tablet that thinner the bloods that 
circulates in the body and make your body perfect… So every day I used to 
explain while giving her the dose.. so in this way she has come to know 
everything about what is warfarin and what is going on’ 
(Mother Kamya, Interview 11, Lines 1949-1958) 
Importantly, the family role extended to the self-management of warfarin dosing and 
monitoring. Michelle and Evan felt very confident in their self-management of warfarin 
dosing and INR monitoring for their child. They also felt that they were better than the 
doctors because they lived with their child, knew all his habits and were aware of any 
change in his eating habits or health status that might influence his INR control. However, 
they stated that they were careful in deciding the warfarin dose and that they had discussed 
the suggested dose with the doctors. In addition, they stated that they were cautious in 
monitoring the INR where they were testing the INR sooner than was recommended when 
the INR was out of the range. 
 
‘I say we know, it’s quite cheeky but I say we know how to handle [the 
child’s] warfarin better than when we ring the consultant sometimes because 
we know what he is like in himself in a day, we know what he’s had to eat, 
we know if he’s not feeling particularly well, we know all of his traits. And 
that can sometimes trigger that his INRs fluctuates or how often we should 
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test. Whereas the consultants differ on that opinion, they’re not with him all 
the time’ 
(Mother Michelle, Interview 1, Lines 19-26) 
‘Well a lot of the time we would discuss it with the consultants and Madison 
will sure say OK what did you give and what’s his range she’s actually, I’ll 
let them know and then come back the next day and they go OK you were 
right then..’ 
(Father Evan, Interview 1, Lines 331-335) 
     Another important aspect of managing warfarin treatment was the communication 
between families and health care professionals. A good relationship was perceived to exist 
between the families and both the doctors and the nurses in the hospital as well as with 
the local general practitioner (GP) clinics and pharmacies. Kamya stated that she 
discussed her concerns about her daughter’s future menstruation and pregnancies with 
the nurse Madison. Besides, both Kamya and Sonya expressed their satisfaction with the 
nurses being flexible about arranging the INR testing times in the hospital. In addition, 
the families had expressed their satisfaction with the local GP clinics and pharmacies 
regarding supplying them with warfarin and also regarding answering any queries about 
the drug. 
‘.. Madison has explained [to] me that when she grows, at that time may 
occur excess bleeding due to warfarin when she gets pregnant, then warfarin 
is not good for the foetus. So at that time they will suggest what treatment… 
or what procedure they have to follow’ 
(Mother Kamya, Interview 11, Lines 1867-1872) 
‘Well the liaison nurses have been really good about it... and they’ve [said] if 
we just come straight from school then whenever we get here we get here and 
that’s when they do it so they’ve been good about it so she’s not had to miss 
any school so far’ 
(Mother Sonya, Interview 8, Lines 1255-1260) 
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‘So we’ve kind of got the easier route because our GP is amazing and he said 
whatever [the child] needs, [the child] can have I will prescribe it, it doesn’t 
bother me, so he was like liquid warfarin? yeah no problem, it might cost me 
however many hundreds of pounds a bottle but if that’s what he needs, that’s 
what he’s having’ 
(Mother Michelle, Interview 1, Lines 374-379) 
6.3.3.2. Warfarin dose decision 
      The responsibility of deciding warfarin dose was discussed with the families. Three 
out of the four families interviewed agreed that the best judge for deciding warfarin 
dosing were the doctors. These families preferred that a professional experienced with 
managing warfarin treatment takes the responsibility of making the dose decision. Grace 
further explained that managing warfarin treatment for a long time could give the families 
the experience in manipulating warfarin dose, however, she preferred that an expert with 
warfarin dosing makes the dose decision to ensure safety. 
‘Well the doctors, I presume yeah I assume I mean they’re the ones that do it, 
they seem to know… because when you have the conditions I know I haven’t 
but John has you do get used to managing, however, from a safety point of 
view the doctors are always the best to dose it’ 
(Mother Grace, Interview 2, Lines 698-707) 
In contrast, Michelle and Evan thought that the parents were the best judge of deciding 
warfarin dose. They felt very confident in their own dose decisions and thought that they 
were better than the doctors in deciding warfarin dose. They explained that they knew 
their child better than the doctors because they were living with him and hence they knew 
his day-to-day eating habits, his general health status and what could cause disturbance 
in his INR control like the growth spurts. They further added that it was very difficult to 
convey all this information through a message left on an answer machine to the busy 
nurses that would in turn convey it to the doctors. The parents, however, added that they 
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would discuss the warfarin dose with the doctors and suggested that communication with 
the doctors be improved so that parents could convey all the information required to get 
the best dose decision. 
‘It’s very rare that we are not correct, isn’t it?... because we know what he’s 
eaten we know how much sleep he had we know if he’s a bit under the 
weather that’s really hard to get across on an answer machine saying it’s 2.7, 
it’s really hard to understand that which is difficult’ 
(Father Evan, Interview 1, Lines 43-48)  
‘.. they have so many hundreds of, I’m sure there is so many hundreds of 
patients that ring up with their INRs dosages everyday so there isn’t much 
information you can give over the phone, whether they’ll be there all the day’ 
502-506 
(Mother Michelle, Interview 1, Lines 503-507) 
‘I think when they’re leaving an answering message, it’s kind of like there 
should be sort of like key factors that are ticked in the box to say he’s 
generally well, he’s generally not fine so we know that that dosage is gonna 
stay on an equal basis because then you’re adding more than one factor as a 
variant..’ 
(Mother Michelle, Interview 1, Lines 509-515) 
6.3.3.3. Adherence to warfarin treatment 
      There were several factors that were perceived to influence adherence to warfarin 
treatment in children after congenital heart surgery. First, the importance of warfarin as 
an anticoagulant drug that was required to prevent clot formation was perceived to be 
very important.  The period at the beginning of warfarin treatment was perceived to be 
worrying to the parents because of the nature of the new drug that was introduced to them. 
However, families were aware of the pivotal importance of this drug in preventing clot 




At the beginning of warfarin treatment, the families were provided with manuals and 
handouts that contained information about warfarin as well as the medicines and foods 
that had potential interactions with it. It was perceived that there was excessive 
information provided and that families needed time to read this information and then 
adjust it to the child’s daily life. However, this information was described as being easy 
to understand and helpful to provide information about warfarin. 
‘I found it quite helpful because there was a lot of things about the warfarin 
that I didn’t really know, and it also helped to have that information because 
she started school this year so it helped with having something written to pass 
on to school so they can see it but yeah it filled a few gaps in for us once 
would sat and read it…’ 
(Mother Sonya, Interview 8, Lines 1155-1160) 
The families then developed their own strategies to adjust to warfarin treatment. These 
ranged from strategies to remember taking the dose, manage to perform the INR tests, 
managing diet, restricting alcohol intake for adolescent patients and taking prophylactic 
measures to avoid incidents that may predispose to bruising and bleeding.  
    In addition, warfarin treatment regimen was also perceived to influence adherence to 
warfarin treatment. This included the dosage regimen and the dosage form of warfarin 
used as well as the INR monitoring. Besides, managing diet and restricting alcohol intake 
in adolescent patients was pivotal in managing warfarin treatment. 
Families explained that once daily dosing was easy to manage and different families had 
developed different strategies as reminders. For example, taking the drug with a particular 
meal or at a particular time of the day or the use of aids like pots to remind them to take 
the drug. However, there were some concerns about missing warfarin doses when it was 
out of the usual daily routines, for example during holidays (Section 6.3.3.1). Regarding 
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the dosage form used, families of younger children expressed more convenience with the 
liquid dosage form of warfarin as they thought that it was more palatable, easier and more 
accurate when manipulating the dose and it had better absorption and better response than 
the tablet dosage form. Conversely, families of the older child and the adolescent patient 
expressed their convenience with the tablet dosage form that was easier to be taken. 
Additionally, they found it easier to distinguish between the different strengths of 
warfarin tablets because of the existence of different colour for those different strengths 
(Section 6.3.3.1).  
Home INR monitoring was perceived to be more convenient for the families, particularly 
for those who lived outside Leicester. These families expressed their preference of the 
home monitoring as it precluded the difficulties of travelling to Leicester to perform the 
test. Evan further added that home INR monitoring enabled them to do more frequent 
testing at the beginning of warfarin treatment because they were anxious about keeping 
the INR within the target therapeutic range. In contrast, the two families who did not 
possess home INR testing machines and who were living in Leicester described hospital 
INR testing as being manageable. They also expressed their convenience with the 
flexibility of the testing times that was provided by the nurses (Section 6.3.3.1).  
As described earlier, managing diet that might interact with warfarin was very important 
for stable anticoagulation. The majority of the families interviewed indicated the 
importance of having a balanced diet that contained balanced amounts of vitamin K 
containing foods. Michelle and Evan went even to say that they were using diet as a means 
to aid in controlling the INR when it was out of the target range. In contrast, Sonya 
indicated that diet did not represent an issue for her daughter as she was already not used 
to have excessive amounts of the foods listed in the list that she was provided with. 
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Besides, restriction of alcohol intake by adolescent patients was also very important for 
stable anticoagulation. Grace expressed her concerns about John’s being different from 
his peer friends as he had to restrict his alcohol intake. John also commented on this point, 
however, he denied it to be annoying to him and even gave a positive perspective of the 
issue in that it would be saving money. 
John: so also with like drinks I’m not allowed to, I do drink a bit of alcohol 
but not enough to make me you know 
Grace: no, quite awake isn’t it and it’s at home 
John: yeah it’s at home so I know they go well I’m not old enough to go out 
drinking yet but I’m sure I will always be the one carrying my friends home 
so that’ll be alright 
Grace: also saves lots of money John 
Interviewer: so do you find this like annoying? 
John: no, to be honest, if you look at it at this perspective of money wise, I 
think it’s no, I’ll save a lot of money… 
(John and Grace, Interview 2, Lines 862-871)  
It was also perceived that warfarin treatment had other implications on the patients’ lives 
which were concerning to the families. The families were worried about the risk of 
bleeding associated with warfarin treatment and how easily their children could bleed. 
Therefore, the families stated that they needed to be very careful to avoid any incidents 
that may predispose to bleeding or bruising. For John, the adolescent patient, this required 
him to be ‘more careful’ whilst performing sports to avoid the risk of bleeding. 
        The other important factor that was perceived to influence adherence to warfarin 
treatment was the family role. The family was perceived to play a central role in warfarin 
treatment. This involved the role of the parents in ensuring that their children took their 
medication and performed the INR tests. It also involved ensuring that children had a 
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balanced diet that would not cause significant changes in the INR control. Moreover, it 
involved the financial support to cover the cost of treatment beyond the age of 18 years 
where patients usually had to afford for their own treatment. Furthermore, it involved the 
role of the family in trying to make their children involved in warfarin treatment so that 
they could hold the responsibility of managing the treatment in the future (Section 
6.3.3.1). 
In addition, the age of the child was another important factor to influence warfarin 
treatment. It was perceived that younger children were completely dependent on their 
parents in managing their warfarin treatment. Therefore adherence to warfarin treatment 
in children was perceived to be mostly dependent on their parents’ adherence to it. For 
example, Michelle and Evan felt very confident in their self-management of warfarin 
treatment whereas Sonya preferred that her daughter’s warfarin treatment be managed by 
the health care professional who possessed experience with managing warfarin treatment. 
In comparison, the responsibility of managing warfarin treatment was gradually 
transferred to the older children and adolescents as their parents made them more involved 
in this process. The issue of adolescents’ adherence to warfarin treatment was perceived 
when Grace expressed her concerns about John’s missing the warfarin dose or the INR 
test. 
      Moreover, communication with the health care professionals was another important 
factor affecting adherence to warfarin treatment. A good relationship was perceived to 
exist between the cardiac liaison nurses and the families. Concerns about warfarin 
treatment were discussed with the nurses who provided the relevant information and 
advice about them. Additionally, families who used to perform the INR tests at the 
hospital expressed their satisfaction with the flexibility of the nurses in managing the 
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testing times. Moreover, the families expressed their satisfaction with the local GP clinics 
and pharmacies in providing them with the medication as well as answering their queries 
about the drug itself (6.3.3.1). 
     Most of the families interviewed were perceived to be adherent to the prescribed 
regimen of warfarin that included the prescribed dose and the INR testing schedule. These 
families preferred to follow the doctors’ advice as they were perceived to have the 
experience in managing warfarin treatment. 
‘It’s all according to the advice of the hospital, the doctors, they say that this 
much dose has to be given and this day she has to check the INR, the reports 
of the INR has to be submitted on this day, so it is once they recommend that 
so and so dose and so and so days, she has to be checked then it is my 
responsibility that I have to carry out all this, yeah’ 
(Mother Kamya, Interview 11, Lines 1705-1711) 
Conversely, Michelle and Evan were perceived to be non-adherent to warfarin treatment. 
They thought that they were managing warfarin treatment sometimes even better than the 
doctors as they knew their child better. They also thought that there was too much 
information about the child’s general condition to be transferred to the doctors to enable 
them to prescribe warfarin dose, the thing that a message left on the answer phone 
machine could not do. The parents also stated that they were changing the INR testing 
schedule according to the child’s general condition. For example, to test earlier than was 
advised when the child was not in a good health condition. However, the parents indicated 
that they tended to be ‘sensible’ when managing warfarin treatment because of its serious 
adverse events and that they had sometimes discussed this dose with the doctors. In 
addition, they suggested to improve the communication between the doctors and the 
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families so that families can convey all the information required to make the best 
judgment of the dose. 
‘I would say a lot of the time the consultants would give a dosage and we 
would say we are not quite sure about that we’ll give what we think and we’ll 
tell you what we’ve given and I would say 99%  that we’re correct. It’s very 
rare that we are not correct, isn’t it?’  
(Father Evan, Interview 1, Lines 40-43) 
‘.. I think… [it] would be better if parents in other way were told when you 
ring up we need to know how he is, is he eating well, what’s his INR, is there 
any signs of anything that is unwell and then make a judgment based on that 
because they are all facts that make massive difference to [the child]… and 
we then base what we think to give him on that’ 
(Father Evan, Interview 1, Lines 475-482) 
6.3.4. The experience of the doctors with the model-based warfarin treatment 
      The doctors’ views about the performance of the Hamberg model were sought. The 
model-based warfarin dosing was found to be reasonable and there was only occasionally 
disagreement with the model-predicted doses. From the doctors’ perspective, the model-
based dosing was useful and acceptable in patients who had stable medical conditions 
with no complexities. These included children with Fontan procedure and those with 
AVR. Sarah also added that model-based dosing was useful in older children including 
those with Fontan procedure as well as those with mechanical heart valves. Besides, the 
doctors thought that model-based dosing was consistent and helped to decrease the inter-
individual variability in doctors’ dosing. Moreover, the model-based dosing was thought 
to be faster to the patients than the usual daily process of prescribing. George even went 
to say that making the model available to the patients to adjust their own doses would be 
more convenient for them. 
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‘I think, I tend to find that the computer doses are sensible.. I think I’ve never 
seen any that have been absolutely crazy. I think I would sort of trust it to do 
much of the warfarin doses in patients who don’t have additional sort of 
complexities’ 
(Dr. George, Interview 3, Lines 2721-2725) 
‘… for Fontan and even for aortic valve normally it is consistent with 
whatever we have prescribing accepting some interpersonal variability as 
well, yeah so I think it is within acceptable range of difference in dosing’  
(Dr. Taj, Interview 7, Lines 3436-3438) 
‘… so there is likelihood of more consistency or uniformity of the dosing 
pattern because among the doctors we have different persons prescribing so 
that sort of variability won’t be there’ 
(Dr. Taj, Interview 7, Lines 3449-3451) 
‘I think the computer dosing most advantage that it turns around probably a 
bit faster for the patients you know at the moment the system is that the 
parents call in the INR, one of the liaison nurses takes that down and they 
have to find a doctor to prescribe it, I think if you can cut that stage out, then 
that’ll be a lot faster…’ 
(Dr. George, Interview 3, Lines 2745-2750) 
However, the doctors pointed out that they occasionally disagreed with the model-based 
dosing in certain cases where having low INR values would be of more risk to the patients. 
These cases were mostly patients with MVR and those patients with fluctuating warfarin 
control. The doctors justified that in such circumstances, the model did not take into 
account the clinical condition of the patient, for example if there was impairment in the 
mechanical valve function that was very important in deciding warfarin dose. Therefore, 
George suggested a combined approach in such cases where model-based dosing to be 
combined with a clinical judgment to get the best dose for those patients.  Taj also 
suggested to modify the target INR range used for the model dose prediction to be similar 
to that used by the doctors in clinical practice as described earlier in section 6.3.1.2.   
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‘The only thing where I’m very careful is mitral valve but again rarely I have 
to change.. so I feel it is.. quite matching what we are prescribing, it’s close 
to that’ 
(Dr. Taj, Interview 7, Lines 3439-3441) 
‘I think sometimes you get a patient who got very labile doses, as long as you 
have an experience in prescribing it, I think probably that might be slightly 
more reliable because we’ve got to take a lot of additional factors into account 
that I think probably the warfarin dosing model doesn’t’ 
(Dr. George, Interview 3, Lines 2725-2730) 
In addition, the doctors were cautious about recommending the model to be used in 
clinical practice. The doctors preferred to have more experience with the new dosing 
approach and to wait for the study results before giving their recommendations. 
‘I think it probably needs more time to establish… but it is difficult to say 
whether to be applied completely in practice.. I think  it is very forward it can 
be a replacement…’ 
(Dr. Taj, Interview 7, Lines 3526-3537) 
‘So we have to look into the over result and the success rate and the failure 
rate and the maybe the rate where it had to be individually re-adjusted or 
didn’t agree and then we will know how much this model fit, in a scientific 
numbers’ 
(Dr. Sarah, Interview 4, Lines 3039-3042) 
6.3.5. The experience of the cardiac liaison nurses with the model-based warfarin 
treatment 
      The cardiac liaison nurses also thought that the model-based warfarin dosing 
performed very well for patients with Fontan procedure. Shirley thought that the model-
based dosing also worked very well for some patients with mechanical heart valves 
whereas Madison did not like its performance in these patients. However, the nurses 
thought that the model-based dosing did not change the warfarin dose when the INR value 
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was very low. They had also added that the model-based dosing was associated with 
frequent INR testing, particularly in patients with mechanical heart valves.  
‘I think from what I can see is the computer dosing for patients who are on 
warfarin, I think they are nice and stable I think it’s working really well I 
think for the valve patients, for some patients again it’s working really well, 
for others, I don’t think it is..’  
(Nurse Shirley, Interview 5, Lines 3955-3958) 
‘Fontan patients fantastic. It’s really good. Mechanical valve patients, I don’ 
like it… because they have to be tested much more often’  
(Nurse Madison, Interview 6, Lines 4287-4290) 
The nurses also talked about the families’ acceptance of the model-based doses. They 
pointed out that there were few families who had not accepted the model-based doses and 
preferred to give their own doses, whereas some other families had questioned the model-
based doses.  
‘… I think for most families they’ve been fine it’s been fairly stable I think 
there are a couple who’ve done their own thing which obviously doesn’t help 
the study. There are a few families who’ve questioned when we’ve said the 
computer doses… but when we’ve explained to them well it’s part of the 
study… families have been fine with that’ 
(Nurse Shirley, Interview 5, Lines 3962-3972) 
Regarding their experience with the study, the nurses stated that the model-based dosing 
had not put any patient at risk and that the dosing process was done in a timely manner. 
However, there was the issue of missed dosing when the families were ringing during the 
weekends. The nurses were also cautious about recommending the model-based dosing 




‘I think for some patients it has worked. I think for others I don’t know the 
research may show differently maybe just be my experience from looking at 
the charts. I guess we have to look at the valve patients to see whether to do 
that proper comparison and then to see who’s more, I don’t think the computer 
system put anybody in danger’ 
(Nurse Shirley, Interview 5, Lines 4013-4018) 
‘I want to see the results before I say anything. I want to see the results. For 
Fontan patients I think it’s fine, but I want to see a hard evidence in front of 
me before I answer that question’ 
(Nurse Madison, Interview 6, Lines 4454-4459) 
6.3.6. The experience of the families with the model-based warfarin treatment 
      Families of Group 1 patients were generally asked about warfarin dose changes and 
the frequency of INR testing without mentioning the model-based approach. Sonya 
pointed out that her daughter’s warfarin doses were consistent and did not have any 
extreme changes. In contrast, she stated that the frequency of the INR testing was irregular 
which might be due to the fact that she was recently started on warfarin treatment, 
therefore, she was not stable enough to have longer periods of testing. Besides, Kamya 
preferred to strictly adhere to what she had been advised about warfarin doses and the 
INR testing schedule as she thought that this was the best for her daughter. However, it 
is important to note that she mentioned that she adhered to the doctors’ and hospital’s 
advice in this regard. 
‘It’s fine. We’ve not had anything, her doses tend to be over a similar pattern 
so it’s not, we’ve not had anything drastic’ 
(Mother Sonya, Interview 8, Lines 1278-1279) 
 
‘It’s just random… I don’t know anyway because you tell us when to come 
back don’t you? We haven’t managed to stabilise, say like I know some 
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people who come every three weeks… but they’ve been on warfarin quite a 
while whereas with [the child] she’s just all over the place’ 
(Mother Sonya, Interview 8, Lines 1237-1243) 
      In contrast, a second interview was conducted with families of Group 2 patients to 
ask them about their experience with the model-based dosing approach. John and Grace 
stated that John’s INR control was balanced and stable within the target therapeutic range. 
They also added that there was not very frequent changes in warfarin doses and the INR 
testing schedule. Conversely, Michelle and Evan were not satisfied with the model-based 
warfarin dosing. They thought that the new dosing approach was associated with very 
long INR testing intervals and were adamant that a three-weeks testing interval was 
recommended to them despite that the child’s INR chart did not contain such an interval. 
The parents also stated that the frequency of INR measurements was not consistent 
whereas that of the doctors’ was of more consistency. Besides, they thought that the 
model-derived warfarin doses were very high that had led to increase the INR level above 
the target therapeutic range. They also felt that the INR values were more out-of-range 
during the Model phase than they were during the Doctor phase. The parents hence felt 
more comfortable with the doctors’ management of warfarin dosing. They explained that 
parents had equal responsibility with the doctors and nurses in managing warfarin 
treatment for their child because they know all his day-to-day habits. They also added 
that the doctors and nurses used to take that into consideration, therefore, they preferred 
the doctors’ approach for a better management of warfarin treatment for their child. 
 
‘and I think as well that the nurses understand that parents are just as 
responsible for the dosage as the clinical liaison nurse and the consultants 
because we’re the ones who see what they clinically look like because we’re 
at home with them and you understand your child’s condition when you are 
a parent… and I think the nurses take that into consideration and the 
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consultants so if you all work on a big team we get it spot on every time with 
him normally and we can stay in range for months can’t we?’ 
(Mother Michelle, Interview 9, Lines 2157-2170) 
6.4. Discussion 
       This study explored for the first time the lived-experience of the doctors, nurses and 
patients/parents with managing warfarin treatment after congenital heart surgery. 
Exploration of the doctors’ lived-experience with warfarin treatment provided a detailed 
insight into the process of warfarin dosing and INR monitoring performed in daily clinical 
practice. It was revealed that the indication for warfarin anticoagulation and the patient’s 
clinical condition were the key determinants of all aspects of warfarin dosing and 
monitoring. Patients with MVR were of particular concern to the doctors and infants with 
small mechanical mitral valves were even more concerning to the doctors. Therefore, they 
tended to be very cautious about warfarin dosing and monitoring in patients with MVR.  
During the process of INR monitoring and warfarin dose adjustments, the doctors were 
not worried about strictly keeping the INR values within the target therapeutic range. 
Instead, they accepted a wider range depending on the indication for warfarin use for 
more consistency in dosing. It’s also important to note that the doctors were not worried 
about the bleeding complications associated with very high INR levels but expressed their 
fears of having thrombotic events with low INR levels, particularly in patients with MVR. 
Therefore, they were very cautious about withholding warfarin treatment when the INR 
levels were very high. This approach to dosing is in discrepancy with the local guidelines 
(Appendix 1) which recommend to adjust warfarin doses to keep the INR within the target 
therapeutic range and to stop warfarin treatment when the INR value is above 4.5. The 
doctors agreed the existence of guidelines for warfarin dosing and monitoring, however, 
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they pointed out that they were individualised according to the patient’s clinical 
condition. 
In addition, it was revealed that maintaining the INR within the target therapeutic range 
was most difficult in two groups of patients, those below 5 years of age and adolescent 
patients. The results of Group 2 patients demonstrated in Chapter 5 Section 5.3.2.8 also 
showed that patients aged 1 to 5 years had the lowest time in therapeutic range among all 
age groups, though this was not statistically significant. However, patients aged 11 to 18 
years were shown to have the highest time in therapeutic range but it was also not 
statistically significant.  
Moreover, the doctors described the INR control in patients with Fontan procedure as 
being stable compared to patients with mechanical heart valves, particularly those with 
MVR. The fluctuating INR control in patients with mechanical valves was attributed to 
the more frequent INR monitoring in this group. The results of Group 2 patients (Chapter 
5 Section 5.3.2.8) also demonstrated that patients with Fontan procedure had statistically 
significantly higher time in therapeutic range as compared to those with mechanical heart 
valves. 
      To our knowledge, there is no study to date that has explored the lived-experience of 
doctors with managing warfarin treatment in congenital heart surgery. The doctors’ 
experience of managing warfarin treatment in elderly patients with atrial fibrillation has 
been investigated (Bajorek et al., 2007; Borg Xuereb, Shaw and Lane, 2016). However, 
the main focus was on the need for customised information to aid in decision-making 
about initiating warfarin treatment in these patients as well as to enhance the day-to-day 
management of warfarin (Bajorek et al., 2007; Borg Xuereb, Shaw and Lane, 2016). 
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Another study explored the physicians’ experience with communicating the diagnosis of 
atrial fibrillation and the need for warfarin use, decision-making of warfarin use and the 
systemic barriers for communicating information (Borg Xuereb, Shaw and Lane, 2016). 
     Exploration of the experience of the cardiac liaison nurses provided another insight 
into the process of warfarin dosing and monitoring. The nurses described their role in the 
process and complained of the time consumed during it. Taking into account their other 
work responsibilities, the nurses lacked the time required to have proper communication 
with families during the daily monitoring process. Therefore, the nurses expressed their 
need for a dedicated anticoagulation service for better communication with families 
which in turn can enhance warfarin treatment. Implementation of anticoagulation clinics 
for children has been shown to improve management of warfarin treatment in this 
population (Murray et al., 2015; Newall et al., 2004). A patient-centred service that was 
dedicated for paediatric cardiology patients was not only shown to improve the time in 
therapeutic range but also to be associated with high satisfaction of the patients and 
providers (Murray et al., 2015). 
The major forms of non-adherence to warfarin treatment, as described by the nurses, were 
non-adherence to the prescribed dose, missing the dose, excessive intake of vitamin K 
containing diet and increased alcohol consumption by the adolescent patients.  
No study, to date, has explored nurses’ experience with managing warfarin treatment in 
children after congenital heart surgery. However, the nurses’ perspectives about warfarin 
use in elderly patients were explored (Bajorek et al., 2006). In this study, the nurses talked 
about the patients’ attitudes towards warfarin treatment, the barriers to using warfarin in 
elderly patients, the process involved during initiation of warfarin treatment, their limited 
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role in managing warfarin treatment and how to improve the use of warfarin in this 
population. 
       Exploring the perspectives of patients/parents also provided a very important insight 
into the long-term management of warfarin treatment after congenital heart surgery. The 
period at the beginning of warfarin treatment was felt to be more worrying to the parents 
because of the nature of the new drug being introduced to the treatment. Despite being 
excessive and requiring time to be considered, the information provided at the beginning 
of the treatment was perceived to be helpful to the families for the day-to-day 
management of warfarin treatment. In a study in elderly patients with atrial fibrillation, 
both patients and physicians perceived the lack of information required for managing 
warfarin treatment, particularly that concerning the drug interactions and vitamin K 
containing diet (Bajorek et al., 2007).  
There were several factors that were perceived to influence the families’ adherence to 
warfarin treatment. First, because of the vital importance of the drug for the patients’ 
medical condition, the families accepted warfarin and developed their own strategies to 
adjust it to their daily life. Adjustment to disease and treatment regimen was shown to 
affect adherence. In children and adolescents with end-stage renal disease, poor 
adjustment to disease and dialysis was one of the factors that correlated with low levels 
of adherence to treatment (Brownbridge and Fielding, 1994).  
Second, age was also viewed as another important factor affecting adherence to warfarin 
treatment. Young children were felt to be completely dependent on their parents to 
manage their warfarin treatment. This ranged from a family that was strictly adhering to 
the prescribed regimen to a family that claimed more parental responsibility in deciding 
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warfarin doses. In contrast, in older children and adolescents, attempts were made to make 
them more involved and responsible about managing their own treatment. The non-
adherence issues encountered in this age group were mostly regarding missing the 
dosing/monitoring of the drug and restriction of alcohol intake as described by the 
doctors, nurses and the parent of the teenager patient. In a study of warfarin therapy in 
children, the more likely cause of having non-therapeutic INR levels in patients older than 
15 years was shown to be the omitted doses of warfarin (Newall et al., 2004).  
Third, family factors were another important influence on adherence to warfarin 
treatment. The parents were perceived to be supportive to their children and engaged in 
managing their warfarin treatment. Besides, it was felt that there was a team-based family 
management to adapt warfarin into the routine daily life of the child. Such cohesive family 
environments has been shown to enhance adherence in children and adolescents (Pereira 
et al., 2008). 
Fourth, the treatment regimen was another essential factor affecting adherence to warfarin 
therapy. The once daily dosage was perceived to be convenient for the families. However, 
there were different preferences of the dosage form used according to the patients’ ages. 
In addition, home INR monitoring was felt to be more convenient for the families, 
however, hospital INR monitoring was also manageable by the families. In a previous 
study on children with congenital heart disease, families expressed their dissatisfaction 
with hospital INR monitoring because it involved time off school/work, cost of travelling 
and inconvenience of venepuncture (Duggan, Pearce and Guilbert, 2001). In contrast, 
home INR monitoring of children on long-term oral anticoagulation was felt to be easily 
managed by the families. Additionally, it provided a feeling of empowerment as families 
had more control and involvement in the drug monitoring process. Moreover, it saved the 
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time and reduced stress and anxiety encountered in hospital monitoring (Jones et al., 
2013). Furthermore, it is highly accurate and reproducible (Jackson et al., 2004). 
Fifth, the relationship with the health care provider was also essential in enhancing 
adherence. Good communication was felt to exist between the families and the doctors 
and nurses in the hospital as well as the local GP clinics and pharmacists. Effective 
communication between the families and the health care providers can significantly 
improve adherence to the prescribed regimen which is especially important in patients 
with chronic diseases (Brand, Klok and Kaptein, 2013). 
An important aspect in the process of warfarin dosing and monitoring was making dose 
decisions subsequent to changes in the INR values. Three of the families interviewed felt 
safer when people experienced with managing warfarin treatment took the responsibility 
of making dose decisions. This may be attributable to the high level of families’ trust in 
the doctors’ medical experience, hence they were relying on the doctors in warfarin dose 
decision-making. In contrast, a different attitude was expressed by one family where the 
parents thought that it’s the parents’ responsibility to take this decision as they know their 
child sometimes better than the doctors. This attitude reflects the parents’ claims to be 
involved in decision-making based on their experience in managing warfarin treatment 
for their child. Interestingly, the nurses agreed that families who used to make dose 
decisions were usually right and they also used the term ‘they know the child the best’. 
These two different attitudes towards warfarin dose decision demonstrate the difference 
between adherence; where there is minimal input in treatment decision making 
(Bosworth, Weinberger and Oddone, 2006) and concordance which involves the patients’ 
participation in treatment decision-making (Britten N and Weiss M, 2004). It is therefore 
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important to understand the different attitudes and perspectives of the families to enhance 
warfarin treatment. 
The experience of older patients with warfarin treatment has been explored (Dantas et al., 
2004; Wild, Murray and Donatti, 2009). In a study to explore the perspectives of elderly 
patients about warfarin treatment, the participants tended to have a minimal role in 
decision-making regarding initiating warfarin treatment. Instead, they were more 
dependent on the physicians’ experience to make this decision. Besides, there was a 
perceived low level of knowledge about the drug by the authors. Moreover, the 
participants reported a low impact of warfarin on their daily lives and expressed 
satisfaction with the care provided (Dantas et al., 2004). In contrast, in another study of 
old patients on oral anticoagulation, the participants found that the treatment was 
troublesome, particularly that regarding the INR monitoring and the restriction of diet and 
alcohol. However, the participants accepted the restrictions of the oral anticoagulant 
treatment and the adjustments that it required in their daily life (Wild, Murray and 
Donatti, 2009). 
    Regarding their experience with the model-based warfarin dosing approach, the 
doctors found the new approach useful and acceptable in patients with stable medical 
conditions. These were generally older children and patients with Fontan procedure and 
AVR. They also thought the new dosing approach was more consistent and time saving. 
Additionally, there was only occasional disagreement with the model-derived doses 
where the doctors preferred to have more clinical input which was mostly in patients with 
MVR. Results of Group 1 patients demonstrated in Chapter 4 Section 4.3.2.8 have shown 
that doses were overridden in only 1.9% of the dose recommendations made by the model. 
In addition, results of Group 2 patients demonstrated in Chapter 5 Section 5.3.2.9 have 
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shown that doses were overridden in only 3.9% of the dose recommendations made by 
the model. The nurses also favoured the model-based dosing for use in patients with 
Fontan procedure. However, both doctors and nurses were cautious about recommending 
the new dosing approach for use in clinical practice. They preferred to have more 
experience with the new approach and to wait for the study results before making their 
recommendations. 
From the families’ perspective, there was only one family where the parents expressed 
their dissatisfaction with the model-predicted doses as well as the inconsistency of the 
INR testing schedule. They have further added that their child’s warfarin treatment was 
better controlled by the doctors and hence they preferred the doctors’ approach. However, 
these parents’ accounts were contrasting to their perspectives that were initially disclosed 
during the first interview where they stated that it’s the parents’ responsibility to manage 
the warfarin treatment for their child. Additionally, their accounts about the model-based 
doses and INR testing schedules and the comparisons that they made with the doctors’ 
approach were incorrect. Moreover, in terms of warfarin control for this child, he had 
better control during the Model phase than the Doctor phase of treatment as indicated by 
both the percentage of INR values within the target range (%ITR) and the percentage of 
time within the target range (%TTR). The %ITR for this child was 51.6% and 39.1% in 
the Model phase and the Doctor phase, respectively, and the %TTR was 69.2% and 53.8% 
in the Model phase and the Doctor phase, respectively. The perspective obtained from 
this family may be due to their inability to discuss the model-based doses whereas they 
were able to discuss and change the doses recommended by the doctors. 
A limitation to this study was the small sample size and hence, the selected sample may 
not have been representative of the population. Other potential participants that could 
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have been included are more families whose children requiring very frequent INR testing, 
more teenager patients and junior medical staff. However, interpretative 
phenomenological analysis (IPA) is usually based on small samples as the issue is the 
quality of data, not quantity (Smith, Flowers and Larkin, 2009). In addition, this 
qualitative study was designed to be complimentary to the quantitative study to explore 
the views of families and health care providres about warfarin treatment and the new 
dosing approach and the limited time and resources available for the study precluded a 
larger sample size.  
This study provided a very important insight into the experience of doctors, nurses and 
patients/parents with the day-to-day management of warfarin treatment. Their 
perspectives about the model-based warfarin dosing approach provided a very important 
idea about the acceptability of the new dosing approach and strategies to improve its 
clinical applicability. Additionally, it also highlighted a very important barrier to its 













Chapter 7: General Discussion 
    This research project has for the very first time prospectively evaluated in routine 
clinical practice, personalised warfarin dosing using a PK/PD model. The study timeline 
is demonstrated in Appendix 8.  
The first step in this project, and prior to the prospective clinical study was to assess the 
predictive performance of the Hamberg model in a cohort of 60 post-operative cardiac 
children on long-term warfarin treatment at the EMCHC. Seventy percent of the predicted 
doses were ideal (within 20% of the observed doses) with a bias of -0.10 and precision of 
0.19. The predictive performance of the Hamberg model was previously evaluated in a 
cohort of 49 children on warfarin treatment (Hamberg et al., 2013). The ideal dose 
prediction was also 70%, but the bias was -0.04 and the precision was 0.57. The results 
of clinical accuracy (ideal dose prediction) obtained from the present study was therefore 
similar to that obtained by Hamberg et al (2013) but the bias was higher (-0.10 in the 
present study compared to -0.04 in the Hamberg et al (2013)). This implies a dose 
underprediction of 0.1 mg compared to 0.04 mg, respectively. Conversely, the dose 
predictions were more precise (0.19 vs. 0.57) in the present study compared to the 
Hamberg et al (2013) evaluation. Therefore, the results obtained from the present study 
provided adequate validation of the model for use in children in the EMCHC and gave 
reassurance for the prospective evaluation of the model in routine clinical practice to be 
started. 
The next step in this research project was the prospective clinical evaluation of the PK/PD 
model in routine clinical practice in two groups of patients. Group 1 included five patients 
starting warfarin treatment for the first time after congenital heart surgery. The results of 
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this study showed that model-based warfarin dosing resulted in 22.6% greater percentage 
of INR measurements within the target therapeutic range (%ITR) and also about 21% 
greater percentage of time within this range (%TTR). In addition, model-based warfarin 
dosing resulted in a longer time before over-anticoagulation occurred, fewer over-
anticoagulated patients and shorter time to reach stable anticoagulation when compared 
with the traditional dosing approach. However, the time to reach a therapeutic INR was 
3 days longer using the model-based dosing approach when compared to the traditional 
dosing approach.  
Group 2 included 26 patients who were maintained on long-term warfarin treatment. The 
overall analysis of the %ITR and the %TTR between the model-based approach and the 
traditional dosing approach showed small improvements in both %ITR (mean difference 
0.92%, p = 0.84) and %TTR (mean difference 5.27%, p = 0.09), though these were not 
statistically significant. However, the %TTR of the model-based approach was 
statistically significantly higher than that of the traditional approach (p = 0.03) after 
excluding 5 patients who experienced medical issues during either phase of treatment. 
Interestingly, the sub-group analysis showed that the %TTR was statistically significantly 
higher in patients with Fontan procedure using the model-based approach than by using 
the traditional approach after excluding the 5 cases with medical issues. In addition, the 
%TTR in patients with mechanical heart valves was also improved by using the model-
based dosing approach, though this was not statistically significant (mean difference 
4.1%, p = 0.51). In addition, the frequency of INR measurements per month was 
comparable between the two treatment approaches. Moreover, the model-based approach 
was associated with lower levels of over-anticoagulation when compared to the 
traditional approach, although this was not statistically significant. However, the number 
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of dose changes was statistically significantly higher in the model-based approach when 
compared to the traditional dosing approach. This was because of the method of dose 
estimation by the model where it adjusts the dose to the mid-value of the target INR range. 
Thus, the model may recommend unnecessary dose changes for only slight changes in 
the INR observations which may not be clinically significant.  
The PK/PD model-based warfarin dosing that takes into account the effect of genetic and 
non-genetic factors on warfarin PK and PD was never tested clinically, on a prospective 
basis in children. However, genotype-guided warfarin dosing was previously investigated 
in children starting warfarin treatment (Tabib et al., 2015). The study revealed that 
genotype-guided dosing of warfarin significantly decreased the time to stable dose and 
hospital stay days but found no difference in time to first therapeutic INR, time before 
over-anticoagulation occurred and bleeding events when compared with the standard 
dosing approach (Tabib et al., 2015). In addition, genotype-guided warfarin dosing was 
also investigated in adults starting warfarin treatment (Pirmohamed et al., 2013). The 
study revealed that genotype-based dosing of warfarin has resulted in significantly higher 
proportion of time in therapeutic INR range, fewer incidents of over-anticoagulation and 
shorter time to therapeutic INR than the standard dosing approach. Moreover, the PK/PD 
model-based warfarin dosing was investigated in adults and was shown to result in 
significantly higher proportion of time in target therapeutic range, lower proportion of 
out-of-range INR values and shorter time to first therapeutic INR and stable 
anticoagulation when compared to the genotype-guided dosing (Perlstein et al., 2012). 
Furthermore, the PK/PD model-based personalised dosing has previously been shown to 
improve the clinical outcome and reduce adverse events of other narrow therapeutic range 
drugs used in children. One such example is busulfan, an alkylating agent that is used 
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prior to haematopoietic stem cell transplantation (Copelan et al., 1991). Busulfan is a 
narrow therapeutic range drug that has wide PK inter-individual variability which was 
attributed to multiple demographic, genetic and clinical factors (Bertholle-Bonnet et al., 
2007; Beumer et al., 2014; Choi et al., 2015; Hassan et al., 1994). Therefore, it is pivotal 
to individualise busulfan treatment to avoid both serious liver toxicity (veno-occlusive 
disease; VOD), and graft rejection (Slattery et al., 1995). A model-based approach was 
implemented to individualise oral busulfan treatment in bone marrow transplantation 
children (Bleyzac et al., 2001). The study showed that decreased busulfan doses were 
required in 69% of patients compared to the conventional doses. The researchers also 
reported that the incidence of VOD was significantly lower than the control group and 
the VOD-free survival was significantly higher than the control group. Moreover, the 
engraftment was successful in all patients who received the adjusted dosage regimen 
whereas graft failure occurred in 12% of the control subjects (Bleyzac et al., 2001). 
Hence, it can be concluded that the model-based dose adjustment of drugs with narrow 
therapeutic range can result in more accurate dosing, decreased incidence of serious 
adverse events and improvement of treatment outcome.  
    The qualitative part of this research project involved exploring the experience of 
doctors, nurses and families with managing warfarin treatment as well as their views 
about the new dosing approach of warfarin. The doctors provided a detailed insight into 
the process of warfarin dosing and monitoring performed in usual clinical practice. They 
revealed that the indication for warfarin use and the patient’s clinical condition were the 
key determinants of all aspects of this process where patients with mechanical mitral 
valves were of particular concern to them. During the dosing/monitoring process, the 
doctors were not worried about strictly keeping the INR values within the target 
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therapeutic range and adopted a wider range depending on the indication for warfarin use 
for more consistency in dosing. In addition, there were less concerns about the bleeding 
complications associated with very high INR levels than about the thrombotic events 
associated with low INR levels, particularly in patients with mechanical mitral valves. 
Moreover, the doctors revealed that INR control was most difficult in of patients below 5 
years of age and adolescents.  
The cardiac liaison nurses provided another insight into the process of warfarin dosing 
and monitoring. They described their role in the process and felt that it was time-
consuming. Therefore, they expressed the need for a dedicated anticoagulation service 
for better communication with families, which in turn can enhance warfarin treatment. 
The nurses also thought that home INR monitoring was more convenient than the hospital 
monitoring for most of the families. In addition, the major forms of non-adherence to 
warfarin treatment, as described by the nurses, were non-adherence to the prescribed dose, 
missing the dose, excessive intake of vitamin K containing diet and increased alcohol 
consumption by the adolescent patients.  
The experience of the doctors and nurses with the model-based warfarin treatment was 
also investigated. There was an overall acceptance of the new dosing approach 
particularly in stable patients who were mostly those with Fontan procedure. However, 
the doctors recommended that model-based dosing is accompanied by clinicians’ 
judgment in patients who have medical complexities. In addition, they suggested the use 
of target INR ranges similar to those used in clinical practice to enhance the clinical utility 
of the model. Moreover, both doctors and nurses preferred to have more experience with 
the model-based warfarin treatment and to wait for the study results before recommending 
it for use in the usual clinical practice. This may be because in order to apply a new 
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intervention in clinical practice, evidence-based information about its safety and efficacy 
is required to support its clinical use. 
To our knowledge, this is the first study exploring the experience of the doctors and nurses 
with managing warfarin treatment in children after congenital heart surgery. Doctors’ and 
nurses’ experience of managing warfarin treatment in elderly patients with atrial 
fibrillation has been previously investigated (Borg Xuereb, Shaw and Lane, 2016; 
Bajorek et al., 2006). However, the focus was on the physicians’ experience with 
communication with elderly patients (Borg Xuereb, Shaw and Lane, 2016), whereas the 
nurses provided their perspectives about these patients and the use of warfarin in this 
population (Bajorek et al., 2006). Obtaining a detailed insight into the process of warfarin 
dosing/monitoring performed in usul clinical practice and the views about the new dosing 
approach is very important to enhance the clinical utility of the model-based warfarin 
dosing in children in the future. 
The families’ experience with managing warfarin treatment was also explored. The period 
at the beginning of warfarin treatment was felt to be more worrying to the parents. 
However, with the aid of the provided information, the families then started to adopt 
different strategies to enhance the daily management of warfarin treatment. Several 
factors were perceived to influence the families’ adherence to warfarin treatment. These 
included the importance of the drug for the patients’ medical condition, patient’s age, 
treatment regimen, family role and relationship with the healthcare providers. The 
families also provided their views of warfarin dose decision. Three of the families 
interviewed felt safer when an expert with warfarin dosing/monitoring took the 
responsibility of making dose decisions. In contrast, one family expressed a different 
attitude where the parents thought that it is the parents’ responsibility to take this decision, 
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and consequently they were opposed to the model-based warfarin dosing approach. These 
two different attitudes towards warfarin dose decision demonstrate the difference between 
adherence; where patients are usually required to follow the advice of the healthcare 
provider with minimal input in treatment decision making (Bosworth, Weinberger and 
Oddone, 2006) and concordance which involves the patients’ participation in treatment 
decision-making (Britten N and Weiss M, 2004).  
One study has investigated the impact of warfarin treatment on children with congenital 
heart disease and their parents focusing mainly on INR monitoring in the hospital 
(Duggan, Pearce and Guilbert, 2001). Patients/parents expressed their dissatisfaction with 
hospital monitoring as it involved time off school/work, travelling cost and inconvenience 
of venepuncture. In addition, both children and parents expressed their concerns about 
the risk of bleeding and the responsibility of ensuring regular intake of the medication 
and keeping the INR within the target therapeutic range (Duggan, Pearce and Guilbert, 
2001). Obtaining the families’ perspectives is very important to enhance warfarin 
treatment in children. In addition, understanding their attitudes about dose decision-
making and the new dosing approach is pivotal for the future implementation of the 
model-based warfarin dosing in clinical practice. 
     The results obtained from the present study have shown that the PK/PD model 
performed very well in the clinical setting. This was reflected not only by demonstrating 
an improvement in the time within therapeutic range but also by virtue of overall 
acceptance of health care prpfessionals to the principles and clinical practice of allowing 
a model-based dosing approach as a basis for predicting the most optimum doses of 
warfarin. This was demonstrated quantitatively by showing that only about 6% of the 
model-predicted doses were overridden by the doctors. In addition, the qualitative 
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research indicated the acceptance of both doctors and nurses to the use of the model-based 
dosing approach in patients with stable medical conditions. This acceptance was also 
reflected through the doctors’ suggestions to enhane the clinical utility of the new dosing 
approach.  
Clinically, these findings demonstrate that the new model can improve the 
anticoagulation control of warfarin and hence can result in minimising potentially serious 
adverse events such as bleeding or, conversely, thrombosis. The model, therefore, can 
potentially reduce the number of hospital admissions that occur due to the need to 
administer intravenous heparin to patients who are under-coagulated or conversely, for 
those with elevated INR levels, admission to administer vitamin K. The results obtained 
from the largest cohort of children on warfarin treatment has shown that the incidence of 
serious bleeding events was 0.5% per patient year whereas that of recurrent thrombosis 
was 1.3% per patient year (Streif et al., 1999).  
The study findings also suggest that the model-based warfarin dosing is more likely to be 
beneficial in patients starting warfarin for the first time after congenital heart surgery. In 
addition, for patients who are on maintenance warfarin treatment, those with Fontan 
circulation who represent the majority of the population at the EMCHC, are more likely 
to benefit from the new dosing approach. Moreover, these findings are likely to replicated 
at other centres, however, further work is required to demonstrate that. Furthermore, if 
this study was repeated at the EMCHC, the findings could have been further improved if 
the target INR range used for dose estimation was interpreted using the same approach as 
doctors, i.e. that it is not rigid and fixed, but rather flexible and dependent on the clinical 
condition of the patient at the time. The current research findings are supportive of the 
pivotal importance of the model-based personalised dosing in improving the clinical 
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outcomes and reducing the adverse events of drugs with a narrow therapeutic range. It 
extends the current knowledge on the importance of adopting the model-based dosing 
approach of warfarin in children after congenital heart surgery in clinical practice to 
enhance the drug’s anticoagulation control and reduce its adverse events. Therefore, it is 
important to demonstrate the advantages and drawbacks of the application of the PK/PD 
warfarin dosing model in clinical practice. Next, the necessary steps before the 
application of the model-based warfarin dosing can be introduced in clinical practice will 
also be considered. 
7.1. Advantages and drawbacks of the application of the PK/PD model in clinical 
practice 
    The clinical application of the PK/PD model had its advantages and drawbacks. The 
dose prediction by the model was easily performed by the researcher for both a priori and 
a posteriori dose estimation. Additionally, there was more accuracy and consistency in 
warfarin dosing which may help in reducing the inter-individual variability in doctors’ 
dosing. Moreover, as indicated in the nurses’ accounts, the process was relatively rapid, 
hence this can reduce the time required for warfarin prescribing in routine clinical 
practice. Furthermore, the use of point of care genotyping of CYP2C9 and VKORC1 
provided rapid turnaround of the genotype results (Howard et al., 2011) which was 
particularly important for Group 1 patients. However, a posteriori dose prediction 
requires the patient’s INR history to be imported from Excel files that have specific 
requirements of file naming and data format. These files are time-consuming when 
initiated particularly for patients with very frequent INR testing. In addition, the plot of 
the predicted and observed INR values needs to be assessed to obtain the best individual 
fit of the curve for the best dose prediction which needs some understanding of the 
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underlying model and the prediction process. Moreover, the model uses the mean of the 
target INR range for dose adjustment which has led to more frequent dose changes which 
potentially may not be convenient for the families. Indeed, the use of the mean of the 
target range sometimes led to dose predictions that were overridden by the doctors, 
particularly in patients with MVR where the doctors favoured to keep slightly high INR 
values. Furthermore, the dose estimation was mostly performed by the researcher and 
occasionally by the clinical supervisor who had dedicated time for this research. This 
process was very challenging for one person to be responsible for it because patients could 
ring the INR test results or come to the hospital for INR testing at any time in or outside 
the working hours/days.  
Therefore, to implement a PK/PD model-based personalised dosing approach in clinical 
practice requires several additional steps, which will be discussed in the next section. 
7.2. Necessary steps to enhance the implementation of the PK/PD model in clinical 
practice 
    In order to enhance the clinical implementation of the PK/PD model, several steps are 
required. First, the predictive performance of the model needs to be enhanced where dose 
estimations should be adjusted to the entire target INR range and not to the mid-value as 
is currently the case. In addition, the use of a wider target INR range similar to that used 
by the doctors in routine clinical practice is important for more consistent dosing and to 
avoid the risk of under-dosing.  
Second, the entire process would benefit from being performed electronically for more 
convenient use. This involves using electronic medical records and electronic INR charts 
into which the model can be integrated. An electronic system could generate reminders 
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and prompts of when dose adjustments are required as well as prompts for clinicians to 
approve the dose recommended by the model.  
Third, pharmacists and doctors are required to be trained to use the model as the process 
of warfarin dosing and monitoring can take place at any time within or outside the 
working hours/days.  
Fourth, point of care genetic testing of CYP2C9 and VKORC1 is recommended for rapid 
achievement of genotype results. However, this process will involve technical challenges 
in establishing such electronic systems in addition to the administrative challenges 
encountered in approving the new dosing approach for use in clinical practice as well as 
obtaining the acceptance of the medical personnel to be involved in this process. 
7.3. Recommendations for future research 
      This research project has shown that the model-based warfarin dosing can improve 
the anticoagulation control in children with congenital heart disease. The study was 
limited by its small sample size, which meant that statistically significant improvements 
could not be demonstrated for most of the measured outcomes. However, given the results 
of the sub-group analyses and the totality of the data, there is sufficient evidence to 
suggest a positive benefit and hence a multi-centre randomised controlled clinical trial to 
evaluate the clinical effectiveness of the model-based warfarin dosing in children after 
congenital heart surgery should be conducted.  
A larger sample size that includes a greater number of children with mechanical heart 
valves and more children with variant alleles of CYP2C9 and VKORC1 would provide a 
more conclusive evaluation of the model-based warfarin dosing. This would also provide 
a better understanding of the effects of genetic and non-genetic factors on warfarin dose 
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requirement and time in therapeutic range in children on long-term warfarin treatment. In 
addition to the evaluation of the clinical utility of the model-based warfarin dosing, an 
economic evaluation of the new dosing approach is also required. Therefore, a 
pharmacoeconomic study which evaluates the cost of the model-based, genotype-guided 
dosing of warfarin and outcomes such as the incidence of major bleeding and thrombotic 
events and hospital admissions for intravenous heparin or vitamin K use is essential to 
inform decision about the wide use of the new dosing approach in clinical practice. 
7.4. Conclusions 
       This research project has extended the current knowledge on the clinical application 
of the model-based, genotype-guided warfarin dosing in children after congenital heart 
surgery. The new dosing approach can improve the anticoagulation control which is more 
likely to be beneficial in children starting warfarin for the first time after congenital heart 
surgery as well as children with Fontan circulation who are maintained on long-term 
warfarin treatment. Besides, it has demonstrated the overall acceptance of the healthcare 
professionals of the new dosing approach. Moreover, it has provided an in-depth 
understanding of how warfarin treatment is managed in routine clinical practice and the 
challenges encountered in this process. Furthermore, an understanding of how families 
handle long-term warfarin treatment was obtained. However, further work is required to 
establish the clinical effectiveness and cost-effectiveness of the new dosing approach in 
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Appendix 1: East Midlands Congenital Heart Centre guidelines for 























































Appendix 4: Rounding of Predicted warfarin doses 
 
Model dose (mg) Practical dose (mg) 
0.35 – 0.64 0.5 
0.65 – 0.79 Alternating 0.5 and 1.0 
0.8 – 0.99 1.0 
1.0 -1.14 1.0 
1.15 -1.34 Alternating 1.0 and 1.5 
1.35 -1.64 1.5 
1.65 -1.79 Alternating 1.5 and 2.0 
1.8 -1.99 2.0 
2.0 -2.14 2.0 
2.15 -2.34 Alternating 2.0 and 2.5 
2.35 -2.64 2.5 
2.65 -2.79 Alternating 2.5 and 3.0 
2.8 -2.99 3.0 
3.0 -3.14 3.0 
3.15 -3.34 Alternating 3.0 and 3.5 
3.35 -3.64 3.5 
3.65 -3.79 Alternating 3.5 and 4.0 
3.8 -3.99 4.0 
4.0 -4.14 4.0 
4.15 -4.34 Alternating 4.0 and 4.5 
4.35 -4.64 4.5 
4.65 -4.79 Alternating 4.5 and 5.0 
4.8 -4.99 5.0 
5.0 -5.14 5.0 
5.15 -5.34 Alternating 5.0 and 5.5 
5.35 -5.64 5.5 
5.65 -5.79 Alternating 5.5 and 6.0 
5.8 -5.99 6.0 
6.0 -6.14 6.0 
6.15 -6.34 Alternating 6.0 and 6.5 
6.35 -6.64 6.5 
6.65 -6.79 Alternating 6.5 and 7.0 
6.8 -6.99 7.0 
7.0 -7.14 7.0 
7.15 -7.34 Alternating 7.0 and 7.5 
7.35 -7.64 7.5 
7.65 -7.79 Alternating 7.5 and 8.0 
7.8 -7.99 8.0 
8.0 -8.14 8.0 
8.15 -8.34 Alternating 8.0 and 8.5 
8.35 -8.64 8.5 
8.65 -8.79 Alternating 8.5 and 9.0 
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8.8 -8.99 9.0 
9.0 -9.14 9.0 
9.15 -9.34 Alternating 9.0 and 9.5 
9.35 -9.64 9.5 
9.65 -9.79 Alternating 9.5 and 10.0 
9.8 -9.99 10.0 
10.0 -10.14 10.0 
10.15 -10.34 Alternating 10.0 and 10.5 
10.35 -10.64 10.5 
10.65 -10.79 Alternating 10.5 and 11.0 





Appendix 5: Topic guides for interviews 
Topic guide (1) Group 1 participants 
Hello, I’m Basma Al-Metwali.  Thank you very much for agreeing to take part in my 
research. The purpose of our meeting is to talk about your son/daughter’s warfarin 
therapy and how you manage it.   
It’s important that I get to know how it is for your son/daughter managing warfarin 
therapy.  I imagine that this has been very new for you and that you may feel that you 
have been on a bit of a journey when learning about how best to manage the warfarin 
medication?  
So, I’d like to start off by asking you to think back to when you first started warfarin 
therapy.  How did you feel when the doctor (or nurse) first explained what warfarin 
therapy is, and why you need to take it?  
Now that you are experienced in warfarin therapy… 
Supplementary prompts (as needed): 
Can you tell me about what you know about warfarin and why it is used after heart 
surgery? 
a. Monitoring (why is this needed?) 
b. How do you know whether the dose needs adjusting up or down? 
c. How do you feel about being involved in the monitoring of warfarin therapy? 
d. Who should take responsibility for monitoring the warfarin dose? (Doctor? Nurse? Self? 
parent?) 
e. Who is responsible for getting this dose right? 
f. How do you feel about the number of INR measurements that are required for 
monitoring the warfarin dose?  
g. Overall, how do you feel about the frequency of warfarin dose changes?  
h. Would you like to comment on other factors that, in your experience, have affected the 
warfarin dose and monitoring process? 
Prompt: e.g. other medicines, diet, and illness. 
 
Topic guide (2) Group 2 participants 
[interviewer will use discretion to determine whether to omit areas that have 
previously been covered during the first interview] 
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Hello, I’m Basma Al-Metwali.  Thank you very much for agreeing to take part in my 
research. The purpose of our meeting is to talk about your son/daughter’s warfarin 
therapy and how you manage it.   
It’s important that I get to know how it is for your son / daughter managing warfarin 
therapy.  I imagine that this has been very new for you and that you may feel that you 
have been on a bit of a journey when learning about how best to manage the warfarin 
medication?  
So, I’d like you to think back to the time when you first knew that you were to receive 
warfarin therapy. How did you feel when you first learned that you have been 
prescribed warfarin? 
Can you tell me about what you know about warfarin and why it is used after heart 
surgery. (note for interviewer: omit in second interview) 
Possible prompts: 
a. Monitoring (why is this needed?) 
b. How do you know whether the dose needs adjusting up or down? 
c. How do you feel about being involved in the monitoring of warfarin therapy? 
d. Who do you think is the best judge to get the dose of warfarin correct? 
e. Based on your experience so far, how confident are you that the dose of warfarin will be 
correct? 
f. How do you feel about the number of INR measurements that are required for 
monitoring the warfarin dose?  
g. Overall, how do you feel about the frequency of warfarin dose changes?  
h. Would you like to comment on other factors that, in your experience, have affected the 
warfarin dose and monitoring process? 
Prompt: e.g. other medicines, diet, illness  
  
Topic guide (3) Health care professional  
Hello, I’m Basma Al-Metwali.  Thank you very much for agreeing to take part in my 
research. The purpose of our meeting is to talk about your experience with warfarin 
dosing/ monitoring before and after using the new warfarin dosing model. 
1. Setting the new warfarin dosing model on one side for a moment, could you reflect 
upon your overall approach to warfarin dosing.  
Prompt: What are the obstacles that you usually encounter in getting and obtaining the 
INR within the therapeutic range? 
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2. Would you tell me about your experience of using the new warfarin dosing model? 
Prompt questions: 
a. Has the new warfarin dosing model influenced your overall approach to warfarin 
dosing?  
Would you like to comment upon any advantages or disadvantages of using the new 
warfarin dosing model?  
b. Would you recommend the new warfarin dosing model to other clinicians in similar 




Appendix 6: Coding of interviews 
1- Families’ interviews: 
 
 Thematic areas  









Anxious at the beginning/ 
worrying 
 x   
Not like aspirin x x   
Fluctuating/flexible dose x x   
Prevents clots in the 
circulation 
x x   
For smooth circulation x x   
Somebody will ring and tell 
what to give the child 
  x  
Manuals/handouts/helpful/ 
beneficial/clear/easy to read 
 x   
Once a day dose is not too 
complicated/comfortable 
x    
Routine/ habit/ at bedtime x    
Test bothering child at 
beginning/ then used to it 
 x   
No changes in diet/balanced 
diet 
x x   
More careful about falls  x   
Newly started warfarin/ no 
events of falls/ injury/ 
antibiotic use 
 x   
More careful with warfarin 
than with aspirin 
 x   
Frequency of tests (model)/ 
random/ not stabilised/ not 
bothered/ not ideal/ not a pain/ 
inconvenient 
   x 
Hospital INR testing is 
manageable 
x x   
Doctor/ me/ pharmacist/ expert 
to decide the dose 
  x  
Similar pattern of doses 
(model) 
  x x 
Liquid form/ easy to manage x x   
Tablet form/ easy to manage x x   
Holidays  x x   
Future problems of periods and 
pregnancy 




 Thematic areas  










relationship with CLN 
x x   
Get the child involved x x   
Warnings about bruising  x   
Warfarin new for them x x   
CLN flexible with testing 
times 
x x   
Easier than was thought at 
the beginning 
x x   
Group 2 parents and teenage patient 
Handle warfarin better than 
consultants 
x x x  
Parents are the best judge of 
dose 
90, 99% of time right 
x x x  
Information on phone call x x   
Bruising only  x   
High INR target/ maintain it x x   
Growth spurt  x x  
Antibiotics don’t change the 
INR 
 x x  
Green vegetables/ not huge 
amount 
x x x  
Do it naturally/ as less 
medicine as possible 
x  x  
List of medicines to avoid x x   
Listen to what have been 
told/ open minded 
x x   
Long list given  x   
Learn your own techniques x x   
Home INR machine/ easier x x   
Sensible with warfarin x x   
Test earlier when unwell/ 
ring in 
x x   
Never enough frequency of 
INR measurements 
 x   
No longer than a week x    
Not ring in when in range/ 
only when need to 




 Thematic areas  








Discuss with consultants  x x  
Liquid warfarin x x   




x x x  
Frequency of testing not 
consistent 
   x 
Dosage so high/ not good 
dosage 
   x 
Person to person is better    x 
Consultant way    x 
Life implications x x   
Risk of bleeding x x   
Restrictions on sports  x   
Drinking (alcohol) x x   
List of foods to avoid x x   
Balance   x   
Test/ hurt fingers/ annoying  x   
Family support/ help x x   
Self test/ responsible x x   
Part of life (warfarin) x x   
Miss checking at college  x    
Pot to remember the dose x x   
Outside the norm/ holidays x x   
Doctors/ best judge of dose   x  
99% confident x  x  
Home machine/ very useful x x   
GP surgery/ pharmacy  x   
Stable (dose changes) x x   
Frequent dose changes/ 
annoying/ manageable 
x x   
Tablet/ preferred/ easy/ 
colours 
x x   
Diet/ careful  x   
Alcohol restriction x x   
Sports restriction  x   
Cost of strips/ warfarin x    
Part of the day x x   
Family  x x   
Life style easier x    
Monitoring easier x    
Balanced/ rarely bad/ stable/ 
within range (INR Model 
phase) 
   x 




2- Doctors’ interviews 
 
 Thematic areas  










 Target INR range         x    
Initial dose and target INR 
range 
x    
  Indication x x x  
Patient’s condition x x x  
Transition from heparin to 
warfarin 
x    
Overlapping time x    
Mechanical valves/ position 
of valves (aortic vs mitral) 
x x x  
Fontan x x x  
Variable target INR range x x   
Target range sometimes 
changed transiently 
x x   
Different INR sets for 
different diagnoses/ MVR, 
AVR Fontan 
 x   
Risk of bleeding  x x  
Not one size fits all x x   
Guidelines/ individualised x x x  
Guidelines  x x x  
Risk of internal bleeding  x   
Monitoring the INR  x   
Valves are tested more 
frequently than Fontan 
 x   
Frequent INR monitoring for 
mitral valve/longer intervals 
for Fontan patients 
 x   
Frequent monitoring/ 
intercurrent illness/ infection/ 
antibiotics 
 x   
Individual approaches x x x  
Rate of change of INR  x x  
Significant INR changes are 
very concerning in MVR 
patients 
 x   
Low INRs are worrying in 
mitral valve patients 
 x   




 Thematic areas  










Indication x x x  
How far out of range x  x  
Underdosing more 
problematic 
  x  
Caution about mechanical 
mitral valves 
x x x  
Caution about reducing/ 
stopping warfarin 
x x x  
Risk of hospital admission 
and IV heparin 
 x x  
Accuracy of home INR kits x x   
Mildly out of range INRs x x x  
Clinical picture x x x  
More concerns about 
mechanical valves than 
Fontan 
x    
Risk of thrombosis/ valve 
thrombosis/ death 
x x x  
Risk of clotting is higher in 
mechanical mitral valve 
x x x  
MVR in infants/ very high 
risk group 
x x x  
Young children with small 
valves in the mitral position 
are very high risk group 
x x x  
Preference to keep slightly 
higher INR 
x x   
Dosing error even with the 
liquid form 
x  x  
Hospital admission 
inconvenient for patients 
 x x  
Personal experience in dose 
decision 
x  x  
INR instability  x   
Unpredictability in children/ 
difficult to control 
 x   
Young children/ frequent 
infections 
 x   
Compliance of teenagers x    




 Thematic areas  










Adolescent patients with 
valves/ dosing/ miss 
warfarin/ alcohol 
x x   
Model dosing is sensible/ 
rarely disagree with 
   x 
Disagree with model dosing 
in certain cases 
   x 
Personal experience in dose 
changing and INR testing 
interval when INR is out of 
range 
x    
Trust in model dosing in 
patients without 
complexities 
   x 
Model dosing is useful in 
older children 
   x 
Model dosing is acceptable 
and consistent in Fontan 
patients 
   x 
Occasional disagreement 
with model doses in mitral 
valve patients 
   x 
Independent prescribing/no 
need for doctors 
   x 
Model doesn’t take clinical 
picture into account 
   x 
Cautions about model doses 
in labile patients 
   x 
Model dosing would be 
faster for patients 
   x 
Some doctors over-treat out-
of-range INRs 
x   x 
Combined approach for 
higher risk patients 
   x 
Modify the target INR range    x 
Need to know the study 
results/ more time to 
establish 








3- Nurses’ interviews 
 
 Thematic area  
Code  Training/ 
education/ 
monitoring 









x     
Family education on 
home INR machines 
if they wish to have 
them 
x     
Home INR testing is 
more convenient 
x  x   
More caution with 
valve patients (esp 
mitral valve) than 
with Fontan 




  x x  
Changing the dose    x  
INR instability   x   
Volume of phone 
calls 
x     
Dosing process is 
time consuming 
x     
Training is time 
consuming 
x     
Families change 
doses less frequently 
than doctors 
 x  x  
Fontan patients are 
stable 
  x   
The more frequent 
testing the more INR 
fluctuations 
  x   
Model working very 
well for some 
families 
    x 
Model works well 
for stable patients 
(Fontans) 







 Thematic area  
Code  Training/ 
education/ 
monitoring 







Model does not 
change dose or 
tell to give 
LMWH when 
INR is very low 
    x 
A couple of 
families who did 
their own dosing 




    x 
More frequent 
INR testing 
    x 
Computer dosing 
did not put 
anybody in 
danger 
    x 
Model dosing 
done in a timely 
manner 
    x 
Missed dosing 
during weekends 
    x 
Issue when can’t 
get hold of 
parents 
x     
A handful of 
non-compliant 
families 




 x  x  
Majority of 
families who do 
their own dosing 
are right 
 x  x  
Teaching about 
warfarin 
x     
Impact on INR   x   
Education takes 
a while to 
register 




 Thematic area 
Code  Training/ 
education/ 
monitoring 









x     
Fontan patients 
are very stable 
  x x  
Patients with 
mechanical 
valves are tested 
more frequently 
  x   
Not admitting 
taking too much 
broccoli 
 x    
Teenagers not 
admitting takin 
too much alcohol 
 x    
Parents know 
their child better 
 x    
No consistency in 
doctors’ dosing 




  x x  
Massive change 
in INR because 
of antibiotics 
  x   
Home INR 
machine 
x  x   
Model is very 
good for Fontan 
patients 




    x 
Message left on 
answer phone 













Appendix 7: Transcripts of the interviews 1 
A- Families’ interviews 2 
1- Interview number 1: participant 2006’s parents. 3 
Interviewer: So..err.. Hello again… 4 
Evan: Hello 5 
Interviewer: errr.. I would like to introduce myself again  6 
Bang bang bang 7 
Interviewer: my name is Basma Al-Metwali errr.. I’m a PhD research student so doing 8 
my research on warfarin so.. er.. as you know the purpose of our meeting today is to.. 9 
errr.. talk about [child’s] warfarin therapy and how you manage that.. so.. umm.. it is 10 
very important to me to know that umm how it is for you managing warfarin treatment 11 
for [child].. umm.. I. I imagine that this has been very new for you .. errr ..you know 12 
getting on with the warfarin treatment.. errr.. so.. and that you may feel that you have 13 
been like on a bit of journey since he.. 14 
Evan: yeah 15 
Interviewer: ever started his warfarin treatment. 16 
Bang bang bang 17 
Evan: yeah.. I mean It’s been OK, hasn’ it? It’s not.. it’s.. it’s.. 18 
Michelle: I say we know.. it’s quite cheeky but I say we know how to handle [child]’s 19 
warfarin better.. than when we ring the consultant sometimes.. because.. we know what 20 
he is likin’ himself in a day.. we know if he’s had a.. ummm.. what he’s had to eat.. we 21 
know if he’s not feeling particularly well.. we know all of his traits…‘n that can 22 
sometimes trigger tha’ his INRs fluctuates or how often we should test 23 
Interviewer: OK 24 
Michelle: whereas the consultants differ on that opinion… they’re not with him all the 25 
time 26 
Child: aaaaaa  27 
Evan: sh sh sh 28 
Interviewer: so.. so yeah… so you think.. so you think that umm umm who is the best 29 
judge to get this dose correct? 30 
Evan: it’s the parents 31 
Michelle: parents 32 
Evan: the parents 33 
Interviewer: aha.. so.. and.. and how confident are you that the dose.. this dose will.. 34 
will be correct? 35 
Evan: umm..  36 
Michelle: 90% 37 
Evan: yeah we are..  38 
Michelle: (at the same time) we get it right 39 
Evan: I would say… a lot of the time the consultants would give a dosage and we would 40 
say we are not quite sure about that we’ll give what we think and we’ll tell you what 41 
we’ve give ‘n   I would say 99%  that we’re correct..  42 
Evan: it’s very rare that we are not correct, isn’ it? 43 
Michelle: yeah.. very rare 44 
Evan: very rare that.. just like Michelle said.. because we know what he’s eaten we 45 
know how much sleep he had we know how much.. if he’s been.. if he’s a bit under the 46 
weather.. that’s really hard to get across on an answer machine sayin’ it’s 2.7, it’s really 47 
hard to understand that which is.. which is difficult…. so I think we are we are ver.. 48 
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maybe not all the parents get it bu’ I think me and Michelle.. we.. really get warfarin.. I 49 
think we’ve.. it’s just as a click with us.. we understand how it works, we understand 50 
why it works, we know… what he can and can’ have, we avoid.. certain foods…. so.. 51 
we do pretty good ‘n we know what’s to look at for like.. bleeding gums and we didn’ 52 
have any of that symptoms, have we? Not at all..  53 
Michelle: never 54 
Evan: but none.. other than bruising we’ve had no.. of this real side effects of warfarin 55 
have we? 56 
Michelle: and he has a really high level.. 57 
Evan: it is 4.. 58 
Michelle: it is between 3 and 4.. 59 
Interviewer: aha yeah 60 
Michelle: so.. so the doctors all say.. don’t be alarmed if he’s bleedin’ ‘n his gums or 61 
nose bleed ‘cause that with his level bein’ quite high ‘n might trigger off for no reason  62 
Child making nosie 63 
Michelle: never 64 
Interviewer: Okay, so.. so according to that how do you feel that his dose needs to be 65 
adjusted? 66 
Evan: I know.. 67 
Michelle: I don’.. think it’s good for him 68 
Evan: it it is functional for his valve we jus’ had the consultant seen it as.. that’s is 69 
really good for his valve to be that high we can maintain it.. 70 
Michelle: ‘cause it stops any clottin’  71 
Evan: we can maintain it.. we can maintain it that, high majority of the time.. I mean 72 
this is.. this is 2.6 today bu’ we gone off off..  73 
Michelle: (at the same time) it’s when it..  74 
Evan: the computer’s diagnosis.. bu’ that does’.. I don’ think that it can take the fact that 75 
he jus’ go’ over a virus 76 
Michelle: (at the same time with Evan) ‘n the thing is as well.. 77 
Evan: so.. (at the same time) that’s the thing is that’s for the judgment comes in. 78 
Michelle: I think.. that the only time we struggle.. with INR dosing ‘an anybody does, 79 
the consultants, we do.. the clinical liaison nurses do.. is when he has a growth spurt 80 
because it just goes from perfect to completely ou’ of the window.. 81 
Evan: either way.. 82 
Michelle: it can go up.. it can go completely rock bottom… and then he’s been on a 83 
growth spurt here before.. ‘n he’s been on heparin ‘n it’s hardly done anythin’ to him 84 
(laugh) 85 
Evan: yeah 86 
Interviewer: (laugh) oh 87 
Evan: yeah he’s had.. 88 
Michelle: it’s no’ gone anywhere because his growth spurt just makin’ it keep.. stay 89 
down ‘n then after a’ he’s got over it… 90 
Evan: because.. they.. when we attended last time with heparin.. 91 
Interviewer: yeah.. 92 
Evan: they..  93 
Child: uhhhh  94 
Evan: said he either had a really big growth spurt or he metabolizes medicine really 95 
quickly because.. we were having to give him a lot of heparin to even get the heparin 96 
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level up.. so it’s therapeutic.. they were really struggli’ there wa’ a test maybe two 97 
hours.. n’ like.. ev.. every six hours whatever.. to tryin’ get his heparin level up… 98 
because it was jus’ no’ goin’ up.. and they were like.. a little bi’.. what we are goin’ to 99 
do… goin’ ‘o ge’ him dalteparin injections on top of the heparin bu’ … luckily they 100 
didn’t need to.. and then.. the next day.. his INR was perfect, so it was like.. oh! we’re 101 
going home.. 102 
Interviewer: ahahaha (laugh) 103 
Evan: isn’ it? 104 
Interviewer: oh 105 
Michelle: yeah.. but that’s the only.. that’s.. the hardest thing to manage is when they 106 
have a growth spurt… it’s so hard then and because it’s… the body is just doin’ 107 
somethin’ really random isn’ it? 108 
Evan: antibiotics..  109 
Michelle: it’s really hard.. 110 
Evan: antibiotics don’t bother him.. and they normally would, they don’t make a 111 
difference to [child], do they?  112 
Michelle: no he’s been on antibiotics before ‘n it doesn’t throw it like growth spurt does 113 
.. growth spurt is.. 114 
Evan: doesn’t make any difference a bit .. you think it will go through the roof but it 115 
doesn’t change it in the slightest.. 116 
Michelle: people do say.. they did say.. warn us and fore -warn us ‘n it’s in our paper 117 
work tha’.. if he’s on antibiotics…. be careful… because it will go off but [child] like 118 
you’ve said ‘at.. 119 
Evan: never.. 120 
Michelle: it dosen’t…  121 
Evan: it doesn’ .. it’s been a few times.. ear infection,  122 
Interviewer: yeah… 123 
Evan: water infection 124 
Interviewer: yeah… 125 
Evan: chest infection.. 126 
Interviewer: yeah.. yeah.. this is the other point that aaa I think you have the full 127 
experience with.. that.. you know.. with the.. what.. what things that affect the dose and 128 
the INR like.. you know.. what types of medicines..  129 
Evan: yeah.. 130 
Interviewer: what type of diet that he has that you think it’s going to affect warfarin? 131 
Evan: yeah.. 132 
Michelle: umm 133 
Evan: yeah.. he doesn’ know we’re we’re really good with his diet.. I mean he.. he does 134 
have some green vegetables but.. we know he can’t have a huge amounts of them he can 135 
have a little bit which is obviously.. if he didn’t do tha’ en’ up have a poor diet… ‘cause 136 
otherwise it will just be carbohydrates and carrots.. 137 
Interviewer: OK 138 
Evan: so.. we do give him some green vegetables but we don’t …. give him huge 139 
amounts and we tend to give him some a little bit everyday.. 140 
Interviewer: alright 141 
Evan: so.. he need to have broccoli he need to have… 142 
Child: waaaooooo 143 
Evan: … a little bit of broccoli everyday.. 144 
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Child: waaaooooo 145 
Evan: ‘n no’ jus’ a lot one day and then none on the next, we don’ mess with it.. so we 146 
we know.. we know.. we know what is he ‘n we know if it’s really high .. for just what’s 147 
happened because high one day we know we can afford to get away with a little bi’ of 148 
garlic in the food.. 149 
Child making noise 150 
Evan: we know it’s goin’ to bring it down but.. we know it’s no’ going to come too far 151 
down.. 152 
Michelle: we’re.. we’re trying to do it naturally, don’t we? 153 
Evan: yeah.. 154 
Michelle: at home.. like.. we’ll say.. like him said.. if it’s really high.. we’ll go to private 155 
nursery and.. I’ll go to nursery and say to ’em… today can he have greens on his 156 
plate… because then I know naturally that’s gonna help bring it down.. ‘n at home we 157 
would go let’s have spaghetti bolognese and give him two pieces of garlic bread.. 158 
Evan: we jus’ won’t give him… 159 
Michelle: things like that.. 160 
Evan: we a.. we a.. we adjust the INR… we adjust the warfarin ta.. what we think his 161 
diet manages… so we try to.. we wan’ to give him less.. as less medicines as possible.. 162 
Interviewer: OK 163 
Evan: that ‘ld be the idea… but we obviously we try to get a good balance with it so.. I 164 
think as a couple we’ve got the INR… with warfarin we got it down I think.. 165 
Michelle: ummm 166 
Evan: I think we could.. 167 
Interviewer: aha so.. aamm apart from antibiotics, aamm do you .. have.. any trouble 168 
with other medications and his INR and warfarin dose? 169 
Evan: not this.. 170 
Michelle: he’s never been on any other medications though, has he? 171 
Evan: even like Calpol 172 
Michelle (at the same time): to affect it.. 173 
Evan: even like paracetamol ‘sn’t affect it I’m not sure if that would.. 174 
Michelle: no.. that’s never been.. that’s not in his book, is it? to affect it.. bu’ he’s never 175 
been on.. he hasn’ really been on any other medications since warfarin.. in the future.. 176 
he will end up on more medicines… again with his valve… whether that affects it, I 177 
don’ know.. 178 
Interviewer: so at the moment he’s just taking warfarin as a.. on a regular basis 179 
Evan: yeah.. yeah that’s it. 180 
Michelle: on it’s own.. 181 
Interviewer: aha.. OK. 182 
Michelle: ‘n then a’ Calpol if he gets… 183 
Child: peeeep peeeeep 184 
Michelle: a little bit poorly ‘cause of.. because of the warfarin obviously he can’ have 185 
any ibuprofen products.. 186 
Evan: we know we know we know what things to avoid like.. anythin’.. any..any oth’.. 187 
any other blood thins or antiinflammatories you know.. 188 
Interviewer: have you got a list like.. um of those.. medicines? 189 
Evan: yeah we know what he can’t have yeah we know he can’t have.. we have a list at 190 
home of what he can and can’t take so… ‘an’t take anything.. i..i.. o.. o-fen do it.. 191 
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Michelle: anythin’ that’s got an ibuprofen.. um.. Calprofen.. Nurofen.. anythin’ like 192 
tha’… ummm he can’t have..  193 
Evan: wha’.. what it comes antibiotics.. 194 
Michelle: (at the same time) at the hospital is quite good as well.. 195 
Evan: he’s had lots of that.. he’s got it usual.. 196 
Michelle: (at the same time) steroids.. can’ have steroids.. 197 
Evan: can’ have steroids.. yeah 198 
Evan: he’s had lots of different types of antibiotics, it’s not jus’ like amoxicillin, he’s 199 
had amoxicillin, he’s had.. cloxacillin and he had.. 200 
Child: peeeeep 201 
Evan: sh sh.. another one that was err targeted for his water infection that looks so.. it 202 
isn’ jus’ one particular antibiotic that dosen’ affect it it’s jus’..  203 
Child: peeeeeep 204 
Evan: I don’ know why.. 205 
Interviewer: OK.. so.. errr.. 206 
Child: peeeep 207 
Interviewer: we might.. errr.. 208 
Evan: sh sh sh 209 
Interviewer: have gone like a bit further, so I just would like to.. from you to think back 210 
to the first time when you learned that [child] is going to go on warfarin.. 211 
Evan: yeah.. 212 
Interviewer: so.. how did you feel about that? and how you managed that? 213 
Evan: we jus’ listened to what we was told.. 214 
Michelle: we’re quite open-minded, aren’t we? 215 
Evan: yeah.. 216 
Michelle: so.. we’ve always took the approach that wha’ other people say to us, we just 217 
take it on board.. 218 
Child: awawawawawaw 219 
Michelle: so at first.. 220 
Child: aaaaawwwww 221 
Michelle: it did seem like.. 222 
Evan: [child].. 223 
Michelle: there was a long list of stuff tha’ he could n’ couldn’ do.. n’..  224 
Child: aawww 225 
Michelle: but then when Evan n’ I.. 226 
Child: aaaaaa 227 
Michelle: actually.. 228 
Child: aaaaaaaa 229 
Michelle: but it’s like anythin’ 230 
Evan: [child].. 231 
Michelle: if people tell you this is what you have to do on your driving license if you 232 
look at it all in the like.. uh, then actually when you ge’ in the driver seat n’ you do it 233 
yourself … you learn your own techniques that how to do it, don’ you? so th’ exactly 234 
the same as me n’ Evan with warfarin, we got told the list.. until you take that list 235 
dissect it down, take i’ in n’ ‘en process i’ ‘n do it yourself , we’ve never have a 236 
problem, have we? since day one.. we’ve never.. 237 
Evan: (at the same time) we were quite lucky though.. we were quite lucky that we got 238 
our own INR machine within.. 239 
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Michelle: yeah 240 
Evan: a couple of weeks.. 241 
Michelle: yeah we were so lucky.. 242 
Evan: Heart Link.. 243 
Michelle: Heart Link is amazing 244 
Evan: so we were able to.. ‘cause for the first for the first wha’ was i’ I be’ i’ was a 245 
month, wasn’ i’? I was.. 246 
Michelle: back ‘n forward .. 247 
Evan: back ‘n forward here.. every every three or four days.. 248 
Interviewer: ooh 249 
Evan: ‘n then one day I came in as if.. you’ve go’ your machine.. 250 
Interviewer: ooh 251 
Evan: so it was like.. ‘n then Michelle and I came ‘n were trained how to use the 252 
machine.. i’ made a lo’ easier have the machine a’ home so we could.. we will then.. 253 
you know.. prob. we were probably test.. 254 
Michelle: without tha’ machine, we would be.. really stuck.. 255 
Evan: yeah.. we’re probably testing..  256 
Michelle: (at the same time) ‘cause we don’ have a warfarin clinic where we live 257 
Evan: (at the same time) we were probably testing too much at the start.. we were 258 
probably testing too often at the start, didn’ we?.. could we be more nervous ‘n anxious 259 
about.. is he in range, ‘s he got.. having a bad day, is i’ because of the warfarin, bu’.. 260 
you soon  you soon quickly learn tha’.. in a.. it’s.. it’s easily managed, I think it’s quite 261 
easily managed if you.. if you if you think abou’ what you’re doin’ ‘n you know the fact 262 
that it is a very strong medicine ‘n it can be very.. potentially.. be very.. harmful to 263 
people you must got to be sensible with it ‘n no’ be like.. I mus’ gonna give him loads 264 
so it shoots right upper ‘an it’s safe ‘cause.. as its complications. 265 
Michelle: the way tha’ we work it if he wakes up once to say for example like we’ve 266 
phoned here and they’ve said righ’.. let’s say for example his INR was three poin’ 267 
eigh’.. ‘n they say righ’ for the next two da.. a four or five days.. we wan’ you to give 268 
2.5 ‘n 3 milligrams… alternate dose.. for tha’ five day period… we woul’ say okay… in 269 
tha’ five day period.. if [child].. appears tha’ somethin’ is no’ right so he migh’ 270 
develop a cough or runny nose.. or he migh’ ‘ave got off his food… we would take it 271 
upon ourselves ‘n test him earlier than that five day period.. 272 
Interviewer: OK 273 
Michelle: ‘n see what we’re lookin’ at.. because we’re normally righ’ ‘n it will drop.. ‘n 274 
i’ so can peakin’ down.. so then we know to phone ‘n say actually.. we phoned early 275 
because he’s not very well.. this is his dose ‘n then we will be dosin’.. (couldn’t be 276 
heard clearly because of the child’s noise) 277 
Child: aaaaaaaaaaa (noise) 278 
Evan: sh sh sh sh 279 
Michelle: ‘n that’s how we… tend to keep on top of it, don’ we? 280 
Evan: yeah.. uh.. yeah.. 281 
Michelle: (at the same time) we jus’ go’ to be on the board with it, if somethin’ is not 282 
the same so not because we probably more than ninety gonna be right  283 
Interviewer: so… um.. um.. 284 
Child making noise 285 
Evan: [child].. [child] 286 
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Interviewer: how do you think.. um.. ai.. you know.. umm.. about .. how do you feel 287 
about the.. the number of INR measurements? 288 
Evan: what do you mean? 289 
Interviewer: umm.. the number of INR measurements.. 290 
Michelle: oh so how frequently.. 291 
Interviewer: yeah.. mm.. the frequency of INR measurements. 292 
Michelle: I don’ think you can ever have enough frequency of INR measurements.. 293 
Evan: it depends, it jus’ depends on how how well he is.. 294 
Michelle: because.. I.. I wouldn’ trust it if somebody said to me righ’.. I want to test… I 295 
want you to test him once a week… umum (indicating no).. I wouldn’ do that… I 296 
wouldn’ trust it to ’ve sa’ a week without me knowin’… what his numbers look like.. 297 
because I would potentially think hold on a minute.. if somethin’ is not going righ’.. if I 298 
know he’s on a s.. if we know he’s on a steady bout, don’t we? 299 
Evan: um 300 
Michelle: we’ll happily do once a week 301 
Evan: yeah 302 
Michelle: no problem. if he starts to appear in that period of time where somethin’ is 303 
not.. 304 
Evan: yeah 305 
Michelle: quite righ’, we use our own initiative, don’ we? 306 
Evan: we sometimes jus’ test, ‘n if he’s in range, we never phone it through.. just.. a 307 
lot.. might be a lot peace of mind so if it is like a sort of seven day testi’ we sort of get 308 
five days and will test ‘n then if it’s.. if.. there is no need to phone through ‘cause he’s 309 
fine, we won’t phone through.. we jus’ test two days later ‘n phone through when we 310 
need to… ‘cause sometimes.. it’s jus’ depends on how he it’s jus’ based on how [child] 311 
is 312 
Michelle: he never really normally goes any longer than a week.. 313 
Evan: yeah 314 
Michelle: without it needin’ a variation..  315 
Evan: yeah 316 
Michelle: in some form 317 
Evan: it’s probably hard as he eats different.. 318 
Michelle: ‘cause of his age 319 
Interviewer: yeah 320 
Child making noise 321 
Evan: I think as he gets older become easier to manage, I’m guessin’.. once he stops 322 
growin’, that ‘ll be a massive difference… ‘cause that’s the biggest problem 323 
Child making noise 324 
Interviewer: OK 325 
Evan: ‘n once he understands what he can ‘n can’t eat he needs to eat.. ‘cause obviously 326 
his diet is massive for him… so if he’s off his food or jus’ dosen’ want to eat that day 327 
‘cause he is too tired or whatever.. ‘n then we’d have to adjust what we’re givin’ the 328 
following day.. 329 
Child making noise 330 
Evan: well a lot of the time we would discuss it with the consultants.. ‘n Madison will 331 
sure say OK what did you give.. 332 
Interviewer: ahha (laugh) 333 
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Evan: ‘n what’s his range.. she’s actually… I’ll let them know ‘n then come back the 334 
next day ‘n ‘n they go they go OK you were right then, we pla’ we play a little bit.. don’ 335 
we, we’re pretty good at it though, we got to say it all depends on how he feels ‘n how 336 
he’s acting.. 337 
Interviewer: yeah.. so.. and and.. um.. yeah this is for for the frequency of INRs ‘n so 338 
how how do you.. find it with the.. dose changes? 339 
Evan: we jus’.. go with the flow.. we go.. majority of time we do what we’re told, don’ 340 
we? 341 
Michelle: it’s fine, it’s jus’.. it doen’ affect you because… you’re doin’ the same thing 342 
regardless… all.. the only difference is one day I drop 3 one day I drop 2.5..  so there is 343 
no difference, it doesn’ affect.. 344 
Evan: yeah.. we’re on the soluble.. we only.. 345 
Interviewer: alright.. the liquid form.. 346 
Michelle: yeah 347 
Evan: yeah.. our GP was a lo’ happy to to keep keep givin’ us that so.. 348 
Interviewer: OK 349 
Evan: it’s.. ‘n we do fine.. that actually that’s better than the tablet form.. 350 
Michelle: umhm 351 
Evan: ‘cause I think the tablet even we he was havin’ the tablets here.. 352 
Michelle: he was nearly sick on it 353 
Evan: no’ only of that.. they were strugglin’ to ge’ i’ up… ‘n then.. ‘cause when we 354 
came the las’ time on heparin, they took my.. medicine off [child], the soluble.. what the 355 
umm.. it was called.. the solution one… ‘n they would givin’ him tablets ‘n it wasn’ 356 
comin’ up ‘n then Madison suggested…try givin’ him ou’ of the bottle…mm the 357 
solution.. ‘n then we wen’ home… ’cause I think.. children.. I’m not sure if this just in 358 
children, but it seems to work better… it does seem to work better than actually havin’ 359 
to like.. break off a tablet or how it work.. 360 
Michelle: it’s harder ‘n tablet, tab.. the tablet when we started here ‘n they’ve said your 361 
doctor might not let you have the liquid… 362 
Evan: because it’s expensive.. 363 
Michelle: we need to show you how to use the tablets… so when they were showin’ us 364 
to crush them mix it with water… draw up the syringe ‘n givin’ him tha’ way... he hated 365 
it..he was nearly sick.. 366 
Interviewer: Ookay 367 
Michelle: havin’ it, becaue.. it must be horrible ‘cause it’s pasty.. so it must be awful.. 368 
Interviewer: ooh 369 
Michelle: whereas the liquid.. is very s.. it’s sweet in mouth..  370 
Evan: (at the same time) it’s like Calpol.. 371 
Michelle: he’s not bothered.. ‘n that’s.. 372 
Evan: (at the same time) he’ll happily jus’ take it himself.. 373 
Michelle: so we’ve kind of got the easier route because our GP is amazin’.. ‘n he said 374 
whatever [child] needs, [child] can have.. 375 
Interviewer: Ookay 376 
Michelle: I will prescribe it, it doesn’ bother me… so he was like liquid warfarin? yeah 377 
no problem, it might cost me.. however many hundreds of pounds a bottle… bu’.. if 378 
that’s what he needs, that’s what he’s havin’ 379 
Interviewer: alright 380 
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Michelle: so until he gets the age of sixteen.. that’s the end of time ‘n he’ll go on 381 
tablets.. my doctor is happy to keep him on liquid warfarin until he gets the stage where 382 
to crush the tablet himself ‘n take it 383 
Interviewer: ok 384 
Evan: I think there is too much margin for error crushin’ the tablets.. I think it.. I 385 
think… if all patients have to go that route… parents, it will be difficult becau’ I think 386 
there is a lo’ of.. it’s okay if you’re goin’ break half a tablet, bu’ if you’re goin’ to start 387 
at one poin’ five.. one poin’ s.. one poin’.. two poin’… 388 
Michelle: it’s so hard. 389 
Evan: we’ even so.. it still a margin for error there, isn’ there? cushin’ tablets down ‘n 390 
addin’ it to water.. did you.. 391 
Michelle: (at the same time) it’s less accurate. 392 
Evan: did you ge’ i’ all upon syringe I can imagine that’s quite difficult I think we’re 393 
jus’ quite lucky to have the soluble version… I’m no’ sure if all GPs are just as are just 394 
as confident at givin’ that out 395 
Interviewer: yeah 396 
Michelle: soluble warfarin definitely helps, uu liquid warfarin definitely helps 397 
Evan: what’s called now… the liquid 398 
Michelle: liquid 399 
Interviewer: brilliant 400 
Michelle: it’s much better.. if everyone could be given the liquid warfarin when they 401 
early on it will help so much. 402 
Evan: so I think the tablets aa tha’ he was strugglin’ here, they were struggling’ here to 403 
get his INR up ‘n then Madison said.. try ‘n give his own medicine at the cupboard ‘n  404 
bu’ then that next day he was fine.. it might ‘ve made a combination but it di’ it di’ I 405 
think the children absorb it better.. I’m not a.. warfarin specialist I couldn’ say how it 406 
works.. bu’ I do, it does seem to work better 407 
Interviewer: umhm.. alright, so.. anything else about his warfarin treatment and and how 408 
you manage it you would like to mention, any concerns aaa anything you might find it 409 
difficult with his umm warfarin. 410 
Evan: the only thin’ that is difficult is is that I find it difficult is the bruisin’ is how 411 
easily.. it causes bruises. 412 
Michelle: yeah, if he goes above four… he can literally walk past the chair, knock i’, 413 
bruise.. 414 
Interviewer: yeah 415 
Evan: yeah, he bruises very easily.. 416 
Michelle: it will bruise really really quickly.. and he can get the point where.. if he 417 
bangs, it comes up quite a bit.. 418 
Evan: he can get a quite big haematoma, was it haematoma that he can get quite 419 
quickly?  420 
Michelle: (at the same time) mmm.. I don’ know.. 421 
Evan: (at the same time) yeah, he can get a quite big haematoma 422 
Michelle: (at the same time) mmm.. just a.. bruise. 423 
Evan: but he’s had he’s had a couple of nose bleeds, hasn’t he? Has he?.. 424 
Michelle: ummm..  425 
Evan: I think it was one when he picked his nose but I think that was probably because 426 
of a different thing.. 427 
Michelle: oh yeah 428 
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Evan: ‘n it’s a.. that was sporadic  that is.. we think  about his finger bruise ‘cause he 429 
then came out with blood in his finger so maybe he picked his nose ‘n bleed, bu’ I don’ 430 
think he’s a nose bleed because of warfarin, has he? 431 
Michelle: I don’t think.  432 
Evan: in fact, that time when he cut his finger… on the gate.. it didn’ even  bleed tha’ 433 
much ‘n his warfarin wasn’ quite high, was it?... ‘cause we were like oh my God ‘n 434 
woul’ take him to A ‘n E  if it was really poor bu’ jus’ we held it ‘n then within a couple 435 
of seconds, it stopped. 436 
Michelle: mm 437 
Evan: ‘n it was like 3.5 wasn’ i.. n’ we needed to test him to make sure how… high it 438 
is.. ‘n it seems fine, so I think it’s managed very well I think,  439 
Interviewer: okay 440 
Evan: I don’ know if all parents are like us, I don’ know.. we’re good at it though. 441 
Interviewer: alright ..so… thank you so much... 442 
Evan: not at all. 443 
Interviewer: for this valuable information.. 444 
Evan: no’ at all. 445 
Interviewer: and for your time.. 446 
Michelle: no no that’s fine. 447 
Evan: not at all. 448 
Michelle: do you need to know anythin’ else? or.. 449 
Interviewer: umm.. anything that you would like to add.. aa for my questions, you have 450 
covered everything.. 451 
Evan: hahaha 452 
Interviewer: so.. if you would like to add anything, you are more than welcome. 453 
Michelle: no I don’, I think that’s pretty much it, just if I was to advise in the future.. 454 
things were to change, I would say tha’.. like to say young children need to be on…the 455 
liquid warfarin, that would be.. that is a massive help from start… like I’ve said at the 456 
beginning we struggled with the tablet ’n then as soon as the liquid ‘s changed, it was 457 
like.. a complete flip reversal.. 458 
Evan: (at the same time) like a new medicine.. 459 
Michelle: that never bothered us at all.. 460 
Evan: like a new medicine, wasn’ i’? 461 
Michelle: ummm ‘n then jus’ the fact of…. I think.. it’s gonna be hard..bu’.. the 462 
communication between consultant ‘n parent ‘cause parent knows that child extremely 463 
well.. 464 
Michelle: ‘n what they’ve been doin’, ‘n have they been eatin’.. ‘n how they are in 465 
themselves.. you can… clinically see a child… I can see [child], on a telephone, they 466 
can’t see him, they can’t say what he looks like, so for them to then diagnose him a 467 
dosage.. based upon…. a potential.. of what they think, whereas if we see  he’s not 468 
particulary well… we’re not a hundred percent on this because… if his warfarin level is 469 
3.4.. bu’ then he’s turned not very well the next day… I… probably…. pu’.. 470 
Evan: mmm 471 
Michelle: money on i’ tha’ he’s goin’ to go in the toes, it’s no’ goin’ to go the way you 472 
wan’ it to go because he’s presentin’ that.. he’s comin’ with a snuffle or somethin’ ‘n 473 
tha’ throw [child] quite significantly.. 474 
Evan: she’s .. the information tha’.. I think people well.. consultants need would be.. 475 
better.. if parents.. in other way.. were told.. when you ring up we need to know how he 476 
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is… is he eatin’ well.. what’s his INR, is there any signs of anythin’.. that is unwell 477 
‘cause.. ‘n then make a judgment based on that because they are all facts that make 478 
massive difference to [child].. 479 
Michelle: yeah 480 
Evan: maybe not all children but to [child].. they make a massive difference ‘n we… we 481 
then base.. our.. what we think to give him… on that. 482 
Interviewer: so.. do you usually.. when you ring in .. do you usually er tell the liaison 483 
nurses about.. 484 
Michelle: yeah 485 
Interviewer: his condition.. 486 
Evan: yeah yeah  487 
Interviewer: about if he is having like a cold.. or.. 488 
Michelle: yeah  489 
Evan: yah, we’re tellin’ yah 490 
Interviewer: changing the diet or something like that? 491 
Evan: yeah, we.. we.. we notice everythin’ like.. if we notice like blood anywhere, we 492 
would say oh he’s had a nose bleed… he’s had a bi’ of blood in his poo.. we’d give i’ 493 
all.. it’s never happened thankfully… or we would say he’s under the weather.. he’s jus’ 494 
go’ over a virus.. or.. you know.. it’s it’s bruising really really quite a bi’ at the moment, 495 
‘n we give ‘s much information ‘s we can… bu’ maybe tha’ always.. doesn’ always ge’ 496 
passed.. on to the consultants, ‘cause I’m sure the liaison nurse gets right 2.7.. takes that 497 
to the consultant, he ju’ goes.. you know.. issue out all these IN.. all these dosages.. 498 
Michelle: umm 499 
Evan: she ‘n can ring us again 500 
Michelle: which is hard for the liaison nurses.. 501 
Evan: yeah, I guess.. 502 
Michelle: they have so many hundreds of… I’m sure there is so many hundreds of 503 
patients tha’ ring up with their INRs dosages everyday so.. there isn’ much information 504 
you can give over the phone.. 505 
Child making noise 506 
Michelle: whether they’ll be there all the day.. 507 
Evan: it’s jus’ more to consider than just a number I think 508 
Michelle: I think when they’re leavin’ an answering message, it’s kind of like.. there 509 
should be sort of .. like key factors that a’ ticked in the box to say.. he’s generally well.. 510 
he’s generally ‘n fine.. so we know tha’ that dosage is gonna stay.. 511 
Child making noise 512 
Michelle: on an equal basis..  513 
Evan: [child].. 514 
Michelle: ‘cause ’en you’re addin’ more than one factor as a… a variant.. whether it’s.. 515 
he’s got a lo’ of snuffle or he’s eatin’ less that day that can twitch tha’ INR to change 516 
massively we notice that with him, don’ we? 517 
Evan: ‘cause some parents don’t, I bet a lot of parents don’ understand the.. like.. what 518 
abou’ vitamin K ‘n how many food it’s in ..  519 
Evan: like… it’s in lots of food.. ‘n it’s.. 520 
Michelle: they get the list, don’ they? 521 
Evan: we eat really healthy.. we don’ have any processed food.. children’s food.. they 522 
add lots of vitamins in.. so they’re no’ readin’ the box ‘n it says with vitamin K or 523 
added this or added that.. A,A (to the child).. ’n then.. the parents won’t know ‘n they 524 
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go wrong ‘n the child eats a plate full of his food that is full of vitamin K ‘n it’s gonna 525 
mess with warfarin. 526 
 527 
2- Interview number 2: participant 20010 and his mother. 528 
Interviewer: so.. umm.. hello again.. 529 
Grace: Hi. 530 
John: Hi. 531 
Interviewer: err.. I’d like to introduce myself, my name is Basma Al-Metwali.. err.. I’m 532 
a PhD research student doing my research on warfarin.. umm.. as you know the purpose 533 
of our meeting is.. to.. err talk about Johns’ warfarin.. 534 
John: yeah 535 
Interviewer: treatment and.. how you manage it.. umm.. it is important that I get to 536 
know how it is for you as a.. as a parent and how for John managing warfarin 537 
treatment.. err.. I imagine that this has been very new for you.. 538 
John: yeah 539 
Interviewer: and… that you may feel that you have been like.. on a bit of journey.. 540 
Grace: umhm. 541 
Interviewer: with warfarin.. 542 
John: yeah.. yeah.. I suppose.. yeah 543 
Interviewer: okay 544 
John: can’t wait to describe it.. yeah 545 
Interviewer: aha, so.. umm.. first I’d like you to think back to the time first .. John was 546 
prescribed warfarin.. 547 
Grace: mm 548 
Interviewer: umm.. could you please tell me and John of course.. um.. how you felt 549 
when first knew that John is going to receive warfarin? 550 
Grace: um.. well can say because of the life implications ‘cause he ‘as to have i’ ‘n tha’s 551 
tha’ bi’ you know.. on things… like health ‘n.. you know.. risk of bleeding.. ‘n the 552 
restriction he was goin’ to have on him havin’ sports at school.. 553 
Grace: ‘n things.. I know they found alternatives but it’s all that.. ‘n then obviously 554 
when he came to teenages… ’n his.. peers are drinkin’ ‘n John can’t .. can’t drink 555 
really.. 556 
Interviewer: aha 557 
Grace: so.. which I know it’s probably minor ‘n everything, but you’re jus’ tryin’.. you 558 
know.. that’s.. 559 
Interviewer: okay 560 
Grace: yeah.. that was probably the concern 561 
Interviewer: so..so.. right at the beginning of.. of prescribing warfarin.. errr.. did you 562 
have.. like any issues with the medicine itself.. right at the beginning of treatment? 563 
John: no.. no.. not that.. remember? do you remember any? 564 
Grace: no.. we jus’.. 565 
John: no 566 
Grace: we were given a list of the foods.. 567 
John: yeah 568 
Grace: to avoid.. ‘n.. you know it’s the balance, isn’ it? So.. he has the vitamin K 569 
vegetables.. bu’ he has them on regular basis.. so he will have broccoli ‘cause he likes 570 
it.. 571 
Grace: but he doesn’t have an excessive amount. 572 
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Interviewer: umhm.. so did you find it easy to follow that list of.. of.. 573 
Grace: yeah 574 
John: yeah 575 
Grace: yeah 576 
Interviewer: of medicines.. you know.. to avoid and.. err.. 577 
John: umhm 578 
Interviewer: umm and food and stuff like that? 579 
John: yeah 580 
Grace: yeah yeah yeah, pretty much.. we just.. we avoid.. we would avoid anythin’ if I 581 
buy anythin’ with cranberries ‘n yet John  582 
John: yeah 583 
Grace: jus’ doesn’ have it.. 584 
Grace: yeah.. no that’s fine. 585 
Interviewer: okay.. so.. could you please ummm.. err… talk to me about what you know 586 
about warfarin and why it’s prescribed after heart surgery? 587 
John: uumm.. so… warfarin thins thins your blood, doesn’ it?.. 588 
John: that’s the purpose of it, so.. after I had heart surgery with my mechanical valve 589 
I’m not… exactly sure that you know more about it than I do, bu’.. I know.. like.. if.. my 590 
blood.. isn’… uumm… wha’ is.. if it’s not thin enough.. then it can clot.. is that the right 591 
thing?  592 
John: so.. yeah… so.. I jus’ need to take it to make sure that it is enough, but I can’t take 593 
it.. in excessive amount so I can’ overdose myself, because… I’m not sure.. what 594 
happens.. is it ae… 595 
Grace: you can.. stroke.. (low voice) 596 
John: stroke.. 597 
Grace: what you mean a’ extreme so it may help it to.. 598 
John: yeah.. yeah.. 599 
Grace: it can bleed.. internally.. 600 
John: yeah.. bleed internally.. that’s what I thought.. 601 
Grace: it can have blood in your wei, blood in your poo..  602 
John: yeah.. 603 
Interviewer: aha.. so… errrrr.. er.. so that’s why you were advised to do the monitoring? 604 
John: yeah 605 
Interviewer: so.. umm could you please…um.. talk about the monitoring? 606 
John: the.. the monitoring is like err I would.. I’d like to say tha’ I do i’ every …. every 607 
time get it all done but it’s…. I’ve got used to it like.. when I’ve started, I remember I 608 
used to hurt my fingers.. 609 
John: I remember that.. ‘n then it’s annoyin’ when I don’ bleed.. enough sometimes 610 
also.. 611 
Interviewer: so.. was it you who who.. used to do the INR right from the beginning?.. or 612 
your parents were helping you? 613 
John: err.. right from the beginning when I was here, I remember… my dad used to help 614 
me.. my mum .. used to help me as well do i’ ‘n then I eventually jus’ …. got err.. 615 
Grace: mmm Madison told.. 616 
John: (at the same time) I know how to do it.. 617 
Grace: John ‘n me so that he…. would manage his own condition, which is better 618 
Interviewer: aha, so do you .. you find that.. umm.. he is the best to do that? 619 
John: yeah.. 620 
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Grace: yeah.. 621 
John: yeah.. 622 
Grace: yeah.. yeah 623 
Interviewer: okay.. 624 
Grace: yeah.. he’s now 625 
Interviewer: so.. umm.. how do you know that er your dose needs to be adjusted up or 626 
down? 627 
John: err depending on how… far my INRs .. how far it is.. so if it’s like er.. if it’s too 628 
low for example.. one poin’… let’s say.. one poin’ seven or something, then… like the 629 
dose will.. wou’ i’ go up or would i’ go down I’m no’… 630 
Grace: it would increase it.. 631 
John: it will increase, yeah.. so… I’m like… also.. I have to have an injection just in 632 
case it goes to far down to bring it back up again.. if it.. 633 
Grace: dalteparin.. 634 
John: yeah.. yeah.. that’s it  635 
Grace: on on occasions when it’s got.. you haven’t had that for a long..  636 
John: no no tha’ was at school.. 637 
Grace: when at school. 638 
John: yeah.. 639 
Interviewer: so.. you have been controlled? 640 
John: yeah.. 641 
Interviewer: well controlled over the.. you know.. the past period of time? 642 
John: yeah yeah 643 
Grace: it’s normally pretty stable now, isn’ i’? 644 
John: yeah 645 
John: normally. 646 
Interviewer: so.. how ..do you feel.. err.. as being involved in the monitoring of.. of 647 
warfarin? 648 
John: I.. I don’ mind i’ I suppose it’s jus’ become.. part of my life.. really.. so.. like.. I 649 
have to do it.. carry on with it.. so.. 650 
Interviewer: aha 651 
John: so so it’s it’s like.. I guess eatin’ now for me…. It’s jus’ .. I’m used to it.. so .. 652 
yeah that’s fine. 653 
Interviewer: and err.. and Grace? 654 
Grace: yeah yeah that’s fine.. yeah we jus’ get used to it.. it’s jus’ makin’ sure.. 655 
sometimes….if.. I think the worst thing is if you’re a bit later but he’s been a teenager, 656 
you’ve got to go to college ‘n you perhaps miss checkin’ it on that day 657 
John: yeah 658 
Interviewer: umhm 659 
Grace: that’s the only thing that is important to do on the same day.. bu’.. he’s been he’s 660 
.. you’ve been  quite stable for quite a while now he’s been checkin’ every two weeks.. 661 
Interviewer: OK, so.. so.. is it you who remind him? or he rem.. remembers that  662 
Grace: yeah 663 
Interviewer: from himself 664 
Grace: yeah yeah 665 
Interviewer: to do that? 666 
John: yeah yeah 667 
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Grace: yeah yeah, it’s it’s .. yeah, we normally double check it with him tha’ we’re 668 
tryin’ get him to.. to be responsible.. but obviously, we still there so.. it’s easy.. ‘n like 669 
we’re takin’ warfarin, we pu’ that in a little pot, don’t we? 670 
John: yeah yeah yeah 671 
Grace: for the week so… 672 
John: so.. 673 
Interviewer: umhm 674 
Grace: it’s it makes easy to remember takin’ i’ 675 
Interviewer: so..umm.. umm.. could you um.. um please explain more? 676 
Grace: um you know.. you can get the little.. um.. you can buy the pots.. with the.. 677 
they’ve got Monday Tue.. the pill.. I can’ think what they’re called 678 
John: they got Monday to Sunday.. 679 
Grace: they got like.. 680 
John: yeah they go’ like err.. 681 
Grace: they’re almost like the blister packs, bu’.. bu’ you buy the pot yourself .. 682 
Interviewer: aha 683 
Grace: ‘n you jus’ dispense it for every day what you know the dose is gonna be..  684 
Interviewer: aha 685 
Grace: John normally gets his for every two weeks which is four poin’ five ‘n five so 686 
we jus’ pull them ou’ occasionally accordingly  687 
Interviewer: aha 688 
Grace: ‘n jus’ to try ‘n give us a reminder to.. most of the time… he do remember.. 689 
John: yeah 690 
Grace: it’s when we do something ‘at’s.. outside the norm you know if we go out or 691 
something rather than.. because normally he take it a’ home with his meal.. 692 
Grace: so it’s if it’s.. you know.. when he do something different.. jus’ that, it’s okay so 693 
I.. it’s fine with tha’.. yeah 694 
Grace: it’s no’ a problem 695 
Interviewer: okay…umm.. so..err.. regarding umm the the warfarin dose, who do you 696 
think is the best judge.. to get this dose correct? 697 
Grace: umm.. well.. the doctors 698 
Grace: I.. I presume.. yeah.. (laughs) I assume.. well.. the bi’.. yeah.. I mean they’re the 699 
ones tha’ do it.. they seem to know.. 700 
John: yeah, I’ld agree 701 
Grace: ah.. he.. I can’ remember when it was, bu’ ai.. ages ago we have queried it with 702 
them when we thought… I think it’s probably dropped.. I can’ remember it slightly ‘n 703 
they’ve increased it quite rapidly.. ‘n we.. we queried it with them.. 704 
Grace: because… because when you man’.. when you have the conditions.. I know I 705 
haven’ bu’ John has.. you do get used to… you know managin’, however, from a safety 706 
poin’ of view.. the doctors are always the best to dose it.. 707 
Grace: yeah.. yeah 708 
Interviewer: so.. okay… and how confident are you that the dose will be correct?.. based 709 
on your experience so far? 710 
Grace: I’ld say.. 711 
John: very confident.. 712 
Grace: very confident yeah 713 
John: yeah 714 
Interviewer: very confident in.. 715 
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Grace: ninety nine percent.. 716 
John: yeah 717 
Interviewer: in doctors’ dose? 718 
Grace: yeah 719 
John: yeah 720 
Interviewer: okay 721 
John: nothin’ ‘s gone wrong… apart from like.. there was only one time really which 722 
you said.. where like.. 723 
Grace: ‘at’s about two years ago.. 724 
John: yeah that was two years ago.. so.. so yeah.. when when it’s been like err.. I ‘n 725 
know.. was it two or something, ‘n they’ve told me to take like…as on like three ‘n 726 
somebody told me to take five.. 727 
Grace: yeah 728 
Grace: they are very competent ‘n then yeah.. they seem very good, yeah. 729 
John: yeah. 730 
John: bu’ tha’ was long time ago. 731 
Interviewer: OK.. so.. umm.. how about the frequency of INR measurements? How do 732 
you feel about that? 733 
John: ffffuuuuu… yeah.. I’m fine with that.. yeah.. suppose. 734 
Grace: we’re lucky he’s got a machine.. 735 
John: (at the same time) yeah 736 
Grace: to do it on rather than have… 737 
John: yeah, have to come in. 738 
Interviewer: so.. errr… yeah, do you do the INRs.. you know.. more regularly? How 739 
often do you do that? 740 
John: aaammm.. I do.. well at the moment, I’m doin’ i’ every two weeks.. 741 
John: because I.. it’s been stable, so it’s normally.. I always.. whenever I miss a dose, I 742 
always.. umm.. do my INR to see what the outcome is.. ‘n like.. if it’s.. fine then.. I jus’ 743 
carry on ‘n call.. call i’ in when.. when I actually need to, bu’ if it’s like.. bad.. 744 
John: then I’ll.. call i’ in.. the day that tested, so.. bu’.. yeah I’m fine with that. 745 
Interviewer: so do you find the the machine.. err.. very useful? 746 
John: yeah, I do find i’ very useful, it’s a lot better than.. havin’ to.. have to go to 747 
hospital every like.. week or two weeks.. 748 
Grace: yeah (at the same time)  749 
John: (at the same time) just to.. check up saves a lot of money as well..  750 
John: so.. yeah. 751 
Interviewer: umhm.. so.. was the machine with you right from the beginning? 752 
Grace: yeah 753 
John: yeah 754 
Grace: yeah 755 
Interviewer: so.. how often… did you.. err.. used to measure the INRs right at the 756 
beginning of treatment before he.. he.. was.. 757 
Grace: it was abou’.. 758 
Interviewer: getting stable? 759 
Grace: daily to start off with.. 760 
Interviewer: aha.. that’s right at the beginning.. 761 
Grace: yeah 762 
Interviewer: and then afterwards? 763 
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Grace: yeah then it probably.. went to.. abou’ every three days..  ‘n then a week.. 764 
Interviewer: OK. 765 
Grace: yeah. 766 
Interviewer: and how about the dose changes? ..Umm.. do you find it.. how do you find 767 
it? 768 
John: uummm.. yeah, I’m fine with i’ normally.. like.. ‘n that’s jus’ like.. somethin’ 769 
drastic, I suppose like.. 770 
Grace: yeah 771 
John: like.. bu’.. nothin’. 772 
Grace: we luckily we live quite close to the GP surgeries they normally will help us 773 
say.. you know.. aa.. ah.. I’m quite.. organised with making sure he’s got enough 774 
medication.. 775 
Grace: bu’ the pharmacy is righ’ next door to us as well.. ‘n.. so they know John as well 776 
so.. ‘n the GP surgery.. so it’s always.. 777 
Grace: we’ve been quite lucky there.. 778 
Grace: so they will always get.. you know.. they get the stuff in quite urgently so.. 779 
Grace: bu’ it is good.. I mean we even had an incident where we were in Spain.. 780 
John: yeah 781 
Grace: ‘n the chip was missin’ out of the the strips.. 782 
Grace: so he couldn’t use them.. so i’ so i’.. 783 
Interviewer: Oh 784 
Grace: we had to buy them.. bu’..umm.. bu’ the pharmacist in Spain.. they got them 785 
delivered.. you know..  by the end of the day that day.. they were really really good, 786 
really helpful.. jus’ took everythin’, so.. it’s good 787 
Interviewer: yeah.. yeah… and umm yeah the dose changing.. umm.. I could.. umm.. 788 
the.. how often did you have like.. those dose changes? Did you have like.. a frequent 789 
dose changes or.. 790 
John: errr 791 
Interviewer: it’s OK? 792 
John: no’.. no’.. at the start… a lo’ of the time, bu’.. righ’.. for the the  past year.. no, it’s 793 
been around from 5 to the lowest of probably say 4..  794 
John: and.. it.. it’s really stable at the moment. 795 
Interviewer: so.. 796 
Grace: for the past.. about three months, it’s been 4.5 ‘n 5 alternate days so it’s it’s.. 797 
Interviewer: so how was it for you.. right at the beginning when there was frequent dose 798 
changing, was it easily manageable? 799 
Grace: yeah 800 
John: yeah, it was manageable I guess it was a bi’ annoyin’, bu’.. 801 
Grace: it was fine, jus’ accept that that’s what we had to do.. ‘n that’s fine.. ‘n I’m like.. 802 
Interviewer: sorry? 803 
Grace: we just accepted that that’s what we had to do.. 804 
Interviewer: aha, OK. 805 
Grace: ‘n we were OK with the tablets ‘n everything.. umm 806 
Interviewer: OK, so which form of of warfarin.. is umm.. John using? Is it the tablet or 807 
the.. 808 
John: tablet. 809 
Interviewer: tablet, right from the beginning? 810 
John: yeah, right from the beginning. 811 
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Interviewer: aha, so.. could you.. were you find it.. umm did you find it easy to use? 812 
John: yeah yeah yeah it’s easy , I jus’ pop it in my mouth ‘n let them down.. 813 
John: also I don’ need use water.. I jus’.. never have done, have I? 814 
Interviewer: you never crushed the tablet? 815 
John: no, I don’t, I jus’.. 816 
Interviewer: just.. 817 
Grace: no, this is (laugh) 818 
Interviewer: (laugh) 819 
Grace: it’s it’s always.. he had to take tablet from being quite little.. well.. I know they 820 
used to give him.. an.. I mean because we have to give him the the.. the suspension 821 
when he was baby.. ‘n I think he was on that many ‘cause he was on diuretics as well.. 822 
Grace: ‘n tha’.. he jus’ began to hate them, so as soon as he was big enough to take 823 
tablets.. it was always.. prefer tablets anyway.. 824 
Grace: even with antibiotics...you know.. if he needed them.. he would rather have the  825 
tablets, it’s jus’ prefers them to the..(laugh) 826 
Grace: so he’d never had to crush the mix, it quite swallows.. it’s quite easy. 827 
John: it’s jus’ easy to get them over ‘n done we really jus’ need put them in ‘n ‘en it’s 828 
done. 829 
Grace: yeah that’s fine. 830 
Interviewer: OK.. yeah. 831 
Grace: ‘n I think with warfarin as well.. I mean.. I think the fact that there are different.. 832 
the colors as well, I think tha’ helps.. people with the dose.. as well. 833 
Interviewer: umhm, so, yeah the one and the.. not point five milligrams 834 
Grace: (at the same time) yeah yeah yeah 835 
Interviewer: so you don’t have that.. problem with.. different err.. strengths of tablets? 836 
John: no. 837 
Interviewer: just take the dose as it is? 838 
John: yeah, I jus’ take it.. as it is 839 
Grace: umm 840 
John: I never have to crush them, never have to.. put them in a liquid or somethin’.. 841 
Grace: no, jus’ takes them. 842 
John: yeah, jus’ take them. 843 
Interviewer: aha.. OK.. so.. ummm.. I would like you to comment on on some.. other 844 
things that in your experience have affected warfarin treatment.. like.. umm diet.. like.. 845 
medicines anything that you think.. 846 
John: uummm well.. there there’s couple of.. so I guess my diet ss.. has to be.. always 847 
has to be.. like I have to make sure I’m careful for wha’ I ea’ for example when I went 848 
to Peterborough hospital.. umm they gave me a full plate of broccoli.. did’n they so.. 849 
Interviewer: (laughs) 850 
Grace: yes.. it’s alright (laugh) 851 
John: yeah.. and.. 852 
Interviewer: did they know that you were on warfarin? 853 
Grace: yeah (laughs) 854 
John: yeah, they gave it as well so.. 855 
Interviewer: oh! 856 
Grace: (laughs) yeah 857 
Interviewer: and they gave you that big plate of broccoli? 858 
John: yeah 859 
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Interviewer: oh! 860 
Grace: never mind. 861 
John: so… errr.. also with like drinks I’m not allowed to.. or.. I don’.. I do drink a bi’ of 862 
alcohol bu’ no’ enough to make me… you know.. 863 
Grace: no.. quite awake isn’ i’ ‘n it’s at home.. 864 
John: (at the same time) yeah yeah.. it’s a’ home.. so.. I know they go.. well.. I’m no’ 865 
old enough to go out drinkin’ yet.. bu’ I’m sure…I will always be the one carryin’ my 866 
friends home.. so that’ll be alright. 867 
Grace: laughs.. also saves lots of money John. 868 
Interviewer: laughs.. so do you find this.. like.. annoying? 869 
John: no..to be.. to be honest, if.. you.. look at i’ at this perspective of money wise… 870 
umm.. I think it’s.. no, I’ll save a lo’ of money.. with.. I suppose sports.. aemm.. used to 871 
love s.. do sports a lo’ than I.. 872 
Grace: yeah. 873 
John: yeah. 874 
Grace: you still can. 875 
John: I still do sports.. like bu’ I’ve always got to be more careful now.. 876 
John: yeah, bu’.. ummm.. tha’s abou’ it really.. like.. yeah. 877 
Grace: yeah, I mean he’s very mu’ he tends to ge’  paitballin’ ‘n things with him and  878 
I’m a little bi’ more concerned.. 879 
John: mum.. 880 
Grace: ‘n 881 
John: yeah 882 
Grace: ‘n.. because tha’ they can bruise quite easily with tha’.. 883 
Interviewer: aha 884 
Grace: ’n this since did i’ ‘n they ‘ve got.. ’n they ‘ve no’ on warfarin ‘n they go’ huge 885 
bruises. 886 
Grace: bu’ you kn’ that’s e’ pace. 887 
Interviewer: okay.. so.. have you ha.. did you have any bruises at all? 888 
Grace: no, he didn’t go.. he d.. you mean normally? 889 
Interviewer: normally? 890 
John: normally.. ummm.. 891 
Grace: no’ really. 892 
John: no, I never really have... I can guess at the start when I used to have.. blood tests 893 
‘n injections like.. used to get a massive bruise.. 894 
Grace: yeah 895 
John: yeah, bu’.. 896 
Grace: that’s from the needle (laugh) 897 
John: that’s from the needle. 898 
Interviewer: aha (laugh). 899 
John: so..yeah. 900 
Interviewer: OK. 901 
John: so I.. I guess maybe when I’m fallin’ over bu’ every body gets bruises they fall 902 
over bu’.. yeah. 903 
Interviewer: aha.. so.. yeah.. other other types, have you had other types of bleed like a 904 
nose bleed or.. 905 
John: ummm.. I don’t.. normally get nose bleeds.. 906 
John: I never really have done.. aaammm tryin’ to fit aaammm 907 
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Grace: do you remember that time when you cu’ your finger in Spain? 908 
John: ah yeah on holiday.. 909 
Interviewer: oh! 910 
John: I was bein’.. I was tryin’ to make some food and.. I sort of .. was bein’ stupid ‘n I 911 
got the knive ‘n I pu’.. 912 
John: I put it put it straight through my finger.. 913 
John: ‘n so that bled quite a bi’. 914 
Interviewer: Oh 915 
Grace: (laughs) that was quite difficult to control. 916 
Interviewer: Oh, so, did it take long to heal?  917 
John: errr.. it took abou’.. probably say two three weeks. 918 
Grace: yeah, it stopped bleedin’ by the end of the night, haven’ it?  919 
John: (at the same time) stopped stopped.. 920 
Grace: Bu’ it’s kept starting ‘n I double stripped it. 921 
John: (at the same time) it bled for abou’.. half an hour 922 
Interviewer: aha, half an hour? 923 
John: yeah, so no’ no’ tha’ long.. like I thought..  that it can be.. 924 
Grace: (at the same time) until he got some steri-strips..  925 
John: (at the same time) ‘n then I.. ‘n then I did tha’.. with my finger.. 926 
John: yeah, ‘n clean it a lot. 927 
Interviewer: alright 928 
Grace: that’s OK. 929 
Interviewer: OK. 930 
John: I got a scar now to.. 931 
Interviewer: umhm. So.. errr.. umm.. overall, do you have any concerns about.. warfarin 932 
treatment as a medication.. err.. as monitoring.. anything that.. err.. you may concern 933 
about that? 934 
Grace: no, er I think the only.. concern I think I mentioned this.. eh.. to you is not really 935 
a concern about the medication other than the fact.. umm.. he’s got a congenital 936 
disease.. he has to have medication.. and yet the act is so ou’ of date with the 937 
government, it’s from 1966 or something.. 938 
Grace: ‘n it doesn’t recognize… um warfarin as… one of the medications, you know 939 
whereas diabetics can have their insulin ‘n things, so he’s gonna have to pay for it, bu’ 940 
that’s fine we’ll help him when he’s young bu’ I still find that.. quite.. 941 
John: disgusting.. that’s the word. 942 
Grace: (laugh) 943 
Interviewer: (laugh) 944 
John: (at the same time) jus’  disgusting people. 945 
Grace: it’s not that I object payin’ i’ bu’ I know that warfarin is one of the cheape’ drugs 946 
on the marke’.. I know the strips aren’, bu’.. 947 
Interviewer: yeah 948 
Grace: you know, ‘n I know.. umm because he’s in full time education.. so I think.. the 949 
pharmacy was sayin’ tha’ we can fill out a form for him ‘n tha’ was sorted for now 950 
anyway.. 951 
Grace: umm.. bu’ it is somethin’ that he will have to pay.. for.. lifelong.. bu’ that’s.. 952 
Interviewer: okay, so.. have you discussed ..those concerns with anyone? Like your GP.. 953 
Grace: um.. 954 
Interviewer: or maybe… the nurses. 955 
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Grace: yeah, yeah.. nothing’ (laugh).. I think.. I think the um British Heart Foundation 956 
‘av appealed it ‘n I’ve written a letter.. ‘n.. no (laugh) 957 
Interviewer: okay 958 
Grace: (laugh) never mind 959 
Interviewer: OK. 960 
Grace: never mind.. that’s fine, we can afford to pay for it, it’s jus’.. like it’s a concern 961 
like you know he’s.. he’s lucky he’s go’.. his family tha’ will hel’ him find the money 962 
bu’ I jus’.. concerns me (laugh) that’s for those people that aren’t you know.. 963 
Interviewer: OK. 964 
Grace: anyway, bu’ no.. for him, no,  it’s fine it’s easy to take.. 965 
Grace: we know how to take it, we.. you know.. we keep on cope with.. we don’t.. keep 966 
too much in stockin’ ‘cause we know it goes ou’ of date which at the date blabla 967 
Grace: it’s fine, it’s easy ‘n i’? 968 
John: yeah yeah yeah 969 
Grace: any queries with any.. other medications.. 970 
Interviewer: yeah 971 
Grace: interactions sometimes, we jus’ check it with the pharmacist.. 972 
Interviewer: aha, so do you have a list of medications that.. umm.. umm.. like to avoid 973 
or to take care about.. 974 
John: umm 975 
Interviewer: the INR monitoring during that time? 976 
Grace: err.. no anti-inflammatory is no’….ummm…no… I mean like he he gets 977 
migraines occasionally, so.. 978 
Grace: we spoke to the pharmacist abou’ tha’ ‘cause he.. i’ was pre.. I tend to go to the 979 
doctors ‘n get it prescribed for him anyway so.. 980 
Interviewer: OK. 981 
Grace: yeah 982 
Interviewer: and the doctor is aware that he is on warfarin? 983 
Grace: yeah 984 
John: umhm 985 
Interviewer: OK, did you have any other troubles like.. umm.. maybe when like on 986 
antibiotics or something and you had some troubles with warfarin? 987 
John: no.. I’ve never had.. any troubles with warfarin.. the only thin’ I’ve had troubles 988 
with is penicillin.. I’ve got allergic to that.. 989 
John: yeah so.. 990 
John: bu’ my dad is allergic to it as well.. 991 
Interviewer: oh 992 
John: yeah. 993 
Interviewer: OK 994 
John: bu’.. tha’s the only thing I’ve ever been allergic to ‘n have a problem with. 995 
John: never had a problem with warfarin, I.. didn’ I used to say go’ lisinopril.. as well.. 996 
John: back.. back when I.. was to start takin’ warfarin. 997 
Grace: they’ve stopped tha’ now. 998 
John: yeah tha’ stopped. 999 
Interviewer: umhm, so at the moment you are just on warfarin? 1000 
John: I’m jus’ only on warfarin yeah. 1001 
Interviewer: aha. So.. umm.. John.. umm.. could you please let me know how do you 1002 
feel.. or how do you see yourself with warfarin in the future? 1003 
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John: uummm.. I guess because I’m used to it now I’ll jus’ be used to it in the future 1004 
‘n… yeah.. like.. jus’… it’s jus’ part of my day so.. it’s jus’ part of my life.. it’s.. it’s.. 1005 
like.. so.. like havin’ breakfast in the morning even though I don’ do that all the time.. 1006 
do I? 1007 
Grace:(laugh) 1008 
Interviewer: (laugh) 1009 
John: uumm…. Yeah.. I can see it jus’.. if I ever have trouble, then I know I’ve 1010 
always… go’.. my family.. 1011 
Interviewer: alright 1012 
John: tha’.. you’ll always be here for me no matter what.. 1013 
Grace:mmm 1014 
John: yeah…. bu’ yeah, I don’t have.. I don’t see myself in the future struggling with 1015 
warfarin.. at all. 1016 
Grace: well at the long term implications for takin’ a drug like warfarin though.. do they 1017 
know.. or .. you know affectin’ so healthwise you know like bleedin’..  1018 
Grace: or anythin’ 1019 
Interviewer: okay. So as long as it is like err.. well controlled.. 1020 
Grace: OK. 1021 
Interviewer: umm.. so.. I think now you are the experts.. 1022 
Grace: yeah. 1023 
Interviewer: you’ve been like err.. around five years? 1024 
Grace: yeah. 1025 
John: yeah. 1026 
Interviewer: with it? 1027 
Grace: yeah. 1028 
Interviewer: so now you are the experts..  1029 
Grace: OK. 1030 
Interviewer: with managing it. 1031 
Grace: yeah yeah yeah. 1032 
Interviewer: so..  1033 
Grace: yeah yeah, that’s true, yeah we have adjusted to it. 1034 
Interviewer: alright, any other comments you would like to add? 1035 
John: there will probably be something in a minute, so we’d better think now.. 1036 
Grace: (laughs) 1037 
Interviewer: OK (laughs) 1038 
John: there is always, there is always something err jus’ like what happen’ in my job in 1039 
few…. (couldn’t be heard clearly because of the laughs). 1040 
Grace: (laughs) 1041 
John: so there will be something.. so.. errr….. do you think of anything right now? 1042 
Grace: no. 1043 
John: ummm… 1044 
Interviewer: please think carefully. 1045 
John: OK, errr… with warfarin like.... if.. say… for example there is a drug in America 1046 
which also.. is of like.. warfarin, what it’s called, do you remember what it’s called? 1047 
Grace: no, bu’ think they use it for people with AF maybe.. 1048 
John: (at the same time) oh 1049 
Grace: here I don’ think they use it for complex medical conditions. 1050 
John: I ‘on’ know. Bu’ errr… 1051 
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Grace: yes, different name ‘n i’? 1052 
John: like.. as the future change I suppose… 1053 
Interviewer: umhm 1054 
John: will warfarin ever change in a way like.. ummm…. I’m not su’, I’m not su’.. well 1055 
I gue’  guess will.. it be easier like…. I can’t.. I’m not really sure wha’.. 1056 
Grace: what you mean would.. would it ever be… replaced for another tablet.. 1057 
John: (at the same time) yeah yeah yeah, that’s that’s.. 1058 
Grace: (at the same time) that you can.. 1059 
John: I can take.. 1060 
Grace: not affect… other.. your other… (laughs) 1061 
John: well.. I mean make my life style easier so.. 1062 
John: yeah, that’s.. so.. 1063 
Interviewer: OK… do you mean regarding monitoring and the doses and all those stuff? 1064 
John: yeah yeah that sort of stuff. 1065 
John: like.. I’m used to it, bu’ I mean there is always a way…. 1066 
Grace: I think.. well isn’t warfarin supposed to be the.. one of the best ones  1067 
John: (at the same time) yeah  1068 
Grace: for doin’ it though isn’ it? 1069 
Interviewer: yeah. So have you ever discussed those concerns with with a doctor like 1070 
changing it to another.. medication? 1071 
John: yeah. 1072 
Grace: yeah, they don’t.. 1073 
John: (at the same time) me.. 1074 
Grace: (laugh) they don’t  they don’t want to that I don’t know why, perhaps it’s… it’s 1075 
fine. 1076 
John: yeah.. yeah, that’s.. that’s all I have.. to think about at the moment.. I suppose as 1077 
technology will.. enhance..umm.. 1078 
Interviewer: yeah. 1079 
John: advance.. so.. 1080 
Interviewer: yeah, of course. 1081 
John: so.. things will improve.. I’m sure in about.. err.. 30 years, surgery will be 1082 
easier…there’ll be more.. like.. I guess.. there might be a different think of the INR 1083 
machine.. 1084 
Interviewer: umhm. 1085 
John: like.. easier.. maybe jus’ you have to put your finger there ‘n scan i’ I don’ know 1086 
like temperature or something. 1087 
Interviewer: alright. 1088 
John: yeah. 1089 
 1090 
3- Interview number 8: Participant 1003’s mother 1091 
INTERVIEWER: umm… hello.. err I’m Basma Al-Metwali.. err I’m a p’ PhD student 1092 
doing my research on err.. warfarin er thank you very much for agreeing to take part in 1093 
my research .. umm the purpose of our meeting is to talk about [child]’s warfarin.. 1094 
therapy and how you manage that.. umm it is important for me that I get to know.. err 1095 
how it is for you.. err managing warfarin therapy for [child].. ummm I imagine that thi’.. 1096 
this has been very new for you.. 1097 
SONYA: yes. 1098 
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INTERVIEWER: and errr you may feel that it has been like a b’.. you have been on a 1099 
bit of journey.. 1100 
SONYA: ya. 1101 
INTERVIEWER: since you.. err since [child] first started.. er warfarin.. therapy. So first 1102 
I would like to start off by.. umm.. err asking you to get back to the first time when you 1103 
first knew that.. er [child] is going to start.. err warfarin how did you feel when the 1104 
doctor maybe the nurse ummm has told you about that? 1105 
SONYA: umm I was a bi’ anxious because I know it takes a bit more… um care or 1106 
attention than the aspirin tha’ she was on. 1107 
INTERVIEWER: umhm. 1108 
SONYA: umm.…… I fe’ I felt a bi’ like I didn’ really know… what was to come.. 1109 
whereas with the aspirin ‘cause she doing on i’ for so long..  1110 
INTERVIEWER: umhm. 1111 
SONYA: we knew what to expect. 1112 
INTERVIEWER: so.. errrrm.. er could you please let me know what.. what you know 1113 
about warfarin and why it is required after surgery? 1114 
SONYA: errrrm it helps to.. thin the blood? as far as I’m aware.. to help stop… blood 1115 
clots.. in [child]’s circulation. 1116 
INTERVIEWER: and errr why do you think um this monitoring.. this INR monitoring 1117 
is required? 1118 
SONYA: Oh to make sure that umm.. it’s not too thin.. or not too thick so it’s at the 1119 
right... consistency I suppose. 1120 
INTERVIEWER: O’ OK so umm how do you know that um this dose needs to bee.. 1121 
adjusted up or down? 1122 
SONYA: how do I know? 1123 
INTERVIEWER: yeah. 1124 
SONYA: so when?.. 1125 
INTERVIEWER: this.. 1126 
SONYA: what do you mean? 1127 
INTERVIEWER: this warfarin dose.. 1128 
SONYA: yeah. 1129 
INTERVIEWER: how do you know this warfarin.. er warfarin dose.. 1130 
SONYA: so if her INR.. INR ‘s too high.. then her dose is lower. 1131 
INTERVIEWER: OK. 1132 
SONYA: an’ then if her.. INR is too low the dose is higher (laugh). 1133 
INTERVIEWER: (laugh) Oh.. 1134 
SONYA: but.. somebody will ring me and tell me.. what to give her. 1135 
INTERVIEWER: OK soo.. er how do you feel about being involved in this process of 1136 
monitoring? 1137 
SONYA: alright (laugh).. I suppose. 1138 
INTERVIEWER: how do you get with that? 1139 
SONYA: umm.. it’s alright.. it’s a bi’.. it’s a bi’ very new since ‘cause start to g’ come 1140 
to the hospital.. for… her INR tests.. so sometimes… will go.. two weeks.. an’ then 1141 
sometimes we’ve been in.. places where it’s been every other day.. 1142 
SONYA: umm…. bu’ tha’ was jus’ because they haven’ go’ the… machines for us to 1143 
have a’ home ye’. 1144 
INTERVIEWER: yeah. 1145 
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SONYA: bu’ the actual…. umm.. the actual INR tests.. she is getting’ used to them so 1146 
they’re no’.. 1147 
INTERVIEWER: not bothering her? 1148 
SONYA: they bother her bu’ no’ as much as they did… to begin with. 1149 
INTERVIEWER: umhm.. so.. when you first started.. err let’s start right from the 1150 
beginning.. err I imagine that you have been given like errrmm a set of information 1151 
maybe.. 1152 
SONYA: yes. 1153 
INTERVIEWER: how did you find that? 1154 
SONYA: errrrrm I found i’ quite helpful… because there was a lo’ of things.. abou’ the 1155 
warfarin tha’ I didn’ really know. 1156 
INTERVIEWER: umhm. 1157 
SONYA: ummm and… i’ also helped to have tha’ information because she started 1158 
school this year so i’ helped.. with having something written to pass on.. 1159 
INTERVIEWER: aha. 1160 
SONYA: umm to school so they can see i’…..umm.. bu’ yeah i’ filled.. filled a few 1161 
gaps in.. for us… once would sat an’ read i’ because nobody really.. on the ward.. 1162 
when.. before we go to home.. nobody actually really sat with us an’.. properly 1163 
explained… the warfarin. 1164 
INTERVIEWER: so who was the person..  1165 
SONYA: so.. 1166 
INTERVIEWER: who explained that to you.. and gave you the handouts? 1167 
SONYA: I don’ think anybody has actually properly explained it to us bu’ we’ve read 1168 
the handouts an’.. 1169 
INTERVIEWER: umhm so who gave you the handouts? 1170 
SONYA: ummm… one of the nurses on the ward.. I can’t remember which one it was. 1171 
INTERVIEWER: OK. And then.. then you.. after you went home that you got those.. 1172 
ummm… went through them? 1173 
SONYA: ye. 1174 
INTERVIEWER: errrmm were they ea’.. those.. that information was it easy to.. like 1175 
err.. 1176 
SONYA: understand? 1177 
INTERVIEWER: yeah. 1178 
SONYA: yeah.. yeah yeah yeah. 1179 
INTERVIEWER: and to go on.. you know to apply it you know with erm.. her daily..  1180 
SONYA: yeah. 1181 
INTERVIEWER: you know.. 1182 
SONYA: yeah. 1183 
INTERVIEWER: activities or daily life? 1184 
SONYA: there is no’ tha’.. many things.. really.. tha’ we.. can an’ can’t do if you know 1185 
wha’ I mean it’s…. pretty.. average. 1186 
SONYA: it’s jus’ tha’.. the things with the diet.. there is no’.. they are no’ things that 1187 
she would eat… excessive amounts of anyway so that doesn’t really apply.. 1188 
SONYA: umm….. an’ then we are always careful if she is climbing anyway an’…… 1189 
it’s jus’ bein’ a little bi’ more careful if she falls an’ hurts herself isn’ i’? it’s jus’.. 1190 
INTERVIEWER: aha. So umm those things that umm.. errrr… you need  to take care 1191 




SONYA: no’ re’.. 1194 
INTERVIEWER: a bit more.. 1195 
SONYA: no’ really.. with.. with the aspirin she never.. she n’t really have any side 1196 
effects with the aspirin. 1197 
SONYA: errrmm…. So i’ didn’ really.. she’s never really been in an instant where she’s 1198 
fallen an’.. banged her head.. quite hard or.. she’s not really.. had i’.. she’s hadn’ any 1199 
trauma till her op or anythin’ like tha’ so we’ve no’ really…. umm… bu’ she never.. 1200 
bruised any.. more than.. any of the other children running round nursery so.. with the 1201 
aspirin. 1202 
SONYA: an’ she hasn’t too much with the warfarin actually.. either. 1203 
INTERVIEWER: OK.. so far (laugh). 1204 
SONYA: so far (laugh) touch wood (bang on the desk). 1205 
INTERVIEWER: (laugh) yeah because (laugh) yeah because she’s like.. you know.. 1206 
regard’.. like as newly started.. 1207 
SONYA: yeah. 1208 
INTERVIEWER: only.. only it’s a few months of.. 1209 
SONYA: yeah. 1210 
INTERVIEWER: errrm warfarin. 1211 
SONYA: so we.. we’re definitely more careful.. we’re more aware.. with the warfarin.. 1212 
than we were… with the aspirin bu’ that’s purely because we’ve.. been told.. by the 1213 
professionals that the warfarin ‘s… a bi’ more.. no’ risky.. you just have to be a bi’ 1214 
more careful. 1215 
INTERVIEWER: OK. So are you aware of what umm… like maybe… adverse effects 1216 
of warfarin? 1217 
SONYA: so… 1218 
INTERVIEWER: if the INR like goes high.. 1219 
SONYA: (at the same time) internal bleeding.. 1220 
INTERVIEWER: (at the same time) or goes low. 1221 
SONYA: could be.. 1222 
SONYA: umm so if she bangs herself.. that what we’ve always been told to look out for 1223 
if she ‘s.. takes a big blow to her head.. to take her to a hospital.. either way.. so i’ could 1224 
be internal bleeding.. umm… bruising.. obviously… bruising easier… umm….. 1225 
INTERVIEWER: yeah OK. 1226 
SONYA: so it’s bruising an’ bleeding. 1227 
INTERVIEWER: so how about when.. err.. if the INR goes very low? 1228 
SONYA: lower blood clots I imagine possibly…. Ummm… I don’ know any other 1229 
effects. 1230 
INTERVIEWER: OK. 1231 
SONYA: which have though. 1232 
INTERVIEWER: umm.. err.. soo yeah… umm.. so let’s go back to thee.. your err.. you 1233 
know.. those umm.. INR and.. measurements and you need to go to come to the hospital 1234 
because you don’t have the machine how do you.. see that umm.. frequency of… INR 1235 
measurements? 1236 
SONYA: it’s.. there is no… it’s jus’ random (laugh) i’ completely.. we haven’ managed 1237 
to.. stabilise… I don’ know anyway because you tell us when to come back don’ you we 1238 
haven’ managed to satbilise.. umm.. say like.. I know some people who come every 1239 
three weeks.. 1240 
INTERVIEWER: aha. 1241 
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SONYA: or have those done every three weeks bu’ they’ve been on warfarin quite a 1242 
while.. umm.. whereas with [child] she’s jus’ shshsh all over the place.  1243 
INTERVIEWER: OK. 1244 
SONYA: it’s no’  it’s no’ too bad.. and.. it doesn’ it dosen’ bother us havin’ to come to 1245 
get i’ done because.. we know she needs i’ doin’.. umm.. an’ I’d rather have it done 1246 
than.. have to deal with.. 1247 
INTERVIEWER: so.. 1248 
SONYA: any formal side effects with it so.. (laugh) 1249 
INTERVIEWER: yeah. 1250 
SONYA: it’s no’… 1251 
INTERVIEWER: yeah. 1252 
SONYA: it’s no’ ideal bu’ it’s no’…… it’s no’ a pain. 1253 
INTERVIEWER: OK. So err do you need like to take some time off school umm? 1254 
SONYA: no she’s.. well thee.. the liaison nurses have been really good about i’ an’ 1255 
they’ve said.. umm.. because she finishes school at quarter pas’ three.. bu’ obviously we 1256 
don’ ge’ back to the car till abou’ tweny pas’ tweny five past depending on how slow 1257 
she’s been umm.. an’ they’ve  if we jus’ come straight from school then whenever we 1258 
ge’ here.. we ge’ here an’ that’s when they do i’ so they’ve been good about i’.. so she’s 1259 
no’ had to miss any school or…. 1260 
INTERVIEWER: OK. 1261 
SONYA: so far. 1262 
INTERVIEWER: so about.. umm.. err.. I need to ask about.. the dose.. of warfarin.. 1263 
errmm.. who do you think that err.. should take this responsibility of deciding the dose? 1264 
SONYA: you (laugh). 1265 
INTERVIEWER: (laugh). 1266 
SONYA: I thought that’s who did i’. 1267 
INTERVIEWER: apart from me.. 1268 
SONYA: a pharmacist.. I would imagine.. maybe.. 1269 
INTERVIEWER: is it like err.. do you prefer it like a doctor maybe? 1270 
SONYA: somebody who knows what they’re doin’ I don’ mind who it is.. because they 1271 
know.. 1272 
INTERVIEWER: OK. 1273 
SONYA: what they’re doin’. 1274 
INTERVIEWER: are you happy with what we are doing? 1275 
SONYA: yes. Yeah yeah yeah. 1276 
INTERVIEWER: and and how about this like dose changes? 1277 
SONYA: it’s.. it’s fine it’s fine. We’ve no’ had anything.. her dose.. her doses.. tend to 1278 
be over a similar pattern so it’s no’.. we’ve no’ had anything.. drastic. 1279 
INTERVIEWER: umhm. 1280 
SONYA: any drastic changes and… they’re easy to remember so it’s no’….. 1281 
SONYA: we’re fine with i’. 1282 
INTERVIEWER: OK. So and er er as far as I know she is on thee err solution or the 1283 
liquid warfarin.. 1284 
SONYA: (at the same time) liquid yeah. 1285 
INTERVIEWER: do you find it easy to use? 1286 
INTERVIEWER: yes. She loves i’. 1287 
INTERVIEWER: Oh! Great. 1288 
SONYA: (laugh). 1289 
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INTERVIEWER: (laugh). 1290 
SONYA: yeah. which is..very easy.  1291 
INTERVIEWER: aha… and umm.. errmm.. how about.. umm you know adjusting the 1292 
dose with the liquid form? 1293 
SONYA: it’s fine.. it’s easy it’s probably easier to adjust with liquid form than it is… 1294 
with a tablet I’d imagine.. I do’ I don’ know because we haven’ used the tablet bu’.. 1295 
with the liquid it’s just… 1296 
INTERVIEWER: so you have never used the tablet even when.. 1297 
SONYA: no’ with the warfarin no. 1298 
INTERVIEWER: even when you were.. inpatient like.. when [child] was.. in the 1299 
hospital.. 1300 
SONYA: no’ for the warfarin no. 1301 
INTERVIEWER: for the first time? 1302 
SONYA: no no. we used with her aspirin.. umm…. bu’.. tha’ was really really easy 1303 
because she was on.. 37.5 milligrams which was half a table’.. umm.. so we jus’ 1304 
dissolve the whole table’ an’ give a half so tha’ was… very easy. 1305 
SONYA: bu’.. I don’ know whether with warfarin tha’ migh’ be a little bi’ more 1306 
difficult because the doses vary so much don’t they? 1307 
INTERVIEWER: OK. So.. yeah.. so you were fine with the um those.. umm dose 1308 
changes? 1309 
SONYA: yes. 1310 
INTERVIEWER: ummm.. so er.. yeah.. so.. in your experience so far what errrr…. 1311 
you.. what have you found that ummm might affect this.. warfarin dose? 1312 
SONYA:…… I actually have no idea… I really don’t know. 1313 
INTERVIEWER: ha’.. haven’t you been in some situations where you realise that those 1314 
particular things affect the INR.. 1315 
SONYA: no.. 1316 
INTERVIEWER: make it go up or.. 1317 
SONYA: (laugh) no. 1318 
INTERVIEWER: (laugh). 1319 
SONYA: I actually haven’t.. (laugh).. I would like for somebody to tell me wha’ affects 1320 
tha’… ‘cause I.. I.. 1321 
INTERVIEWER: (at the same time) maybe like some.. 1322 
SONYA: haven’t got a clue. 1323 
INTERVIEWER: let’s say.. maybe her diet? 1324 
SONYA: … Oh… pass.. she is.. pretty much the same things.. all the time.. she doesn’t 1325 
really.. have any….. I don’t know. 1326 
INTERVIEWER: like umm.. it’s like.. you know ummm.. her normal.. her.. er regular 1327 
diet? 1328 
SONYA: yeah. 1329 
INTERVIEWER: and you are adjusting.. the err… warfarin or the INR with it? 1330 
INTERVIEWER: there hasn’t been like.. 1331 
SONYA: (at the same time) err.. 1332 
INTERVIEWER: massive changes.. 1333 
SONYA: we haven’ changed her diet at all because thee…. the list of foods that we 1334 
were given that we should.. so we were give a list of foods that we should.. just.. stay 1335 
clear of.. ones that we should be careful with.. 1336 
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SONYA: umm.. ones tha’ she can have a bi’ of.. bu’ no’ an excessive amount of an’ she 1337 
doesn’.. the only one on there tha’ she likes.. anyway.. is broccoli.. but she’ll only have.. 1338 
like one or two stocks.. maybe twice a week so.. it’s no’… she doesn’ have an excessive 1339 
amount of any of this.. tha’ kind of food anyway. 1340 
INTERVIEWER: what other types of food that ummm  1341 
SONYA: (at the same time) err.. 1342 
INTERVIEWER: (at the same time) you were made aware of.. that might affect.. the 1343 
INR? 1344 
SONYA: I can’ remember…. I know this had anythin’ green pretty much (laugh). 1345 
INTERVIEWER: (laugh). 1346 
SONYA: which is she doesn’ ea’ anyway. 1347 
INTERVIEWER: so.. so.. what I can understand.. 1348 
SONYA: cranberry juice.. I know cranberry juice is err.. an’ cranberries bu’ she doesn’t 1349 
like.. she doesn’ touch tha’ anyway so.. that’s no’ an issue. 1350 
INTERVIEWER: OK. 1351 
SONYA: yeah. 1352 
INTERVIEWER: so.. so you took that ummm.. errrr.. list of.. let’s say diet.. 1353 
SONYA: yeah. 1354 
INTERVIEWER: and err.. 1355 
SONYA: I’m tryin’ to remember what’s on i’ now. 1356 
INTERVIEWER: yeah.. so..  1357 
S making signs indicating that she can’t remember 1358 
INTERVIEWER: but.. (laugh) you made it like.. you know tailored it to her.. (laugh).. 1359 
usual.. 1360 
SONYA: well I looked a’ i’ an’ I thought it’s no’… i’ ge’ a falls in place with her die’ 1361 
anyway so we haven’ had to…  1362 
INTERVIEWER: OK. 1363 
SONYA: change anythin’ really. 1364 
INTERVIEWER: so.. 1365 
SONYA: yeah. 1366 
INTERVIEWER: er OK, that’s with diet.. 1367 
SONYA: unless there’s something I don’ know about that’s affecting her INR.. 1368 
INTERVIEWER: well it’s usually.. e’ everything sh’.. should be there on that list.. 1369 
SONYA: yeah. 1370 
INTERVIEWER: but you need to.. umm.. be aware of.. 1371 
SONYA: yeah. 1372 
INTERVIEWER: ummm.. so how about other.. er medicines? 1373 
SONYA: …… Oh I don’ know. 1374 
INTERVIEWER: antibiotics maybe? 1375 
SONYA: yeah we haven’ had any of those yet since she’s been on… INR so we haven’ 1376 
had that experience ye’. 1377 
INTERVIEWER: err.. any ummm.. 1378 
SONYA: she’s now on.. diuretics.. she’s on spiro (spironoactone) an’ furoso 1379 
(furosemide).. and.. movicol.. an’ ranitidine. bu’ she’s been on them… all a long 1380 
anyway. 1381 
INTERVIEWER: yeah. So up to now she is on those err.. 1382 
SONYA: yeah. 1383 
INTERVIEWER: stuff. 1384 
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SONYA: so I don’ know if they affect her INR or no’….. I don’ know (laugh). 1385 
INTERVIEWER: (laugh). 1386 
SONYA: I jus’ give her  wha’ I’m told. (laugh) 1387 
INTERVIEWER: OK (laugh). So and.. umm any other.. errmm.. may be illnesses.. that 1388 
..she might have been… through? 1389 
SONYA: she.. she’s no’ been poorly she’s had.. a cough.. an’ tha’s about i’.. since she’s 1390 
had her op. touch wood. 1391 
INTERVIEWER: (laugh). 1392 
SONYA: which is brilliant for her.. it’s very good she’s no’ had any.. 1393 
INTERVIEWER: yeah. 1394 
SONYA: I assume maybe sickness an’ diarrhea tha’ possibly would tha’ affect i’? 1395 
SONYA: tha’ seem to affect everything doesn’ i’ I don’.. bu’ she’s no’ had any of tha’. 1396 
INTERVIEWER: any types of maybe fever or something. 1397 
SONYA: yeah. 1398 
INTERVIEWER: she hasn’t got any.. of that? 1399 
SONYA: no. 1400 
INTERVIEWER: errrr.. I can’t remember is that.. was that o’.. [child] that had ummm 1401 
chicken pox? 1402 
SONYA: Oh she did bu’ tha’ was before…. tha’ was before her op. 1403 
INTERVIEWER: after. 1404 
SONYA: was i’? 1405 
INTERVIEWER: because yeah I I can remember that.. 1406 
SONYA: Oh i’ was after her op  1407 
INTERVIEWER: yeah. 1408 
SONYA: because we couldn’ to bring.. we were no’ allowed to bring her in.. for her 1409 
INR.. 1410 
INTERVIEWER: yeah. 1411 
SONYA: because she had chicken pox yeah. 1412 
INTERVIEWER: yeah. 1413 
SONYA: sorry. (laugh) 1414 
INTERVIEWER: (laugh) it’s alright. 1415 
SONYA: mum brain (laugh). 1416 
INTERVIEWER: yeah so.. umm during that period have you found that er.. there.. 1417 
umm.. was something.. umm… her dose needed to be adjusted.. or.. the INR went up or 1418 
something? 1419 
SONYA: we didn’ have a test did we when she had the chicken pox so I don’ know. 1420 
INTERVIEWER: um. 1421 
SONYA: we didn’.. we had i’ tested like the week before.. an’ then the week after an’ 1422 
I.. honestly I should ‘ve brought my book ‘cause I can’ remember wha’ the INR as well. 1423 
INTERVIEWER: yeah. 1424 
SONYA: umm. 1425 
INTERVIEWER: I can remember that the.. the doctor has recommended to decrease the 1426 
dose. 1427 
SONYA: yeah. (laugh) 1428 
INTERVIEWER: yeah because I was doing the computer dose and then.. umm.. the 1429 
doctor decided to decrease that. 1430 
SONYA: decrease i’ while she has chicken pox? 1431 
INTERVIEWER: yeah. 1432 
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SONYA: yeah. 1433 
INTERVIEWER: and asked if there were any.. like sign of.. bleeding or bruising.. 1434 
SONYA: Oh yeah they did say to me if there is any.. bleedin’ under the skin.. 1435 
INTERVIEWER: yeah. 1436 
SONYA: or on the spots then to.. ring.. straight away. bu’ she didn’ ge’ any of tha’ she 1437 
had.. she had a very mild case to be fair she only.. had 8 or 9 spots.. an’.. 1438 
INTERVIEWER: so yeah and and umm.. what.. kind of medicines that she err have 1439 
got.. has got form.. while she were.. 1440 
SONYA: with the chicken pox? 1441 
INTERVIEWER: yeah. 1442 
SONYA: I jus’ gave a calpol.. I didn’ give.. jus’ gave a calpol. 1443 
INTERVIEWER: OK. 1444 
SONYA: I know some people who give like Piriton an’ stuff weren’t they for itching.. 1445 
INTERVIEWER: sorry? 1446 
SONYA: some people give Piriton.. an’ stuff for itching.. bu’ she was… I jus’ gave a 1447 
calpol. She was fine. 1448 
INTERVIEWER: so it was mild? 1449 
SONYA: yeah. Ya ya  ya very mild. 1450 
INTERVIEWER: umhm… umm.. yeah.. so.. umm…. those that are the main things 1451 
umm.. err.. that I need to ask umm you know.. err your experience with warfarin. 1452 
SONYA: yeah. 1453 
INTERVIEWER: err so do you have any.. errr  other things that you like to add? 1454 
SONYA: umm.. 1455 
INTERVIEWER: err.. 1456 
SONYA: the only thing  I will add is.. tha’.. I exp’.. she hasn’.. with the bruising an’ 1457 
stuff ‘cause we were warned abou’.. bruising weren’t we… an’ like you said she’s only 1458 
put on i’ a short time bu’ we haven’ noticed any.. drastic changes we have the ank’ 1459 
bruise where.. I wouldn’ say she’s bruised easier.. bu’ the knock she had caused like er.. 1460 
nastier looking bruise than i’ normally would.. umm.. bu’ we’ve no’ had any…. major 1461 
bruisin’ or… anythin’ bigger than.. a ten p. (laugh) 1462 
INTERVIEWER: aha OK. 1463 
SONYA: bu’ she’s quite impressive I thought i’ was.. glad abou’ tha’. 1464 
INTERVIEWER: yeah so ummm errm any other maybe concerns.. regarding this 1465 
whole.. warfarin treatment.. err.. whether it’s regarding.. the INR monitoring.. the 1466 
doses..  1467 
SONYA: umm.. 1468 
INTERVIEWER: maybe the overall… thre’.. therapy? 1469 
SONYA: we are as happy with i’.. as you can be for bein’ on warfarin (laugh). 1470 
INTERVIEWER: (laugh). 1471 
SONYA: no were umm… we don’ have any complaints I mean… obviously the comin’ 1472 
to.. havin’ to drive to hospital to have her INR done. 1473 
SONYA: is a li’le bi’ incovien’ bu’.. it needs doing so…it’s no’ the end of the world 1474 
and.. I’m imagining at some poin’ along the line.. they migh’ receive some machines for 1475 
us to me be do i’ a’ home (laugh). 1476 
INTERVIEWER: (laugh) yeah. 1477 
SONYA: so we.. it still very new for us isn’ i’ so we just… just go along with i’. 1478 
INTERVIEWER: aha. So do you find it easy to go? 1479 
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SONYA: yeah it’s no’ difficult…. the the… the liaison nurses are very.. umm flexible 1480 
with i’ as well we’re like.. we’re meant to be coming.. next Tuesday.. bu’ [child] does 1481 
swimming lessons on Tuesday so they’ve said well.. come Monday or Wednesday 1482 
they’re no’… they.. very much would do i’ around our schedule rather than… tellin’ us 1483 
she have to be here on this day at this time.. which would make i’ more difficult.. so no 1484 
it’s pretty easy. 1485 
SONYA: jus’ keep to. 1486 
INTERVIEWER: aha. And umm how about.. err.. er just er.. I got that in my mind list 1487 
of umm.. thee medicines.. have you been given any list of.. maybe medicines that er to 1488 
avoid or to take care about? 1489 
SONYA: no. 1490 
INTERVIEWER: so any medicines that interact.. may interact with warfarin go.. make 1491 
the INR go up or.. 1492 
SONYA: no (laugh).  1493 
INTERVIEWER: (laugh) 1494 
SONYA: Should I have been?.. No no one’s given me tha’. 1495 
INTERVIEWER: aha. So an’.. 1496 
SONYA: maybe I should ask for one of those. 1497 
INTERVIEWER: umm. and no one has told you about anything about you know 1498 
medicines that may… affect the INR go up or down? 1499 
SONYA: no. 1500 
INTERVIEWER: OK. Yeah so any other comments? overall? 1501 
SONYA: no’ tha’ I can think of… I’m pretty happy.. as happy as we can be (laugh).. no 1502 
it’s good. 1503 
INTERVIEWER: alright great. 1504 
SONYA: it’s been easier than we though’ i’ would be.. which is nice. 1505 
INTERVIEWER: so at the first time you thought that it would be.. 1506 
SONYA: Oh yeah we thought i’ would bee.. pretty…. well.. we thought i’ would be 1507 
more… I don’ know how to describe i’.. we thought i’ would worry us more than i’ 1508 
does bu’ we’re.. we go on.. abou’ things.. as we did.. before pretty much we jus’ know 1509 
in the back of our heads.. to be a li’le bi’ more careful with her. 1510 
SONYA: bu’ she still does evry thing.. an’ more.. than she did before her op so.. 1511 
 1512 
4- Interview number 11: Participant 1005’s mother 1513 
INTERVIEWER: um good morning and thanks you so much for coming and.. for 1514 
agreeing to take part in my research…ermm the purpose of.. our meeting is to.. talk 1515 
about.. err [child’s] warfarin therapy and err.. erm how best you manage that. 1516 
KAMYA: OK. 1517 
INTERVIEWER: ermm.. it is important.. that I get to know.. how it is for you.. err 1518 
managing ermm..  [child’s] warfarin therapy.. ermm.. I imagine that this has been very 1519 
new for you.. 1520 
KAMYA: u’um. 1521 
INTERVIEWER: and.. errmm it.. looks like that it.. you have been on a bit of journey.. 1522 
erm.. to learn how.. to manage warfarin for [child].. 1523 
KAMYA: OK. 1524 
INTERVIEWER: errmm so I.. would like to start off by… erm asking you to think back 1525 
to the first time when the doctor.. or.. may be the nurse.. first explained what warfarin 1526 
therapy is and why [child] needs to take it. 1527 
298 
 
KAMYA: ya. Errmm.. err it’s been explained that err it is very important medicines for 1528 
[child].. and she has to take it as er.. like er.. modern.. er.. types of medicines that er.. 1529 
helpful for the cardiac patients especially.. like [child].. so.. it is very useful for her to 1530 
take and st’.. er means to tinner (thinner) the bloods.. and.. for the… smooth circulation 1531 
of the blood so… er in that sense er we have accepted er.. that er.. yeah.. errm if it is so 1532 
good for [child’s] health so we’ll accept it yeah. 1533 
INTERVIEWER: OK. Errmm so.. errmm as you said it.. it ermm helps to thin the blood 1534 
any more information.. ermm.. you know about warfarin.. why erm.. why it is especially 1535 
needed for.. 1536 
KAMYA: (at the same time) yeah. 1537 
INTERVIEWER: (at the same time) these circu’.. for.. [child’s] surgery? 1538 
KAMYA: yeah. Err it’s been ex’.. explained that er.. warfarin is a tablet.. ummhhm.. 1539 
that err.. control the circulation so sometimes it’s high it’s err.. errmm.. when the.. 1540 
bloods become.. too tin (thin) then we have to.. lessen the dose.. 1541 
KAMYA: or.. if it is more thick then.. err.. the dose has been increase. So.. er according 1542 
to the INR means the blood.. err..  go’.. errmm.. the ratios.. err the warfarin dose has 1543 
been fluctuatin’ an’ it’s been flexible so.. it is not like a regular dose like aspirin we 1544 
have to take once a day.. two a day.. it’s not like that. 1545 
KAMYA: it has to be.. errmm regulated and it has been control an’ it is flexible 1546 
changing.. the dose.. err.. ar’.. according to the bloods yeah. 1547 
INTERVIEWER: erm so er how do you feel about erm being involved in this process of 1548 
warfarin monitoring? 1549 
KAMYA: yeah it’s er feel quite satisfied that err… we are.. in the safest zone like er.. 1550 
we are.. err.. it’s not going to happens.. means err.. errmm any difficulties or any kinds 1551 
of problems that may occur in futures because everything is in control so… it’s quite 1552 
satisfacting an’ we.. feel that it is.. good for her an’.. for us also.. that err… testing the 1553 
INR every time an’.. er.. changing the dose all the time it means that it shows that e’.. 1554 
she is in a stable conditions. 1555 
INTERVIEWER: OK erm so erm let’s go.. back to the.. you know.. for the.. first time.. 1556 
when the.. erm the doctor.. or maybe the nurse errmm.. gave you the information about 1557 
warfarin.. 1558 
KAMYA: (at the same time) umm. 1559 
INTERVIEWER: (at the same time) and how to monitor it.. erm.. can you please tell me 1560 
more about that? 1561 
KAMYA: OK errmm.. that explain as err.. well ermm by providing hers the.. the.. 1562 
manuals.. 1563 
INTERVIEWER: (at the same time) sorry? 1564 
KAMYA: the manuals. 1565 
INTERVIEWER: aha. 1566 
KAMYA: they given us a manual.. err I go trough (through) the manuals and read 1567 
what’s the effect what’s the sides effect what’s the benefits.. everything I’ve gone 1568 
trough (through).. an’.. also the doctors.. and the nurse have explains that.. how.. err.. 1569 
warfarin.. err.. useful for the [child].. 1570 
KAMYA: an’ ermm.. they ‘s explain us.. err.. errmmm… yamm like… I’d said that err.. 1571 
it helps the blood circulations that occurs and the.. the clots has been.. err manage an’ 1572 
everything else they had been explained. 1573 
KAMYA: an’.. more of the benefits I’ve got from the manuals reading the manuals so.. 1574 
everything is clear listed it in the manuals that.. what.. 1575 
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INTERVIEWER: so were errmm those manuals were they like erm easy to read and to 1576 
go through? 1577 
KAMYA: (at the same time) yeah yeah yeah it was quite easy and quite beneficial so I 1578 
can understand it it’s very easily.. yeah. 1579 
KAMYA: as a parent I can easily understands like.. language of the doctors.. 1580 
sometimes.. err it’s confuse but..manuals.. make it little bit clear.. more about clear us. 1581 
yeah. 1582 
INTERVIEWER: so.. errmm about errmm.. you know.. managing this.. er warfarin.. 1583 
errm therapy with her.. let’s say.. daily life.. erm.. do you find it easy to manage that? 1584 
KAMYA: …. Yeah it’s not too much complicated because once in a day.. she has to 1585 
take ‘er medicines an’ now it’s become like a routine that.. before going to sleep… she 1586 
takes ‘er warfarin. 1587 
KAMYA: so… it has become like a routine that err.. she has to take the dose an’ err.. it 1588 
has become like a habit so… more or less.. it’s not a much problem.. it’s very easy.. 1589 
an’.. it is very comfortable as well. 1590 
KAMYA: so.. it’s not like err twice a day tris (three times) a day.. she has to take ‘er 1591 
medicine it’s only once a day an’ that’s also.. bedtime. easy to manage (laugh) yeah. 1592 
INTERVIEWER: OK. Errmm so how about like errmmm other things.. errr.. like erm 1593 
her diet.. errm if she is.. like.. taking other medicines.. erm how do you fit that with 1594 
warfarin? 1595 
KAMYA: … err it has been explained that some kinds of medicines are restricted with 1596 
the warfarin. 1597 
KAMYA: like antibiotics ibuprofen so… err.. we are aware of that.. an’ even that 1598 
[child] has been aware.. er I had made her aware that.. such types of ‘e medicines you 1599 
have to… errm.. be careful… while taking with the warfarin. 1600 
KAMYA: otherwise.. errmm.. err.. with oder (other) medicines it’s OK.. doctor has 1601 
suggested as per the suggestions has been a prescriptions… advice of the doctor.. we are 1602 
giving the medicines regularly. 1603 
INTERVIEWER: so at the moment which medicines.. err.. she is.. 1604 
KAMYA: (at the same time) she is taking.. er sildenafil tris a day three time a day.. err 1605 
furosemide once a day an’ lisinopril once a day. an’.. warfarin. 1606 
INTERVIEWER: OK. And err for those er.. medicines that.. erm.. she.. you were 1607 
errmm.. err.. like were made aware of.. like the antibiotics and.. ibuprofen and stuff,  has 1608 
she ever needed to use the? 1609 
KAMYA: no no,  not yet.. not yet. No.. no such kinds of condition has been occurred 1610 
like err.. for.. err.. severe pain so that I can give ibuprofens or.. err.. 1611 
INTERVIEWER: (at the same time) so she’s been.. 1612 
KAMYA: (at the same time) antibiotics.. 1613 
INTERVIEWER: (at the same time) well since.. 1614 
KAMYA: (at the same time) yeah yeah she’s she’s heal’.. healdy (healthy).. taking diet 1615 
properly.. 1616 
INTERVIEWER: (at the same time) alright (laugh). 1617 
KAMYA: (at the same time) eating all the times mean.. 1618 
INTERVIEWER: (at the same time) alright. 1619 
KAMYA: (at the same time) so.. no problem at all touch wood yeah. 1620 
INTERVIEWER: (laugh). 1621 
KAMYA: (laugh). 1622 
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INTERVIEWER: alright. So.. and and  how about her diet, how you manage that with 1623 
warfarin? 1624 
KAMYA: err normally.. I can has to means err.. whatever the normal.. diet she has to 1625 
take.. I won’t… used to take.. much care that… you won’.. eat that.. you won’.. eat.. 1626 
whatever she wants, but I.. usually prefer the healdy (healthy) foods.. to hers.. no junk.. 1627 
no.. no more junk foods.. sometimes.. err the childrens wants like err… pizza an’ err 1628 
burger an’ also.. once in a week or.. 1629 
INTERVIEWER: (at the same time) yeah. 1630 
KAMYA: (at the same time) I used to take.. 1631 
INTERVIEWER: (at the same time) yeah of course yeah. 1632 
KAMYA: (at the same time) but a r’.. regular diet err.. I’m concenting (she may mean 1633 
concentrating) on the regular diet and she also take perfectly the reg’.. the diet.. 1634 
INTERVIEWER: (at the same time) OK. 1635 
KAMYA: (at the same time) an’ all this food. 1636 
INTERVIEWER: so.. erm have you got a list of.. diet that may.. may interact with 1637 
warfarin? 1638 
KAMYA:… ermm.. diet ermm.. er no but since yet I have not interact with the diet 1639 
means.. I have not concentrated on her diet.. with the warfarins.. because.. err.. I say that 1640 
erm.. err.. in form that vitamin K is useful.. means err.. has to be maintained like.. green 1641 
vegetables or… like errmm… alls type of spinach or green leaves vegeta’.. leafy 1642 
vegetables I used to prefer.. the soups an’ all.. to her.. that so that she can maintains err.. 1643 
with the.. warfarins yeah. 1644 
INTERVIEWER: so.. er were you made aware of any type of food to.. like.. take care 1645 
of?... not to take in excessive amount? 1646 
KAMYA:… ah ya.. ya so…. Err excess amount means err… o’ her.. like her.. errmm 1647 
according to her age.. she won’t take some.. more like er.. everything in the.. err right 1648 
proportions.. right means.. not more not less.. 1649 
INTERVIEWER: OK. 1650 
KAMYA: if she likes something er.. er with a green vegetables she won’ts go on eating 1651 
the green vegetables all the time. 1652 
INTERVIEWER: (at the same time) of course (laugh). 1653 
KAMYA: (at the same time) (laugh). 1654 
INTERVIEWER: (at the same time) does she does she like the green.. vegetables? 1655 
KAMYA: (at the same time) yeah yeah yeah she likes the salads an’ all.. too much.. but 1656 
err.. but she takes like.. not all the day the green vegetables.. once in a day.. 1657 
INTERVIEWER: OK. 1658 
KAMYA: like.. so.. all kinds of foods like pulses.. errm meat.. fish.. everything.. once 1659 
in a day she used to take so.. she is like very.. err fully like.. (laugh) 1660 
INTERVIEWER: (laugh) 1661 
KAMYA: so.. she needs all kinds of foods means not.. err.. stucks on a one.. that rice.. 1662 
or chapatis.. no not that. 1663 
KAMYA: er.. she.. every.. er.. erm.. all the day.. she needs some.. different kinds of 1664 
foods (laugh) 1665 
INTERVIEWER: (laugh) aha. 1666 
KAMYA: so I have to manage that (laugh). 1667 
INTERVIEWER: alright. Ermm so erm yeah.. ermm so.. like erm you are aware of 1668 
what type of food that.. that may interact with warfarin and cause like.. disturbance in 1669 
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her INR…aren’t you? Any type of food so… anyone told you about err.. specific types 1670 
of food that may interact with warfarin? 1671 
KAMYA: .. ermm.. no.. still yet not.. err.. I have.. I have no idea about err.. 1672 
INTERVIEWER: (at the same time) in your.. in the.. the list of er.. or in the manual.. 1673 
that you were given er.. was it.. ever mentioned that erm.. certain types  of food that.. 1674 
interact with warfarin? so.. you have to take care about? 1675 
KAMYA: ermmmm I don’t have much idea about that, sorry. 1676 
KAMYA: errmm but errr… errmm.. I had been informed that err.. she has to take some 1677 
green vegetables.. 1678 
KAMYA: more in amount..  so it’s good for her. 1679 
INTERVIEWER: more or less? 1680 
KAMYA: more or le’.. means errrr… what you say like err…. er is the INR.. 1681 
INTERVIEWER: (at the same time) balanced.. amount like? 1682 
KAMYA: sorry? 1683 
INTERVIEWER: balanced amount? 1684 
KAMYA: yeah, the balance amount means not more not less.. as I said as she is fond of 1685 
er.. er salads an’ all, but she takes once in a day. 1686 
KAMYA: not all the time. 1687 
INTERVIEWER: OK. 1688 
KAMYA: yeah? 1689 
INTERVIEWER: yeah. 1690 
KAMYA: so… it has been in a.. proportions like.. it is the ratios all the time it’s going 1691 
so. 1692 
INTERVIEWER: OK. 1693 
KAMYA: yeah yeah. 1694 
INTERVIEWER: errmm so yeah. And now back to the.. err.. this monitoring process 1695 
of.. the dose.. and the INR who.. er.. do you think should take the responsibility.. of.. 1696 
monitoring INR? 1697 
KAMYA: … mmm the brought her hospitals, myself.. parents as a parents.. errmm… er 1698 
everybody is responsible for that (laugh). 1699 
INTERVIEWER: (laugh). 1700 
KAMYA: (at the same time) because.. 1701 
INTERVIEWER: (at the same time) alright.. 1702 
KAMYA: (at the same time) yeah. 1703 
INTERVIEWER: (at the same time) can you please.. 1704 
KAMYA: ah yeah.. so.. it’s all according to the advice of the hospitals, the doctors, they 1705 
says.. that err.. this much dose has to be given.. and.. this day she has to be check the 1706 
INR. 1707 
INTERVIEWER: umhm. 1708 
KAMYA: the reports of the INR has to be submitted on this day, so it is err.. once they 1709 
say.. they recommend err that.. so an’ so dose an’ so an’ so days, err.. he has to be.. she 1710 
has to be check.. then it is my responsibility that I have to.. carry out all this, yeah? 1711 
INTERVIEWER: alright, alright. So and about.. you know.. deciding.. this.. errm dose 1712 
of.. when you.. when the hospital tells you that erm you need to give this dose and to.. 1713 
monitor.. erm.. erm.. do you find.. ermm  like ermm do you feel that this is err the right 1714 
person or you need to do the dosing yourself or.. who who do you think the best judge.. 1715 
KAMYA: (at the same time) no. 1716 
INTERVIEWER: (at the same time) to get this dose.. 1717 
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KAMYA: (at the same time) yeah yeah. 1718 
INTERVIEWER: (at the same time) and monitoring right? 1719 
KAMYA: of course I can decide it myself because.. er I.. just follow the instructions.. 1720 
all the doctors and the hospital says.. err and the experts of warfarin says. so.. I can 1721 
decides of myself that how many dose I..  used to gi’.. I.. feel that.. I.. no doctor has said 1722 
4 but I used to give 2, it’s not that. Err once it is said that er 4.. 4  m g (milligram) per 1723 
day.. then I have to follow.. strictly.. the 4 m g per day (laugh). 1724 
INTERVIEWER: (laugh) alright. 1725 
KAMYA: yeah (laugh). 1726 
INTERVIEWER: so yeah you you prefer to.. like.. 1727 
KAMYA: (at the same time) yeah yeah.. 1728 
INTERVIEWER: (at the same time) follow what the doctor’s.. 1729 
KAMYA: (at the same time) yeah yeah.. 1730 
INTERVIEWER: (at the same time) advice? 1731 
KAMYA: advice yeah of course.. of course. 1732 
INTERVIEWER: OK. 1733 
KAMYA: mm. 1734 
INTERVIEWER: erm so and errm then.. errmm.. how about your responsibility in the 1735 
house.. err.. 1736 
KAMYA: yeah everybody is responsible for that (laugh).  1737 
INTERVIEWER: (laugh). 1738 
KAMYA: 4 m g means 4 m g.. everyday (laugh). 1739 
INTERVIEWER: (lagh). 1740 
KAMYA: 3 mg means 3 m g everyday, everybody is responsible to look after that she 1741 
has taken 4 m g.. per day or not yeah? 1742 
INTERVIEWER: alright. And ermm how about you know the.. this number of INR 1743 
measurements how do you feel about that? 1744 
KAMYA:… yeah.. I feel that errmm.. as per the dose.. according to the dose. 1745 
KAMYA: errmm the INR changes so.. I.. jus’ err notice.. the changes.. that someti’.. 1746 
when the dose is less.. INR is also comes less means err it’s like.. her normal range is 2 1747 
to 3. 1748 
KAMYA: so… if I foun’ it is 2.. or two point zero (2.0) or 2.1 2.3 I think that she needs 1749 
some more.. like err.. err more doses in. But err.. as per the doctor suggestions they says 1750 
that.. she has to be given 4 m g 3 m g I strictly follow that. 1751 
KAMYA: then… whatever maybe the results.. it’s upon.. the doctors and the.. experts 1752 
yeah? 1753 
INTERVIEWER: OK. Errm I mean.. you know the frequency of INR measurements 1754 
how frequent you need to come to hospital and.. test the INR how do you find that? 1755 
KAMYA: yeah errmm… err twi’ er once.. in er.. 15 days that e’.. two.. er once in a two 1756 
err two weeks.. 1757 
KAMYA: err it’s OK. But now.. as the charity has provided us the machines ‘at at home 1758 
so.. we used to do it at home an’.. they had also recommended that.. every two week er.. 1759 
‘at she has to be monitored. 1760 
KAMYA: (at the same time) an’ I was.. 1761 
INTERVIEWER: (at the same time) so now you have got the machine at home? 1762 
KAMYA: (at the same time) yeah yeah machine at home yeah.. 1763 
KAMYA: yeah. An’ before that I was coming.. every two weeks in the hospital for err.. 1764 
for the test. 1765 
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INTERVIEWER: so.. how.. was it.. how do you.. how did find that you know.. coming 1766 
to the hospital every two weeks… how did you find that? 1767 
KAMYA: …. Errmm.. yeah it’s OK I can manage it err.. to come to the hospitals an’ do 1768 
the test so… err it’s not much a problem like.. yeah. 1769 
INTERVIEWER: so.. you .. do.. like erm did you need to take like some.. time.. off.. 1770 
work or take erm.. 1771 
KAMYA: (at the same time) yeah of.. 1772 
INTERVIEWER: (at the same time) [child] off school? 1773 
KAMYA: yeah yeah errmm… err.. school already knows about the.. her health 1774 
conditions. 1775 
KAMYA: so I already.. been explained that err.. she is on warfarin an’.. she has to be.. 1776 
err.. tested so.. as per.. the hospital. So.. any time I need to go means er.. they had been.. 1777 
suggested that err.. err.. I ‘ve been calling after two.. two weeks. So they.. most 1778 
probably know.. that today is ‘er test day.. or Friday.. I have to go for the blood test so.. 1779 
KAMYA: they directly give the permissions regarding that. An’ also.. err.. err.. I had 1780 
suggested to the hospital that.. Thursday Friday is my off day.. so I manage to come so 1781 
it’s easily.. err I can manage it yeah. 1782 
INTERVIEWER: aha. OK. And errmm.. errmm this is errmm.. erm you.. like erm.. so it 1783 
was OK for you.. 1784 
KAMYA: (at the same time) yeah yeah. 1785 
INTERVIEWER: (at the same time) managing that coming to the hospital.. 1786 
KAMYA: (at the same time) yeah it’s OK. 1787 
INTERVIEWER: (at the same time) and.. doing the test. 1788 
INTERVIEWER: and errmm how about the.. errmm the dose changes so n’ you know 1789 
every time like you get.. a different dose how did you feel about that? 1790 
KAMYA: … yeah I feel that errrmm.. whatever has been suggested it is good for her. 1791 
KAMYA: so… (laugh).. I don’t err.. include myself means err.. my suggestion or my 1792 
advice because I’m n’.. not.. much.. experts an’.. ‘m not.. aware.. about.. all these things 1793 
so… whatever.. has been told to me I strictly follow.. it yeah. 1794 
INTERVIEWER: so.. and erm I mean errmm… errr.. errmm you know.. so the d’.. the.. 1795 
so did you find it OK to like.. you know.. make those.. d’.. d’ those.. err dose.. changes? 1796 
KAMYA: yeah yeah. 1797 
INTERVIEWER: like.. was it easy for you regarding..er as far I.. 1798 
KAMYA: (at the same time) yeah yeah. 1799 
INTERVIEWER: (at the same time) as.. I know she is taking the tablet so how you 1800 
manage that?.. with tablet. Was it easy or.. did you find it difficult like.. 1801 
KAMYA: (at the same time) no no.. 1802 
INTERVIEWER: (at the same time) with the tablet? 1803 
KAMYA: (at the same time) it’s easy it’s easy because er.. as per the dose er.. I get my.. 1804 
medicines from my surgery.. 1805 
KAMYA: so… I easily manage.. to get.. I can say that er.. it is er.. recommended er.. 1806 
such a dose.. in er.. once a days that’s 4 m g (milligram). It’s frequently changing.. so 1807 
they also cooperate an’ I.. I get the medicine easily.. er warfarin er.. from my.. 1808 
pharmacis’.. 1809 
KAMYA: so nearby.. 1810 
KAMYA: so.. it’s easy to.. manage all those things it’s not much difficult then… not 1811 
med’ err.. problem get it at all. 1812 
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INTERVIEWER: aha. Errmm… so.. errrm… errm.. do you have any other errmm… 1813 
concerns about… err.. warfarin treatment with.. for [child]? Anything that erm.. you 1814 
may be concerned of? 1815 
KAMYA: errmm.. the concern means errr.. it may happen that er.. suddenly I have to 1816 
go.. out means abroad.. for the holidays.. an’.. I have to manage.. with this dose..  1817 
KAMYA: everything else so.. I feel that time.. but.. it won’ happens all the time like.. 1818 
KAMYA: err once in a year. 1819 
INTERVIEWER: OK. 1820 
KAMYA: or.. once in a two year.. it may happen. 1821 
INTERVIEWER: umhm. 1822 
KAMYA:  but not it’s.. frequent so… I don’t think so that it’s a problem an’.. if it’s a 1823 
problem then.. it can be easily manange. Because er.. the thing has to do is to follow the 1824 
dose. 1825 
KAMYA: as per.. the INR yeah? 1826 
KAMYA: so… err.. if I am abroad.. I can err.. send err.. INR test trough (through) 1827 
email.. I have the telephone contacts. 1828 
KAMYA: whatever so.. err.. I can manage it yeah (laugh). 1829 
INTERVIEWER: OK. 1830 
KAMYA: yeah. 1831 
INTERVIEWER: errmm.. so.. any other concerns regarding let’s say the.. maybe the 1832 
side effects of warfarin? 1833 
KAMYA: err yeah. Err it is said that err.. the overdose may cause.. a bleeding and the 1834 
less dose may cause the clot. 1835 
INTERVIEWER: OK. 1836 
KAMYA: yeah? so… ummm.. the mm dose.. means the warfarin.. that is given to her.. 1837 
errr.. the dose that is given to her.. that was… according.. err.. er to her INR an’.. it has 1838 
to be maintain.. an’.. err the ratio has to be maintained for the lifetime yeah? 1839 
KAMYA: so.. what.. the standard has been err.. 1840 
INTERVIEWER: yeah. So other things like errr.. maybe.. errmm maybe concerning to 1841 
you like.. you know she is a child, she might be… err predisposed to bruises or things 1842 
like that.. err has she ever got something like that or maybe nose bleeds or things like 1843 
that? 1844 
KAMYA: um um um. 1845 
INTERVIEWER: because she is on warfarin? 1846 
KAMYA: um um um. 1847 
INTERVIEWER: so ermm.. ermm.. has she got anything like that? 1848 
KAMYA: n’.. not yet because err she’s just now.. 9 years ol’ an’.. all this problems 1849 
err… I think after two or three years err will come an’ will face all.. all these difficulties 1850 
after two or three years. 1851 
KAMYA: so… n’ er now he is a chil’.. she is growing.. young.. so… now it’s going 1852 
everything OK.. but.. when these problems occur.. I think I get an experience after that 1853 
(laugh). 1854 
INTERVIEWER: (laugh) OK.. 1855 
KAMYA: (at the same time) what to do (laugh). 1856 
INTERVIEWER: (at the same time) so touch wood there is nothing (laugh). 1857 
KAMYA: (at the same time) yeah yeah of course (laugh). 1858 
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INTERVIEWER: so yeah errmm.. so anything else ermm that you would like.. er to 1859 
add.. errmm for the.. you know.. the overall process of like.. warfarin.. errmm 1860 
treatment.. for [child].. any concerns that you.. 1861 
KAMYA: yeah. 1862 
INTERVIEWER: (at the same time) may have? 1863 
KAMYA: there was some doubts err regarding this dose that when she grow.. young.. 1864 
errmm.. what will the problems err regardings her periods regardings her pregnancy an’ 1865 
all. 1866 
KAMYA: so…mmm.. the expert has er.. Madison has explained me.. that er when she 1867 
grow.. at that time.. may occur.. excess bleeding.. errmm due to warfarin when she get 1868 
pregnants.. 1869 
KAMYA: err then.. it’s.. warfarin is.. not good for the fetus. So at that time.. they will.. 1870 
sugges’.. that what treatmen’ or what kinds of err.. err dose or what er.. for the treatmen’ 1871 
or what.. procedure they have to follow. 1872 
KAMYA: yeah so.. (laugh). 1873 
INTERVIEWER: alright (laugh). 1874 
KAMYA: so it’s err.. out of her.. all my.. attentions an’ all (laugh). 1875 
INTERVIEWER: (laugh) OK. Erm anything elso you would like to add.. about the 1876 
overall process of.. warfarin.. treatment? 1877 
KAMYA: yeah I’m quite happy with all this treatments an’ all an’.. our family alls are.. 1878 
too much happy regarding all this er.. facilities an’ all this er.. procedures that is.. going 1879 
with the er.. er [child] an’ it is good for her health an’.. I think that I had become 1880 
attention free.. for her health for the lifetime (laugh). 1881 
INTERVIEWER: (laugh) OK. So and erm.. you know ermm.. er..erm.. this er.. your 1882 
erm.. you know contact with the doctors and with the nurses.. ermm.. how do you find 1883 
that regarding this.. 1884 
KAMYA: (at the same time) it’s.. it’s very friendly I say it’s very.. like.. I can’t err.. err 1885 
believe that er.. they are… the different peoples of my.. range or my family circles. I 1886 
feel that all are family an’ all.. like er our relatives like our brothers sisters an’ all 1887 
(laugh) they are helping they are.. too much helpful an’ I.. I feel very.. close to them 1888 
an’.. 1889 
KAMYA: I feel very friendly.. to explain my views to.. accept their views.. everything 1890 
is very friendly. 1891 
INTERVIEWER: so.. erm have you come.. have you ever come.. er er like had got an 1892 
incidence where you discussed something with them regarding warfarin? 1893 
KAMYA: um um. 1894 
INTERVIEWER: er with the doctor or with the nurse like you had some concern and 1895 
discussed that with them? 1896 
KAMYA: yeah of course then.. err yeah.. err.. I.. used to discuss with the Madison an’ 1897 
err.. she used to.. err.. give me.. err the.. right.. err suggestions and the right advice and 1898 
the right recommendations that.. this has to be going to happen this has to be going to, 1899 
so it feels very relax for me that everything is in the safe hand OK. 1900 
INTERVIEWER: OK. So erm can you please tell me like.. what.. type of things that 1901 
ermm you were talking about like any.. erm.. apart from the pregnancy and the pre’ 1902 
periods.. 1903 
KAMYA: mm. 1904 
INTERVIEWER: er other things like.. errmm have you.. queried about? 1905 
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KAMYA: errr yeah er I had just asked about that er… if we are.. out of.. the country.. 1906 
like we are going for the holidays or.. in the out.. other country so.. err.. at that time how 1907 
can I manage errr how can I contac’ you. 1908 
KAMYA: an’.. all that question has been solved so.. everything has been err suggested 1909 
to me that you can do this this this, you can do.. that, you can phone us, this is our 1910 
phone number, this is our email ID.. err this is our contac’ so.. everything become very 1911 
easy for me (laugh). 1912 
INTERVIEWER: alright. Oh brilliant. 1913 
KAMYA: umm. 1914 
INTERVIEWER: errmm so errmm one last thing se’ errmm.. last comment if you 1915 
would like.. anything you would like to add? 1916 
KAMYA: … (laugh) all about is err.. I’m satisfied. (laugh) 1917 
INTERVIEWER: (laugh) great. 1918 
KAMYA: yeah. It’s no worry about at all an’.. err I think err it’s err... biggest relas relax 1919 
of my life that err I had been err.. facing for.. that I was been worried that for the life 1920 
time.. I have to take care of her, I have to look after her.. health, I was worried about 1921 
that what is going to.. happen to her in the life.. in the future life but err after.. 1922 
INTERVIEWER: sorry was that regarding warfarin or regarding her.. 1923 
KAMYA: no no before before warfarin but after.. that I feel that.. it is everything been 1924 
OK. 1925 
KAMYA: an’.. now… er she can live a normal life. 1926 
INTERVIEWER: (at the same time) alright. 1927 
KAMYA: (at the same time) like other.. 1928 
INTERVIEWER: so regarding her.. like her medical condition overall? 1929 
KAMYA: yeah yeah. 1930 
INTERVIEWER: and how about warfarin? 1931 
KAMYA: yeah the medical conditions.. before surgeries an’ before warfarin.. that I said 1932 
that I was.. too much worried about her future. 1933 
KAMYA: but err.. now I think it’s.. she is in the safest han’ an’… she can live, she can 1934 
manage, she can understand.. what is going on, what the procedure is going on in her 1935 
life. 1936 
KAMYA: so… she can.. err I think that in the future life she will understands that what 1937 
has happened to her.. and what’s going to happen with her. 1938 
KAMYA: so.. err…. so as a parent… we are very much satisfied.. an’ as a patient 1939 
[child].. er she is also very much satisfied an’ she is also.. think that she is safe (laugh).. 1940 
INTERVIEWER: (at the same time) alright. 1941 
KAMYA: (at the same time) for the life in the future. 1942 
INTERVIEWER: so errmm.. err.. as [child] like you know.. she is 9 years old.. errmm 1943 
is she aware of warfarin err.. or maybe you.. maybe you are trying to get her.. 1944 
KAMYA: (at the same time) I’m trying.. 1945 
INTERVIEWER: (at the same time) involved.. 1946 
KAMYA: (at the same time) I’m trying to invol’ an’… not like err.. everything I 1947 
explains once in a day. 1948 
KAMYA: I used to… take one one sentence.. warfarin is a tablet that.. tinner (thinner) 1949 
the bloods.. that circulates in the body an’ make your body perfect. 1950 
INTERVIEWER: alright. 1951 
KAMYA: that’s one sentence for the once a day. 1952 
INTERVIEWER: ahh! 1953 
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KAMYA: (laugh) then the next day.. that err.. if you take a less dose, it thicks.. it 1954 
become a clot.. you’ll become lazy.. you won’ be able to… do your normal activities. 1955 
That’s the second thing. So everyday I used to explain while giving her the dose that 1956 
this is the, so… in this way she has came to know.. everything about.. 1957 
KAMYA: what err is warfarin an’ what is going on an’. 1958 
INTERVIEWER: yeah and to be involved in this process. 1959 
KAMYA: yeah yeah an’.. er all the time she used to ask me how long I have to take this 1960 
tablet, I said it’s for the life time. 1961 
INTERVIEWER: Oh! 1962 
KAMYA: all the life time used to take it. 1963 
INTERVIEWER: Oh! 1964 
KAMYA: Oh! So err did I manage to get it, yeah of course you.. manage to get this 1965 
medicine easily.. because surgery is next to our door.. an’ you can get from the 1966 
surgeries, you can get from the pharmacy I used to take her in the pharmacy in the.. err 1967 
surgery as well.. so that sometime if I am not there.. you.. yourself can manage to do, so 1968 
in this way I’m jus’ trying to.. train her that er you.. become a self dependants.. in future 1969 
(laugh). 1970 
INTERVIEWER: alright. 1971 
KAMYA: yeah. 1972 
INTERVIEWER: alright and then.. to take the responsibility of.. 1973 
KAMYA: (at the same time) yeah er.. 1974 
INTERVIEWER: (at the same time) handling warfarin. 1975 
KAMYA: (at the same time) herself yeah (laugh). 1976 
INTERVIEWER: yeah. Of course. Errm anything.. else? 1977 
KAMYA: that’s it yeah. 1978 
 1979 
5- Interview number 9: Second interview with Participant 2006’s parents 1980 
INTERVIEWER: so.. hello… again and I’m very pleased to see you again.. errrmm.. 1981 
after those months.. errrmm so this time I have only.. a few questions for you.. umm 1982 
regarding the.. umm dosing and err.. INR.. so could you please let me know how do you 1983 
feel about the…frequency of INR measurements in.. since the last time we met? 1984 
Michelle: errrmmm… well.. i’d been.. various.. so sometimes we phoned up they’ve 1985 
gone.. the longest we had was not long ago… which is a 3 weeks didn’t.. ‘ave not testin’ 1986 
him.. according to the computer. 1987 
INTERVIEWER: OK. 1988 
Michelle: but… umm.. we tested every week still.. because.. we didn’ feel tha’ 3 weeks 1989 
was a good amount of time we were a bi’.. apprehensive abou’ tha’.. and [child]… 1990 
ummm.. was gettin’ a li’l bi’ ill anyway so.. luckily he stayed in range.. 1991 
Michelle: bu’.. he was out of range when he was told to take only… an’ test in 3 weeks 1992 
time.. which normally.. we wouldn’t do.. 1993 
INTERVIEWER: (at the same time) I can’t remember that we have.. 1994 
Michelle: (at the same time) he was at 4.6.. 1995 
INTERVIEWER: (at the same time) we have give him that.. long period. 1996 
Michelle: yeah.. he was at 4.6.. and.. he had to test 3 ml.. and test again in 3 weeks time. 1997 
Evan: I definitely took that phone call I defini’ remember i’.  1998 
Michelle: (at the same time) umm.. 1999 
Evan: an’ ‘ve said to Michelle that’s far too long. 2000 
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Michelle: and then we t’.. yeah.. then we phoned back.. bu’ w’ we tested i’ ourselves a’ 2001 
home didn’ we? 2002 
Evan: yeah. 2003 
Michelle: umm bu’ tha’ was the computer testin’ so.. 2004 
Michelle: the computer isn’ good in.. doin’ things like tha’ so.. 2005 
Evan: unless (couldn’t be heard as mum was talking at the same time). 2006 
Michelle: (at the same time) we’re alright.. 2007 
Evan: (at the same time) from.. bein’ told on the phone call.. (couldn’t be heard 2008 
clearly).. because his note don’t say 3 weeks either. 2009 
INTERVIEWER: so could you please rep’.. repeat that again? 2010 
Evan: maybe tha’.. because his notes.. does’.. don’t say there was a 3 week period of 2011 
testing.. bu’.. she definitely told me 3 weeks on the phone. 2012 
Evan: one hundred percent ‘cause as has Michelle e’.. show away.. 2013 
INTERVIEWER: O’.. OK. 2014 
Evan: 3 weeks is far too long. 2015 
Evan: so we still tested every week. we didn’t ring it through. we were jus’ makin’ sure 2016 
tha’ he was in range. 2017 
Michelle: we did tweek…. a li’le bi’ though? 2018 
Evan: I think we tweeked one or two days.. 2019 
Michelle: (at the same time) where it’s 2.5.. 2020 
Evan: yeah.. 2021 
Michelle: so it’s heading quite high a’ one poin’.. 2022 
Evan: (at the same time) yeah. I mean…. when i’ comes to the computer.. frequency.. 2023 
it’s.. it’s.. no’… as errmm.. 2024 
Michelle: every week. 2025 
Evan: yeah it’s no’ as consistent.. it can be.. 3 days.. 2026 
Evan: 2 weeks.. 5 days.. a week.. it’s no’ consistent. 2027 
INTERVIEWER: OK. 2028 
Evan: do you know.. where.. where with the human er’.. with the human.. or the 2029 
consultant.. it was generally test in a week.. test in a week.. 2030 
Evan: and tha’ was in general senses.. tha’ we would test once a week.. on a Sunday or a 2031 
Monday every week and tha’ way.. we felt we were.. a lot more comfortable in.. 2032 
Evan: tha’ was more ensuring wha’ [child] was bein’ in. 2033 
Michelle: [child] fluctuates too regularly.. 2034 
INTERVIEWER: OK. 2035 
Evan: yeah.. so the computer wasn’.. 2036 
Michelle: (at the same time) he is no’ a consistent.. 2037 
Evan: (at the same time) (not heard clearly) consistency enough for me. 2038 
INTERVIEWER: yeah.. so it’s it’s the consistency? 2039 
Evan: yeah. 2040 
Michelle: yeah. 2041 
Child’s toy is playing in the background. 2042 
Evan:  no’.. it’s no’. 2043 
Michelle: an’ the dosage.. 2044 
Evan: dosage so.. 2045 
INTERVIEWER: and the doses yeah. 2046 
Evan: sometimes it’s.. 2047 
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Michelle: (at the same time) the dosage.. was.. silly like.. a’ 4.1 he was sittin’ a’ 4.6  an’ 2048 
the dose was to continue a’ three.. 2049 
Michelle: for quite some time.. for us.. that’s no’ a good dosage ‘cause… normally.. if 2050 
he’s a book his so his target is 3 to 4.. so he was already above his target a’ 4.6.. we 2051 
would normally.. alternate.. 2.5 3 for a week period.. an’ that’s wha’.. the nurses here do 2052 
an’ wha’.. was ourselves would do. 2053 
Michelle: bu’ the computer came ou’ a’.. three.. for.. 2 or 3 weeks.. so wha’ we ‘ve got 2054 
told.. so that’s quite a length of time an’ i’ did… go higher.. 2055 
Michelle: it wasn’ a good dosage.. tha’ did go higher. 2056 
Evan: we have had.. through the computer dosage.. we have had an 8. 2057 
Michelle: yeah we ended up comin’ in. 2058 
Evan: we had an 8. 2059 
INTERVIEWER: yeah. 2060 
Michelle: because of the computer dosage. 2061 
Evan: an’ tha’ was the computer dose an’ tha’ was.. testin’.. tha’ was… 3.5 test in 2 2062 
weeks a’ some lon’ of tha’ an’ it was a’ 8. 2063 
INTERVIEWER: yeah. 2064 
Evan: an’ he wasn’.. there was no sickness.. no diarrhea.. no vo’.. no illness of [child].. 2065 
he was eatin’ as normal.. an’ we had to come here an’ have the proper.. 2066 
Michelle: tha’ was two months ago. 2067 
Evan: a proper test.. blood test.. 2068 
INTERVIEWER: yeah. 2069 
Michelle: it was in September. 2070 
Child making noise. 2071 
INTERVIEWER: yeah. 2072 
Evan: he was a’ 8.. he actually was.. our machine met 8 an’ an’ i’ was 8.4. for a required 2073 
umm.. an’ then… the funny thing was.. it put into the computer.. an’ the computer ‘ve 2074 
said.. to dose 3 ml test in a week. 2075 
INTERVIEWER: um no.. 2076 
Michelle: no it didn’. 2077 
INTERVIEWER: it wasn’t. 2078 
Michelle: no it did not.. 2079 
INTERVIEWER: (at the same time) it wasn’t.. 2080 
Michelle: (at the same time) it was.. 0.5.. 2081 
INTERVIEWER: (at the same time) I just checked the record it’s.. 2082 
Evan: (at the same time) 0.5.. ah was i’.. 2083 
Michelle: (at the same time) it was 0.5.. 2084 
INTERVIEWER: yeah. 2085 
Michelle: but George said.. do no’ test.. 2086 
INTERVIEWER: yeah. 2087 
Michelle: at all. 2088 
Evan: yeah. 2089 
Michelle: but the machine said 0.5 an’ then we tested again the next day an’ i’ hadn’ 2090 
even dropped at all.. 2091 
Evan: yeah. 2092 
Michelle: so George said.. the machine is tellin’ you again to do 0.5 bu’ we’re jus’ goin’ 2093 
ignore tha’ completely.. 2094 
INTERVIEWER: yeah. 2095 
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Michelle: because for [child]’s safety the machine is sayin’ 0.5 bu’.. 2096 
INTERVIEWER: yeah. 2097 
Michelle: we a’ sayin’ as human bein’s.. this is ridiculous.. 2098 
INTERVIEWER: yeah. 2099 
Michelle: don’t give him a dosage at all. 2100 
INTERVIEWER: yeah. 2101 
Evan: an’ then we don’ understand how it works.. obviously i’ 3 days later or 2 days 2102 
later.. 2103 
Michelle: so.. in that sense.. 2104 
Evan: (at the same time) so think why.. we tryin’ to.. keep warfarin to the system. 2105 
Michelle: bu’ in tha’ sense for a valve.. [child] can’ afford to be sittin’.. a’ 8.. an’ 2106 
higher.. 2107 
Michelle: because of.. the thinness is blood goin’ an’ the pressure puts his valve under.. 2108 
so he can’ afford to be doin’ tha’ so… I think.. bec’.. in tha’ basis.. human bein’ person 2109 
to person nurse to.. nurse to human…. is much better. 2110 
Michelle: an’ overall.. in our opinion… a compu’ er.. a computer isn’… wha’.. needs to 2111 
dose.. a child.. with a valve replacement on warfarin. 2112 
Child making noise. 2113 
Michelle: because they fluctuate too much.. for a computer to.. 2114 
INTERVIEWER: yeah. 2115 
Michelle: to take that into a consideration. 2116 
INTERVIEWER: yeah. 2117 
Evan: especially if.. bein’ so small.. I think.. tell me I’m no’ sure.. we can’.. we are no’ 2118 
able to ring up an’ say.. oh he’s had a growth spurt.. tha’ is gonna… have to go on his 2119 
up. 2120 
Michelle: yeah. 2121 
Child’s toy is playing in the background. 2122 
Evan: when it’s.. when we’re talkin’ to someone it’ll go.. you know how he’s bein’ 2123 
actually he’s been alright he’s.. you know.. he’s grown a li’le bi’ or he’s lost a bi’ of 2124 
weight or.. 2125 
INTERVIEWER: yeah. 2126 
Evan: he’s no’ eatin’ particularly well for some reason or another.. 2127 
INTERVIEWER: yeah. 2128 
Evan: he’s.. tha’ could be a bi’ more accountable. 2129 
INTERVIEWER: yeah.. we always need er.. you know.. ask for weight but.. we do not 2130 
want to put that burden on parents.. 2131 
Evan: yeah yeah. 2132 
INTERVIEWER: so that they can go.. er to a clinic and weigh the child..  2133 
Evan: yeah. 2134 
INTERVIEWER: so.. we always rely on the weight that we have.. but of course.. 2135 
weight.. you know.. 2136 
Evan: we can.. we can weigh him if it makes any.. any difference we could weigh him 2137 
at home.. obviously. 2138 
INTERVIEWER: yeah. 2139 
Michelle: yeah. 2140 
INTERVIEWER: we can take..  2141 
Child making noise. 2142 
Evan: [child]. 2143 
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INTERVIEWER: it’s we can only take a weight when.. once he is in clinic and stuff 2144 
like that.. ummm.. but for the doses overall.. err it’s only.. umm.. the dose is.. is 2145 
prescribed when the consultant is happy with that. 2146 
Evan: yeah yeah. 2147 
INTERVIEWER: so it’s all the time.. 2148 
Child making noise. 2149 
INTERVIEWER: with all patients.. in the study. 2150 
Michelle: umhm. 2151 
Evan: (at the same time) yeah. 2152 
INTERVIEWER: umm so umm yeah and umm anything else that you would like to 2153 
add? 2154 
Evan: I don’ know.. I’ve jus’.. we jus’ prefer when we… when we know we get a.. a 2155 
dosin’ from a consultant who understands.. 2156 
Michelle: (at the same time) an’ I think as well the.. tha’ the nurses understand.. 2157 
Child making noise. 2158 
Michelle: tha’ parents.. are jus’ as responsible for the dosage as.. the clinical liaison 2159 
nurse an’ the consultants because.. we’re the ones who see wha’ they clinically look 2160 
like.. because we’re a’ home with them.. 2161 
INTERVIEWER: OK. 2162 
Michelle: an’ you understand your child’s condition when you are a paren’.. umm so 2163 
you know when they’re no’ lookin’ too.. they’re lookin’ a bi’ gippy or.. they’re off the 2164 
food tha’ day you can kind o’ go well actually he’s no’ eatin’ a particularly grea’ 2165 
amoun’ so.. in a fact tha’ is goin’ to affect his warfarin which ‘as an effect..  2166 
Evan: mmm. 2167 
Michelle: you can.. you can.. mentally start to do it yourself. 2168 
INTERVIEWER: yeah. 2169 
Michelle: an’ I think the nurses take tha’ into consideration an’ the consultants so.. if 2170 
you all work on a big team we ge’ i’.. spot on every time.. with him normally an’ we 2171 
stay in.. we can stay in range for months can’ we? 2172 
Evan: yeah. 2173 
Michelle: withou’ a problem. 2174 
Evan: yeah we can. 2175 
Michelle: umm.. 2176 
Evan: (at the same time) an’ it’s jus’ ’cause we.. 2177 
Michelle: (at the same time) as long as you work as a team. 2178 
Evan: we know wha’ he’s eatin’. we know wha’ he’s feelin’.. we know.. we can.. we 2179 
can tend.. generally tell.. if he is.. under the weather an’ he’s no’ feelin’ bu’ we def’ 2180 
know he’s go’ a  growth spurt obviously ‘cause we ge’ him dressed everyday if a T-2181 
shirt doesn’ fit.. it’s kind of.. you go’ a reason why.. you know.. so we can..  2182 
Michelle: yeah. 2183 
Evan: we know a lo’ abou’ him.. abou’.. 2184 
Michelle: yeah. 2185 
Evan: an’ if we think.. oh it’s been a week you jus’ test him there is no’.. he hasn’ eaten 2186 
too much.. you jus’ test him  an’ if it’s within range we don’ ring in.. it’s fine bu’ we 2187 
sometimes.. 2188 
Evan: sometimes we test three times in two weeks ‘cause.. especially if he is… like go’ 2189 
a bi’ of diarrhea.. an’ we always test then.. we just in case.. 2190 
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Evan: an’ we get a bit more cautio’ bu’ we mean.. we find i’ bad me an’ Michelle 2191 
within.. when we have consultant led.. dosage we feel a lo’ more comfortable. 2192 
INTERVIEWER: alright. 2193 
Evan: a lo’ more comfortable. 2194 
Michelle: ummm. 2195 
INTERVIEWER: alright. 2196 
Evan: I think just in general we didn’.. 2197 
INTERVIEWER: yeah.. OK.. umm so.. anything would you like to add? 2198 
Michelle: um no no’ really jus’ tha’.. this this particular way.. isn’.. for [child] I don’ 2199 
think.. 2200 
Evan: no. 2201 
Michelle: like computer.. 2202 
Evan: yeah. 2203 
INTERVIEWER: alright. 2204 
Michelle: yeah.. bu’ I think.. definitely stick with the.. consultant way. 2205 
Evan: I think in the last 6 months.. we’ve had.. 2206 
Child making noise. 2207 
Evan: a lo’ more time was i’.. when out of range.. than we was the previous 6 months 2208 
when it was been consultantly led. 2209 
Evan: do you know what I mean that’s we we.. 2210 
Michelle: (at the same time) we’ve compared i’ against tha’ haven’ we? 2211 
Evan: (at the same) we’ve go’ back his book his yellow book.. 2212 
INTERVIEWER: yeah. 2213 
Evan: so we e’.. we try it to.. perhaps bein’ part of the pro’ this program.. 2214 
INTERVIEWER: so.. 2215 
Evan: i’ w’ good an’ then..  2216 
INTERVIEWER: so.. 2217 
Evan: since then. 2218 
INTERVIEWER: so during that period when you had.. those errr… INRs out of range.. 2219 
Evan: yeah. 2220 
INTERVIEWER: then you.. said that it was a long interval and you tested it at home 2221 
why didn’t you ring in and said this is.. the INR.. at this time? 2222 
Evan: because it.. they told us not to test  for 3 weeks.. so we were doin’.. for our for 2223 
our own med’ 2224 
INTERVIEWER: (at the same time) yeah but.. 2225 
Evan: (at the same time) for our own well be’  2226 
INTERVIEWER: it would be great for us.. 2227 
Evan: (at the same time) oh! 2228 
INTERVIEWER: (at the same time) to know.. 2229 
Evan: (at the same time) didn’ know.. 2230 
INTERVIEWER: yes because it would be great for us.. 2231 
Evan: (at the same time) he was in range. 2232 
INTERVIEWER: you know because the.. we are.. recording the INRs especially when 2233 
it is.. out of range and we try to.. um adjust the dose so we need to know.. after that 2234 
period of time maybe a few days or.. a week so we  need to know when.. that INR.. 2235 
came back to range. 2236 
Evan: no he was in range.. 2237 
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Evan: it happens tha’ when we.. this is when.. I think one of the only times.. when 2238 
we’ve go’ tha’ time when it’s actually stayed.. pretty well we tested we didn’ ring in 2239 
because.. if it ‘d been ou’ of range we would ‘ve rung in. 2240 
Evan: bu’ it jus’ happens tha’ e’ e’ twice we tested.. 2241 
Child making noise. 2242 
Evan: he was in range. only like a’ 3.1 an’ then the other time it was like 3 ml so it was 2243 
only just..  it was like he was.. bu’ in range is in range isn’ i’ so… range is 3 to 4 would 2244 
e’ ring in e’ do we 2245 
Michelle: when it’s been ou’ of range we phoned. 2246 
Evan: yeah. when it’s ou’ of range.. we would phone i’. 2247 
INTERVIEWER: so we don’t.. ring in when he is in range? 2248 
Evan: we.. no we we ring in when we are asked to.. like.. if they say test in.. 2249 
Evan: so when let’s say test in two weeks.. we ring up an’ if it is in.. tha’ normal bu’ 2250 
they si’ date was.. don’ test for 3 weeks. 2251 
Evan: tha’ almost.. 2252 
Michelle: (at the same time) they actually no’ often do this.. ‘cause he in range for 3 2253 
weeks. 2254 
Evan: yeah. 2255 
Michelle: a’ when he was a’ his highest bu’ then assume when he’s a’ his highest.. 2256 
Evan: umm. 2257 
Michelle: wha’.. why didn’ you ring in. 2258 
Evan: we don’. 2259 
Michelle: because we were.. we went off the dosage so... for examp’.. I don’ know wha’ 2260 
the dose or was a particular time bu’ say for example he was 3.7 and the dosage of the 2261 
computer said… 3 mls test in… 4 days. 2262 
Michelle: when we did tha’ a’ 4 days that’s when it was sky high.. so i’ i’ sent i’ really 2263 
really high. 2264 
Michelle: umm…. whereas a dosage for [child].. no think i’ ‘as 3.5.. wasn’ i’ whereas 2265 
as.. if [child] is.. within his range.. 2266 
Michelle: our.. standardised level that we would give [child] and.. the nurses would 2267 
give [child] would be.. 2.5 3 alternate days for a week.. an’ tha’ is where he woul’ si’ 2268 
quite comfortably..  2269 
Evan: (at the same time) generally yeah. 2270 
Michelle: (at the same time) an’ coast along. 2271 
Evan: (at the same time) generally. 2272 
Michelle: it’s only if somethin’ interferes with i’ where he is no’ well.. or he’s ‘ve had a 2273 
bi’ of growth spurt tha’ i’ will interfere.. other than tha’.. tha’ is quite a good level for 2274 
him. 2275 
Evan: [child]..  2276 
Michelle: bu’ we noticed tha’ the computer would give.. 2277 
Evan: (at the same time) sh sh sh. 2278 
Michelle: different.. dosages.. a’ a therapeutic level.. that’s the only difference we 2279 
noticed. 2280 
Evan: umm. 2281 
INTERVIEWER: yeah. 2282 
Michelle: so.. yeah that’s only thing we noticed tha’ when he sits within range.. it will 2283 
give a dosage of like 3.5 test in 4 days.. when really that’s no’ where he sits 2284 
comfortably.. he’s normally 2.5 3 alternately. 2285 
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Michelle: we would ‘ve probably seen a more sustainable level.. 2286 
Michelle: tha’ way. 2287 
INTERVIEWER: aha.. OK. 2288 
Michelle: bu’ yeah. 2289 
INTERVIEWER: I’ve got yeah that umm incident and then the nurses told me.. ummm 2290 
have let me know that umm you preferred that dose and we went with that and then we.. 2291 
Evan: (at the same time) yeah. 2292 
INTERVIEWER: adjusted the dose again.. 2293 
Evan: (at the same time) yeah. 2294 
INTERVIEWER: umm after that period of time. So it’s just like umm errm we would 2295 
be very happy if.. when.. you have tested..  2296 
Evan: (at the same time) umm. 2297 
INTERVIEWER: on your own and then let us know.. 2298 
Child making noise. 2299 
INTERVIEWER: it would be quite.. quite great for us.. yeah.. yeah.. anyway.. umm 2300 
anything else.. that you would like to add? 2301 
Evan: no thank you. 2302 
 2303 
6- Interview number 10: Second interview with Participant 20010 and his mother 2304 
(telephone interview) 2305 
INTERVIEWER: hello John. 2306 
JOHN: hi. 2307 
INTERVIEWER: hello are you alright? 2308 
JOHN: yeah I’m fine thank you how are you? 2309 
INTERVIEWER: I’m good thank you. I’m very glad to speak to you again. 2310 
JOHN: sorry wha’ was that? 2311 
INTERVIEWER: I’m very glad to speak to you again. 2312 
JOHN: oh nice to speak to you too. 2313 
INTERVIEWER: umm so errr.. can you please errr let me know about your.. err 2314 
warfarin dose and INR.. control.. over the past er six months? 2315 
JOHN: it’s been.. rarely bad.. I’d say.. 2316 
JOHN: yes so.. yeah my INR level ‘as been around.. yeah.. around what.. what it’s… 2317 
supposed to be.. I’ve never.. (couldn’t be heard clearly) 2318 
INTERVIEWER: can you please repeat that? 2319 
JOHN: my warfarin erm.. so.. my INR level ups an’ downs ‘n umm.. so i’ hasn’t gone 2320 
too high up or too far er.. too low. 2321 
INTERVIEWER: OK so.. is there any reason behind that? 2322 
JOHN: ummm no.. no. 2323 
INTERVIEWER: like erm was there any.. err.. change.. in.. diet maybe or… umm other 2324 
things? 2325 
JOHN: no.. no change in my diet. 2326 
INTERVIEWER: OK. 2327 
INTERVIEWER: so errm.. how.. what.. how do you think about the… erm the dosing 2328 
and err.. frequency of  INRs over the last.. err.. the past 6 months? 2329 
JOHN: yeah I think it’s been fine yeah…. yeah. 2330 
INTERVIEWER: so erm could you please reflect more on that? 2331 
JOHN: sorry? 2332 
INTERVIEWER: could you please say more on that? 2333 
315 
 
JOHN: errrrrrmmm….. one.. 2334 
Grace: (was not close to the phone so not heard clearly). 2335 
JOHN: wha’s tha’? 2336 
Grace: (couldn’t be heard clearly). 2337 
JOHN: (at the same time) yeah..  2338 
Grace: (couldn’t be heard clearly). 2339 
JOHN: when it’s er.. yeah I normally have to check my INR every… two weeks. 2340 
INTERVIEWER: yeah 2341 
JOHN: so.. yeah. 2342 
INTERVIEWER: yeah? 2343 
JOHN: yeah.. ya.. umm.. I’d say well.. my…... I don’ know how to say i’. 2344 
Grace: (couldn’t be heard clearly). 2345 
JOHN: …jus’ tryin’ to think. 2346 
Grace: (couldn’t be heard clearly). 2347 
JOHN: no I don’ know how to explain i’. 2348 
INTERVIEWER: erm so can you.. er.. erm can.. pl’.. Grace can you please come closer 2349 
to the phone so that I can.. hear you? 2350 
Grace: oh he said test i’.. every two weeks. 2351 
INTERVIEWER: aha. 2352 
Grace: it was you that’s it.. that’s the large though.. ?? test it it’s fine.. it is tha’……. 2353 
INTERVIEWER: and and err.. the second six months of treatment? 2354 
Grace: sorry? 2355 
INTERVIEWER: and how about the second six months.. like the past six months of 2356 
treatment? 2357 
Grace: wha’ recheck in six months? 2358 
INTERVIEWER: no erm.. sorry.. err.. the INR.. 2359 
Grace: oh yeah yeah yeah it’s been fine yeah.. yeah. 2360 
INTERVIEWER: was it OK so erm.. because.. erm er.. John was telling me that it was 2361 
bad? 2362 
JOHN: no I didn’ say i’ was bad.. I said it was.. balanced. 2363 
Grace: he said it’s balanced.. it was stable. 2364 
INTERVIEWER: sorry? 2365 
Grace: it was stable.. within normal range.. where it should be. 2366 
INTERVIEWER: aha and.. so how do you think about.. erm.. the frequency of the 2367 
measurements? 2368 
Grace: tha’ absolutely fine because he.. he’s stable.. he’s within normal range. 2369 
Grace: it’s fine.. it is wha’ i’ is. 2370 
INTERVIEWER: aha and what about the dose changes? 2371 
Grace: we haven’t really changed on the dose have you? 2372 
JOHN: (at the same time) no.. no.. erm. 2373 
Grace: so that was fine. 2374 
INTERVIEWER: the dose.. the the frequency of dose changes in the past six months? 2375 
Grace: that’s.. that’s you missed her John… but he has been stable. 2376 
Grace: ‘asn’ been really changin’ that frequent. 2377 
INTERVIEWER: OK so err.. were you happy with the.. err dosing over the.. past six 2378 
months? 2379 
Grace: yes. Yes. 2380 
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INTERVIEWER: OK brilliant errmm.. so err.. would you like to add anything.. 2381 
regarding err.. the computer dosing or anything that we have done errmm… in the past 2382 
six months? 2383 
Grace: no. 2384 
INTERVIEWER: John? 2385 
JOHN: yes. 2386 
INTERVIEWER: John would you like to add anything? 2387 
JOHN: ….. no I’m fine thank you. 2388 
 2389 
B- Doctor’s interviews 2390 
1- Interview number 3: HCP1 2391 
INTERVIEWER: So.. umm.. hello again.. 2392 
GEORGE: Hi. 2393 
INTERVIEWER: errr.. thanks so much for agreeing to take part in my research.. err.. 2394 
the purpose of our meeting is to talk about your experience with warfarin dosing.. 2395 
GEORGE: umhm 2396 
INTERVIEWER: and monitoring before and after using the new warfarin dosing 2397 
model, so let’s first set the dosing model aside for a moment.. err.. could you please let 2398 
me know about the overall approach that is being used for warfarin dosing and 2399 
monitoring right from the beginning when the patient starts warfarin treatment? 2400 
GEORGE: OK.. err.. that tends to .. a fairly standard  initial dose of warfarin that we use 2401 
within 200 micrograms per kilo.. up to a maximum of about 10 milligrams.. for an 2402 
initial.. loading dose then we re-check the level.. the following day.. 2403 
INTERVIEWER: OK 2404 
GEORGE: if the level is still.. err.. low then we’d repeat that.. ‘n then if it’s.. at a 2405 
reasonable level ‘at point we’d  half that dose of 200 micrograms per kilo.. 2406 
INTERVIEWER: OK.. so.. errr.. when do you usually first.. err.. give the first.. the very 2407 
first dose? 2408 
GEORGE: Oh, when.. so.. that’s.. pretty much depends.. on the indication.. and on.. 2409 
errr.. and on the.. the patient’s condition.. 2410 
GEORGE: ‘n so it’s obviously when they’re.. they’re havin’ enteral feeds ‘n we get to 2411 
know they’re absorbing.. 2412 
GEORGE: so ‘at’s the first stage.. errr.. secondly.. err.. quite often we’ll transition 2413 
patients from.. heparin onto warfarin.. 2414 
GEORGE: errr.. so.. again it’s sort of.. depending on the clinical ‘at we have.. so it’s 2415 
very.. so there’s never a set time for that.. 2416 
GEORGE: it’s.. sort of.. very dependant. 2417 
INTERVIEWER: so.. that.. let’s say.. the overlapping time.. is there like a specific time 2418 
for  overlapping between heparin and warfarin? 2419 
GEORGE: err, not really, it’s just.. again.. it depends.. on the indication, some patients 2420 
need to have.. therapeutic.. err.. aPTTs.. 2421 
GEORGE: err.. constantly, so for example.. patients with mechanical valves.. they’re 2422 
goin’ to need constant anticoagulation whereas other patients where the.. the warfarin 2423 
indication may be not quite so important maybe that’s with.. the extra-cardiac Fontans 2424 
‘n things.. they may not need ‘at monitored heparin dose prior to that they may run at 2425 
that ground level of heparin then transition into warfarin at some point prior to stop 2426 
when they are able to. The other thing that we need to take into account is this patient 2427 
having any procedure’s stand which may require rapid reversal of anticoagulation, so if 2428 
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they’ve got.. trends of pacing wise ‘n other things that sometimes change the timing for 2429 
transition of heparin to warfarin.. 2430 
INTERVIEWER: umhm.. OK.. and.. how about the target..errr.. therapeutic range.. 2431 
target INR range?  2432 
GEORGE:target INR range.. errr… that’s.. is.. quite variable. 2433 
INTERVIEWER: yeah.. again (laugh).. 2434 
GEORGE: (laugh) 2435 
INTERVIEWER: this is the.. (laugh)..the issue. 2436 
GEORGE: errr…it’s errrr… individual consultants have previously had.. individual 2437 
targets that they tend to set for their.. various patients.. but.. we’ve started to standardise 2438 
tha’ a bit more now so patients.. the volume more common indications we have is those 2439 
patients with the extra-cardiac Fontan.. conduits.. 2440 
GEORGE: who attend to have a target INR of 2 to 3.. errr.. patients with mechanical 2441 
mitral valves tend to have a range between 3 ‘n 4, patients with mechanical aortic valves 2442 
tend to have a range between 2.5 ‘n 3.5. 2443 
GEORGE: so.. those are... those are kind of rough areas, but sometimes again we do.. 2444 
customise that for various patients with various things.. 2445 
INTERVIEWER: yeah. 2446 
GEORGE: we have had patients who’ve had internal cranial bleeds ‘n things like that 2447 
who we’ve tar’.. ‘n.. particularly.. eer.. that we’ve targeted lower INRs on, other patients 2448 
who’ve had.. narrow.. prosthetic valves who we’ve targeted slightly higher INRs ‘n so.. 2449 
it’s not.. it’s not.. a.. one size fits all.. usually.. often. 2450 
INTERVIEWER: yeah, but.. yeah.. so.. umm.. I was just asking if there are like.. err.. or 2451 
there should be.. or supposed to be guidelines to.. guide the target INR, the dosing.. 2452 
GEORGE: there are.. there are guidelines, but… they can be individualised to a certain 2453 
degree.. err.. 2454 
INTERVIEWER: OK. 2455 
GEORGE: to various circumstances. 2456 
INTERVIEWER: OK.. so.. err.. from where can I get like.. a copy of those guidelines? 2457 
GEORGE: there is a.. there is a.. postoperative anticoagulation guideline.. 2458 
INTERVIEWER: sorry? 2459 
GEORGE: there’s a postoperative anticoagulation guideline on the PICU.. shared 2460 
drive.. 2461 
INTERVIEWER: PICU.. OK. 2462 
GEORGE: ummm.. then in terms.. I think there is also aeee.. think there is a Fontan 2463 
guideline but I’m not entirely sure about that. 2464 
GEORGE: there’s not necessary a hard ‘n fast guideline for mechanical valves.. then we 2465 
tend to use the.. the target INRs suggested by the BNF. 2466 
INTERVIEWER: umhm, yeah.. umm.. so.. like.. umm.. it’s not specific for the UHL? 2467 
those guidelines? 2468 
GEORGE: errr..not.. generally no.. not all of them anyway. 2469 
INTERVIEWER: general..  2470 
GEORGE: yes. 2471 
INTERVIEWER: so general guidelines. OK, so.. once the patient is.. has started 2472 
warfarin.. err.. how often do you usually… monitor him let’s say.. err.. monitor the INR 2473 
and change the dose? 2474 
GEORGE: you.. you.. to start off with daily.. until.. until we have a sort of steady state 2475 
over the range that’s usually.. 2476 
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INTERVIEWER: umhm, and then afterwards? 2477 
GEORGE: afterwards.. it very much.. 2478 
INTERVIEWER: (at the same time) how often? 2479 
GEORGE:  depends on the rate of change of the INR.. 2480 
GEORGE: ummm.. so if you’ve hit the steady state.. on the current dose.. and you’re 2481 
getting…  you’re getting consistent INRs on that dose.. you know initially you can have 2482 
once every 2 or 3 days and then once we’re happy.. then if we’ve got a steady state at 2483 
that point, I’ll drop it down to weekly then two weekly then four weekly. that’s my 2484 
general.. approach. 2485 
INTERVIEWER: OK, alright.. and again (laugh), are there any guidelines for it? 2486 
GEORGE: no (laugh). 2487 
INTERVIEWER: it’s done individually? 2488 
GEORGE: yes. 2489 
INTERVIEWER: OK, and.. then.. err.. the.. increment of dose changing when you have 2490 
like.. the INR above or below range..err.. when…umm.. let’s say.. how this dose is 2491 
usually changed? and the increment of dose changes? 2492 
GEORGE:OK. Umm.. again it depends upon.. err.. both the indication.. for the.. for the 2493 
warfarinisation and how.. far out of range it is. 2494 
GEORGE: there are patients who… you n’.. well known to have.. umm.. very labile 2495 
INRs.. and in certain situations.. you often find that.. umm.. underdosing then tends to 2496 
be more a problem.. and then.. you get some pattern if.. you underdose them, they’re 2497 
going low, you have to obviously go high.. it’s sort of playing around quite a lot 2498 
particularly.. that’s particularly if you’re checking the INRs very frequently.. 2499 
GEORGE: umm.. patients for example, with mechanical mitral valve.. I tend to be very 2500 
cautious about reducing the dose on.. too rapidly.. and I’ll tolerate.. ‘n I’ll.. I’ll err on 2501 
the side you keep the INR slightly high as long as there is no evidence of active 2502 
bleeding.. 2503 
GEORGE: so if you have had a patient with mechanical mitral valve whose INR of 5.. 2504 
or.. or 6, you wouldn’t  necessarily completely stop the warfarin at that dose.. 2505 
GEORGE: err.. you may want to reduce it down to a.. to a lower dose..  sometimes 2506 
instead of.. I don’ know how often the.. the standard approach with these stop the war’.. 2507 
stop the warfarin at that dose, we often find ‘at we get a rebound drop.. then that’ll 2508 
need to be admitted for intravenous heparin treatment because he can’t have a.. an.. a 2509 
lower INR with the.. mechanical mitral valve. 2510 
GEORGE: so.. I’ll often.. you know.. come down to a very low dose maybe.. a quarter 2511 
or less of the usual dose.. for a day.. then recheck it and.. you sort of looking to jus’ 2512 
move out of that trough that you get if you actually stop that dose.. 2513 
GEORGE: obviously, if there is any sign that they.. they’ve got active bleeding or 2514 
anything like that, then to stop it and if the INR is substantially high.. like.. over about 2515 
6, I’ll put even the dose, but.. 2516 
GEORGE: you know.. tend to be very cautious about jus’ stopping the dose for those 2517 
with very high INRs. 2518 
INTERVIEWER: yeah.. umm.. and.. I have like.. noticed on that some.. sometimes 2519 
when.. when the.. patient.. the patient’s INR is just out of the range.. 2520 
GEORGE: umhm. 2521 
INTERVIEWER: errrr.. it’s variable again.. like.. some people try to.. I mean some 2522 
doctors try.. umm.. for some patients, they give.. they change the dose and they give a 2523 
long interval, but for some others, they do like.. change the dose but with a.. 2524 
319 
 
GEORGE: yes. 2525 
INTERVIEWER: shorter interval. 2526 
GEORGE: (laugh) err.. I think.. umm… err.. I think.. I always I bare in mind that the.. 2527 
the home INR testing kits do have a.. a range of accuracy to that..  err.. to probably 2528 
around by about plus poin’.. plus or minus point five.. 2529 
GEORGE: so therefore if you do have a.. an INR that is very mildly out of range.. again 2530 
you have to take the clinical.. picture into account… if you’ve got.. errr.. if you’ve got a 2531 
patient who has a Fontan.. 2532 
GEORGE: circuit.. who’s on long term.. who’s on long term anticoagulation.. it’s not.. 2533 
a hundred percent critical where the INR is 2 as a persisting 1.9 or 1.8. 2534 
GEORGE: if you have a patient with mechanical valve in… and their INR is very 2535 
slightly high you got a target of 3 to 4 ‘n it’s 4.1, again.. I’m not worried about that so 2536 
much. If you have patient his INR erring on the low side he’s got mechanical valve then 2537 
yes I would do something about that, so it’s very much take the.. 2538 
INTERVIEWER: OK. 2539 
GEORGE: take the clinical picture in. 2540 
INTERVIEWER: aha.. yeah.. so.. what’s the reason behind being.. you know.. the 2541 
patients with valves.. with mechanical valves.. are being more worrying.. err.. than 2542 
others with Fontan or maybe with err.. than others with the aortic valve? 2543 
GEORGE: so.. it’s the.. it’s danger.. so aortic.. aortic mechanical valves are less prone 2544 
to getting thrombosis because they got high velocity jets going past them, so the blood.. 2545 
INTERVIEWER: sorry, high what? 2546 
GEORGE: high velocity blood flow.. 2547 
INTERVIEWER: aha. 2548 
GEORGE: so.. the blood flow is faster.. there is less stagnation of blood flow therefore 2549 
you’re less likely to get thrombosis.. 2550 
GEORGE: on the aortic valve, so which is why the target INR is lower.. umm.. so.. 2551 
quite often we.. tolerate ee.. we can tolerate the.. the INR going down to two.. two point 2552 
o (2.0).. err.. on the mechanical aortic valves even though the bottom range is 2.5 2553 
sometimes even down to 1.8.. we’ll often give low molecular weight heparin to patients 2554 
whose.. with mechanical aortic valve whose INR dropped a little bit ..err.. as is.. if the.. 2555 
if the INR is still between one.. still over 1.5 we might give them.. we might give them 2556 
subcut.. umm.. dalteparin or enoxaparin to target through until we get the.. the INR back 2557 
up again ..umm.. that’s because it’s reasonably safe.. err.. to do that.. umm.. the patients 2558 
with mechanical mitral valves because you’ve got low velocity blood flow past i’.. and 2559 
you’re entering it’s.. potential stagnation of blood flow they’re more prone to having 2560 
thrombi, more prone to having.. mechanical valve.. 2561 
INTERVIEWER: mm.. yeah. 2562 
GEORGE: err.. problems with a low INR, so we’re usually very cautious with those 2563 
most of the consultants would.. admit ‘at patient to start an intravenous heparin if the.. if 2564 
the INR goes below 2. 2565 
INTERVIEWER: alright. 2566 
GEORGE: umm.. particularly in smaller patients.. err.. so… err.. mechanical mitral 2567 
valves in.. infants are very very high risk group. 2568 
GEORGE: err..there is very high.. incidence of valve not functioning getting.. systemic 2569 
emboli from them as well so that’s another group we need to be very very cautious with. 2570 
INTERVIEWER: alright. 2571 
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GEORGE: there’s also the group that have the hardest warfarin control as well because.. 2572 
the… dose change per body weight is such a.. such a fine thing even when you use the 2573 
solutions tha’.. err.. even a change of 0.2 0.3 of a milligram can be very difficult ‘n also 2574 
administering that.. small dose.. 2575 
INTERVIEWER: exactly. 2576 
GEORGE: makes the.. the error can be mess, so they do tend to be patients with a 2577 
higher risk as they’ve got a.. much rather..  a small valve and a small heart and they’ve 2578 
got labile.. err.. labile INRs anyway. 2579 
INTERVIEWER: OK. 2580 
GEORGE: so.. to.. aid avoid the risk of having this thrombosis I think.. it’s more 2581 
dangerous to have a slightly low INR than to have a slightly higher INR..  2582 
GEORGE: so therefore, when I’m dosing them I keep that in mind and I tend to.. err on 2583 
the side of keeping it slightly high. 2584 
INTERVIEWER: alright. 2585 
GEORGE: and..um.. the other thing is one seen from the point of view of the patients 2586 
that.. if their INR does go too low then they have to be admitted.. have intravenous 2587 
access.. have regular blood tests.. it’s not very nice for them. 2588 
INTERVIEWER: yeah, exactly. 2589 
GEORGE: so.. from the point of view of err.. you know the patient.. it’s not very 2590 
(laugh).. 2591 
INTERVIEWER: yeah. 2592 
GEORGE: OK it’s much better to.. if you.. you know.. if I have to choose between a 2593 
mechanical valve having an INR of 2 ‘n an INR of 5, I’d rather have 5. 2594 
INTERVIEWER: Oh yeah. 2595 
GEORGE: yeah. 2596 
INTERVIEWER: alright. So.. err.. what are the obstacles that you usually have.. in 2597 
getting a therapeutic INR and in maintaining it? 2598 
GEORGE: err.. so.. umm.. it’s very individual for the patient.. 2599 
GEORGE: some patients will just anticoagulate on a.. a dose of warfarin and I’ll stand 2600 
that dose for.. forever.. and.. you know that they are very very well controlled, you 2601 
check the INR once a month and everything is absolutely fine.. 2602 
GEORGE: that.. tends to be the slightly bigger children.. I think they got much more.. 2603 
they got much more stable absorption.. umm.. the other thing is that it tends to come 2604 
down if got any bugs and illnesses and get antibiotics.. as.. 2605 
GEORGE: the younger children.. err.. they can even have quite labile.. err.. warfarin 2606 
control particularly patients under the age of one.. they are very very difficult. 2607 
GEORGE: they use warfarin solutions and.. I think… I think again.. it’s very important 2608 
parents know that they need to mix the solution.. I think.. sometimes you get the 2609 
impression that in some terms the solution changes as they.. err.. as it settles maybe 2610 
they’re not shaking the bottles quite enough that’s important thing to take care about 2611 
that. 2612 
INTERVIEWER: yeah. 2613 
GEORGE: sometimes I think administering the.. the same... dose.. when you’re talking 2614 
about a giving 0.2 mls or 0.3 mls again there is a little bit of variability there.. umm.. the 2615 
other thing is when patients are.. small babies they’re on.. formula. Formulas are 2616 
supplemented with vitamin K.. and that can make it a little bit more unstable as well but 2617 
not difficult to treat.. umm.. other more things that happen are small children frequently 2618 
get bugs.. and.. they frequently go on antibiotics, so if they get a bug.. particularly if 2619 
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they get vomiting and diarrhea, the absorption of warfarin goes down and.. then also if 2620 
they are on antibiotics then.. the.. antibiotics change the liver enzyme metabolism.. ‘n 2621 
‘erfore the INR changes as well so it can either reduce or inhibit the liver enzymes that 2622 
for you get instability that way.. so we quite often find patients who give a leap above 2623 
their INR it goes.. it goes out of range for a few days then it comes back again , bu’ see 2624 
you kind of need to see more their.. their usual background ranges and see what’s 2625 
happened when the.. when they notes to have that.. it’s pretty much.. (laugh) 2626 
INTERVIEWER: (laugh) yeah… so.. and.. 2627 
GEORGE: and we ‘ve had.. we’ve also had some patients we get particularly teenagers 2628 
who.. where compliance with taking the medication… we can never know for sure.. bu’ 2629 
we think that has been an issue in those patients as well, so.. again you sometimes get 2630 
these patients who… you think probably don’t take as much as tha’ been prescribed.. 2631 
INTERVIEWER: OK. 2632 
GEORGE: or don’t take it at all or miss some doses or intimately miss doses then.. their 2633 
INR control tend to be extremely difficult. 2634 
INTERVIEWER: umhm. OK and of course you have already mentioned the problem 2635 
with the mechanical valves and those patients on.. yeah.. of course.. definitely those are 2636 
more difficult than others. Alright.. so.. umm.. now.. errr… errr.. we go to the model.. 2637 
the new warfarin dosing model, so could you please tell me about.. your experience so 2638 
far with this new dosing.. 2639 
GEORGE:(at the same time) I mean I think.. 2640 
INTERVIEWER: (at the same time) algorithm? 2641 
GEORGE: day to day.. maintenance I think it’s.. pretty good, it’s.. you know.. I’ve.. I’ll 2642 
look to the doses that it gives and.. I’ve.. rarely seen any tha’ I.. disagree with I think 2643 
it’s.. quite good I think what.. the model doesn’t.. do is it doesn’t have that.. that kind of 2644 
bias.. in it so they have.. I think the only times I’ve ever… disagreed with the doses 2645 
have been those patients where.. umm… you definitely don’t want ‘em to go low so 2646 
you go to a slightly higher level.. and the model minus a’ all give this much ‘n I’ve.. ‘n 2647 
I’ve seen that dose not enough gone.. I think if we give that there is a danger.. that it 2648 
might drop below range and I would rather.. come down more slowly and stay in range.. 2649 
I pro’.. you know tolerate staying in the.. slightly high area than.. come.. 2650 
INTERVIEWER: OK, so this is.. when the INR is on the lower range or.. or below.. 2651 
GEORGE: this is usually when the INR is in a higher range..on the patients where you 2652 
don’t want to risk it going too low.. 2653 
GEORGE: I think sometime’.. you know.. it would be fine if it’s a patient who can 2654 
tolerate having a lower INR..I wouldn’t have a problem with the dose that it’s 2655 
suggesting… bu’ think in these patients where lower INR would be more risky.. 2656 
GEORGE: umm… you .. you kind of.. you bias your.. what I tend to do is ‘at I tend to 2657 
say.. rather to get a lower range I’ll probably do this.. ‘n err.. maybe.. yeah I don’.. ‘n 2658 
jus’ say.. so come up a little bit on what I suspect…we need .. ‘n then tolerate having 2659 
that slightly high INR for longer.. to see if it come down more slowly rather than trying 2660 
to get back to the.. err.. into the middle of the therapeutic range ‘n then overshoot ‘n end 2661 
up.. having too low, so I think that’s really been in times ‘n the other things maybe 2662 
sometimes those.. err.. there’s other things where you need jus’ apply a little bit of 2663 
judgement on children who are.. unwell.. 2664 
GEORGE: who.. you know.. you might think.. OK.. what’s goin’ to happen when they.. 2665 
they are unwell.. when usually that’s the case it’s jus’ monitoring ‘n see what happens.. 2666 
umm.. I was… I’m no’ a hun’re’ (hundred) sure about how the… timing of the.. 2667 
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rechecking occurs because ‘at dose and ‘en the.. the model doesn’t provide.. the 2668 
intervals for checking ‘e INR.. 2669 
INTERVIEWER: no, it doesn’t provide intervals so it depends on.. my judgment.. 2670 
GEORGE: yeah. 2671 
INTERVIEWER: my personal judgment again.. and.. err.. I try to follow what the 2672 
doctors’ judgement.. 2673 
GEORGE:(laugh) right. 2674 
INTERVIEWER: I see.. you know.. I try to compare with those who are on the.. you 2675 
know.. doctor dosing and see how frequent is the monitoring and again depending on 2676 
how stable is the patient and then I decide the.. the interval, but sometimes again I get 2677 
like.. maybe.. a doctor that .. doesn’t agree with this.. 2678 
GEORGE: yeah. 2679 
INTERVIEWER: interval either making.. well mostly doing it on a shorter interval.. 2680 
GEORGE: umhm. I mean I.. I.. 2681 
INTERVIEWER: (at the same time) I’ve got that incidence. 2682 
GEORGE: I try to extend the interval to as long as I can because I think.. umm.. if you 2683 
measure a transitional INR… it’s OK as long as you.. realise that it’s a transitional INR 2684 
it’s not goin’ to be.. where you’re.. you don’t.. you don’t react to it too much. ‘n I think 2685 
sometimes it’s useful to do.. short term INRs to see.. a sort of a rate of change.. so you 2686 
can kind of see where things.. err.. where thing are likely to head ‘n if your.. if your rate 2687 
of change is too high then it might make you come up a little bit on the next dose.. err.. 2688 
bu’ I usually.. if I do a dose change I’ll usually try  ‘n leave it a’ least 3 days before 2689 
rechecking ’n that’s the thing as a.. danger………. 2690 
INTERVIEWER: sorry.. err.. could you please repeat that again because I think I’m not 2691 
getting you.. 2692 
GEORGE: OK. 2693 
INTERVIEWER: exactly? 2694 
GEORGE: so if.. if you have sort of a high INR.. and you.. you want to check.. you 2695 
change the dose ‘n recheck it.. umm.. sometimes I… the when you recheck it’d be a 2696 
difficult question.. 2697 
GEORGE: because if you do.. er.. if you do a large dose reduction, you won’t see the… 2698 
result of that dose reduction until around abou’ 48 hours after you’ve done i’, so 2699 
therefore the argument is that you should really be checking the INR the following day.. 2700 
INTERVIEWER: OK. 2701 
GEORGE: now.. some people.. for whatever reason.. we observed do have very rapid 2702 
change their INR ‘n response to doses ‘n they will change within 24 hours I think 2703 
sometimes.. although that’s not the destination where the INR is goin’ to be when you 2704 
recheck in 24 hours, it could sometimes give you.. if make sure abou’ how quickly the 2705 
INR is dropping ‘n response to what you’ve done.. 2706 
GEORGE: err.. so if you do see a very rapid drop when you reduce the dose somethin’ 2707 
‘at might change your… way you’re going to put your next dose to sort of.. instead of 2708 
coming down very steeply you come down in a more shallow fashion. 2709 
INTERVIEWER: yeah. 2710 
GEORGE: umm.. bu’ sometimes you know.. you know it’s not changed at all ‘n then.. 2711 
the temptations to come down even lower.. bu’ err.. you do avoid that.. so.. it’s a very… 2712 
it’s a dark art (laugh).. so..you know. 2713 
INTERVIEWER: yeah, it is quite tricky we.. we do have some people.. some patients 2714 
like..err…err.. they have a rapid.. very rapid drop of the INR within 24 hours.. 2715 
323 
 
GEORGE: yeah. 2716 
INTERVIEWER: so.. yeah.. this is another.. problem.. so..umm.. has this err.. new 2717 
computer dosing  had influenced your overall approach to warfarin doses.. dosing? 2718 
GEORGE: how I prescribe that.. I don’t think so (laugh). 2719 
INTERVIEWER: (laugh). 2720 
GEORGE: I think I’ve always stood what I’ve done but err.. you know.. I think the.. I 2721 
tend to find that the computer doses are.. are sensible.. I mean it’s just like.. err.. er.. I 2722 
think I’ve never seen any that ’ve been absolutely crazy.. umm.. I think I would sort of 2723 
trust it to do much of.. much of the warfarin doses in patients who.. don’t have.. 2724 
additional sort of complexities about.. about what’s going on I think sometimes you get 2725 
a patient who got very labile doses.. as long as you have an experience place in 2726 
prescribing i’.. I think.. probably ‘at might be slightly.. more reliable because we’ve got 2727 
to take a lot of.. err.. additional factors into account that I think probably the.. the 2728 
warfarin dosing model doesn’t. 2729 
INTERVIEWER: yeah. 2730 
GEORGE: umm.. so.. I think it’s the.. all of those extreme of things like.. you know… 2731 
these patients who.. who do have the.. who are a’ higher risk because you know this 2732 
patient has a mechanical valve that isn’t functioning well.. therefore you got to be extra 2733 
cautious about not dropping the INR too much I don’t think you can.. program that into 2734 
the model the model will always do what it.. what it says, more of those patients who 2735 
are havin’ that’s very.. that’s very up and down doses you may want to.. tolerate the 2736 
INR going out of range just to stay on a consistent dose for a while.. 2737 
GEORGE: umm.. I think sometimes you may want to start over.. over-treating those 2738 
oscillations … err.. in INR.. umm.. rather than jus’ trying to actually find out what’s 2739 
happening in the steady state.. think those are the only things bu’ I think gen’.. by in 2740 
large it’s.. it.. does pretty much what I would… I would do I think. 2741 
INTERVIEWER: umhm.. so.. err.. umm.. would you please comment on any 2742 
advantages or disadvantages of this computer dosing? depending on your experience so 2743 
far? 2744 
GEORGE: I think the computer dosing most advantage that the.. it turns around 2745 
probably a bit faster.. for the patients.. you know.. umm.. if.. err.. at the moment.. you 2746 
know.. the.. the system is that the parents call in the INR.. 2747 
GEORGE: err.. one of the liaison nurses takes that down ‘n they have to find a doctor to 2748 
prescribe it.. I think.. if you can cut that stage out.. uhm pardon me.. err.. then that’ll be 2749 
a lot faster ‘n then I.. I can potentially see the person calling up ‘n.. ‘n getting the result 2750 
or.. even makin’ the.. the system available to the patients so that they can jus’ directly 2751 
input what the INR is ’n then get a dose.. back out again.. 2752 
GEORGE: obviously with.. safety parameters that if the it’s out of range then they 2753 
should… contact simply bu’ I could see that being a.. a much.. much easier for the.. for 2754 
the patients to use potentially.. 2755 
GEORGE: umm.. I also think.. sometimes.. err.. I could say.. I think.. sometimes some 2756 
of the doctors over-treat… the slightly high slightly low results and tend to not.. have 2757 
the idea of what’s happening with tryin’ to smooth everything out.. umm.. I think 2758 
that’s.. sometimes people have tha’ reaction tha’ they over-treat these.. these 2759 
circumstance it could be potentially better for that.. ummm.. bu’ I would.. I would say 2760 
that it would need be careful… oversight ‘n if there is ones that are just.. aren’t settling 2761 
or those higher risk patients I think it might be better.. being done in a.. err.. with more.. 2762 
clinician input. 2763 
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GEORGE: so I think.. I think maybe a combined approach with the higher risk patients 2764 
having a computer suggested dose.. bu’ then saying.. agree or disagree with that ‘n 2765 
havin’ the ability to override that then that’d be better. 2766 
INTERVIEWER: great.. umm.. and the disadvantages? 2767 
GEORGE: err.. disadvantages are.. just the potential to like have those.. situations 2768 
where.. you would change things jus’ the clinical picture not being taken to.. to account 2769 
I think that’s probably the.. the biggest.. the biggest difference.. umm.. yeah. 2770 
INTERVIEWER: yeah, alright.. so would you recommend.. umm.. the warfarin dosing 2771 
model or the computer dosing.. err.. to other clinicians in the same.. situations? 2772 
GEORGE: I think so yeah,  I think it’s very useful yeah. 2773 
INTERVIEWER: umhm.. brilliant.. umm.. err.. OK.. so do you have any other 2774 
comments.. 2775 
GEORGE: err.. no. 2776 
INTERVIEWER: that you would like to add? 2777 
GEORGE: no, I’ve said everything. 2778 
 2779 
2- Interview number 4: HCP2 2780 
 2781 
INTERVIEWER: umm.. hello.. thank you very much for.. agreeing to take part in my 2782 
research.. umm.. the purpose of our meeting is.. to.. err.. talk about your experience with 2783 
warfarin dosing and monitoring.. err.. before and after using the warfarin.. the new 2784 
warfarin dosing model.. err.. so.. err.. first let’s .. err.. set the.. err.. warfarin dosing 2785 
model aside.. and err.. could you please.. err.. let me know about.. err.. the overa’ your 2786 
overall approach that is being used for warfarin dosing and monitoring umm.. right from 2787 
the beginning when the patient first start.. starts warfarin? 2788 
SARAH: err so.. thank you for asking me to participate.. err.. usually.. we start the 2789 
warfarin mostly post-surgical.. so it’s usually in the intensive care unit or on the ward as 2790 
a transition from warfarin so if we want to put our patient.. on warfarin usually we start 2791 
with the heparin infusion and gradually introduce.. the dose and overlap till we achieve 2792 
our INR target then we stop the heparin. 2793 
INTERVIEWER: umhm.. so.. errr… what about.. er.. the dose the first initial dose and 2794 
how the.. target  therapeutic range is decided.. err.. are there any guidelines for that? 2795 
SARAH: er.. so it is depend on the underlying diagnosis so.. and the difficulties during 2796 
surgery and.. the size.. of the patient and for example the artificial valve so there is err.. 2797 
and the cardiac function. So usually there is a general consensus.. regarding what we 2798 
give for the mitral valve.. what if the valve put in a smaller than usual or impaired 2799 
function.. we increase our target.. err.. aortic valve the same usually it is a less of an 2800 
INR range than the mitral valve but if the cardiac function if is impaired or the valve is 2801 
too small.. err.. for the patient we try to allow for more.. err.. a larger.. err.. scope.. there 2802 
is different ones for.. err.. obviously the Fontan circulation.. where we maintain a lesser 2803 
INR er.. range… and.. ummm… those are the main really indications... are the left- 2804 
sided valves for the right-sided valves.. it is a new evolving era with the adult 2805 
congenital tissue valves and the valve ‘n valve.. err monitoring… but going back er to 2806 
the children.. we find that children below 2 years are extremely difficult to monitor.. 2807 
their INR ‘n sometimes we resort to long term subcutaneous heparin instead. 2808 
INTERVIEWER: umhm.. so.. err.. are there any.. like.. guidelines.. errr.. documented 2809 
somewhere..err.. for.. 2810 
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SARAH: for the dosing we have a general.. er.. guideline as for the dosing.. and.. umm.. 2811 
and it’s the experience of the unit.. and… err.. there is a documentation of a consensus 2812 
between professionals.. on what.. we expect within our unit for our patients it’s difficult 2813 
to… errm… to… standardise that all over the country but most of the guidelines are 2814 
based on.. err.. err.. experience.. err.. somewhere else and our own experience so it’s a 2815 
combination. 2816 
INTERVIEWER: aha.. alright.. and.. err.. how do you usually first start dosing of 2817 
warfarin? 2818 
SARAH: so we start with 100 to 200 mics.. err.. per kilo.. as a starting dose and then we 2819 
build up gradually as per INR.. err.. an’.. err…. and it is depending if there is ongoing 2820 
bleeding pos’ surgery and there is other concerns.. but usually till we build it up we 2821 
cover with therapeutic doses of heparin. 2822 
INTERVIEWER: umhm.. so.. errr.. is there any specific time for overlapping between 2823 
heparin and warfarin? 2824 
SARAH: usually it takes about.. er.. 4 days to a week for the warfarin to produce the 2825 
target INR.. er.. and.. we s’.. we usually stop our heparin depending on our target so if 2826 
we.. our target is 3 and we achieve a target of INR of 2.. we stop at that.. err.. stage and 2827 
then carry on upgrading the.. the warfarin. 2828 
INTERVIEWER: aha.. so.. how about the frequency of the INR measurements? 2829 
SARAH: it’s usually once a day.. however if they have concerns.. and… the patient is 2830 
bleeding or we are not achieving the target we use it by the machine and if we are not 2831 
happy with the machine we do a blood sample to compare.. and the other thing is if 2832 
there is sudden.. er.. err.. unstability of the INR measurement either too low or too 2833 
high.. 2834 
SARAH: we re-look at the machines and see if it had been standardised.. and then we 2835 
do a lab blood sampling.. but we find with young children less than 2 years.. it is 2836 
extremely difficult to control their INR. 2837 
INTERVIEWER: aha so this is at the beginning of treatment it’s done daily.. and so.. 2838 
how about when… later on? 2839 
SARAH: well it’s depending if.. there is a group of patients who have very stable INR 2840 
and you.. do them every 4 to 6 weeks and there is patients that still.. wa’ need er 2841 
especially the children remain a concern on the long term.. 2842 
INTERVIEWER: umhm. SARAH: they need at least twice weekly or once weekly.. er.. 2843 
measurement.. with frequent admissions. 2844 
INTERVIEWER: alright so.. what are the obstacles that you usually encounter in 2845 
obtaining and maintaining a target therapeutic.. INR range? 2846 
SARAH: it is the unpredictability in children for the… er we don’t know is that it is the 2847 
liver metabolism or pharmacokinetics in children.. that prevent them from.. err.. either 2848 
they over.. er.. metabolise the warfarin or they retain it.. err.. so…. it is a quite unstable 2849 
group. 2850 
SARAH: that we haven’t been able to scrutinise what is… the reason of the unstable 2851 
INR but the grou’.. those patients.. er.. the infants and patients up to 5 years.. are a big 2852 
problem in INR control. 2853 
INTERVIEWER: aha.. so… yeah.. so those.. this regarding the age infants and up to 5 2854 
are there any.. umm.. other.. risk factors let’s say.. that .. err.. contribute to the 2855 
instability of the INR? 2856 
SARAH: well it could be the..  the frequency of infection the requirement for 2857 
antibiotics.. the regular change in diet with unpredictable response.. er.. of the INR to 2858 
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that.. er.. which includes.. err... unknown factors.. err.. we usually give the families a 2859 
list of things to avoid.. 2860 
SARAH: but still.. it doesn’t always.. work out but with infection and antibiotic there is 2861 
consistent.. er.. derangement of the INR that.. we usually try to.. to be aware that they 2862 
will be increase frequency of testing during that period. 2863 
INTERVIEWER: aha.. alright.. and how about the.. err.. the indication those with 2864 
valves and those with Fontan.. err.. is there any.. err.. like.. err.. do they differ in their.. 2865 
err.. stability of INR? 2866 
SARAH: well it’s depending Fontans with stable liver function and.. err.. especi’.. err.. 2867 
the non-failing Fontans it’s again it’s a difficulty because the liver metabolism.. err.. is 2868 
is.. err.. is very unpredictable and abnormal but stable Fontans.. usually have a reflect 2869 
on a stable INR again it is the diet and the other infections that.. may destabilise things 2870 
but... most of the Fontan population is.. er.. stable in that regard especially as they grow 2871 
older. 2872 
SARAH: err… err.. but the.. the patients with difficulties are the young patients who 2873 
needed mitral valve or aortic valve replacement are the main concern. 2874 
INTERVIEWER: aha.. alright.. err.. so yeah.. umm.. it’s just like.. err.. during my audit 2875 
or my usual work with wa’.. with the warfarin dosing.. er.. the.. er.. I sometimes see that 2876 
when patients are.. let’s say.. just out of the range.. err.. so some doctors tend to.. for 2877 
some patients tend to give like.. change the dose and give longer interval but for some 2878 
other patients they tend to do.. a more frequent.. INR. 2879 
SARAH: yeah we do that because.. the patients who are stable.. errr.. and… there is.. no 2880 
conce’.. for example we are more lenient with.. the Fontans because there is.. er.. no 2881 
immediate risk.. if they drop significantly on the.. conduit but.. with valve especially 2882 
mitral valve.. we become very anxious if there is.. a change.. a significant change in the 2883 
INR.. so we test them more frequently so we tend to test the valves more frequently.. 2884 
errmm.. and less frequently so if the Fonta’.. for the Fontans.. and if they need changes.. 2885 
we.. and and.. we what we look we look at the whole profile of the previous.. 2886 
SARAH: err.. err.. their.. err.. tendencies.. so some patients again it’s become 2887 
individualised.. that they are stable over a long time so you don’t need to to test them 2888 
very frequently.. and some patients they are just very variable that you can not trust.. 2889 
that if you go’ give them a longer period that they will have err… a stable INR. 2890 
INTERVIEWER: alright. 2891 
SARAH: so it is just on the case.. there is no rule to it it’s just goes by case on case. 2892 
INTERVIEWER: aha.. so.. errr.. is there any specific reason of why those patients with 2893 
valves being more.. risky? 2894 
SARAH: the patients with… the ones who have valves are more risky because.. if they 2895 
drop their INR and we have given them a long period.. and we haven’t tested them or 2896 
checked them.. that the valve will clot.. and then this means urge’.. you know risk of 2897 
sudden death.. as.. urgent need for surgery so  we can not afford to leave them for a long 2898 
times. 2899 
SARAH: especially in young children with unstable INR.. so more of grown up children 2900 
10 years onwards and young adults.. usually they have more stable INR unless they 2901 
have a major infection.. or a major problem.. but the.. the young children they very 2902 
unpredictable so we can not give them a blanket.. of non testing or long testing or 2903 
automated testing.. in couple of day.. err.. in couple of weeks we can not afford to do 2904 
that.. because they are very high risk.. especially the small valve.. in the mitral position.. 2905 
is very high risk so it is not like the adult mitral valve. 2906 
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SARAH: so it is not like the adult mitral valve.. ‘n usually in small children they use 2907 
inverted aortic valve.. with unpredictable behaviour.. so that’s why they need higher 2908 
INR range and frequent testing. 2909 
INTERVIEWER: alright brilliant.. umm.. so.. errr.. now we can.. err.. we come to the.. 2910 
er.. the new warfarin dosing model could you please let.. me know about your 2911 
experience so far with this.. new.. dosing.. of warfarin? 2912 
SARAH: so the new dosing with warfarin we find it useful in… in.. in the older 2913 
children.. that’s finds usually consistent and no problem.. we finding it difficult to.. rely 2914 
on.. and we always have to question.. err.. in younger children because it it 2915 
sometimes… it is not aware of the clinical background so yes that’s a mitral valve it 2916 
should be 2 to 3 but it doesn’t take in account why we change that because maybe we 2917 
happen to do a scan.. and the cardiac function is impaired… so.. or there is arrhythmia.. 2918 
so we want to have higher range during that period.. just to cover.. that high risk period 2919 
before we go back.. or you give a period ‘n ‘e you say OK we’ll derange very quickly.. 2920 
as sometimes the parents who are used to dosing with frequency sometimes they are not 2921 
happy to adhere with it..  and they want to change it more frequently.. umm.. and there 2922 
is… few but important incidence where longer.. errm… recommendation.. err.. might 2923 
have..  resulted in.. the fact that.. the INR went very high and we didn’t test it early 2924 
enough or too low.. so we still.. have to take a bit of a part of control in the younger 2925 
population. 2926 
INTERVIEWER: aha.. so.. yeah.. umm so could you please let me know about.. you 2927 
know.. the.. advantages and disadvantages that.. er.. you may think.. with with this.. err.. 2928 
is associated with this.. err.. dosing model? So we have got this.. umm.. err.. that it 2929 
doesn’t take into account the clinical situation are there any.. err.. advantages or 2930 
disadvantages? For this.. er.. model? 2931 
SARAH: hhh I think the advantages it will work for certain groups very well ‘n it will 2932 
help with that.. but it still that model have not… helped us with the young groups 2933 
because.. it still.. have.. I don’t think it have worked out…. why that particular group.. 2934 
err need more frequent.. dosing it still… it still not happy to.. to give them the 2935 
frequency that we need.. so you end up.. with a blanket.. dosing. 2936 
INTERVIEWER: yeah. 2937 
 SARAH: so I’m not sure I want to know from you.. have we taken in account the 2938 
pharmacokinetics in the very young.. 2939 
INTERVIEWER: yeah.. 2940 
SARAH: infants? 2941 
INTERVIEWER: it takes into account the pharmacokinetics and the 2942 
pharmacodynamics but it doesn’t give.. err.. the interval or the time for the next INR 2943 
checking so this again depends on.. err.. on the.. err.. our.. 2944 
SARAH: clinical? 2945 
INTERVIEWER: yeah. 2946 
SARAH: so and and that’s why the clinical factor have to look at that and say OK.. this 2947 
is what the automated thing.. does and this is what we usually deduce what the 2948 
automated decision.. then we say.. OK yes we are happy with this or no.. we have 2949 
assessed this patient today and we are not exactly happy we’ll just test a bit earlier.. or 2950 
give a different dose.. 2951 
SARAH: so we look at the dosing first.. that given the automated doses.. and then… s’.. 2952 
assess yes we agree or not.. so there is still a clinical input that is important. 2953 
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INTERVIEWER: so you are.. errr.. so your main concern.. is it the dose.. or.. the 2954 
interval? 2955 
SARAH: sometimes both. 2956 
SARAH: so sometimes both because… OK.. sometimes we put the target.. and then.. 2957 
during.. or.. depending on the clinical situation we change our target OK my target was 2958 
2 to 3.. but something now happened the cardiac function is more impaired.. 2959 
SARAH: or there is.. he out grown his size.. or there is a patient.. valve mismatch.. and 2960 
I decided that I will increase my target and I want to test him more frequently..  2961 
SARAH: so sometimes the clinical situation.. will change.. what.. the automated 2962 
decision based it on. 2963 
INTERVIEWER: aha.. so do you mean that.. err.. changing the target is like.. err.. 2964 
temporary.. temporarily? 2965 
SARAH: sometimes yes change the target temporary because there is an acute change 2966 
in the situation.. then when it resolves you go back to your.. previous target. 2967 
INTERVIEWER: yeah and again we can do that with the.. err.. you know.. with the 2968 
automated dosing.. 2969 
SARAH: yes.. 2970 
INTERVIEWER: so we can put that.. 2971 
SARAH: yes we usually.. we put a note that please change the target.. and change the 2972 
dose.. 2973 
INTERVIEWER: alright. 2974 
SARAH: and.. most of the time.. there is OK many occasions that… they show you the 2975 
dosing.. errmm.. and then you say OK  I.. I’m fine I’m happy with it. 2976 
SARAH: so  we don’t always we reject the dosing… most of the time it works.. but 2977 
there’s.. certain groups that we request… that… we want to know what’s happening 2978 
with the dosing so we just.. keep… on top of it. 2979 
INTERVIEWER: aha.. OK. So.. err.. at the moment with the two groups of people 2980 
who... the indications for warfarin.. the long term warfarin are those with Fontan and 2981 
those with valve.. err.. so which group do you think that the.. automated dosing.. works 2982 
better? 2983 
SARAH: … for most of the Fontans.. err.. it works OK because usually we do our 2984 
Fontans four years onwards.. with the slightly younger Fontan and that’s why we 2985 
stopped giving it for Glenns because they are very young and it’s difficult.. to 2986 
warfarinise them we’ll rather put them on aspirin.. 2987 
SARAH: so.. err.. it works for.. the older valves…a’.. and the older Fontans.. it works 2988 
fine. 2989 
INTERVIEWER: aha so you think it’s it’s mainly.. the main concern is the age? 2990 
SARAH: the age group.. yes. 2991 
INTERVIEWER: aha. Alright.. umm.. so.. umm.. 2992 
SARAH: the age group and the cardiac function. 2993 
INTERVIEWER: exactly.. umm.. so.. err.. would you recommend this dosing model  2994 
for other clinicians in the same circumstances? 2995 
SARAH: .. err.. you mean in congenital heart disease? 2996 
INTERVIEWER: yeah. 2997 
SARAH: I think.. it is it is it is a useful model.. it is just we need to.. err… reach the 2998 
consensus of the flexibility of the model.. 2999 
SARAH: so once the model is flexible to accommodate the much younger group that 3000 
needs more.. frequent dosing.. I think it should work OK.. but as with automated 3001 
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things.. I I think with.. our complex patients.. there has to be always a degree of 3002 
judgment clinical judgement.. and input.. 3003 
INTERVIEWER: yeah. 3004 
SARAH: it.. can not be just.. an automated.. err.. service. 3005 
INTERVIEWER: alright. 3006 
SARAH: because the result of unpredactabilities. 3007 
INTERVIEWER: yeah exactly.. um.. so.. umm… do you have.. err.. any 3008 
recommendations regarding this.. err.. model?.... so to make it.. work better? 3009 
SARAH: …. I’m not sure what will work in that model from a mathematical point o’ 3010 
view so if a patients is.. for example if we take a patient who’s very unstable who needs 3011 
frequent testing.. and frequent dosing.. 3012 
SARAH: would.. the model re-adjust that particular patient? 3013 
INTERVIEWER: err.. so.. er.. umm.. if w’ umm... as much.. err.. INRs as we get.. so 3014 
the better.. it will predict so.. err.. the more the INR input into the model the more it will 3015 
be able to.. adjust the dose.  3016 
SARAH: so.. understand the profile of the patient. 3017 
INTERVIEWER: yeah. 3018 
SARAH: so you can.. you basically can individualise.. 3019 
INTERVIEWER: yeah. 3020 
SARAH: each model.. 3021 
INTERVIEWER: yeah. 3022 
SARAH: you know tailor it.. 3023 
INTERVIEWER: yeah. 3024 
SARAH: to each patient.. 3025 
INTERVIEWER: yeah. 3026 
SARAH: that particular patient.. 3027 
INTERVIEWER: yeah. 3028 
SARAH: with the.. it is pharmacokinetics. 3029 
INTERVIEWER: so this is what we are doing at the moment.. 3030 
SARAH: yeah. 3031 
INTERVIEWER: we are taking the INR histories for those.. err.. for those starting 3032 
warfarin for the.. err.. who are stabilised on warfarin.. so we take.. err.. their history of 3033 
INRs for a specific per’ period of time.. so the model can predict the pharmacokinetics 3034 
and pharmacodynamics for that specific patient.. err.. and then.. will be able taken into 3035 
account target range and the baseline INR.. and.. errr.. so it will predict the dose for that 3036 
patient and.. once we.. err.. as more as we can get from the INRs we update that.. so.. it 3037 
will be like updating.. err.. whenever we get a new INR. 3038 
SARAH: so we have to look into the over result and.. the success rate and the failure 3039 
rate and.. the maybe the rate where.. it had to be.. errmm… individually re-adjusted or 3040 
didn’t agree and then we will know.. how much this model fit.. in a scientific… 3041 
numbers. 3042 
INTERVIEWER: aha. And for those people who are starting for the first time we are 3043 
doing a genetic test for them.. for the enzymes involved in metabolism and the enzyme 3044 
VKORC1 the vitamin K epoxide reductase to see.. how sensitive they are to warfarin 3045 
and we are using that as well.. err.. for them.. to predict their warfarin doses. 3046 
SARAH: OK so it’s this will deal with the rapid and the slow metabolisers 3047 
INTERVIEWER: yeah yeah so.. this.. this is our.. 3048 
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SARAH: because this is one of the.. other.. difficult problems is is.. err.. the.. the rate of 3049 
the metabolism as well.. ‘n who is a fast metaboliser ‘n who is a slow one. 3050 
INTERVIEWER: yeah yeah alright.. err.. do you have any other comments? 3051 
SARAH: no no.  3052 
 3053 
3- Interview number 7: HCP5 3054 
 3055 
INTERVIEWER: hello.. and thank you very much for agreeing to take part in my 3056 
research.. err the purpose of our meeting is to.. talk about.. your experience with 3057 
warfarin dosing and monitoring.. before and after using the.. new warfarin dosing 3058 
model. Err.. first of all I would like to.. err.. talk about thee overall approach.. err.. that 3059 
is being used for cur’.. currently for warfarin dosing and monitoring.. umm could you 3060 
please let me know about that.. right from the beginning when the.. patient first start.. 3061 
warfarin treatment? 3062 
TAJ: err.. I mean we have been dosing.. on alone.. with the.. intermittent obviously 3063 
intermittent sort of… erratic INR.. changes.. with this WATCH study…most of the 3064 
time.. I feel that it is.. inconsistent with what we are prescribing.. 3065 
INTERVIEWER: um sorry.. I just need to know.. first.. the.. usual practice.. in warfarin 3066 
dosing and monitoring like.. when the first.. when you first start.. dosing the patient.. 3067 
errmm.. the INR.. the target INR range.. those stuff.. right from the beginning of.. of 3068 
warfarin treatment. 3069 
TAJ: ya so.. we.. have different INR.. sets for.. different.. sort of.. diagnosis.. 3070 
TAJ: for valve.. and e’ if it is like mitral valve we normally keep.. more than 2 or 2.5 to 3071 
4.. err similarly for aortic valve we have slightly.. err.. less.. umm INR reading.. 3072 
acceptable.. and.. the other commonest.. umm sort of.. err warfarin prescribing is for.. 3073 
univentricular heart this Fontan post Fontan.. and that is again has a.. big range 3074 
accepting anywhere from 1.5 to 3 depending on.. sometimes.. err.. different consultants’ 3075 
preference… so.. in general.. when we start… aiming that INRs will start with a sort 3076 
of.. loading.. dose.. of is.. which is 200 microgram per k g (kilo).. 3077 
TAJ: normally.. I prescribe within.. that range.. sometimes we have to give that dose.. 3078 
err few days… while patient is in and observing.. to get to the.. target INR.. and err.. 3079 
yeah we start monitoring from.. day.. one.. after giving.. that dose before we end up 3080 
having.. maintenance dose. 3081 
INTERVIEWER: so and er how about the um the that period of overlap with heparin… 3082 
how long? 3083 
TAJ: e’ e’ it’s normally 2 to 3 days.. as minimum.. er when we start… mmm soo and 3084 
sometimes.. as I said it takes.. even longer.. err because few patients.. like in my 3085 
experience last one.. we gave him.. same two poin’ er 200 microgram per k g (kilo) per 3086 
dose.. but.. next day.. even we had.. to go even higher.. which was nearly 300.. 3087 
microgram.. err and still we did not achieve INR until fourth day. 3088 
TAJ: the target INR. So sometimes it is prolong.. but normally we do get to the INR on.. 3089 
second day or third day so 3 days of overlap. 3090 
INTERVIEWER: alright. So umm.. are there any guidelines for.. err.. you know.. 3091 
starting.. the starting dose.. the target INR range.. umm the time of overlap with heparin 3092 
are there any specific guidelines for.. for these things? 3093 
TAJ: …. Ah.. I’m not fully aware of.. of any guideline.. but I.. what.. I’m aware of is the 3094 
practice.. here.. which is err as I said.. starting with 200 micrograms and then going to 3095 
hundred microgram.. 3096 
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INTERVIEWER: OK. 3097 
TAJ: after 2 days. 3098 
INTERVIEWER: OK. And the target INR.. 3099 
TAJ: (at the same time) target INR.. 3100 
INTERVIEWER: (at the same time) range? 3101 
TAJ: again varies between.. the different diagnosis.. sometimes it is accepted as low as 3102 
1.5.. for.. er.. Fontan patients.. where we have low risk of.. for v’.. valve and mechanical 3103 
valves obviously more than 2. So once we get to more than 2.. normally we stop err.. 3104 
INTERVIEWER: so what’s the reason behind those people with valves.. getting.. higher 3105 
target.. range? 3106 
TAJ: …. Err.. er.. there is more risk of clotting.. in those mechanical valves.. especially 3107 
low pressure valve which is mec’.. umm mitral valve so that’s why the risk of err.. you 3108 
know.. 3109 
INTERVIEWER: so er could you please clarify what you mean by low pressure valve? 3110 
TAJ: err.. where.. we have er.. umm the press’.. the.. mitral valve.. where blood flow.. 3111 
from.. left atrium to.. right ventricle (I think he meant left ventricle).. the.. thee.. thee.. 3112 
flow gradient or flow velocity is much low.. so there is more stasis sort of thing.. e’ e’ it 3113 
is not stasis but the flow velocity is less so blood is not rushing.. so there is more chance 3114 
of er.. stagnation.. there is more chance of.. having clot.. in that valve. 3115 
TAJ: err.. comparing.. mitral valve to aortic valve.. aortic valve again.. when blood is 3116 
ejected it’s a high pressure.. sort of ejection from the left ventricle which is.. if we 3117 
compare.. it is hundred m m h g (mmHg) versus.. 5 to 10 m m h g so that is.. a 3118 
comparative difference.. so e’ e’ it’s less chance of clotting or stagnation… on er.. on.. .. 3119 
on er mit’.. on aortic valve compared to mitral valve.. so that’s how.. we.. determine.. a 3120 
higher INR.. ratio for.. those valves mechanical.. mitral valve. 3121 
INTERVIEWER: alright. 3122 
TAJ: and err.. similarly.. umm..in in Fontan.. again.. there.. there is there isn’t any 3123 
mechanical valve kind of  thing.. it’s just the slow movement or stagnation of blood.. so 3124 
you are just pre-empting.. sort of.. so that’s how you.. accept.. relatively lower INR or 3125 
lower thinning.. for definite valves. 3126 
INTERVIEWER: umm.. so umm.. how about thee frequency of INR measurements the 3127 
monitoring? 3128 
TAJ: yeah. 3129 
INTERVIEWER: at the beginning and then afterwards? 3130 
TAJ: for mitral valve.. we do very frequent INR monitoring.. and simple reason being.. 3131 
there is more risk.. so we just don’t want to.. er.. we want to avoid.. any sort of low INR 3132 
situation.. hidden.. so that’s er.. but ideally.. err.. e’ two weeks… one to two weeks is.. 3133 
acceptable sort of monitoring for mitral valve.. 3134 
TAJ: e’ if we have a stable INR situation.. but sometimes while we are still achieving a 3135 
therapeutic or stable INR situations we do… relatively 2 to 3 days or.. quite.. regular 3136 
monitoring.. especially when the patients are jus’ started on.. or newly started on. 3137 
TAJ: for.. a Fontan sort of thing.. since we have a big range acceptable range… from 3138 
low to.. so.. we monitor three weekly or four weekly. 3139 
TAJ: .. and er.. very rarely we.. get to surprised that.. er.. in four weeks.. we… get.. you 3140 
know.. e’ e’.. erratic reading… in terms of high or low.. so normally we get.. you know.. 3141 
er.. sort of stable reading.. 3142 
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TAJ: even before er.. a four.. four weeks’ or three weeks’ monitoring.. with the.. umm.. 3143 
er.. if we have a.. big acceptable range.. for er.. for an aortic valve.. normally two 3144 
weeks.. is quite acceptable. 3145 
TAJ: although in practice we had to do… relatively sooner.. because.. because of this 3146 
population… you know.. where you.. have some unseen things like diet an’… for for 3147 
kids and these things.. 3148 
TAJ: intercurrent illness.. sometimes.. they are on antibiotic or.. even.. infection so… 3149 
that is.. that determines their… you know.. intermittent… err change in the.. follow up 3150 
or frequency of err.. INR checking. 3151 
INTERVIEWER: umhm so they usually umm.. 3152 
TAJ: one to two weeks.. is quite acceptable or quite.. er.. in practice.. for um.. aortic 3153 
valve. 3154 
TAJ: … err.. for mitral valve I would say… we.. aim to.. do two weeks.. in most of the 3155 
situation but…. in practice rarely we get to that.. so we have to monitor.. relatively 3156 
sooner and that is simply because.. mitral valve nobody would like to take.. chance of 3157 
low INR. 3158 
INTERVIEWER: umhm. OK. So ummm.. what are thee umm.. obstacles that you 3159 
usually.. encounter.. err.. when.. doing the dosing.. and the INR monitoring er like in 3160 
getting the INR into the range and maintaining it into the range do you have any.. 3161 
obstacles or any difficulties in that?... and in what situations? 3162 
TAJ: ….. er… th’ th’ there are few patients.. adolescent patient.. with the.. mechanical 3163 
valves.. who we sometimes question their dosing and they have er.. sort of.. um.. you 3164 
know recreation thing or.. alcohol an’ all these things.. so that sometimes.. er.. interfere 3165 
with the… controlling of.. their INR.. within range.. and er.. few of them.. would.. even 3166 
miss… er warfarin.. so we are not sure exactly.. whether it is.. true reflection of er.. you 3167 
know.. INR changes… or is it.. something because of er… compliance issue. 3168 
INTERVIEWER: alright. 3169 
TAJ: err that we see. And.. in younger age group… because… again.. heart.. problem 3170 
and.. they get frequent chest infection and these things… so.. that.. situation arises 3171 
with… nearly.. every kid.. during the year when they get.. er.. you know infection.. then 3172 
their INR definitely.. changes.. and sometimes we have to admit them to… control in 3173 
either way with very high INR.. going above 6 or something.. and err.. with very low 3174 
INR as well. 3175 
INTERVIEWER: OK. So yeah those things like er infections and err.. 3176 
TAJ: infections compliance.. and obviously diet and these things... 3177 
INTERVIEWER: OK. 3178 
T : these affects err.. 3179 
INTERVIEWER: umm so err.. let.. yeah.. umm just need to ask about compliance and 3180 
and er patients when they do.. umm.. I’ve got some patients who do their own dosing.. 3181 
or non.. non compliance regarding the interval of INR measurements so.. umm.. what is 3182 
your reaction… with those patients.. usually? 3183 
TAJ: so we we try to e’ err.. do frequent monitoring.. again.. because all of them.. are.. 3184 
doing.. home monitoring.. 3185 
TAJ: er and then calling us. So.. e’ e’ er.. there are only few patients which we have 3186 
recognised who have very.. sort of.. variable reading.. er.. within ‘is.. so those we do 3187 
frequent monitoring.. 3188 
INTERVIEWER: those who.. who make their own dosing so they.. they just do not 3189 
follow the doctor’s dose. 3190 
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TAJ: e’ e’ the the.. most of the.. oh.. thi’ this is very rare thing.. normally they follow 3191 
what.. what you advise. 3192 
INTERVIEWER: yeah. 3193 
TAJ: yeah. It’s er.. it’s the missing the dose and sometimes.. for.. some reason.. 3194 
TAJ: it’s only I think.. one.. patient or.. I would say one or two. 3195 
INTERVIEWER: so yeah. What do you usually do in those circumstances when they do 3196 
their own dosing? 3197 
TAJ: yeah umm….again.. er.. we can never know we only know is their.. INR.. once.. 3198 
how fluctuates.. that is.. so if it still within range.. with.. bit of fluctuation or acceptable.. 3199 
sort of fluctuation.. 3200 
TAJ: um I mean accepting slightly higher INR.. in that situation.. so we still dose 3201 
whatever reading we have.. 3202 
INTERVIEWER: OK. 3203 
TAJ: accordingly. 3204 
TAJ: errr.. and that’s thee…. er.. there are.. one or two as I said patients who.. who miss 3205 
the dose for some reason and once we check and we find out.. we have found out that it 3206 
is going low.. then we had to admit them.. to observe few days.. and that documents.. 3207 
when they are admitted.. their INR.. behaves like er um um relatively.. stable sort of 3208 
thing so their.. doc’.. that.. er tells us that.. probably there is compliance issue with.. 3209 
with them. 3210 
INTERVIEWER: OK. 3211 
TAJ: because when you monitor them in hospital.. three days four days.. admitting them 3212 
for.. other anticoagulation starting on heparin an’ givin’.. so their INR in hospital… 3213 
looks more stable.. 3214 
TAJ: while…. time to time.. at home so.. there is complian’.. so this.. these are the 3215 
measures.. so.. frequent monitoring.. and er if we have sort of.. 3216 
INTERVIEWER: is there any specific like formal action with them?.. especially if you 3217 
find that they they do they do their own dosing and the INRs are unstable? 3218 
TAJ: yeah. 3219 
INTERVIEWER: or out of range? 3220 
TAJ: yes when they are admitted there is some counselling sort of advice.. kind of 3221 
things when we just suggest and that’s talking to them.. errr… mostly they do 3222 
understand and try to it is… but still it happens. 3223 
INTERVIEWER: OK. So in those few cases that.. they do their own doses do you find 3224 
them.. right in their dosing or.. no.. usually.. those cases? 3225 
TAJ: because e’ e’ this is difficult to know.. this is only when they skip an INR goes 3226 
low so obviously they are.. not taking probably.. 3227 
INTERVIEWER: OK. 3228 
TAJ: regularly. But.. own dosing if we have an INR within range.. umm…. it’s difficult 3229 
to say whether they are doing their dosing because we have prescribed something and 3230 
we are getting the INR.. exactly what… you would like to be. 3231 
TAJ: it’s only when they don’t take.. 3232 
TAJ: normally they.. they follow.. whatever you are.. it’s only few.. errr… mothers.. 3233 
who sometimes.. ya that.. also.. one of the thing happens because sometimes.. umm…. 3234 
we prescribe the dose.. just looking into.. one or two previous.. dosing pattern.. err.. an’ 3235 
in that case mothers they are.. probably more sensible they.. they ask us they discuss us.. 3236 
they don’t they suggest.. 3237 
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TAJ: OK probably doctor this dose is err.. I think this is.. a bit too much his INR will go 3238 
very high because that has happen.. sometime I got that.. so we… with that discussion.. 3239 
normally wee.. we come to an agreed dose.. 3240 
INTERVIEWER: alright. 3241 
TAJ: it.. but um.. er.. even patients they.. they don’t do their own dosing without being.. 3242 
informing the doctor because.. on that side.. even they feel that.. the doc’.. the 3243 
prescribed dose is not.. accurate.. 3244 
TAJ: still they would like to discuss because they don’t want.. take chances of.. 3245 
prescribing themselves. 3246 
INTERVIEWER: OK. 3247 
TAJ: so that is.. e’.. err.. generally not happening or I… in my practice I don’t see that.. 3248 
patients are doing without.. doctor being aware of.. their own dosing. Because once 3249 
they.. ask us.. they would like to discuss so we know the dosing sometimes we 3250 
change… in.. you know with patient’s experience.. and.. that is.. again if we feel that is 3251 
sensible.. that is that is err.. umm that does work.. I mean that does happen that.. 3252 
patients have suggested different dose.. and the doctor has agreed with that. 3253 
INTERVIEWER: alright. 3254 
TAJ: so.. that is occasionally. 3255 
INTERVIEWER: OK. Um so I just wanted to ask about thee err.. stability.. of INRs 3256 
like you know.. keeping them in range.. umm.. we see that some pa’.. some people are 3257 
quite… nice and they are.. let’s say.. most of the time in range and some.. people are 3258 
not.. and they are quite unstable.. umm so err.. are there any specific reasons behind 3259 
that? 3260 
TAJ: …. err… again you never know.. err.. dietary pattern.. ummm.. which affects.. 3261 
INR. 3262 
TAJ: errr….. e’ it is true that there are a few patients whom would do see.. more 3263 
fluctuation or I would say… they have um.. a greater response of little change in the 3264 
dose.. so if you… increase dose slightly.. because of.. their.. low reading.. you find it.. 3265 
going very high so they have a very narrow sort of dosing.. range. 3266 
INTERVIEWER: OK. So is there a specific reason behind that? 3267 
TAJ: ahhh.. I’m.. I’m.. I’m not sure exactly what is their… metabolism or kind of 3268 
whatever.. liver function… err… how does that affect because there are few known 3269 
factors…. interactions with drug and these things which you… but n’.. 3270 
INTERVIEWER: yeah the known factors.. what are those known factors? (laugh) 3271 
TAJ: yeah I mean these are antibiotics and these things.. we know them. 3272 
INTERVIEWER: OK. 3273 
TAJ: errr vitamin K sort of th’ situation if they are taking.. umm.. some some 3274 
vegetables.. who are rich in vitamin K.. there are few.. so something like that but.. 3275 
sometime.. not every time you know exactly why it is happening with some patients 3276 
whether it is.. own.. coagulation.. cascade kind of thing.. which affects their.. individual 3277 
INR. 3278 
INTERVIEWER: OK. 3279 
TAJ: but in practice I do see.. that there are patients who have a very.. narrow sort of er.. 3280 
dosage range. 3281 
INTERVIEWER: yeah. 3282 
TAJ: that little change.. their INR changes.. 3283 




TAJ: yeah er but.. 3286 
INTERVIEWER: is there any reason that you can maybe.. deal with.. to get them more 3287 
stabilised? And what kind of patients are those with.. fluctuating INRs? 3288 
TAJ: errr.. it’s only few.. it’s very few it’s not er… because if.. wee… percentage bu’ I 3289 
can not say.. percentage.. 3290 
INTERVIEWER: yeah of course they are very few. 3291 
TAJ: but they are.. definitely very few patients.. errr.. they definitely need.. more 3292 
frequent monitoring.. and err.. 3293 
INTERVIEWER: do they have like a specific… disease like you know.. Fontan’s 3294 
versus valves? Or age maybe.. play that part.. so they have this labile INR? 3295 
TAJ: I.. I’m.. not sure.. I haven’t er.. tried to explore this in.. in fact. 3296 
TAJ: er it is er.. exactly. 3297 
INTERVIEWER: from my own.. experience with people I can see that those with 3298 
valves.. 3299 
TAJ: umm. 3300 
INTERVIEWER: especially those with.. mechanical valves mechanical mitral valve.. 3301 
TAJ: umm. 3302 
INTERVIEWER: er tend to bee.. unstable.. and they have very.. you know fluctuating 3303 
INRs and.. as well as those who are very young.. 3304 
TAJ: yeah. 3305 
INTERVIEWER: like you know one two.. or maybe below one year old.. so.. have 3306 
you.. got umm.. 3307 
TAJ: now that is.. that is true.. but e’ e’ on the other hand.. that is.. we are monitoring 3308 
them more.. carefully or more.. closely so that’s how.. we get all these fluctuations.. 3309 
more.. recorded or more documented.. 3310 
TAJ: mitral valve especially.. umm.. compared to Fontan because we have a big range 3311 
we are.. much relax in prescribing Fontan patients because we know.. there is.. we can 3312 
accept as low as 1.5 and we can accept as high as 4 or 5..  3313 
TAJ: so there is a big range of them.. we are not.. so.. and we are not monitoring that 3314 
closely so.. that maybe one reason. 3315 
TAJ: we are not.. picking them.. or their fluctuation. 3316 
INTERVIEWER: OK. 3317 
TAJ: there there is more chance of fluctuation because they have a derange liver.. err 3318 
Fontans.. because of the stasis and these things so we can ex’.. expect.. more 3319 
fluctuation.. with someone who has derange liver function.. 3320 
TAJ: which is Fontan group.. but we are not seeing much there because.. we are er.. 3321 
monitoring them.. four weekly or.. less frequently.. so.. that maybe one reason.. 3322 
INTERVIEWER: OK. 3323 
TAJ: that we are documenting more… if we are doing more monitoring… three days 3324 
five days check in mitral valve so you will see more fluctuation.. if we m’.. errr.. you 3325 
know.. monitor them in two weekly probably we would have… similar sort of err.. 3326 
monitoring profile with them. 3327 
INTERVIEWER: alright so umm… er the other thing is the.. err.. the INR monitoring.. 3328 
err so sometimes I see for some patients err when the INR is just out of range.. errmm.. 3329 
the doctor.. like stays on the same dose and gives a long interval but for some others 3330 
they do change the dose and give a shorter interval is there.. which was confusing for 3331 
me so errr.. is there any reason for that? 3332 
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TAJ: … you know mitral valve... especially mitral valve… and aortic valve.. or 3333 
mechanical valve thing.. 3334 
TAJ: there err… we do change the dose.. sometimes because we are doing very frequent 3335 
monitoring.. and the range for them is er.. th’… the upper range probably we can extend 3336 
and we can accept.. relatively higher range.. but thee.. you know.. below therapeutic we 3337 
are not accepting so.. above 2 or 2.5 in.. most of the cases. 3338 
INTERVIEWER: OK. 3339 
TAJ: so that is.. one of the reasons there.. there many dose changes… and Fontan 3340 
group.. although they are on.. there is.. e’ e’.. because you are not worried of bleeding 3341 
even… after 6 even.. if INR.. in.. you know.. practic’.. in practice I haven’t seen.. 3342 
patient.. who bled.. even with high INR. 3343 
TAJ: so you are not worried yes you want to maintain them somewhere between 1.5 to 3344 
4 but even 5 an’ 6 an’ 7.. we haven’t seen many bleeding in practice. 3345 
INTERVIEWER: OK so you so you do concern about those.. with low INRs greater 3346 
than those with.. 3347 
TAJ: (at the same time) espe’ 3348 
INTERVIEWER: (at the same time) high. 3349 
TAJ: yeah especially with the.. mechanical valve. 3350 
INTERVIEWER: OK. 3351 
TAJ: because there is.. element of clotting. 3352 
TAJ: in er.. err.. Fontan group even their INR is low.. we can still.. build up in.. next 3353 
few days so we are not worried of.. you know.. if they have a transient.. few days.. of 3354 
low INR. 3355 
TAJ: and that is the reason for.. checking them less frequently.. err and… upper range 3356 
I’m not.. concerned most of the times because we first.. we seee.. we haven’t seen any 3357 
complication. 3358 
INTERVIEWER: bleeding one? 3359 
TAJ: bleeding.. yeah er I mean.. with the with the reading of 6 or 7. 3360 
TAJ: and rarely we have to admit.. even if it is.. err you know very high to give them 3361 
vitamin K. so we haven’t managed.. or we um didn’t need to manage.. 3362 
TAJ: with high INR group….. as frequently.. because err first there isn’t any.. sort of.. 3363 
bleeding and once you stop the dose you come down and then you just observe. So 3364 
rarely we have to manage but low INR group because of the risk of clotting.. is much 3365 
higher.. 3366 
TAJ: there you have to admit.. 3367 
INTERVIEWER: (at the same time) alright. 3368 
TAJ:  (at the same time) and give heparin. 3369 
INTERVIEWER: yeah. 3370 
TAJ: errr and in Fontan group.. you are relax.. because you know higher.. won’t give 3371 
them bleeding.. most of the time.. because we are accepting range much lower than 3372 
theeee e’ where you have the risk of bleeding but say upper.. higher limit is 3 or 4.. but 3373 
umm.. 6 7 8 even up to.. we have seen.. we don’t do anything most of.. except for 3374 
observing. 3375 
INTERVIEWER: OK. 3376 
TAJ: so there is much big room for them.. even they fluctuate. 3377 
INTERVIEWER: alright. 3378 
TAJ: and even they go lower.. 1.5 or low.. still.. er it’s it’s not much.. that risk of 3379 
clotting because there isn’t any mechanical valve. 3380 
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INTERVIEWER: OK. 3381 
TAJ: so we can only get away with a.. you know.. four weekly monitoring in that group 3382 
even… this dose prescribing can I jus’.. 3383 
INTERVIEWER: yeah yeah. 3384 
TAJ: yeah even WATCH study dose prescribing.. I never have.. er problem with the.. 3385 
with the.. as far I remember.. with.. Fontan group. Whatever dose.. usually it is.. quite 3386 
acceptable and consistent. 3387 
TAJ: er.. maybe if I’m going to prescribe maybe I would prescribe the same or.. 3388 
slightly.. so tha’ I don’t see big err.. mismatch.. in sort of er.. err.. you know.. computer 3389 
pres’ prescribing and my prescribing.. and.. even if there is little.. it is acceptable. But 3390 
um with the mechanical valve.. where you ha’.. you are.. monitoring more closely so 3391 
you see more fluctuation…. simply because you are monitoring them.. 3392 
INTERVIEWER: (at the same time) yeah. 3393 
TAJ: (at the same time) on daily basis. 3394 
INTERVIEWER: (at the same time) yeah. 3395 
TAJ: and you have less range of you know acceptability… of er.. low INR.. err.. so 3396 
that’s how… there.. you’re more… but this WATCH study dose again I see.. problem 3397 
with that.. errrr.. with mechanical valves sometimes. 3398 
INTERVIEWER: yeah. 3399 
TAJ: sometimes.. and umm again because of.. worry of low INR.. I do change.. rarely.. 3400 
but again it’s not.. that frequent.. most of the time it is er.. acceptable but if I have to 3401 
change anything it’s only if I have some concern.. that is only in that group.. err mitral 3402 
valve.  3403 
INTERVIEWER: (at the same time) with mitral valve. 3404 
TAJ: where you are really worried of low INR. 3405 
INTERVIEWER: yeah er so with theee hi’ very high INRs when do you usually stop 3406 
warfarin at which level of INRs? 3407 
TAJ: .. er it’s er…. there is some guidelines.. or.. some prac’ individual practices as 3408 
well. 3409 
TAJ: if it is more than 6.. still you do not stop… you just umm.. decrease the dose or 3410 
half the dose because if you.. completely stop.. and then the next day or the following 3411 
day if it goes below their.. you know therapeutic that is more risky period. 3412 
INTERVIEWER: alright. 3413 
TAJ: if it is goes below… say 2.. that is more risk.. of clotting or.. clotting the valve. 3414 
INTERVIEWER: yeah. 3415 
TAJ: sooo you still you decrease the dose.. but you don’t stop.. currently.. unless it is 3416 
very very high if it is like 8 or sometimes we have from peripheral hospital refer 3417 
admission with 8. 3418 
TAJ: you obviously admit them.. and suggest them close monitoring… but again on 3419 
these valve group especially mitral valve group we rarely.. ask them to give.. you 3420 
know.. vitamin K and these.. sort of things. 3421 
INTERVIEWER: yeah. 3422 
TAJ: again  because of the risk because.. when you give.. and the INR goes low then 3423 
(laugh) you end up.. givin’ them heparin an’.. keepin’ longer in the hospital. 3424 
INTERVIEWER: exactly. Umm OK so umm.. we can.. umm.. let’s talk about like.. the 3425 
new dosing.. model.. warfarin could you please.. errrmm reflect on your experience 3426 
with.. with theee.. computer dosing? 3427 
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TAJ: yeah er it is… I would say comparable or.. consistent.. with the.. dosing.. err.. 3428 
slight variation… even there is some some.. you know.. interpersonal variation among 3429 
the doctors… err.. the dose which I’m going to prescribe.. not.. necessarily exactly the 3430 
same dose would be prescribed by my other colleague. 3431 
INTERVIEWER: alright. 3432 
TAJ: so there is some.. so.. within that sort of.. err.. acceptable variability I see the 3433 
same.. dosing pattern in.. err.. computer because.. er…. I rarely have to change… or.. 3434 
ask for change or.. have to call you.. and that rare situation is with mitral valve..  3435 
TAJ: but for err.. for Fontan.. and even for aortic valve.. normally it is consistent with.. 3436 
whatever we have prescribing.. accepting.. some.. interpersonal variability as well.. err.. 3437 
yeah so.. I think it is it is… within acceptable range of difference.. in dosing. 3438 
TAJ: the only thing where I’m very careful is um.. mitral valve.. but again.. rarely I 3439 
have to change.. it’s only few occasion when I have to call you or.. err.. so I feel it is.. e’ 3440 
e’.. I don’ know how.. it is quite matching what we are.. prescribing.. it’s close to that.. 3441 
if not exactly… 3442 
INTERVIEWER: the same. So are there any advantages or disadvantages that.. um you 3443 
have noticed with this process of dosing? 3444 
TAJ: … umm….. errr.. advantage in the sense um…. that er.. obviously there maybe.. 3445 
more consistency. 3446 
TAJ: if it works… er.. or if it cont’… er.. if.. you know.. we have seen it.. more.. I’m 3447 
not sure because if… we have a consistent dose.. if we have a sort of comparable dose 3448 
or correct dose prescribing an’ it continues.. so there is.. likelihood of more 3449 
consistency.. or uniformity.. of the dosing pattern.. because… among the doctors.. we 3450 
have different persons prescribing so that sort of.. variability won’t be there. 3451 
TAJ: err if there.. and if weee.. could document sort of.. more er.. longer.. errm.. INR 3452 
stability. 3453 
TAJ: … errr… then obviously.. that is that is.. err.. sort of advantage on the… yeah.. e’ 3454 
e’ less confusion for the paren’ maybe patients as well. 3455 
TAJ: err.. because of the.. umm… stable dosing.. or coming up with the computer an’.. 3456 
yet maintaining the INR within range… errr… disadvantage being…. I haven’t seen.. 3457 
but you may miss sometime if we.. are trusting too much.. 3458 
TAJ: you know what I mean because.. sometimes I do see I say OK.. an’ I e’ e’ agree 3459 
with that.. but if err.. you know.. sometimes you have to really question.. err.. that er… 3460 
errr.. whether that umm… is safe… umm.. in terms of mitral valve.. like I have to.. do it 3461 
f’.. err.. one or twice.. umm.. I felt that my dosing was.. obviously.. err.. correct.. in 3462 
terms when we.. when we saw the response… so the.. disadvantage maybe.. potential 3463 
disadvantage that if it is missed.. if it is overlooked.. the dose which has been 3464 
prescribed.. 3465 
INTERVIEWER: sorry what do you mean by missed? 3466 
TAJ: er I mean not cross checked.. sometimes.. if you are trusting too much.. because I 3467 
don’ know whether.. err.. a dose.. 3468 
INTERVIEWER: so do you mean the doctor .. miss the checking.. the dose? 3469 
TAJ: yeah.. if the doctor.. 3470 
INTERVIEWER: because we always.. there.. there should be always.. 3471 
TAJ: (at the same time) yeah there is a cross check.. 3472 
INTERVIEWER: (at the same time) a doctor that signs for this. 3473 
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TAJ: yeah if trusting sometimes if it is like.. er.. trusting…… the dose what.. where has 3474 
been prescribed by the computer.. because when.. you are prescribing you go through 3475 
definitely in.. (laugh) every detail.. 3476 
INTERVIEWER: (laugh) yeah. 3477 
TAJ: you see the INR you see the previous you see the pattern an’ all these things 3478 
because you are prescribing… errr.. an’ if there is a dose prescribe and you are jus’ 3479 
signing.. sometimes you may.. not see the whole pattern.. so you.. you may miss the 3480 
doctor who’s cross checking.. 3481 
INTERVIEWER: yeah. 3482 
TAJ: that maybe has.. so like but I’m not sure.. 3483 
INTERVIEWER: so do you mean that umm.. thee err.. computer might not.. taking the 3484 
clinical picture into account? 3485 
TAJ: … because I have.. since I have…. corrected in my.. sort of understanding once or 3486 
twice.. 3487 
TAJ: and.. err e’.. I wa’… e’.. I was not agreeing.. exactly the dose prescription by the 3488 
computer.. 3489 
TAJ: e’ again.. very.. few occasions.. I would say two… two.. yeah two or three maybe.. 3490 
err ’nt that many.. so if er on those two or three occasion… I may have.. I may agree 3491 
with the er.. you know thee dose prescribed by the computer.. 3492 
INTERVIEWER: OK. 3493 
TAJ: so I may jus… um.. you know.. the’ that is something… err I’m not sure whether.. 3494 
errr.. that was going to impact the patient… if we have.. checked the INR so that is 3495 
something.. er.. if.. trusting… wholy.. on the.. WATCH… is.. it is premature… whether 3496 
we can just do that.. so that I feel that umm… there isn’t any harms (laugh) so far.. 3497 
INTERVIEWER: yeah.. but.. yeah.. 3498 
TAJ: but that I see as er.. as er… at the moment.. errr… that you have to re’ be really go 3499 
through… that whatever.. we have like cross checking thee.. computer dosing. 3500 
INTERVIEWER: ya this is this is thee ethical errmm… the ethical approval we haven’t 3501 
got that till we.. we have to assure that the doctor would.. should review the dose and 3502 
check it and then.. prescribe it we can not do that.. without.. you know..  3503 
TAJ: umm. 3504 
INTERVIEWER: the doctor’s agreement.. in any way.. 3505 
TAJ: yeah. 3506 
INTERVIEWER: soo.. yeah. 3507 
TAJ: ya I mean if we are trusting that may.. sometimes it.. it may happen because 3508 
those.. two or three occasions I am talking about… it maybe again.. I would have.. 3509 
agreed.. there was a.. chance.. that I.. may have OK that’s fine.. probably with the 3510 
computer dosing rather than exactly.. questioning and these things. 3511 
INTERVIEWER: OK. 3512 
TAJ: so that is something.. er I would just like to say at this point. 3513 
INTERVIEWER: alright. so any other disadvantages.. with the computer dosing? 3514 
TAJ: …..mmm.. I don’t see any major difference or any.. sort of er..... at this point.. to 3515 
bring out as far.. 3516 
TAJ: because… most of the time.. we… we are not.. errr… and… advantage an’ 3517 
another thing that.. you don’t (laugh) have to.. wait for the doctor’s time to.. calculate.. 3518 
he has to just… agree. 3519 
INTERVIEWER: yeah. 3520 
TAJ: er… heee.. er.. doesn’t need to think.. 3521 
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INTERVIEWER: (laugh). 3522 
TAJ: err.. (laugh) about going through.. er. 3523 
INTERVIEWER: so.. ummm.. err do you recommend this.. computer dosing to.. would 3524 
you recommend that to other clinicians in the same area of congenital heart disease? 3525 
TAJ: …… um…. er.. I think it….. e’ e’.. probably needs more time or more… to 3526 
establish.. that it is yes.. it is.. convenient. 3527 
TAJ: in the sense that you… sometimes you can prescribe.. and there is very little sort 3528 
of err.. discrepancy if there is any… those.. few occasions where I change the dose.. 3529 
again.. that may happen with my other colleague..  he may have.. have agreed.. so 3530 
computer dosing I feel is um.. err…… quite appropriate um.. I think it is.. but it is.. 3531 
difficult to say whether err.. 3532 
INTERVIEWER: to be applied like in the usual.. 3533 
TAJ: (at the same time) to be applied completely.. ye’.. 3534 
INTERVIEWER: (at the same time) usual clinical care? 3535 
TAJ: e’ in in practice.. but um… again it seem whatever.. I think e’ it is.. very forward.. 3536 
it can be.. a replacement.. without.. because if doctor is not.. the point where.. I think 3537 
we should be aiming at that.. there isn’t any need for doctor… still we are cross 3538 
checking so there hasn’t been any independent prescribing but er.. so if that is the case.. 3539 
still I think it is it is um.. probably very forward… because.. mm we have only few 3540 
occasions.. where we need to change the dose so that means it is er.. in vast majority it 3541 
is quite applicable.. and umm.. err.. it’s fine and even.. if.. we take it that few occasion 3542 
where I have to change the dose.. if would.. would happen with.. with other colleague or 3543 
with.. you know.. sometimes.. 3544 
INTERVIEWER: yeah of course. 3545 
TAJ: you have.. so you do see.. um um.. sort of fluctuation in INR anyway.. in normal 3546 
prescribing.. 3547 
INTERVIEWER: yeah. 3548 
TAJ: so if computer is.. prescribing and then you see that fluctuation… that is again.. 3549 
we we can increase sort of margin of safety accepting slightly higher dose or higher 3550 
range.. for those valve group.. 3551 
TAJ: where.. we can.. we know there isn’t.. there is not much risk of high INR.. or there 3552 
is greater risk of low INR so if you put a higher.. range.. then you have an.. computer 3553 
dose pre’ prescribing would be even more safe.… because you.. are then not going low. 3554 
INTERVIEWER: alright yeah. 3555 
TAJ: so that err.. in that ca’.. in few cases where you can just.. give a more safety 3556 
margin.. and then you can accept this computer prescribing.. in practice sort of.. errr as a 3557 
way forward. 3558 
INTERVIEWER: alright. So like um do you prefer it like to.. um.. to replace the doctor 3559 
dosing.. totally or like to be in combination like a computer dose plus… doctor’s.. 3560 
TAJ: yeah.. 3561 
INTERVIEWER: judgment? 3562 
TAJ: yeah until we all (laugh) until we have.. er.. as I said it looks quite acceptable.. it 3563 
looks umm comparable… with err few exceptions which is again which can happen in 3564 
normal practice.. soo.. it can replace.. it can replace doctor prescribing.. because it’s 3565 
um.. errr… there isn’t err.. a sort of.. risk of harm.. 3566 
TAJ: or there is very minimal risk of harm if we jus’… address with few sort of err 3567 
situations where we can avoid that.. I think computer.. can computer dose pres’ 3568 
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prescribing can be.. a good practice.. err or as an alternative…. umm.. to doctor’s err 3569 
prescription. 3570 
INTERVIEWER: yeah. 3571 
TAJ: prescribing. 3572 
INTERVIEWER: so umm any other recommendations? Umm regarding this computer 3573 
dosing? 3574 
TAJ: ….. umm…… mm…… I think that er….. I’m not sure whether we have any data 3575 
of… errr.. you know this monitoring thing.. the space… space thee you know this um… 3576 
checking of.. umm this.. INR monitoring thing.. we can.. as a firs’ step.. we can do.. less 3577 
frequent monitoring for.. especially for those cases.. errr who have stable INR or these 3578 
things… e’ prescribe by the computer I don’ know how.. you determine that 3579 
monitoring.. so if we.. 3580 
INTERVIEWER: so’ sorry do you mean the interval.. of the.. 3581 
TAJ: (at the same time) interval of.. 3582 
INTERVIEWER: (at the same time) INR monitoring? 3583 
TAJ: yes.. interval of.. 3584 
INTERVIEWER: it doesn’t give the.. the interval of monitoring it’s it depends on my 3585 
judgment so and it depends on how stable is the patient. 3586 
TAJ: so who who is er picking up all case.. do in three days or two days.. or one week 3587 
or two week? 3588 
INTERVIEWER: er it’s me. 3589 
TAJ: yeah. 3590 
INTERVIEWER: yeah. 3591 
TAJ: so if we.. change that or we.. increase that sort of err umm interval.. 3592 
INTERVIEWER: increase the interval? 3593 
TAJ: interval.. and see the stability.. because more frequent you err check more frequent 3594 
you do the changes. 3595 
INTERVIEWER: yeah. 3596 
TAJ: accepting a bigger range…. and.. er.. e’.. differing or changing the interval.. 3597 
TAJ: to err sort of err.. e’.. longer period.. 3598 
INTERVIEWER: yeah. 3599 
TAJ: … err to start with.. and that probably.. an’ then.. in few months we may.. er.. 3600 
INTERVIEWER: yeah. 3601 
TAJ:  feel that it maybe.. 3602 
INTERVIEWER: we’ve got yeah this problem because umm umm.. the.. practice is 3603 
different from you know.. from research um because it’s a research so when the INR is 3604 
just out of the range I have to do like.. monitoring more frequent.. because.. I have to be 3605 
stringent with my target range but in practice it’s.. different so you may go for… 3606 
TAJ: yeah. 3607 
INTERVIEWER: a longer.. you know longer interval and just.. accept that dose.. but 3608 
because of.. research purposes so.. we are doing a study so we need to know.. how.. 3609 
efficient is the computer in adjusting the dose.. so that’s why we are umm… dosing 3610 
more frequently.. in some cases. 3611 
TAJ: yeah. 3612 
INTERVIEWER: but again if it is stable and it is within range for some people so we do 3613 
like a wider range.  3614 
TAJ: yeah if we incre’ if we widen the range.. probably that would help.. in reducing 3615 
you know.. checking the.. monitoring thing.. and that would also relax.. because e’ in 3616 
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practice I do see.. bigger range.. even they’re fluctuating.. we put a target range… two 3617 
to three two to four.. and then.. we see it is going to 4.4 or 4.5 or.. it is till acceptable. 3618 
TAJ: ya you can bring it down.. 3619 
INTERVIEWER: yeah. 3620 
TAJ: but it is still acceptable… er.. but in few cases especially in.. valve cases you don’t 3621 
want it to go… lower than certain.. so if we put.. sort of higher range.. from 2 to 5.. 2 to 3622 
4.5.. 3623 
TAJ: because we know we.. I have not seen a single bleeding with 5. 3624 
INTERVIEWER: OK. 3625 
TAJ: few exceptional cases you have to do individual monitoring.. 3626 
INTERVIEWER: (at the same time) so it all depends on.. 3627 
TAJ: (at the same time) you can.. leave them.. 3628 
INTERVIEWER: (at the same time) practice. 3629 
TAJ: (at the same time) yeah so if we increase the range.. bigger range.. wider range.. 3630 
that would.. relax the dosing even.. we know we are.. and we just.. up the lower… limit. 3631 
TAJ: OK it has to be above say.. 2.5. 3632 
INTERVIEWER: OK.. the lower limit is going up. 3633 
TAJ: yeah so we know.. there is a safety margin added.. that even if it goes below.. 3634 
lower than that or.. fluctuates within.. that narrow INR.. still it would be.. not very low.. 3635 
and then.. upper limit we increase extend it too.. yeah.. so that would er.. and then we do 3636 
less frequent monitoring.. 3637 
INTERVIEWER: yeah. 3638 
TAJ: maybe that would…. umm.. that would er relax the dosing sort of thing… I think 3639 
still we do.. frequent monitoring.. I would like to say that.. even for valves.. it should be 3640 
more than two weeks…. ideally I would la’.. 3641 
INTERVIEWER: er is it like the.. is that the doctor’s.. prescribing.. or the computer’s 3642 
prescribing? 3643 
TAJ: … e’ it’s the practice here I would say.. it’s just the practice. 3644 
INTERVIEWER: so you would like to make it longer? 3645 
TAJ: yeah.. ideally two weeks minimum.. er er for the for the valve thing.. e’ in in 3646 
obviously in Fontan group three weeks four weeks monitoring is.. reasonable. 3647 
INTERVIEWER: alright.. alright. Do you have umm any other comments that you 3648 
would like to add? 3649 
TAJ: .. I think  I have (laugh) said what I.. err had to say.. that’s err .. these are the only 3650 
things. 3651 
TAJ: thank you for giving this opportunity. 3652 
 3653 
C- Nurses’ interviews 3654 
 3655 
1- Interview number 5: HCP3 3656 
INTERVIEWER: umm.. hello.. 3657 
Shirley: Hi. 3658 
INTERVIEWER: and thank you so much for agreeing to take part in my research.. err.. 3659 
the purpose of our meeting is to talk your.. experience with warfarin dosing and.. 3660 
monitoring before and.. after using the new warfarin dosing model.. err.. so first I would 3661 
like to set  the new warfarin dosing model aside and.. I would like that.. umm.. you let 3662 
me know.. err.. about.. the general approach that is being used for warfarin.. dosing and 3663 
monitoring and your.. role in this process. 3664 
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Shirley: OK.. umm… I think the way that families have been recruited has been really.. 3665 
really good.. umm.. I think there’s probably… family who.. ‘a migh’ be.. probably 3666 
wouldn’t ‘ve recruited.. umm.. who.. e e.. you know.. had maybe not been too compliant 3667 
beforehand.. umm.. so I think them so’ of joinin’ the study…. I probably would ‘ve 3668 
said.. no.. bu’ I think the process for the other families has been fine.. I think it’s been a 3669 
good mixture of families as well.. umm.. 3670 
INTERVIEWER: err.. excu’.. sorry.. 3671 
Shirley: it’s OK. 3672 
INTERVIEWER: err.. I just need to.. to know the.. approach.. the usual approach used 3673 
in warfarin dosing and monitoring before.. err.. 3674 
Shirley: err.. sorry.. 3675 
INTERVIEWER: the trial. 3676 
Shirley: OK.. 3677 
INTERVIEWER: it’s alright (laugh). 3678 
Shirley: so beforehand.. umm.. obviously if if patients who are going to start on 3679 
warfarin.. umm.. we would see them in the.. pre-operative clinic.. 3680 
Shirley: umm.. give them some.. written information about.. warfarin.. umm.. effects of 3681 
it.. umm.. and go through all that information with them.. and then when the patient 3682 
came to the ward.. um.. after surgery.. umm.. we would again if.. go through tha’ 3683 
information with them.. umm.. so if they’ve go’ any questions.. and then.. if the family 3684 
were wishin’ to do home monitorin’.. umm.. then we would go through the trainin’ 3685 
package for doing home monitoring for them. Some families don’t wish.. to do tha.’.. 3686 
umm.. for various reasons.. umm… some families jus’ don’ want to be.. pricking the 3687 
child’s finger.. 3688 
Shirley: umm.. jus’ say no they’d rather.. you know.. we.. we did it.. umm.. some 3689 
families have gone to the local hospitals although that’s sometimes qui’ difficult to try 3690 
to organise that ‘cause a lo’ of centres will only see.. adults not children.. umm.. or 3691 
they’ll have set times for the GP surgery or the.. hospital.. which again is a down side 3692 
for families because.. they ‘ve had pos’ take time off work or time off school to actually 3693 
go.. to those appointments.. 3694 
Shirley: umm…. So that’s th’.. the way that we see the families all families who.. err.. 3695 
all children who are gonna start warfarin would see all those families and hopefully 3696 
we‘ve met them ‘n give them the information beforehand.. 3697 
Shirley: umm.. weee….as a… as East Midlands team.. we.. prescribe for all of our 3698 
families.. so I know in some centres the.. umm.. children refer refer back locally.. umm.. 3699 
to the local hospital and they would do the dosing bu’ where if e’ families are within the 3700 
East Midlands.. umm.. our doctors here would still continue to do the.. the dosing.. 3701 
Shirley: whether they would being home monitored or they were.. umm.. bein’ tested 3702 
elsewhere.. 3703 
Shirley: umm… we do have a couple of families who.. do actually get dosed by the 3704 
local hospitals as well but the majority.. umm.. stay.. stay with us.. and stay with us 3705 
untill they’re 18..umm.. and then transfer of it to adults services which is another issue.. 3706 
(laugh) 3707 
Shirley: umm.. so.. umm…. So if the families who who are gonna do the home 3708 
monitoring.. we would do.. the training package which would normally be probably sort 3709 
of 3 training sessions with them.. 3710 
Shirley: we have a contract.. umm.. that families need to sign to say that they will.. 3711 
umm.. do the testin’.. umm.. to say that they will bring the machine to back in for 3712 
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comparison check against our machines.. the GP has to be in agreement.. umm.. that 3713 
they will prescribe strips for them.. 3714 
Shirley: so the machines get bought for us by charity.. umm..  but the strips have to be 3715 
prescribed by the GP.. 3716 
Shirley: we did have an issue with that a number of years ago when tha’ lots of GPs 3717 
would say they wouldn’t prescribe them.. because.. umm.. they’re already provided in 3718 
anticoagulation service the GP practice.. 3719 
Shirley: and therefore.. they were prepared to then be payin’ up for prescriptions.. for 3720 
wha’ they source of separate service.. 3721 
Shirley: that changed and.. umm.. certainly there was a new agreement with the 3722 
Leicestershire GPs.. that they would all sign up to.. to children havin’ the.. the warfarin 3723 
strips.. and I think that.. umm… that ‘ad sort o’ come from the government.. umm… but 3724 
it’ll als’.. sorry from the company.. umm… but it’ll also from sort of charity isn’ that as 3725 
well.. umm.. so that they change so we don’ have the promise that we used to have 3726 
with.. umm… GPs saying… though we won’t do the testing… 3727 
Shirley: which for some families was.. was… you know.. a nightmare really trying to 3728 
get here.. 3729 
INTERVIEWER: so in your experience.. errr… with the families.. errr.. do you usually 3730 
see that it’s easier for them to check at home or it’s.. easier for them to.. go.. or to  check 3731 
locally? 3732 
Shirley: I think it’s easier for them to check a’ home because they can.. they can do it 3733 
before school after school before work after work.. 3734 
Shirley: so that they’re not takin’ time off work or school.. they.. barin’ in mind that 3735 
families ‘ve.. had a huge amount of time off work or school to be in hospital anyway.. 3736 
Shirley: umm… I think if the children are poorly or they ‘ve started medication then 3737 
obviously we’d say to check sooner.. which again.. if that’s the weekend.. that’s a 3738 
problem if.. if they’re goin’ locally ‘cause clinics are usually jus’ Monday to Friday.. 3739 
Shirley: umm.. if they’re goin’ on holiday.. they can take the machine with them.. bein’ 3740 
in this country or.. or abroad.. umm.. so I think the machines make made a huge 3741 
difference.. 3742 
INTERVIEWER: alright. 3743 
Shirley: I think certainly when I firs’… started in this role.. all the families had to go to 3744 
the local hospital.. or they used to have to travel here for it doin’ so some families will 3745 
travel two hours.. for a blood test n’ then get back home again.. 3746 
INTERVIEWER: oh. 3747 
Shirley: so completely changed people’s lives. 3748 
INTERVIEWER: great.. so.. umm.. now we go to the.. er.. process of warfarin dosing 3749 
and.. monitoring.. errr.. when does.. err.. when do doctors usually start.. warfarin.. for 3750 
patients? 3751 
Shirley: so it depends how they’ve come to us so if it’s a patient who maybe a Kawasaki 3752 
patient.. you wouldn’t.. be.. 3753 
INTERVIEWER: sorry? 3754 
Shirley: the patient with Kawasaki’s.. disease.. 3755 
INTERVIEWER: umhm. 3756 
Shirley: wouldn’t.. they would come in as a.. as an emergency admission so that 3757 
wouldn’t be.. somethin’ that you’ve planned for in advance.. umm.. so they would.. start 3758 
that when the’.. they are admitted.. umm.. for children where it’s a planned.. umm.. have 3759 
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a valve replacement or for Fontan’s circulation.. umm.. they would be on heparin and 3760 
then they would.. umm.. start the warfarin as soon as they were toleratin’.. 3761 
Shirley: the.. oral feeds.. umm.. so usually a few days post.. post-surgery.. ‘n then 3762 
they’d have an overlap between warfarin and.. the heparin.. umm.. until they get the 3763 
levels.. levels up. 3764 
INTERVIEWER: alright. And.. umm.. err.. how about the.. errr.. INR monitoring and 3765 
dose change changes how often.. err.. are they usually made? 3766 
Shirley: ... 3767 
INTERVIEWER: at the beginning and then.. 3768 
Shirley: at the beginnin’ it’s if.. it’s usually daily.. that they’re tested.. umm.. and then it 3769 
changes to.. either of a few days or a week until they’re nice an’ stable.. umm.. they ten’ 3770 
not to go more than a week.. when they’re… when they’re first.. started.. 3771 
Shirley: umm… and probably a lit’.. a little bit more cautious.. well certainly are a bi’.. 3772 
are more cautious with the.. valve patients than they are the..  say the Fontan circulation. 3773 
INTERVIEWER: umhm. So.. umm.. what’s the reason behind that? Being more 3774 
cautious with valve patients? 3775 
Shirley: some centres don’t actually give.. warfarin for Fontan patients.. umm.. but 3776 
obviously we.. we do here.. ummm.. so their range is lower.. umm.. and.. if their levels 3777 
are lower then it’s not as a disastrous the fact as it would be if you got aee.. mitral valve 3778 
in place ‘n their INR is low.. umm.. which obviously could be.. be disastrous ‘n the 3779 
valve could block off so.. umm.. so that’s why they’re more.. more cautious with them. 3780 
INTERVIEWER: aha. So.. errr.. and.. umm.. what are the obstacles that.. err.. do you 3781 
usually encounter in getting the INR into the target range and in maintaining it.. in the 3782 
target range? 3783 
Shirley: I… th..ink that.. sometimes it’s when your doctor start.. umm.. I think if you 3784 
go’ a new.. wa’.. here.. we only have our cardiology registrars ‘n i’ only the registrar 3785 
who can prescribe...umm.. so the paediatric registrars can’t.. umm.. so again it depends 3786 
how much experience they ‘ve had of prescribin’ warfarin.. umm.. and they’re 3787 
sometimes probably a little bit more.. cautious.. umm would maybe say.. check more 3788 
sooner than…some of the.. more senior doctors.. 3789 
Shirley: umm… umm…..I think some tryin’ to ge’.. sometimes tryin’ to ge’ hold of the 3790 
doctors to actually.. prescribe them.. other tha’ is gettin’ better.. now we all share an 3791 
office together we go’ easier access to them we used to spend huge amount of time to.. 3792 
chasin’ them.. umm…. I think the families ringing in.. umm.. I think initially families 3793 
are very good at ringin’ in.. and… when you say to families well.. you know.. some 3794 
families do not ring for a month or 6 weeks ‘n they meant to ‘n they’ve always shocked 3795 
by tha’.. ‘n then the other ones who.. you know.. you’re ringin’ them sayin’ you’ve not 3796 
checked the dose.. umm.. others are absolutely on the day they’ll.. they’ll phone 3797 
through.. err.. very meticulously.. umm…… I think they are the main problems to.. jus’ 3798 
repeat the question again.. I missed a bit.. 3799 
INTERVIEWER: umm.. (laugh) 3800 
Shirley: (laugh) sorry. 3801 
INTERVIEWER: yeah.. the obstacles in maintaining.. getting the INR into the target 3802 
range and in.. err.. maintaining it.. 3803 
Shirley: yeah. 3804 
INTERVIEWER: in the range. 3805 
Shirley: I think sometimes people…. ‘n again if they don’t know the child sometimes 3806 
will make changes in the doses.. when.. if you actually look back over.. the child’s 3807 
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prescription chart you see they do fluctuate slightly but actually if you leave them.. so 3808 
certainly some of the teenage girls.. ‘n I know that the haematologist will say.. the 3809 
menstruation makes no…. difference to it.. a lot of our girls will say their INR is very 3810 
different when they’re menstruatin’.. ‘n actually if you jus’ look at tha’ pattern bu’ you 3811 
leave them on the same dose.. they will return back to normal.. umm.. but I think people 3812 
who maybe aren’t as.. familiar with them will change the dose.. ‘n then you spen’ weeks 3813 
tryin’ to… ge’ back to where you.. you were to get back into range.. 3814 
INTERVIEWER: umhm. 3815 
Shirley: umm.. ‘n again it tha’ seems sometimes jus’.. tweakin’ little doses or….. do’ 3816 
not realisin’ that actually the.. it’ll take a couple of days to you actually see that effect 3817 
so givin’ the medication checkin’ the next day.. umm.. ‘n then makin’ an’.. another 3818 
change.. before allowin’ that to sort of coming.. I think tha’.. you end up then sort of 3819 
chasin’ your tail.. to try to get back in range. 3820 
INTERVIEWER: so are there like.. err types of.. patients.. or indications I don’t know 3821 
certain conditions.. err… that.. err.. might affect.. the INR stability? 3822 
Shirley:…. So again if a child go’ an infection.. umm.. or startin’ antibiotics.. umm.. we 3823 
do find when children go on holiday.. if they’re eatin’ different.. things as well on 3824 
holiday or.. drinking.. so the.. teenagers who might be having the.. a drink.. umm.. so 3825 
they’ll have an effect on it as well..  3826 
Shirley: umm.. sometimes people do mit.. miss a dose.. ‘n I have ‘o say mos’ of our 3827 
parents are very honest ‘n ‘ll say.. completely forgot to givin’ the dose at the weekend 3828 
so.. again we’d rather know that.. when you… when you’re dosin’ to know that they’ve 3829 
missed the dose rather than.. you know.. altering’ a dose thinkin’ you’re not givin’ the 3830 
correct one.. 3831 
Shirley: umm..  I think some of the teenagers when the parents are tryin’ to get them to.. 3832 
umm… to s’.. to start takin’ control of their own medication.. they will often forge’ er.. 3833 
forget the dose.. but again.. they tend to be fairly honest ‘n say.. I forgo’ to take it.. 3834 
INTERVIEWER: (laugh). 3835 
Shirley: ummm…so… that the main thing I think.. yeah.. holidays.. food diet.. 3836 
Shirley: changes in diet.. babies’ weaning.. umm.. ‘n we haven’ got many youn’ babies 3837 
on.. warfarin I think we probably only go’ one….. I can say under one bu’ actually he’s 3838 
over one now.. umm.. but certainly.. know tha’ er as a baby.. he was very difficult to 3839 
tryin’.. manage his levels.. umm.. 3840 
Shirley: obviously as he was growin’ ‘n ‘en he started his weaning diet ‘n.. umm.. ‘n he 3841 
was changin’ formula feeds as well which.. umm…  3842 
Shirley: obviously the content of the formula feeds ‘n they‘ve got vitamin K in…. 3843 
so…umm..  it’s jus’ those sorts of things will change it. 3844 
INTERVIEWER: alright.. and.. yeah how about.. errr… now the process of… errr… 3845 
the.. process of.. ringing in the  INR and then that  process of.. prescribing and.. er.. 3846 
getting back to patients the compliance of both patients and the.. all this process.. 3847 
Shirley: um. 3848 
INTERVIEWER: ummm… do you usually encounter any difficulties in that? 3849 
Shirley: .. hh… I think sometimes it’s volume of calls.. we get.. (laugh).. 3850 
INTERVIEWER: (laugh). 3851 
Shirley: I think that certainly increased.. umm.. you know when I think.. when we first 3852 




Shirley: umm.. ‘n then number of calls we get now so like some days we can have 3855 
maybe 25 calls in a day.. umm… which barin’ in mind that’s.. part of our extended part 3856 
of our role it consumes a huge amount of time.. umm.. I think tha’ probably there is a 3857 
need for an anticoagulation.. service.. umm… I think..ye’.. you know..  if you takin’ 3858 
the.. amount of trainin’ that’s havin’ with families ‘n callin’ them back to recheck the 3859 
machines.. err.. takes a huge amounts of time so.. it is time consumin’ umm.. I think 3860 
families get to know us though.. when we are phonin’ them ‘n I I think they like.. tha’.. 3861 
that is a regular person contactin’ them.. I think.. families are… we’ve certainly got 3862 
some families who are very good ‘n ‘ll say.. this is what their INR is today this is what 3863 
they‘ve been havin’ this is what I think they should have.. ‘n ‘en the doctors ‘n ‘ll say.. 3864 
umm yeah that’s yes I agree with that.. 3865 
Shirley: so.. ‘n they usually correct.. 3866 
INTERVIEWER: aaa..  3867 
Shirley: umm.. 3868 
INTERVIEWER: the families are usually correct? 3869 
Shirley: they are.. they are.. yeah.. 3870 
INTERVIEWER: sorry to focus on that point.. why do you usually.. err.. why.. do you 3871 
think that they are correct? in deciding the dose? 3872 
Shirley: I think because they’re looking at… they know the child the best they.. they…. 3873 
I think look a’ wha’ pattern there’s been I suppose to maybe jus’ lookin’ at the last 3874 
couple o’ doses.. 3875 
Shirley: I think they look back ‘n say.. well you know… we dropped before.. this is 3876 
wha’ happened.. de de de.. be stayed on this dose.. ’n ‘n we went back to it.. so.. I don’t 3877 
know I think they just… seem to know better.. 3878 
INTERVIEWER: (laugh). 3879 
Shirley: ‘n I think… I think parents probably don’.. change the doses as much as.. the 3880 
doctors would do.. 3881 
Shirley: I think parents are often… are happier to say well actually.. it’s dropped 3882 
before.. umm.. we left it at this.. ‘n i’ jus’ went back.. umm.. whereas I think we’re 3883 
probably a little bit more cautious ‘n think OK we will change i’.. umm.. but then often 3884 
it’ll be out of range though. 3885 
INTERVIEWER: aha. So.. so.. err.. who do you think is the best judge is it the parent or 3886 
the doctor? 3887 
Shirley: …. Have to say for the parents who actually.. leave the doses the parents are 3888 
normally right.. (laugh). 3889 
INTERVIEWER: (laugh). 3890 
Shirley: for the fear tha’ we have.. who say what they would.. I think they are.. usually 3891 
right.. I think umm…. I think there are exceptions.. umm… to it.. umm.. ‘n some.. 3892 
INTERVIEWER: do you have many of those families that do.. their own dosing? 3893 
Shirley: hhh… there are a couple of teenage.. umm.. ones ‘n some younger ones where 3894 
the.. families are doin’ it.. umm.. what we’ve said is that we.. that the consultant has to 3895 
say.. that they are agreein’ to it.. umm.. because again.. part of the agreement when they 3896 
sign the contract it said they’ll phone in ‘n we do the dosin’.. umm.. so in those 3897 
situations when families ‘ve said well I.. I don’t want you to do the prescribin’ because I 3898 
think… mine is correct.. 3899 
Shirley: we’ve said that the consultants must write ‘n say that they agree to the family.. 3900 
doing it ‘n that is then not our responsibility or the registrars’ responsibility.. 3901 
INTERVIEWER: so it’s the responsibility of the family? 3902 
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Shirley: the family and the consultant who’s agreed i’.. umm.. so.. yeah. 3903 
INTERVIEWER: and how about the others who are on who follow the doctor dosing 3904 
are.. how.. how is their INRs?.. stability? 3905 
Shirley:… I think it’s a mixture I think there ‘r some.. some children ‘r absolutely 3906 
beautifully.. stable.. 3907 
Shirley: umm.. you know ‘n they’re bein’ tested every.. you know say the Fontans 3908 
they’re bein’ tested every month.. ‘n they ‘ve been on the same dose for ages maybe till 3909 
they ‘ve a growth spurt ‘n then they we need to increase them so I think there is some 3910 
patients who were.. beautifully stable.. I think they are all the patients who.. nothing 3911 
changes the diet doesn’t change they ‘ve not ‘ad a growth spurt.. and they.. just.. are not 3912 
stable ‘n we.. we don’t know why.. 3913 
Shirley: ummm… you know I can think of a teenager patient who ‘ve had who.. her 3914 
dose goes up ‘n down all the time she’s adamant that she takes it when she’s.. 3915 
INTERVIEWER: sorry? 3916 
Shirley: she’s adamant that she.. takes the dose.. umm.. bu’ her levels were dropped 3917 
really low.. ‘n then the next thing they really high..Shirley: umm… one of th’ things we 3918 
looked at a one stage was she had actually changed her tablets of.. rather ‘an havin’ 3919 
just.. one milligram tablet.. she’d gone to havin’ some 5 milligram tablets as well.. 3920 
Shirley: umm.. ’n there was a change in her actual.. umm… warfarin level her INR 3921 
then.. umm.. so we didn’ know whether there was…. e’.. we.. we didn’ think it should 3922 
‘ve made a difference ‘cause she was still actually getting’ the same amount of 3923 
milligrams.. umm… bu’ i’.. the.. change seem to coincide with the change in the actual 3924 
tablets.. so.. we couldn’ prove tha’ bu’ i’.. you know.. 3925 
Shirley: they coincide.. ummm…. bu’ ‘n I don’ know why some patients just 3926 
are….beautifully stable.. ‘n others.. er.. are no’. 3927 
INTERVIEWER: dose it have a relation with their… errr…errr.. indication of why they 3928 
are taking warfarin? 3929 
Shirley: …. I would say the Fontan patients are probably more….stable.. but I think 3930 
that’s maybe because they are not tested as frequently.. 3931 
Shirley: whereas the valve patients are tested more frequently ‘n I think sometimes there 3932 
is more.. room there for… changes in the dose… which then affects.. the range.. so.. 3933 
ummm…. yeah.. yeah. 3934 
INTERVIEWER: in your experience is there any specific reason of why those patients 3935 
with valves have this fluctuating INRs? And unstable.. INR.. control? 3936 
Shirley: I can’ think of a reason.. no.. we jus’.. they jus’ seem to.. ‘n whether it is the.. 3937 
the.. they’re testin’.. more regularly ’n therefore the doses changin’.. bu’ in some 3938 
patients it’s changin’ more regularly.. 3939 
Shirley: umm…because I believe in adults.. they don’t test as frequently.. umm.. 3940 
INTERVIEWER: er adults with valves? 3941 
Shirley: adults with valves.. yeah.. ummm.. ‘n whether they are more stable or no’ I 3942 
don’ know.. ummm.. but I know tha’.. w’.. s’.. certainly for children we’d say to test 3943 
more frequently than the adults do.. 3944 
Shirley: umm.. so.. whether this is a good thing or a bad thing I don’ know if they’re.. if 3945 
they are stable. 3946 
Shirley: ummm… you know bu’ i’ get.. if you get a result.. you’ve obviously got to 3947 
react to tha’.. the result that you get.. ummm… but.. um.. I guess it goes on.. in between 3948 
those.. two measurements you’ve got you don’t know you know it could adopted to lot 3949 
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lower in between.. ummm… so.. I don’ know why in some it is.. isn’.. isn’… don’t 3950 
know. 3951 
INTERVIEWER: alright. Umm.. OK. So.. er.. now.. I would like to.. talk a bit about the 3952 
new warfarin dosing model so could you please let me know about.. errr… er.. your 3953 
experience so far with this.. new dosing model? 3954 
Shirley: OK. Umm….. I think.. from wha’ I can see.. is the… the computer dosin’ for 3955 
patients who are on warfarin… I think they are nice ‘n stable.. ‘n I think they.. they are.. 3956 
I think it’s workin’ really well.. I think for the valve patients… for some patients again 3957 
it’s working really well.. for others.. umm… I don’t think it is ‘n I know there is a few 3958 
occasions when we’ve.. overridden.. the computer dosin’.. umm.. you know if ‘e levels 3959 
‘ve been low.. ummm… then.. the computer is jus’ at all give another dose.. whereas 3960 
actually.. we would ‘ve maybe givin’ some.. some dalteparin or givin’ a bigger dose.. 3961 
Shirley: umm.. so know i’ has been overridden.. umm… so.. ‘n I think…. for most 3962 
families it’s been.. they’ve been fine it’s been fairly stable I think there are.. a couple 3963 
who’ve.. (laugh) done their own thing.. 3964 
INTERVIEWER: (laugh). 3965 
Shirley: which obviously doesn’ help the study.. 3966 
Shirley: umm…. there are a few families who’ve questioned when we’ve said well the 3967 
computer doses ‘n..‘n.. again ‘ve said well actually we’d been on this dose for a certain 3968 
amount of time why ‘as the computer changed it.. 3969 
Shirley: umm... bu’ when we’ve explained to ‘em well it’s.. it’s part of the study and 3970 
you know.. it may be different what we would ‘ve given…but actually.. that is part of 3971 
the process that’s what we are trying to compare families have been fine with tha’.. 3972 
umm.. certainly if they ‘ve no’ been then we’ve come back ‘n.. that you talk to the 3973 
doctors ‘n said.. there is families ‘ve said they’re not happy with this dose they already 3974 
is gonna go one way or the other.. umm.. bu’ I think most of ‘em.. ‘ve sort of accepted 3975 
tha’.. that’s what the computer said so we jus’.. they’d go with it..  3976 
INTERVIEWER: so.. ummm.. are there any.. errr… or errr… could you please let me 3977 
know about advantages and disadvantages of this.. er.. er.. dosing model? 3978 
Shirley: ..hh..umm.. I think for some patients.. ‘i.. it’s… been dosin’ more frequently.. 3979 
umm.. ‘n certainly there is a.. tha’.. the little one I was talkin’ about his.. his dosin’ on 3980 
the computer system initially was.. umm.. he was been tested everyday.. umm… 3981 
whereas.. I think if the doctors done i’ we wouldn’t have done it everyday.. 3982 
Shirley: umm.. ‘n think our concern form tha’ point of view was.. umm… his mum said 3983 
he’s not bothered about i’ ‘n it doesn’ bother him but I think we w’.. we were on long 3984 
term the effects of having it… been for you.. dosed up everyday.. umm.. so I think tha’ 3985 
was one worry was sort of highlighted tha’ was very frequent tha’ was bein’ tested.. 3986 
Shirley: umm.. bu’ equally.. his does.. his.. his INR does.. fluctuate a lot as well.. ‘n 3987 
whether that’s because of his age ‘n obviously they’ve been changin’ diet because of 3988 
he.. he’s weanin’ ‘n he’s growin’ I don’t know.. umm……. I think that’s the main.. the 3989 
main thing really.. I think this.. this.. 3990 
INTERVIEWER: the main disadvantage. 3991 
Shirley: ..yeah I think that’s it that was disadvantage was the more.. more frequent.. 3992 
well then tha’ probably is balances out with.. some of the other doctors who.. you 3993 
know.. so he probably fairly even I guess tha’.. tha’ particular patient jus’ brings to 3994 
mind.. 3995 
Shirley: umm.. because it was frequent ‘n we were.. we were concerned about i’.. umm.. 3996 
INTERVIEWER: so it was for that one particular patient.. 3997 
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Shirley: yeah.. 3998 
INTERVIEWER: what about.. for.. the others? 3999 
Shirley: to the others it’s.. again it’s sometimes more frequent than we probably would 4000 
‘ve done certainly for the Fontan patients who.. maybe would ‘ve ‘n normally done 4001 
every month.. umm sometimes they’ve been more frequent.. 4002 
Shirley: umm.. then for other patients it’s been.. umm.. you know they’ve been given 4003 
longer than perhaps the doctors would ‘ve given so.. 4004 
Shirley: ummm…. but I think for the.. I think the ones who’ve been stable.. umm tend 4005 
to be the Fontan patients more than the valve patients.. 4006 
INTERVIEWER: again Fontans are more.. (laugh) 4007 
Shirley: yeah. 4008 
 INTERVIEWER: more stable than the valve.. (laugh). 4009 
Shirley: yeah. 4010 
INTERVIEWER: OK.. err..so.. umm… err.. do you recommend this dosing.. err.. model 4011 
for other clinicians in the same.. area?.. the congenital cardiac.. patients? 4012 
Shirley: yeah….. I think for s’.. for some patients I think it has worked... I think for 4013 
others… I don’ know the.. the research may show differently maybe jus’ be my 4014 
experience from looking at the charts.. umm… I guess we have to look at the.. the valve 4015 
patients to see whether…. to do tha’ proper comparison ‘n ‘en to see.. to see who’s 4016 
more.. I do’.. I don’ think there is…. the computer system has not…. I don’ believe pu’ 4017 
anybody in danger.. 4018 
Shirley: umm.. by doin’ i’ I think there are.. obviously a few occasions where we’ve.. 4019 
we’ve questioned that it’s not said give dalteparin or give a higher dose.. umm... but I 4020 
think… you would always have that fail safe... anyway.. 4021 
Shirley: ummm…. don’ know I think it seems to ‘ve worked.. worked well… yeah. 4022 
INTERVIEWER: OK. So.. umm..do you have any recommendations to... for this model 4023 
to make it work better? 4024 
Shirley: ….. umm…….. I can’ think of any (laugh) 4025 
INTERVIEWER: laugh 4026 
Shirley: laugh. I can’ think of any no.. er apart from maybe having a designated 4027 
anticoagulation service would be lovely..  4028 
INTERVIEWER: laugh. 4029 
Shirley: ‘n then having tha’.. havin’ tha’ model  with… you know with tha’ because 4030 
think.. I think it’s been… hugely time consuming.. 4031 
Shirley: umm.. ‘n think certainly when I.. I agreed to (nurse).. umm.. doin’ the project I 4032 
didn’ realise it would be.. quite as time consuming as it.. as it was.. umm... but actually 4033 
if the end result is going to be good and it’s move the service forward or actually shows 4034 
that.. you know yes we do need a dedicated service.. I think that’s really positive.. I 4035 
think maybe jus’ because of our staffing.. levels at the moment.. 4036 
Shirley: umm.. it’s.. it’s obviously had an impact on us.. umm.. but I think if the long 4037 
term.. I.. you know..  4038 
INTERVIEWER: (at the same time) so at the moment does it have a.. 4039 
Shirley: (at the same time) it’s going to improve the care.. 4040 
INTERVIEWER: yeah. 4041 
Shirley: ‘n.. er.. you know ‘n ‘n a better service for families.. then that’ll be.. be good. 4042 
INTERVIEWER: so at the moment does it have like.. er.. a negative impact on your 4043 
service? Or a positive.. does it have like.. err.. putting mo’.. more pressure on you? 4044 
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Shirley: …I don’ think it’s puttin’ more pressure on us I thi’.. I think tha’.. tha’ sort of.. 4045 
e’.. the initial work that (nurse) was doin’ I think it did.. I think the day to day basis 4046 
doesn’t unless.. families are not phonin’ in when they should ‘n it’s in the evening ‘n 4047 
obviously we having to then contact you in the evening.. umm.. or.. but I think most of 4048 
the time it’s.. you know.. either you aren’t around or umm.. you know to return the call 4049 
so it’s not as if we’re waitin’.. for calls comin’ through.. so I think on a day to day basis 4050 
it’s not…. not changed it really.. 4051 
Shirley: ‘n obviously if you are not around you’ve always told us.. you know you’re not 4052 
gonna be around bu’ I’ll be back later on so.. umm.. no I think the dosin’ it’s always 4053 
done in a timely.. timely manner that’s.. that’s not changed so..hh..  4054 
Shirley: hopefully it’ll.. it’ll… improve i’ (laugh). 4055 
INTERVIEWER: hopefully. 4056 
Shirley: hopefully. 4057 
INTERVIEWER: alright. So do you have any other comments that you like to add? 4058 
Shirley: umm.. 4059 
INTERVIEWER: any other issue that.. umm… you.. may.. highlight you would like to 4060 
highlight? 4061 
Shirley:… no I don’t know how much information was.. given to.. sort of the nursin’ 4062 
staff on the ward ‘n tha’.. before it started I don’.. I don’t know.. umm.. because you 4063 
know some of the.. the times we found is that the.. the families have phoned in over the 4064 
weekend.. is that.. the staff ‘ve got the.. doctors to.. prescribe it.. umm.. ‘n then realised 4065 
afterwards that.. although I’ve done that sometimes as well.. umm.. bu’ then.. umm.. so 4066 
it’s only then when we picked it up after the weekend we realise actually the doctors 4067 
have prescribed it rather than the computer.. 4068 
Shirley: umm… so umm… I’m not sure how much.. they were aware or whether it’s 4069 
jus’ because they’re busy it’s jus’ consumedly do the INRs.. 4070 
INTERVIEWER: yeah. 4071 
Shirley: because again the doctors were aware so the doctors who are prescribin’.. 4072 
should see on the system I think the system worked quite well with the stickers on the 4073 
folders that is clear.. umm.. who’s supposed to be doing it so.. bu’ I think that’s 4074 
probably.. maybe skewed some of your figures.. (laugh) 4075 
INTERVIEWER: yeah. 4076 
Shirley: a bit so.. 4077 
INTERVIEWER: we’ve got those incidents. 4078 
Shirley: yeah.. yeah.. umm…… no can’t.. can’t think of anything else.. no. 4079 
 4080 
2- Interview number 6: HCP4 4081 
 4082 
INTERVIEWER: umm.. hello. 4083 
MADISON: hello. 4084 
INTERVIEWER: and thank you so much for agreeing to take part in my research.. err.. 4085 
the purpose of our meeting is to talk about.. your experience with warfarin dosing and 4086 
monitoring.. err.. before and after using the new warfarin dosing.. model.. umm.. so.. 4087 
err… at first please let’s set.. the warfarin dosing model apart.. could you please let me 4088 
know about the overall approach.. er.. that is being used in warfarin dosing and 4089 
monitoring? 4090 
MADISON: err.. yes it’s OK….. for me this is.. this interview is really simple.. right? 4091 
… when it comes to the machine.. the computer dosin’.. the patients.. 4092 
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INTERVIEWER: err sorry.. err.. I.. I just need to know the.. usual process.. 4093 
MADISON: Oh the usual process? 4094 
INTERVIEWER: yeah. 4095 
MADISON: well the usual process is… (cough) excuse me.. (cough).. parents call 4096 
through the INR.…we listen to the answer phone message.. we take it down in the 4097 
designated INR diary.. er.. we take out the INR prescription charts.. we write down.. 4098 
what parents have.. called in.. 4099 
MADISON: we give them to a paediatric registrar.. who does the dosin’… we then call 4100 
parents back.. we tell them how much warfarin their child needs to take.. and when they 4101 
need to re-test. 4102 
INTERVIEWER: err.. so is that process.. always straight forward? Like contacting the 4103 
families and.. 4104 
MADISON: nine times out of ten… i’ only becomes as issue when you’re tryin’ to call 4105 
a parent back.. and they’re not answerin’ their mobile.. or.. the mobile number says.. 4106 
this phone is not available an’ then you’re in panic station thinkin’ how am I goin’ to 4107 
get hold of these parents.. to tell them how much warfarin to give their child and when 4108 
they’re goin’ to retest..and am I goin’ to be able to get hold of them today.. 4109 
INTERVIEWER: umhm. So.. and.. err.. how about the.. err.. families’ compliance 4110 
with.. with what.. you are prescribing? 4111 
MADISON: errr.. there.. are.. a handful of families.. who.. are not compliant.. ummmm 4112 
and there are some families who will.. query what has been prescribed.. because they 4113 
say they know their child better than the person… doin’ the dosin’ ‘n actually for some 4114 
of our parents.. there is a lot to be said for that.. because they do know their children.. 4115 
much better.. and ‘e final ones who… nine times out of ten the parents who do query the 4116 
dose a’ actually the parents who are very compliant. 4117 
INTERVIEWER: umhm… so do you find that.. like those parents who do their own 4118 
dosing.. err.. do you find them right? 4119 
MADISON: errrrr… majority…majority of them. 4120 
INTERVIEWER: so they were right in.. 4121 
MADISON: (at the same time) there’s there’s.. yeah.. the majority. 4122 
INTERVIEWER: so and they getting control of their.. uhm.. sorry.. 4123 
MADISON: yeah.. ‘n they only ring.. when there’s actually an issue when.. it’s out of 4124 
range. 4125 
INTERVIEWER: umhm.. OK. So.. again back to the process of.. of warfarin initiation.. 4126 
err.. right from the beginning of the treatment.. err.. of.. ‘n.. when.. warfarin is.. 4127 
prescribed.. when the patient first start that and your role in this process. 4128 
MADISON: my role? 4129 
INTERVIEWER: yeah.. right from the beginning. 4130 
MADISON: right from the beginnin’.. umm… I find tha’ I have to teach the parentssss 4131 
about.. umm… what warfarin is.. why it’s used…things ‘a can interfere with warfarin 4132 
and… practical things.. umm… like….vitamin K is found in.. for example green 4133 
vegetables.. 4134 
MADISON: umm.. and…. teachin’ them simply tha’.. warfarin is used to thin the 4135 
blood...and…. there are certain food stuffs that contain vitamin K an’ vitamin K clots 4136 
your blood.. aaaannnd.. that… if like me.. you loved broccoli.. 4137 
MADISON: it’s all about consistency so….. dependin’ on.. an’.. an’ it’s not to be used 4138 
as tha’ I always go’ vitamin K an’ I can’ have it.. you can.. but it’s about consistency 4139 
so.. if you always have a cupful of  broccoli.. e’ know if.. if you like broccoli… decide 4140 
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how much you gonna have.. is it gonna be half a cupful or is it gonna be a cupful.. and 4141 
stick to it.. you can’t do wha’ I might do.. 4142 
MADISON: an’ that is at a weekend think Oh do you know what I fancy great big plate 4143 
of bro’ broccoli…’cause I have to teach them that.. your body has got used to… 3 4144 
milligrams let’s say 3 milligrams of warfarin.. 4145 
MADISON:… annnd.. if you star’ havin’… a cupful of broccoli….. your body is goin’ 4146 
get used to that.. however.. at the weekend you think Oh do you know what.. I’m gonna 4147 
have a great big bowl of broccoli.. we’ve just added more clotter….more vitamin K to 4148 
your blood.. 4149 
MADISON: so therefore.. your INR.. is goin’ to be shorter.. so.. it will be.. umm… it 4150 
takes.. less time to clot so it’s goin’ to be….umm.. around one… or..1.2.. or somethin’.. 4151 
umm an’ I find with the older patients uhuhm.. we have to have conversations about…. 4152 
alcohol.. because that too.. has an impact. 4153 
MADISON: and if you’re goin’ to have…umm… a pint o’ beer.. you can always have a 4154 
pint of beer… (cough).. excuse me.. (cough) what you can’t do at the weekend is goin’ 4155 
to have a binge.. that down the pub at the weekend.. because that too will interfere.. 4156 
with your.. warfarin levels.. so it’s a lot of…teachin’ and education.. bu’.. doin’ that 4157 
teaching.. and education in very practical ways.. so that they understand what you’re 4158 
talking about. 4159 
INTERVIEWER: aha. And.. errr.. how.. do you usually find the parents and older.. 4160 
children.. 4161 
MADISON: (at the same time) ummm.. I find.. 4162 
INTERVIEWER: (at the same time) their response to that? 4163 
MADISON: (at the same) that it takes a while for that to register.. I think.. errr.. ‘cause 4164 
they have lots of the other things.. that they need to take on board..  with comin’ to 4165 
clinics and why they’re comin’ ‘n.. you know bein’ stressed out because they might 4166 
need to be.. er.. admitted for a procedure or.. so.. it’s constant ongoin’ education.. that is 4167 
wha’ I find. 4168 
INTERVIEWER: OK. ummm.. and.. umm.. how often.. errrr.. do the INR monitoring 4169 
usually takes.. take place? The INR monitoring and the dose changing.. how often…. 4170 
does that happen? 4171 
MADISON: you mean as per patient? 4172 
INTERVIEWER: yeah. 4173 
MADISON: ummm.. for me.. I find that nine times ou’ of ten.. Fontan patients.. are.. 4174 
quite stable.. aannnd.. err… I think it’s good that the majority.. are… tested once a 4175 
month. 4176 
MADISON:… obviously there are occasions when… you know.. if they’ve had a 4177 
growth spurt.. or… some parents have admitted that they’ve forgotten to give.... 4178 
warfarin.. ummm.. annd.. that does actually have a massive impact that sometimes it can 4179 
take… about a week.. or two before they get back to bein’ stable.. 4180 
MADISON: (cough)… I find… ummmm… patients who’ve got mechanical valves… 4181 
they’re a bit more tricky.. errrr.. ‘cause they seem to get tested… a lot…. and for some 4182 
patients.. I can see.. that they need to be an’ for some others I can’t.. I jus’.. don’t.. get.. 4183 
why they’ve been tested so often. 4184 
INTERVIEWER: umhm. So is there a specific reason behind.. err.. being.. errr.. those 4185 
patients with valves being less stable than those with Fontan? 4186 
MADISON: I have no idea ‘cause I do try to find out I do try to ask why do you think.. 4187 
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MADISON: umm… and…. there is never…. a justifiable reason sometimes I mean.. the 4188 
altercation is ‘cause parents ‘ve said ‘ve forgotten.. to give.. umm…... they never say 4189 
we’ve had too much of broccoli or we’ve had.. too much alcohol I mean.. nine times ou’ 4190 
of ten for some of my.. adolescent patients.. I know… that they’ve been drinkin’.. bu’ 4191 
they are no’ admittin’ to i’.. bu’ you jus’ know tha’ they are. 4192 
MADISON: because over time you get er…. when you look back at the drug chart 4193 
might ‘ve you think mmmm.…effff… it’s called good feeling.. 4194 
MADISON: an’ I know you can’t.. er.. you know…that’s not fact is it? bu’ err…. for 4195 
some patients.. they find it difficult to admit actually.. that’s wha’ I have been doin’. 4196 
INTERVIEWER: ummm…. So is their life style.. errr.. so apart from the life style the 4197 
diet and alcohol and those stuff.. errrr.. er.. is there any like.. medical reason.. behind.. 4198 
or a clinical reason behind those with valves being unstable? 4199 
MADISON: …… I don’t know the answer to that question to be honest.. 4200 
MADISON: I know I know some kids have growth spurts… (cough).. bu’ I do’ I don’t 4201 
know. 4202 
INTERVIEWER: aha. So.. errr.. what are.. usually the obstacles that you encounter in.. 4203 
in getting the INR in range and in maintaining it in.. in the range? 4204 
MADISON: errrrr….… well it’s…… well I don’ know.. what I’ll call an obstacle.. I 4205 
don’t know. 4206 
INTERVIEWER: some patients that are.. harder to maintain their INRs in the range or 4207 
getting them into the range. 4208 
MADISON: (at the same time) there is quite a lo’.. there is quite a few.. mechanical.. 4209 
valve patients.. 4210 
MADISON: umm….. Sometimes it can be I can look at the chart an’ I can think I don’t 4211 
know why that registrar ‘as…. done that dosin’…. an’ sometimes I might say why ‘ve 4212 
you… done tha’. 4213 
MADISON: an’ they have their justification for i’.. I’m no’ a prescriber.. so.. you 4214 
know.. it’s not down to me but I do question.. sometimes.. jus’ like I question some of 4215 
the dosin’ from the.. from the.. errr.. the computer. 4216 
MADISON: ….. sometimes I think I don’t understand why they.. have been.. tested.. so 4217 
often….. um ‘cause I think it’s cruel... to be tested… uhhuhm… every day… or every 4218 
other day…. especially when children don’ like i’… 4219 
MADISON: umm….. but I do see the purpose and the point behind the study.. so.. you 4220 
know.. once we’ve got proof then we we will… know in which direction we’re goin’ 4221 
won’t we? 4222 
INTERVIEWER: yeah.. yeah exactly. Sooo.. yeah.. er.. so do.. do you encounter like 4223 
some.. occasions when the patients are.. errr.. fluctuating in their INRs? 4224 
MADISON: yes. an’ when they’re fluctuatin’ we say to the parents why do you think 4225 
it’s gone up or why do you think it’s gone down.. 4226 
MADISON: parents will say well…. eefff… I told you tha’ the doctor the registrar who 4227 
dosed i’.. you know I’ve said to you it would go.. up or down.. you know.. we shouldn’t 4228 
‘ve done such an’ such.. an’ that’s where sometimes parents actually… do know their 4229 
child better. 4230 
INTERVIEWER: umhm. So is that regarding.. 4231 
MADISON:  an’ sometimes there is no consistency because..  you know.. we are all  4232 
individual people. errr.. some registrars….. because they are all different.. they will 4233 
have their own perspective an’ will see things you know…. some are.. much more 4234 
consistent some aren’t. 4235 
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INTERVIEWER: OK. So.. errr.. again back to my question.. errr… depending on the 4236 
patient’s general condition.. errr.. are there any times that their INRs are fluctuating.. 4237 
apart from their diet or alcohol.. 4238 
MADISON: (at the same time) alright.. 4239 
INTERVIEWER: (at the same time) intake. 4240 
MADISON: you want that when they’re on medication when they’re on antibiotics. 4241 
INTERVIEWER: aha. 4242 
MADISON: yes.. 4243 
INTERVIEWER: OK. 4244 
MADISON: yeah yeah yeah yeah….. I forgot abou’ tha’ yes sometimes.. bu’ we know 4245 
don’t we? well I know.. tha’ if they are on antibiotics an’ I always tell parents.. tha’ if 4246 
your child has started antibiotics.. 4247 
MADISON: you need to ignore the fact tha’ we’ve told you to call to test in two 4248 
weeks.. you need to test it… the day after the antibiotic has been started because we 4249 
know there is going to be a massive change. 4250 
MADISON: an’ when they ring up.. I say… umm… if I’ve told you to ring in two 4251 
weeks but you’ve started…. at the end of this week antibiotics.. I need you to test the 4252 
day after the antibiotic has been given… an’ when you ring up you jus’ say…. umm… 4253 
my child’s INR is such ‘n such ‘n the reason it’s out of range is because he’s 4254 
commenced on amoxicillin 250 milligrams for so ‘n so.. 4255 
MADISON: so that we can see….. why there has been a deviation an’ a change. 4256 
INTERVIEWER: umhm… OK. And.. yeah one more question please.. ummm… I do’.. 4257 
know part fr’.. you’.. is.. your training is training on the INR machine.. errr.. 4258 
MADISON: I was trained by a rep. 4259 
INTERVIEWER: aha. So.. yeah.. I mean training the patients on the INR.. 4260 
MADISON: (at the same time) alright yeah. 4261 
INTERVIEWER: (at the same time) machine.. so.. errrrr… do you find that all families 4262 
like to have the INR home INR.. testing.. machine? 4263 
MADISON: yes they do. 4264 
INTERVIEWER: ummm.. do they find it easy to use? 4265 
MADISON: errrr… 4266 
INTERVIEWER: or they prefer to come to the hospital to check their INRs? 4267 
MADISON: I think….. I think there is only a couple of patients.. who’ve…who’ve 4268 
actually preferred to come to the hospital ‘n.. ‘n get checked. 4269 
INTERVIEWER: aha.. is that.. is.. 4270 
MADISON: ‘n I know a girl who lives in.. who lives down the road from here actually 4271 
‘n she is a.. teenager ‘n she could ‘ve had.. the family could ‘ve had an INR machine.. 4272 
when she was.. umm.. a child. 4273 
MADISON: uhmuhm… ummm….. I know whenn errr…. ‘cause she could ‘ve had a 4274 
home.. machine.. but she never wanted one….. never.. wanted one. 4275 
INTERVIEWER: so.. is there a specific reason behind that? 4276 
MADISON: errrr…. She jus’ doesn’ wan’ ‘o do i’…. she jus’ wants to come here ‘n 4277 
have it done. 4278 
INTERVIEWER: it’s more convenient for her. 4279 
MADISON: it’s more convenient for her to come here ‘n have it done she doesn’t want 4280 
one. 4281 




MADISON: OK. 4284 
INTERVIEWER: so could you please let me know about your experience so far with 4285 
the overall process.. of.. 4286 
MADISON: (at the same time) Fontan patients fantastic.. it’s really good.. errrr.. 4287 
mechanical valve patients… umm.. I don’ like i’. 4288 
INTERVIEWER: OK. Soo.. again I will ask is there a specific reason behind that? 4289 
MADISON: because they have to be tested much more often. 4290 
INTERVIEWER: so.. 4291 
MADISON: one days two days.. 4292 
INTERVIEWER: so.. OK.. so.. as compared with the.. with the frequency of.. err.. 4293 
testing.. err.. according to the doctors’.. err.. prescription.. er.. is it comparable or 4294 
different? do doctors usually do the same or… they tend to less…. err.. frequently 4295 
testing them? the valve patients. 4296 
MADISON: …. hhhh… some patients it’s abou’ the same I think.. if there’s been.. 4297 
‘cause there are some patients who… who are not.. stable at all.. ‘n it’s very difficult to 4298 
work out why they’re not stable.…. Bu’ for those tha’ are…… I think.. the machine… 4299 
still.. ask them to test…much more often.. than what the registrar does. 4300 
INTERVIEWER: OK. So this leads me to another question is that when the INR is just 4301 
out of the range.. err.. I can see sometimes some of the doctors they give the same dose 4302 
they.. still on the same dose for some patients.. 4303 
MADISON: yeah. 4304 
INTERVIEWER: and give a long interval  4305 
MADISON: yeah. 4306 
INTERVIEWER: but for some others they change the dose and test in a shorter interval. 4307 
MADISON: I know they do.. uuhm.. 4308 
INTERVIEWER: yeah.. so.. is there a specific reason behind that? 4309 
MADISON: … you’d have to ask the registrars ‘cause I’m not the prescriber.. ‘n I do 4310 
say to them why ‘ve you done tha’.. ‘n they give me their give me their justification for 4311 
it… sometimes I migh’ agree with i’ sometimes I don’t.. bu’ at the end of.. 4312 
INTERVIEWER: (at the same time) so what type of justification that they usually.. 4313 
MADISON: err.. because it was.. it was.. umm… higher there.. ‘n then it went low.. and 4314 
now it’s just about.. to err.. to sort it out fast we jus’ want to.. check it.. tomorrow.. just 4315 
to see if it’s gonna get back in range. 4316 
INTERVIEWER: umhm.. OK.. and are you convinced with their justification? 4317 
MADISON: sometimes…. Sometimes yes ‘n sometimes no. 4318 
INTERVIEWER: aha. alright. 4319 
MADISON: an’ it’s very difficult to answer.. on a huge population of patients..right? 4320 
INTERVIEWER: umhm. 4321 
MADISON: to answer those.. questions properly you’d have to take.. an individual.. 4322 
INR chart look at it.. look a’… everythin’… an’ then… justify. 4323 
INTERVIEWER: OK. 4324 
MADISON: so.. you know.. broad spectrum very difficult.. to give.. specific answers.. 4325 
because at the end of the day this is about individual.. 4326 
INTERVIEWER: exactly. 4327 
MADISON: patient.. prescription. 4328 
INTERVIEWER: so the judgment depends on the general.. status of the.. 4329 
MADISON: (at the same time) absolutely it’s the individual.. 4330 
INTERVIEWER: (at the same time) the general status.. 4331 
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MADISON: (at the same time) yeah. 4332 
INTERVIEWER: (at the same time) of the.. 4333 
MADISON: (at the same time) of the child. 4334 
INTERVIEWER: (at the same time) of the specific child. 4335 
MADISON: (at the same time) yeah. 4336 
INTERVIEWER: yeah. OK.. errr.. so.. ummm… ummm.. would you.. could you please 4337 
let me know about.. the advantages and disadvantages of this new model? 4338 
MADISON: errrrrr.. it’s all the same to me ‘cause I still have to listen to the 4339 
messages… I still have to get somebody to prescribe i’ ‘n I still have to call the 4340 
parents…. to errr… tell them… what need to take so.. it’s no change for me.. 4341 
MADISON: the only difference is.. instead of… umm.. puttin’ theeeee.. chart.. in.. righ’ 4342 
I still need to put i’ into the registrar’s notes ‘cause he still got to sign the prescription.. 4343 
INTERVIEWER: of course yes. 4344 
MADISON: so for me.. there is.. you know.. it’s no change whatsoever. 4345 
INTERVIEWER: umhm. So regarding.. errrr... the patients.. er.. so this.. 4346 
MADISON: I think the Fontan patients.. err from conversations we’ve had like the.. 4347 
computer model.. I think.. patients that I’ve had conversations with.. with the.. err.. 4348 
computer dosin’.. 4349 
MADISON: .. ummmm.. I think it’s half ‘n half.. half were OK with i’ half think well.. I 4350 
could do i’ better myself (laugh). 4351 
INTERVIEWER: (laugh). 4352 
MADISON: (laugh).. do you know what I mean? So.. you know. We will see at the end 4353 
of i’ won’t we? We will see wha’ you’ve come up with. 4354 
INTERVIEWER: yeah of course and err.. are there any disadvantages? 4355 
MADISON: no because we’re tryin’ to make.. you know.. this.. is.. a research study.. 4356 
isn’ it? So the whole point of it.. is to make.. prescribin’.. on an individual.. patient 4357 
basis better. 4358 
INTERVIEWER: exactly. 4359 
MADISON: so.. you know.. we need to be able to prove.. which is.. the best.. way to 4360 
go don’t we? 4361 
INTERVIEWER: exactly so that.. that is what I’m asking is there any something 4362 
positive or something negative so that we can work on the positive make it better and.. 4363 
try to.. 4364 
MADISON: yeah well.. you know.. like I’ve said to you.. the positive for me is the 4365 
Fontan patients it’s good.. we need to get to the bottom of why.. for patients who’ve got 4366 
mechanical valves.. 4367 
INTERVIEWER: alright. 4368 
MADISON: why they are still.. why it’s.. you know.. it’s it’s not quite a’ 4369 
straightforward. 4370 
INTERVIEWER: OK. 4371 
MADISON: right now is that because the patients… is it because of their diet.. I mean 4372 
do we…have an in dep’ conversation.. you know when I ask them why do you think it’s 4373 
ou’ of range.. 4374 
MADISON: there ‘ve been some patients actually ‘n the reason it’s been ou’ of range is 4375 
because they’ve been on antibiotics.. bu’ for some others… it’s… I don’t know why.. 4376 
INTERVIEWER: OK. 4377 
MADISON: if they’ve had a massive growth spurt.. 4378 
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MADISON: have their parent forgotten to give the warfarin you know there is a 4379 
whole… 4380 
INTERVIEWER: yeah. 4381 
MADISON: re’.. there is a whole…. host of factors.. where it could be.. 4382 
INTERVIEWER: yeah.. yeah exactly so.. errr.. according to that during the usual phone 4383 
call.. err.. how much... of information.. can you get.. 4384 
MADISON: (at the same time) the problem is.. is tha’…. the message is left on the 4385 
answer phone.. 4386 
MADISON: so… you know… we can only do our best to tell parents.. if it’s out of 4387 
range can you tell us.. are they on antibiotics… have they had a growth spurt are they 4388 
generally unwell.. 4389 
MADISON: you know these are the things when we tell parents…. if they.. you know... 4390 
are generally unwell.. vomitin’ diarrhea… on antibiotics…. umm… even had a fall.. had 4391 
a bang.. you know…. you need to test their INR… you need to ring on.. the answer 4392 
phone.. ‘n you need to tell us.. 4393 
MADISON: if you’re callin’ out of the time sl’.. given time slot… why.. 4394 
MADISON: when you’re callin’ parents back… so tha’ you can have a conversation 4395 
with them……. sometimes you can’t.. because you have to leave a message on the 4396 
answer phone ‘n you have to write on the chart.. message left on answer phone.. 4397 
MADISON: so sometimes you’d like to have a dialogue… bu’ you know with the work 4398 
load in the day.. we don’t have a designated anticoagulation nurse.. 4399 
MADISON: I think actually that this is a full ti’ well.. at least a part time job we need to 4400 
have somebody dedicated to it.. at least… every day..… because there are a huge 4401 
amount of.. factors.. 4402 
INTERVIEWER: of course. 4403 
MADISON: you know constant education… I think…..’n even now….. parents 4404 
who‘ve.. been usin’ the INR machines for a few years.. when they come in every 6 4405 
months… to have their comparison check.. ‘n you watch them prick the finger ‘n the 4406 
way they put in the blood.. on the strip.. you thinkin’ to yourself that’s not how I told 4407 
you how to do it.. 4408 
MADISON: so you have to rego back ‘n say….. actually no.. don’ keep doin’ that.. 4409 
because if you doin’ that you’re actually stoppin’ the blood flow.. you need to gently.. 4410 
just.. milk the finger.. so you ge’ a nice drop o’ blood. 4411 
MADISON: and.. if you’re doin’ tha’.. you know you haven’ got an adequate supply.. 4412 
you’re no’….. to pu’ your finger on top of the thing…. you are no’ actually goin’ to get 4413 
much blood from there.. ‘n if you do this ‘n if you keep it by the side so.. you know.. 4414 
it’s constant constant constant education.. 4415 
INTERVIEWER: exactly. 4416 
MADISON: so… as you give them information as you’ve taught them ‘n they come 4417 
back.. there is only so much of that actually they’ve retained.. which is why I think.. we 4418 
need full time anticoagulation nurse.. 4419 
INTERVIEWER: OK. 4420 
MADISON: who’s goin’ to be there all the time… to….. constant education. 4421 
MADISON: a parents have queries.. whatever.. 4422 
INTERVIEWER: exactly. 4423 
MADISON: ‘e can call you so.. they can call you up.. ‘n you can… address the issue. 4424 
INTERVIEWER: exactly.. so how about those patients who do their own dosing.. errr.. 4425 
what do you usually do in those circumstances? 4426 
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MADISON: errrr… tell them tha’ they shouldn’ be doin’ i’. 4427 
INTERVIEWER: OK is there any… errr.. like.. errr….. telling the… doctor that they 4428 
are doing their own dosing so.. 4429 
MADISON: yeah we do have conversations with the consultants about i’. ‘n some.. 4430 
INTERVIEWER: (at the same time) so is there a specific action? 4431 
MADISON: (at the same time) ‘n some consultants ‘n some consultants will say.. ah 4432 
well actually they’re doin’ a better job. 4433 
INTERVIEWER: OK so they agree with that? 4434 
MADISON: yes some consultants do agree the patients.. do their own dosin’. 4435 
INTERVIEWER: and how about others? 4436 
MADISON: … some say no bu’ there are some who are quite happy.. ’cause they know 4437 
the parents ‘n they think well.. they can do.. just a good job. 4438 
INTERVIEWER: aha… OK and how do you see.. err.. the.. err.. the families’ 4439 
compliance with the computer dosing and the frequency of  INRs? 4440 
MADISON: errrrr there’s been a couple of parents who’ve.. said no I’ve no’ given tha’. 4441 
because it’s gonna make it ou’ of range. 4442 
INTERVIEWER: OK and about the frequency? 4443 
MADISON: errr yeah. Well actually no we’ve had one family.. we had to take them off 4444 
because.. she was….. doin’ her own thing. 4445 
INTERVIEWER: yeah. 4446 
MADISON: and……… I think she jus’ got into our red from day one. 4447 
MADISON: to be honest. It was time I remember.. when I did the education program 4448 
with her.. ‘n I said to her that.. there are some families who.. do their own thin’ ‘n.. ‘n 4449 
she was like.. Oh that’s terrible I’d never do that bla bla bla  well she is a very one isn’t 4450 
she? 4451 
INTERVIEWER: (laugh) yeah.. OK so err.. do you recommend this errr….. computer 4452 
dosing… model for other clinicians in the same area of congenital heart disease? 4453 
MADISON: I want to see the.. I want to see the results before I say anythin’.. I want to 4454 
see the results. 4455 
MADISON: for Fontan patients I think it’s fine.. bu’ I want to see.. I want to see.. (bang 4456 
bang bang on the desk)…. a hard evidence.. 4457 
INTERVIEWER: (at the same time) (laugh) 4458 
MADISON: (bang bang on the desk).. in front of me before I.. I answer that question. 4459 
INTERVIEWER: OK. 4460 
MADISON: uhuh. 4461 
INTERVIEWER: errr.. so any.. err.. recommendations.. err.. so to make this.. model.. 4462 
working better? 4463 
MADISON: errrrr let me see the evidence let me see what you come up with. 4464 
INTERVIEWER: and then you make your recommendations. 4465 
MADISON: (at the same time) and then I’ll make my recommendations. 4466 
INTERVIEWER: Oh great.. brilliant.. err.. any other comments? That you would like to 4467 
add? 4468 
MADISON: no. 4469 
INTERVIEWER: any other issue maybe.. that we have forgotten to discuss? 4470 
MADISON: errrrrrrr I think.. that weee… need to beee asking parents once a month to 4471 
weigh their child.. and.. when we.. ring them up we say.. what was their last weight. 4472 
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INTERVIEWER: yeah. This is O’ yeah.. great.. that this is very important for the.. you 4473 
know for the computer dosing.. but.. err.. we do not want to put much burden on.. 4474 
parents because.. 4475 
MADISON: (at the same time) I know.. 4476 
INTERVIEWER: because it.. it will take.. 4477 
MADISON: but.. it has an impact ‘asn’ i’? 4478 
INTERVIEWER: yeah of course.. we’re trying.. we were trying and always trying our 4479 
best to get the…. most updated weight.. 4480 
MADISON: yeah. We do get it every six months.. when they do turn up.. for the 4481 
comparison. 4482 
INTERVIEWER: exactly yeah. 4483 
MADISON: eeefff but I think for younger children…. I think it has a much more… 4484 
im’.. much more impact.. 4485 
MADISON: because because.. 4486 
INTERVIEWER: (at the same time) definitely it has. 4487 
MADISON: we’re testin’ them more often are’t we? 4488 
INTERVIEWER: definitely and we’ve got one of our patients we were requesting mum 4489 
to do.. more frequent.. err weighing. but.. sometimes we get a weight sometimes we 4490 
don’t.. because.. 4491 
MADISON: I know. 4492 
INTERVIEWER: yeah. 4493 
MADISON: ‘cause.. yeah I know. 4494 
INTERVIEWER: we can’t for’.. we can’t.. 4495 
MADISON: you can’ any but try. 4496 
INTERVIEWER: yeah.. exactly.. so.. I’ve got one more.. more question soo.. errrr.. is 4497 
that.. er.. the WATCH study.. err.. has put much pressure on you as cardiac liaison 4498 
team? 4499 
MADISON: no.. not really. 4500 
INTERVIEWER: Oh brilliant. 4501 
MADISON: no. it’s may my brain work though ‘cause I’m thinkin’ now why you’ve 4502 
done tha’.. an’ I have to look back.. and umm.. I try to work out.. why.. but no not 4503 
really.. 4504 
INTERVIEWER: alright.. brilliant. Thank you so much.. 4505 
MADISON: you welcome. 4506 
INTERVIEWER: for your time.. for participating in the study.. for this valuable 4507 
information.. 4508 
MADISON: OK. 4509 
INTERVIEWER: and I will stay.. you know.. looking forward for your.. 4510 
recommendations.. after the study. 4511 
MADISON: I’ll read it.. an’ I’ll say if I agree or disagree.. an’ you know me I’ll be very 4512 
honest (laugh) 4513 
INTERVIEWER: yeah of course.. of course.. yeah. And we want.. you know.. those..  4514 
because.. err.. this is theee.. thing that will make.. it.. work.. right. 4515 
MADISON: yeah. 4516 
INTERVIEWER: yeah  4517 
MADISON: yeah absolutely. 4518 
INTERVIEWER: thank you so much. 4519 
MADISON: it’s OK Basma.   4520 
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